Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also referred to as FORM PTO-1465) REQUEST FOR EX PARTE REEXAMINATION	TRANSMITTAL FORM
Address to: Mail Stop <i>Ex Parte</i> Reexam Commissioner for Patents	Attorney Docket No.: LT00831 REX
P.O. Box 1450 Alexandria, VA 22313-1450	Date: June 17, 2013
1. This is a request for ex parte reexamination pursuant to 37 Cl issued August 27, 2002 . The request is made by	FR 1.510 of patent number <u>6,440,706</u>
patent owner.	
2. The name and address of the person requesting reexaminatio	n is:
Life Technologies Corporation	
5791 Van Allen Way	
Carlsbad, CA 92008	
3. Requester claims small entity (37 CFR 1.27) or	micro entity status (37 CFR 1.29).
4. a. A check in the amount of \$ is enclosed to	cover the reexamination fee, 37 CFR 1.20(c)(1);
b. The Director is hereby authorized to charge the fee as se to Deposit Account No. 503994;	et forth in 37 CFR 1.20(c)(1)
c. Payment by credit card. Form PTO-2038 is attached; or	
d. Payment made via EFS-Web.	
5. Any refund should be made by check or _v credit to 37 CFR 1.26(c). If payment is made by credit card, refund mu	Deposit Account No. 503994
6. A copy of the patent to be reexamined having a double column enclosed. 37 CFR 1.510(b)(4).	nn format on one side of a separate paper is
7. CD-ROM or CD-R in duplicate, Computer Program (Appendix Landscape Table on CD	k) or large table
8. Nucleotide and/or Amino Acid Sequence Submission <i>If applicable, items a. – c. are required.</i>	
a. Computer Readable Form (CRF)	
b. Specification Sequence Listing on:	
i. CD-ROM (2 copies) or CD-R (2 copies); or	
ii. 🔲 paper	
c. Statements verifying identity of above copies	
9. A copy of any disclaimer, certificate of correction or reexaminates.	ation certificate issued in the patent is included.
10. Reexamination of claim(s) 1-12, 14-16, 19-32, 38-44, 46	is requested.
11. A copy of every patent or printed publication relied upon is su Form PTO/SB/08, PTO-1449, or equivalent.	bmitted herewith including a listing thereof on
12. An English language translation of all necessary and pertinen publications is included.	t non-English language patents and/or printed

[Page 1 of 2]
This collection of information is required by 37 CFR 1.510. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of information is required by 37 CFR 1.310. The information is required to obtain or retain a benefit by the public which is to file (and by the OSF1O to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 18 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Ex Parte Reexam, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/57 (02-13)
Approved for use through 07/31/2015. OMB 0651-0064
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

13. The attached detailed request includes at least the	following items:							
 a. A statement identifying each substantial new question of patentability based on prior patents and printed publications. 37 CFR 1.510(b)(1). 								
b. An identification of every claim for which reexamination is requested, and a detailed explanation of the pertinency and manner of applying the cited art to every claim for which reexamination is requested. 37 CFR 1.510(b)(2).								
14 A proposed amendment is included (only where the	e patent owner is the requester). 37 CFR 1.510(e).						
a. It is certified that a copy of this request (if filed by other than the patent owner) has been served in its entirety on the patent owner as provided in 37 CFR 1.33(c). The name and address of the party served and the date of service are: Banner & Witcoff, Ltd., Attorneys for client 001107, 1100 13th Street N.W., Suite 1200, Washington DC 20005-4051								
Date of Service:		; or						
b. A duplicate copy is enclosed since service on parameters and to serve patent owner is attached. See		An explanation of the efforts						
16. Correspondence Address: Direct all communication ab	out the reexamination to:							
The address associated with Customer Number:	52059							
OR Firm or Individual Name Address								
City	State	Zip						
Country								
Telephone	Email							
The patent is currently the subject of the following a. Copending reissue Application No. b. Copending reexamination Control No. c. Copending Interference No. d. Copending litigation styled: United States District Court for the Middle District	concurrent requests in related of North Carolina Greensboro Division	(Esoterix Genetic Labs, LLC, & The						
Johns Hopkins Univ. vs. Life Techs. Corp., Applied Biosystems, LLC, and Ion Torrent Systems, Inc., Case No. 12-1173 (Oct 31, 2012)								
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
/Ashita A. Doshi/	6/17/13							
Authorized Signature	Date							
Ashita Doshi	57,327	For Patent Owner Requester						
Typed/Printed Name	Registration No.	✓ For Third Party Requester						

[Page 2 of 2]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 6,440,706

Inventor: Bert Vogelstein et al.

Assignee: Johns Hopkins University

Issued: August 27, 2002

Application No.: 09/613,826

Filed: July 11, 2000

Control No.: To Be Assigned

Reexamination Filing Date: To Be Assigned

Art Unit: To Be Assigned

For: DIGITAL AMPLIFICATION

CERTIFICATE OF SERVICE ON PATENT OWNER FOR EX PARTE REQUEST FOR REEXAMINATION

I hereby certify that a copy of the Request for *Ex Parte* Reexamination by Third Party Requester filed on this date was served in its entirety on Patent Owner by First Class Mail, addressed to the following Correspondence Address of record for U.S. Patent No. 6,440,706:

Banner & Witcoff, Ltd. 1100 13th Street N.W. Suite 1200 Washington DC 20005-4051

Dated: June 17, 2013 Respectfully submitted,

By: /Elizabeth Morgan/ Elizabeth Morgan Patent Paralegal Life Technologies Corporation 2130 Woodward St., Bldg. 1 Austin, TX 78744 512-721-3690 Elizabeth.Morgan@lifetech.com

Customer No. 52059

Electronic Patent A	\ pp	olication Fee	Transmi	ttal	
Application Number:					
Filing Date:					
Title of Invention:	Dig	gital Amplification			
First Named Inventor/Applicant Name:	Bei	rt Vogelstein			
Filer:	Asł	nita Amu Doshi/Eliz	abeth Morgan		
Attorney Docket Number:	LTO	00831 REX			
Filed as Large Entity					
ex parte reexam Filing Fees					
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:					
REQUEST FOR EX PARTE REEXAMINATION		1812	1	12000	12000
Pages:					
Claims:					
Miscellaneous-Filing:					
Petition:					
Patent-Appeals-and-Interference:					
Post-Allowance-and-Post-Issuance:					
Extensiုပ္ခု _{င္} ၀ှf _ဝ ှTiက <u>ွာရ</u> း					

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
	Tot	al in USD	(\$)	12000

Electronic Ack	knowledgement Receipt
EFS ID:	16048211
Application Number:	90012894
International Application Number:	
Confirmation Number:	8442
Title of Invention:	Digital Amplification
First Named Inventor/Applicant Name:	Bert Vogelstein
Customer Number:	52059
Filer:	Ashita Amu Doshi/Elizabeth Morgan
Filer Authorized By:	Ashita Amu Doshi
Attorney Docket Number:	LT00831 REX
Receipt Date:	17-JUN-2013
Filing Date:	
Time Stamp:	16:32:23
Application Type:	Reexam (Third Party)

Payment information:

yes
Deposit Account
\$12000
3829
503994

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Plages at 224 ditional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Copy of patent for which reexamination is requested	LT00831REX-Exhibit1- US6440706.pdf	1297861	no	20
347			b4bd9b4fe944bd0a5ebf1a068389a676a76 714f6		
Warnings:					
Information:			T		
2	Reexam - Affidavit/Decl/Exhibit Filed by 3rd Party	LT00831REX-Exhibit3- US6440706-file-history.pdf	9057225	no	207
			0b514d510082f06c05e4bfd2e202920a254 bbd52		
Warnings:					
Information:					
3	Reexam - Affidavit/Decl/Exhibit Filed by	LT00831REX-	1540417	no	39
	3rd Party	Exhibit4-60146792.pdf	912ebfcc55bebefb1d81e60bfbe84d87a38 6bf21		
Warnings:					
Information:					
4	Reexam - Affidavit/Decl/Exhibit Filed by	LT00831REX-Exhibit5-	12475043	no	189
7	3rd Party	US13071105-file-history.pdf	807ae0d932ca18c3d391b03adf1ad510f10 1f5dc	110	
Warnings:					
Information:					
5	Reexam - Affidavit/Decl/Exhibit Filed by	LT00831REX-Exhibit6-	3796691	no	14
	3rd Party	Kuppers-1993-4955.pdf	76621a66bc8c079aac5be8990b0a488edbe 50f81		
Warnings:	·			•	
Information:					
6	Reexam - Affidavit/Decl/Exhibit Filed by	LT00831REX-Exhibit7-	5486030	no	12
0	3rd Party	Wolf-1996-3418.pdf	621c85dd2dc95107fa575b6ed1ab0fc19be ef38e	110	12
Warnings:					
Information:					
7	Reexam - Affidavit/Decl/Exhibit Filed by	LT00831REX-Exhibit-PA1-	474790	no	5
,	3rd Party	Li-1998.pdf	3cce9a423bcafda3cbfd7c1721cce8d332e1 bb90	110	,
Warnings:					
Information:					
8	Reexam - Affidavit/Decl/Exhibit Filed by	LT00831REX-Exhibit-PA2-	8167591	no	6
	3rd Party	Zhang-1992.pdf	b686a0f3cacda90fc6a0423f9c2c3fd43776c 0d4		
Warnings:	of 1224			'	
age /	-				

Information:					
9	Non Patent Literature	LT00831REX-Exhibit-PA3-	15549635	no	20
9	Norr atent Literature	Jeffreys-1988.pdf	47789347f3441ca6da0508c904b2fd644d8 acdf7	110	20
Warnings:		1		'	
Information:					
10	Non Patent Literature	LT00831REX-Exhibit-PA4-	8517931	no	7
	Non ratem Eneratare	Kalinina-1997-1999.pdf	9f3eab3092041cd3fbc7b13f8620af7091b9 0565		,
Warnings:					
Information:					
11	Non Patent Literature	LT00831REX-Exhibit-PA5-	874158	no	8
		Chou-1992-1717.pdf	80b63820ab73ed4ba8f3c7c884f0e052ef9e 9d40	0	
Warnings:					
Information:					
12	Non Patent Literature	LT00831REX-Exhibit-PA6-	11113342	no	7
'2	Non ratem Eneratare	Burg-1989-1787.pdf	dbd934ddfba779f6a97e58157d27c1754e9 a3788	no	′
Warnings:					
Information:					
13	Non Patent Literature	LT00831REX-Exhibit-PA7-	24684508	no	20
	Non ratem Eneratare	Trumper-1993-3097.pdf	9c4f7a630f39e0f53dd6e4754a5e5b87e77f d8f8	110	
Warnings:					
Information:					
14	Non Patent Literature	LT00831REX-Exhibit-PA8-	12057722	no	9
		Kanzler-1996-3429.pdf	b457da6c4c12302140f928b1f6c8757a9dca dbd8		
Warnings:					
Information:					
15	Non Patent Literature	LT00831REX-Exhibit-PA9-	4239688	no	10
		Gravel-1998-2866.pdf	210edc8f3f3c40bc22f66c78a942d5775c2b 01bb		
Warnings:					
Information:					
16	Non Patent Literature	LT00831REX-Exhibit-PA10-	7432863	no	5
		Marcucci-1998-790.pdf	2b58de8f9756530ad6286d1103f624ba066 ae607		
Warnings:					
Information:					
17	Non Patent Literature	LT00831REX-Exhibit-PA11-	381469	no	9
		Flint-1997-2469.pdf	ecfa37f2c69afa51ec12a478b597f3e412048 ccd		
Warnings: 8 of 1	224				

18	Information					
Marmings:	10	Non Potent Literature	LT00831REX-Exhibit-PA12-	1784465		12
Page	18	Non Patent Literature	Ponten-1997-45.pdf		no	12
Page	Warnings:					
Name	Information:					
Mandani 1996-03-2-poin Mandani 1996-03-2	19			5469597	no	5
Reexam		3rd Party	Mandahl-1996-632.pdf			
Recam	Warnings:					
Recam	Information:					
Marrings: Information:	20		LT00831REX-Exhibit2-SB08.pdf		no	3
Property Property		Filed by 3rd Party		ad98141d0c4284a7e6bb97726677ef456e8		_
Receipt of Orig. Ex Parte Request by Third Party LT00831REX-reexam-request-6-17-13.pdf 3ds/374b/588e2/864-643e4s-13c/b147cafc 97174 no 168						
Receipt of Orig. Ex Parte Request by Third Party LTOO831REX-reexam-request-6-17-13.pdf Adult Miles Resolution Adult Party Adult Part	Information:					
Name	21			616962	no	168
Information:		Third Party	request-6-17-13.pdf			
Transmittal of New Application	Warnings:					
Transmittal of New Application LT00831REX-reexam-request-transmittal-6-17-13.pdf C4993d3b4aff1 [ffee624bf056d5d54208f15 of Orc Part	Information					
Warnings: Information: 23 Reexam Certificate of Service LT00831REX-certificate-service reexam-request-6-17-13.pdf 277491547b094b56252f6d5a177.cN57/d5 2944c Warnings: Information: 24 Fee Worksheet (SB06) fee-info.pdf 400749c7111444f65d549f9fdd1181aefdc2 647 Warnings: Information:	22	Transmittal of New Application		243291	no	2
Information: 23 Reexam Certificate of Service LT00831REX-certificate-service-reexam-request-6-17-13.pdf 4277491547b034b5625275d5a177c0457d5 2944c						
Reexam Certificate of Service LT00831REX-certificate-service reexam-request-6-17-13.pdf 4277491547b034b56252f5dsa177c0457ds 2904c no 1 Warnings: Information: 24 Fee Worksheet (SB06) fee-info.pdf 4407d9c771f14d4f6f5db49fdd1181aefde2 647 no 2 Warnings: Information:	Warnings:					
Reexam Certificate of Service reexam-request-6-17-13.pdf 4277491547b034b56252f5d5a177c0457d5 29d4c no 1 Warnings: Information: Pee Worksheet (SB06) fee-info.pdf 29588 no 2 Warnings: Information:	Information:					
Warnings: 24 Fee Worksheet (SB06) fee-info.pdf Warnings: Unformation: 29588 407/d9/cf7/if14d4f6f5db4f9fdd1181aefde2 647 Warnings: Information:	23	Reexam Certificate of Service		87905	no	1
Information: 24 Fee Worksheet (SB06) fee-info.pdf Warnings: Information:			reexam-request-6-17-13.pdf		110	·
24 Fee Worksheet (SB06) fee-info.pdf 29588 d407d9cf71f14d4f6f5db49fdd1181aefde2 647 no 2 Warnings: Information:	Warnings:					
24 Fee Worksheet (SB06) fee-info.pdf d407d9cf7lf14d4f6f5db4f9fdd1181aefde2 647 Warnings: Information:	Information:					
Warnings: Information:	74	Fee Worksheet (SR06)	fee-info pdf	29588	no	2
Information:	<u> </u>	, ee wondheet (5500)	rec into.put			
	Warnings:					
Total Files Size (in bytes): 135469645	Information:					
			Total Files Size (in bytes)	1354	69645	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

EXHIBIT 1



US006440706B1

(12) United States Patent

Vogelstein et al.

(10) Patent No.: US 6,440,706 B1

(45) **Date of Patent:** Aug. 27, 2002

(54) DIGITAL AMPLIFICATION

(75) Inventors: **Bert Vogelstein**, Baltimore; **Kenneth W. Kinzler**, BelAir, both of MD (US)

(73) Assignee: **Johns Hopkins University**, Baltimore, MD (US)

*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

(21) Appl. No.: 09/613,826

(22) Filed: Jul. 11, 2000

Related U.S. Application Data

(60) Provisional application No. 60/146,792, filed on Aug. 2, 1999.

(56) References Cited

U.S. PATENT DOCUMENTS

5,670,325	Α		9/1997	Lapidus et al.	
5,804,383	Α		9/1998	Gruenert et al.	
5,858,663	Α		1/1999	Nisson et al.	
5,925,517	Α	*	7/1999	Tyagi et al	435/6
5,928,870	Α		7/1999	Lapidus et al.	
6,020,137	Α		2/2000	Lapidus et al.	
6,037,130	Α	*	3/2000	Tyagi et al	435/6
6,143,496	Α		11/2000	Brown et al.	

FOREIGN PATENT DOCUMENTS

EP	0643140 A	3/1995
WO	WO 95/13399	5/1995
WO	WO 99/13113	3/1999

OTHER PUBLICATIONS

Newton Essential PCR pp. 51-52 1995.*

Darren G. Monckton, et al., "Minisatellite "Isoallele" Discrimination in Pseudohomozygotes by Single Molecule PCR and Variant Repeat Mapping", Genomics 11, pp. 465–467, 1991.

Gualberto Ruano, et al., "Haplotype of Multiple Polymorphisms Resolved by Enzymatic Amplification of Single DNA Molecules", Proc. National Science USA, 1990 vol. 87 pp 6296–6300.

W. Navidi, et al., "Using PCR in Preimplantation Genetic Disease Diagnosis", Human Reproduction, vol. 6, No. 6, pp. 836–849, 1991.

Hongua Li, et al., "Amplification and Analysis of DNA Sequences in Single Human Sperm and Diploid Cells", Nature, vol. 335, Sep. 29, 1988 pp. 414–417.

Ramon Parsons, et al., "Mismatch Repair Deficiency in Phenotypically Normal Human Cells", Science, vol. 268, May 5, 1995 pp. 738–740.

Lin Zhang, et al., "Whole Genome Amplification from a Single Cell: Implications for Genetic Analysis", Proc. National Science USA, vol. 89, pp. 5847–5851, Jul. 1992. David Sidransky, et al., "Clonal Expansion of p53 Mutant

Cells in Associated with Brain Tumor Progression", Nature, Feb. 27, 1992 vol. 355, pp. 846–847.

Alec J. Jeffreys, et al., "Mutation Processes at Human Minisatellites", Electophoresis, pp. 1577–1585, 1995.

C. Schmitt, et al., "High Sensitive DNA Typing Approaches for the Analysis of Forensic Evidence: Comparison of Nested Variable Number of Tandem Repeats (VNTR) Amplification and a Short Tandem Repeats (STR) Polymorphism", Forensic Science International, vol. 66, pp. 129–141, 1994.

Paul M. Lizardi, et al., "Mutation Detection and Single-Molecule Counting Using Isothermal Rolling-Circle Amplification", Nature Genetics, vol. 19, Jul. 1988 pp. 225–232.

A. Piatek et al., "Molecular Beacon Sequence Analysis for Detecting Drug Resistance in Mycobacterium Tuberculosis", Nature Biotechnology, Apr. 1998, pp. 359–363, vol. 16, No. 4.

S. Tyagi et al., "Multicolor Molecular Beacons for allele discrimination", Nature Biotechnology, pp. 303–308, Jan. 1998, vol. 16, No. 1.

J. A.M. Vet et al., "Multilex Detection of Four Pathogenic Retroviruses Using Molecular Beacons", Proceedings of the National Academy of Sciences of the United States, May 25, 1999, pp. 6394–6399, vol. 96, No. 11.

S. Tyagi et al., "Molecular Beacons: probes that Fluoresce Upon Hybridization", Nature Biotechnology, 1996, pp. 303–308, vol. 14, No. 3.

W. P. Halford et al., "The Inherent Quantitative Capacity of the Reverse Transcription-Polymerase Chain Reaction", Analytical Biochemistry, Jan. 15, 1999, pp. 181–191, vol. 266, No. 2.

B. Vogelstein et al., "Digital PCR", Proceedings of the National Academy of Sciences of the United States, Aug. 3, 1999, pp. 9236–9241, vol. 96, No. 16.

K. D.E. Everett et al, "Identification of nine species of the Chlamydiaceae Uisng PCR-RFLP", Apr. 1999, pp. 803-813, vol. 49, No. 2.

Primary Examiner—Jeffrey Siew (74) Attorney, Agent, or Firm—Banner & Witcoff, Ltd.


(57) ABSTRACT


The identification of pre-defined mutations expected to be present in a minor fraction of a cell population is important for a variety of basic research and clinical applications. The exponential, analog nature of the polymerase chain reaction is transformed into a linear, digital signal suitable for this purpose. Single molecules can be isolated by dilution and individually amplified; each product is then separately analyzed for the presence of mutations. The process provides a reliable and quantitative measure of the proportion of variant sequences within a DNA sample.

64 Claims, 7 Drawing Sheets


^{*} cited by examiner

FIG. 1A






STEP 2 ADD FLUORESCENT PROBES **FLUOROMETRY**





-) = NO PCR PRODUCT
- = WILD TYPE PCR PRODUCT
- \geqslant = MUTANT PCR PRODUCT


Aug. 27, 2002

US 6,440,706 B1













FIG. 5



DIGITAL AMPLIFICATION

This application claims the benefit of U.S. Ser. No. 60/146,792, filed Aug. 2, 1999.

The U.S. government retains certain rights in this invention by virtue of its support of the underlying research, supported by grants CA 43460, CA 57345, and CA 62924 from the National Institutes of Health.

TECHNICAL FIELD OF THE INVENTION

This invention is related to diagnostic genetic analyses. In particular it relates to detection of genetic changes and gene expression.

BACKGROUND OF THE INVENTION

In classical genetics, only mutations of the germ-line were considered important for understanding disease. With the realization that somatic mutations are the primary cause of cancer (1), and may also play a role in aging (2,3), new 20 genetic principles have arisen. These discoveries have provided a wealth of new opportunities for patient management as well as for basic research into the pathogenesis of neoplasia. However, many of these opportunities hinge upon detection of a small number of mutant-containing cells 25 among a large excess of normal cells. Examples include the detection of neoplastic cells in urine (4), stool (5,6), and sputum (7,8) of patients with cancers of the bladder, colorectum, and lung, respectively. Such detection has been shown in some cases to be possible at a stage when the 30 primary tumors are still curable and the patients asymptomatic. Mutant sequences from the DNA of neoplastic cells have also been found in the blood of cancer patients (9-11). The detection of residual disease in lymph nodes or surgical margins may be useful in predicting which patients might 35 benefit most from further therapy (12-14). From a basic research standpoint, analysis of the early effects of carcinogens is often dependent on the ability to detect small populations of mutant cells (15–17).

Because of the importance of this issue in so many settings, many useful techniques have been developed for the detection of mutations. DNA sequencing is the gold standard for the detection of germ line mutations, but is useful only when the fraction of mutated alleles is greater than ~20% (18,19). Mutant-specific oligonucleotides can sometimes be used to detect mutations present in a minor proportion of the cells analyzed, but the signal to noise ratio distinguishing mutant and wild-type (WT) templates is variable (20-22). The use of mutant-specific primers or the digestion of polymerase chain reaction (PCR) products with specific restriction endonucleases are extremely sensitive methods for detecting such mutations, but it is difficult to quantitate the fraction of mutant molecules in the starting population with these techniques (23-28). Other innovative approaches for the detection of somatic mutations have been reviewed (29-32). A general problem with these methods is that it is difficult or impossible to independently confirm the existence of any mutations that are identified.

Thus there is a need in the art for methods for accurately and quantitatively detecting genetic sequences in mixed populations of sequences.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide methods 65 for determining the presence of a selected genetic sequence in a population of genetic sequences.

2

It is another object of the present invention to provide molecular beacon probes useful in the method of the invention

These and other objects of the invention are achieved by providing a method for determining the presence of a selected genetic sequence in a population of genetic sequences. A biological sample comprising nucleic acid template molecules is diluted to form a set of assay samples. The template molecules within the assay samples are amplified to form a population of amplified molecules in the assay samples of the set. The amplified molecules in the assay samples of the set are then analyzed to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence. The first number is then compared to the second number to ascertain a ratio which reflects the composition of the biological sample.

Another embodiment of the invention is a method for determining the ratio of a selected genetic sequence in a population of genetic sequences. Template molecules within a set comprising a plurality of assay samples are amplified to form a population of amplified molecules in each of the assay samples of the set. The amplified molecules in the assay samples of the set are analyzed to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence. The first number is compared to the second number to ascertain a ratio which reflects the composition of the biological sample.

According to another embodiment of the invention, a molecular beacon probe is provided. It comprises an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end. The loop consists of 16 base pairs and has a T_m of 50–51° C. The stem consists of 4 base pairs having a sequence 5'-CACG-3'.

A second type of molecular beacon probe is provided in another embodiment. It comprises an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end. The loop consists of 19–20 base pairs and has a T_m of 54–56° C. The stem consists of 4 base pairs having a sequence 5'-CACG-3'.

Another embodiment provides the two types of molecular beacon probes, either mixed together or provided in a divided container as a kit.

The invention thus provides the art with the means to obtain quantitative assessments of particular DNA or RNA sequences in mixed populations of sequences using digital (binary) signals.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A, 1B, 1C. Schematic of experimental design. (A) The basic two steps involved: PCR on diluted DNA samples is followed by addition of fluorescent probes which discriminate between WT and mutant alleles and subsequent fluorometry. (B) Principle of molecular beacon analysis. In the stem-loop configuration, fluorescence from a dye at the 5' end of the oligonucleotide probe is quenched by a Dabcyl group at the 3' end. Upon hybridization to a template, the dye is separated from the quencher, resulting in increased fluorescence. Modified from Marras et al. (C) Oligonucleotide design. Primers F1 and R1 are used to amplify the genomic region of interest. Primer INT is used to produce single stranded DNA from the original PCR products during a subsequent asymmetric PCR step (see Materials and

Methods). MB-RED is a Molecular Beacon which detects any appropriate PCR product, whether it is WT or mutant at the queried codons. MB-GREEN is a Molecular Beacon which preferentially detects the WT PCR product.

FIG. 2. Discrimination between WT and mutant PCR 5 products by Molecular Beacons. Ten separate PCR products, each generated from ~25 genome equivalents of genomic DNA of cells containing the indicated mutations of c-Ki-Ras, were analyzed with the Molecular Beacon probes described in the text. Representative examples of the PCR 10 products used for Molecular Beacon analysis were purified and directly sequenced. In the cases with Gly12Cys (SEQ ID NO: 11) and Gly12Arg (SEQ ID NO: 10) mutations, contaminating non-neoplastic cells within the tumor presumably accounted for the relatively low ratios. In the cases with Gly12Ser (SEQ ID NO: 8) and Gly12Asp (SEQ ID NO: 12), there were apparently two or more alleles of mutant c-Ki-Ras for every WT allele (SEQ ID NO: 7); both these tumors were aneuploid. Analysis of the Gly13Asp mutation is also shown (SEQ ID NO: 9).

FIG. 3. Detecting Dig-PCR products with MB-RED. Specific Fluorescence Units of representative wells from an experiment employing colorectal cancer cells with Gly12Asp or Gly13Asp mutations of the c-Ki-Ras gene. Wells with values >10,000 are shaded yellow. Polyacrylamide gel electrophoretic analyses of the PCR products from selected wells are shown. Wells with fluorescence values <3500 had no PCR product of the correct size while wells with fluorescence values >10,000 SFU always contained PCR products of 129 bp. Non-specific products generated during the large number of cycles required for Dig-PCR did not affect the fluorescence analysis. M1 and M2 are molecular weight markers used to determine the size of fragments indicated on the left (in base pairs).

FIG. 4. Discriminating WT from mutant PCR products obtained in Dig-PCR. RED/GREEN ratios were determined from the fluorescence of MB-RED and MB-GREEN as described in Materials and Methods. The wells shown are the same as those illustrated in FIG. 3. The sequences of PCR products from the indicated wells were determined as described in Materials and Methods. The wells with RED/GREEN ratios >3.0 each contained mutant sequences while those with RED/GREEN ratios of ~1.0 contained WT sequences. WT c-Ki-Ras (SEQ ID NO: 7), Gly12Asp (SEQ ID NO: 13), and Gly13Asp (SEQ ID NO: 9) were analyzed. 45

FIG. 5. Dig-PCR of DNA from a stool sample. The 384 wells used in the experiment are displayed. Those colored blue contained 25 genome equivalents of DNA from normal cells. Each of these registered positive with MB-RED and the RED/GREEN ratios were 1.0+/-0.1 (mean +/-1 standard deviation). The wells colored yellow contained no template DNA and each was negative with MB-RED (i.e., fluorescence <3500 fluorescence units.). The other wells contained diluted DNA from the stool sample. Those registering as positive with MB-RED were colored either red or green, depending on their RED/GREEN ratios. Those registering negative with MB-RED were colored white. PCR products from the indicated wells were used for automated sequence analysis. The sequence of WT c-Ki-Ras in well K1 (SEQ ID NO: 7), and mutant c-Ki-Ras in wells C10, E11, M10, and L12 (SEQ ID NO: 14), and well F21 (SEQ ID NO: 15) were analyzed.

DETAILED DESCRIPTION OF THE INVENTION

The method devised by the present inventors involves separately amplifying small numbers of template molecules 4

so that the resultant products have a proportion of the analyte sequence which is detectable by the detection means chosen. At its limit, single template molecules can be amplified so that the products are completely mutant or completely wild-type (WT). The homogeneity of these amplification products makes them trivial to distinguish through existing techniques.

The method requires analyzing a large number of amplified products simply and reliably. Techniques for such assessments were developed, with the output providing a digital readout of the fraction of mutant alleles in the analyzed population.

The biological sample is diluted to a point at which a practically usable number of the diluted samples contain a proportion of the selected genetic sequence (analyte) relative to total template molecules such that the analyzing technique being used can detect the analyte. A practically usable number of diluted samples will depend on cost of the analysis method. Typically it would be desirable that at least 1/50 of the diluted samples have a detectable proportion of analyte. At least 1/10, 1/5, 3/10, 2/5, 1/2, 3/5, 7/10, 4/5, or 9/10 of the diluted samples may have a detectable proportion of analyte. The higher the fraction of samples which will provide useful information, the more economical will be the overall assay. Over-dilution will also lead to a loss of economy, as many samples will be analyzed and provide no signal. A particularly preferred degree of dilution is to a point where each of the assay samples has on average one-half of a template. The dilution can be performed from more concentrated samples. Alternatively, dilute sources of template nucleic acids can be used. All of the samples may contain amplifiable template molecules. Desirably each assay sample prior to amplification will contain less than a hundred or less than ten template molecules.

Digital amplification can be used to detect mutations present at relatively low levels in the samples to be analyzed. The limit of detection is defined by the number of wells that can be analyzed and the intrinsic mutation rate of the polymerase used for amplification. 384 well PCR plates are commercially available and 1536 well plates are on the horizon, theoretically allowing sensitivities for mutation detection at the ~0.1\% level. It is also possible that Digital Amplification can be performed in microarray format, potentially increasing the sensitivity by another order of magnitude. This sensitivity may ultimately be limited by 45 polymerase errors. The effective error rate in PCR as performed under our conditions was <0.3\%, i.e., in control experiments with DNA from normal cells, none of 340 wells containing PCR products exhibited RED/GREEN ratios >3.0. Any individual mutation (such as a G- to C-transversion at the second position of codon 12 of c-Kiras) is expected to occur in <1 in 50 polymerase-generated mutants (there are at least 50 base substitutions within or surrounding codons 12 and 13 that should yield high RED/ GREEN ratios). Determining the sequence of the putative mutants in the positive wells, by direct sequencing as performed here or by any of the other techniques, provides unequivocal validation of a prospective mutation: a significant fraction of the mutations found in individual wells should be identical if the mutation occurred in vivo. Significance can be established through rigorous statistical analysis, as positive signals should be distributed according to Poisson probabilities. Moreover, the error rate in particular Digital Amplification experiments can be precisely determined through performance of Digital Amplification on 65 DNA templates from normal cells.

Digital Amplification is as easily applied to RT-PCR products generated from RNA templates as it is to genomic

DNA. For example, the fraction of alternatively spliced or mutant transcripts from a gene can be easily determined using photoluminescent probes specific for each of the PCR products generated. Similarly, Digital Amplification can be used to quantitate relative levels of gene expression within an RNA population. For this amplification, each well would contain primers which are used to amplify a reference transcript expressed constitutively as well as primers specific for the experimental transcript. One photoluminescent probe would then be used to detect PCR products from the 10 reference transcript and a second photoluminescent probe used for the test transcript. The number of wells in which the test transcript is amplified divided by the number of wells in which the reference transcript is amplified provides a quantitative measure of gene expression. Another group of examples involves the investigations of allelic status when two mutations are observed upon sequence analysis of a standard DNA sample. To distinguish whether one variant is present in each allele (vs. both occurring in one allele), cloning of PCR products is generally performed. The 20 approach described here would simplify the analysis by eliminating the need for cloning. Other potential applications of Digital Amplification are listed in Table 1. When the goal is the quantitation of the proportion of two relatively common alleles or transcripts rather than the detection of rare alleles, techniques such as those employing TaqMan and real time PCR provide an excellent alternative to use of molecular beacons. Advantages of real time PCR methods include their simplicity and the ability to analyze multiple samples simultaneously. However, Digital Amplification may prove useful for these applications when the expected differences are small, (e.g., only ~2-fold, such as occurs with allelic imbalances (55)).

The ultimate utility of Digital Amplification lies in its ability to convert the intrinsically exponential nature of PCR ³⁵ to a linear one. It should thereby prove useful for experiments requiring the investigation of individual alleles, rare variants/mutations, or quantitative analysis of PCR products.

In one preferred embodiment each diluted sample has on average one half a template molecule. This is the same as one half of the diluted samples having one template molecule. This can be empirically determined by amplification. Either the analyte (selected genetic sequence) or the reference genetic sequence can be used for this determination. If the analysis method being used can detect analyte when present at a level of 20%, then one must dilute such that a significant number of diluted assay samples contain more than 20% of analyte. If the analysis method being used

6

requires 100% analyte to detect, then dilution down to the single template molecule level will be required.

To achieve a dilution to approximately a single template molecule level, one can dilute such that between 0.1 and 0.9 of the assay samples yield an amplification product. More preferably the dilution will be to between 0.1 and 0.6, more preferably to between 0.3 and 0.5 of the assay samples yielding an amplification product.

The digital amplification method requires analysis of a large number of samples to get meaningful results. Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. As in any method, the accuracy of the determination will improve as the number of samples increases, up to a point. Because a large number of samples must be analyzed, it is desirable to reduce the manipulative steps, especially sample transfer steps. Thus it is preferred that the steps of amplifying and analyzing are performed in the same receptacle. This makes the method an in situ, or "one-pot" method.

The number of different situations in which the digital amplification method will find application is large. Some of these are listed in Table 1. As shown in the examples, the method can be used to find a tumor mutation in a population of cells which is not purely tumor cells. As described in the examples, a probe for a particular mutation need not be used, but diminution in binding to a wild-type probe can be used as an indicator of the presence of one or more mutations. Chromosomal translocations which are characteristic of leukemias or lymphomas can be detected as a measure of the efficacy of therapy. Gene amplifications are characteristic of certain disease states. These can be measured using digital amplification. Alternatively spliced forms of a transcript can be detected and quantitated relative to other forms of the transcript using digital amplification on cDNA made from mRNA. Similarly, using cDNA made from mRNA one can determine relative levels of transcription of two different genes. One can use digital amplification to distinguish between a situation where one allele carries two mutations and one mutation is carried on each of two alleles in an individual. Allelic imbalances often result from a disease state. These can be detected using digital amplification.

Biological samples which can be used as the starting material for the analyses may be from any tissue or body sample from which DNA or mRNA can be isolated. Preferred sources include stool, blood, and lymph nodes. Preferably the biological sample is a cell-free lysate.

TABLE 1

	Detection Applications	-f Di- DOD						
	Potential Applications of Dig-PCR							
Application	Example	Probe 1 Detects:	Probe 2 Detects:					
Base substitution mutations	Cancer gene mutations in stool, blood, lymph nodes	mutant or WT alleles	WT PCR products					
Chromosomal translocations	Residual leukemia cells after therapy (DNA or RNA)	normal or translocated alleles	translocated allele					
Gene amplifications	Determine presence or extent of amplification	sequence within amplicon	sequence from another part of same chromosome arm					
Alternatively spliced products	Determine fraction of alternatively spliced transcripts from same gene (RNA)	minor exons	ccomon exons					
Changes in gene expression	Determine relative levels of expression of two genes (RNA)	first transcript	reference transcript					
Allelic discrimination	Two different alleles mutated vs. one mutation in each of two alleles	first mutation	second mutation					

TABLE 1-continued Potential Applications of Dig-PCR Application Probe 1 Detects: Probe 2 Detects: Example Allelic imbalance Quantitative analysis with non-polymorphic marker from test marker from reference chromosome chromosome

Molecular beacon probes according to the present invention can utilize any photoluminescent moiety as a detectable moiety. Typically these are dyes. Often these are fluorescent dyes. Photoluminescence is any process in which a material is excited by radiation such as light, is raised to an excited electronic or vibronic state, and subsequently re-emits that excitation energy as a photon of light. Such processes include fluorescence, which denotes emission accompanying descent from an excited state with paired electrons (a lower state with the same multiplicity, i.e., a quantummechanically "allowed" transition. Photoluminescence also includes phosphorescence which denotes emission accompanying descent from an excited triplet or singlet state to a lower state of different multiplicity, i.e., a quantum mechanically "forbidden" transition. Compared to "allowed" transitions, "forbidden" transitions are associated with relatively longer excited state lifetimes.

7

The quenching of photoluminescence may be analyzed by a variety of methods which vary primarily in terms of signal 30 transduction. Quenching may be transduced as changes in the intensity of photoluminescence or as changes in the ratio of photoluminescence intensities at two different wavelengths, or as changes in photoluminescence lifetimes, or even as changes in the polarization (anisotropy) of 35 photoluminescence. Skilled practitioners will recognize that instrumentation for the measurement of these varied photoluminescent responses are known. The particular ratiometric methods for the analysis of quenching in the instant examples should not be construed as limiting the invention 40 to any particular form of signal transduction. Ratiometric measurements of photoluminescence intensity can include the measurement of changes in intensity, photoluminescence lifetimes, or even polarization (anisotropy).

Although the working examples demonstrate the use of 45 molecular beacon probes as the means of analysis of the amplified dilution samples, other techniques can be used as well. These include sequencing, gel TaqMan™ (duallabeled fluorogenic) probes (Perkin Elmer Corp./Applied Biosystems, Foster City, Calif.), pyrene-labeled probes, and 50 other biochemical assays.

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention.

EXAMPLE 1

Step 1: PCR amplifications. The optimal conditions for 60 PCR described in this section were determined by varying the parameters described in the Results. PCR was performed in 7 ul volumes in 96 well polypropylene PCR plates (Marsh Biomedical Products, Rochester, N.Y.). The composition of the reactions was: 67 mM Tris, pH 8.8, 16.6 mM NH₄SO₄, 65 6.7 mM MgCl₂, 10 mM β-mercaptoethanol, 1 mM dATP, 1 mM dCTP, 1 mM dGTP, 1 mM TTP, 6% DMSO, 1 uM

primer F1, 1 uM primer R1, 0.05 units/ul Platinum Taq polymerase (Life Technologies, Inc.), and "one-half genome equivalent" of DNA. To determine the amount of DNA corresponding to one-half genome equivalent, DNA samples were serially diluted and tested via PCR. The amount that yielded amplification products in half the wells, usually ~1.5 pg of total DNA, was defined as "one-half genome equivalent" and used in each well of subsequent Digital Amplification experiments. Fifty ul light mineral oil (Sigma "singlet" state) or unpaired electrons (a "triplet" state) to a 20 M-3516) was added to each well and reactions performed in a HybAid Thermal cycler at the following temperatures: denaturation at 94° for one min; 60 cycles of 94° for 15 sec, 55° for 15 sec., 70° for 15 seconds; 70° for five minutes. Reactions were read immediately or stored at room temperature for up to 36 hours before fluorescence analysis.

8

EXAMPLE 2

Step 2: Fluorescence analysis. 3.5 ul of a solution with the following composition was added to each well: 67 mM Tris, pH 8.8, 16.6 mM NH₄SO₄, 6.7 mM MgCl₂, 10 mM β-mercaptoethanol, 1 mM dATP, 1 mM dCTP, 1 mM dGTP, 1 mM TTP, 6% DMSO, 5 uM primer INT, 1 uM MB-GREEN, 1 uM MB-RED, 0.1 units/ul Platinum Taq polymerase. The plates were centrifuged for 20 seconds at 6000 g and fluorescence read at excitation/emission wavelengths of 485 nm/530 nm for MB-GREEN and 530 nm/590 nm for MB-RED. The fluorescence in wells without template was typically 10,000 to 20,000 fluorescence "units", with about 75% emanating from the fluorometer background and the remainder from the MB probes. The plates were then placed in a thermal cycler for asymmetric amplification at the following temperatures: 94° for one minute; 10–15 cycles of 94° for 15 sec, 55° for 15 sec., 70° for 15 seconds; 94° for one minute; and 60° for five minutes. The plates were then incubated at room temperature for ten to sixty minutes and fluorescence measured as described above. Specific fluorescence was defined as the difference in fluorescence before and after the asymmetric amplification. RED/ GREEN ratios were defined as the specific fluorescence of MB-RED divided by that of MB-GREEN. RED/GREEN ratios were normalized to the ratio exhibited by the positive controls (25 genome equivalents of DNA from normal cells, as defined above in Example 1). We found that the ability of MB probes to discriminate between WT and mutant sequences under our conditions could not be reliably determined from experiments in which they were tested by hybridization to relatively short complementary single stranded oligonucleotides, and that actual PCR products had to be used for validation.

EXAMPLE 3

Oligonucleotides and DNA sequencing. Primer F1:

5'-CATGTTCTAATATAGTCACATTTTCA-3' (SEQ ID NO: 1); Primer R1:

5'-TCTGAATTAGCTGTATCGTCAAGG-3' (SEQ ID NO: 2); Primer INT:

Page 23 of 1224

5'-TAGCTGTATCGTCAAGGCAC-3' (SEQ ID NO: 3); MB-RED:

5'-Cy3-CACGGGCCTGCTGAAAATGACTGCGTG-Dabcyl-3' (SEQ ID NO: 4);

MB-GREEN: 5'-Fluorescein-CACGGGAGCTGGTGGCGTAGCGTG-Dabcyl-3' (SEQ ID NO: 5). Molecular Beacons (33,34) were synthesized by Midland Scientific and other oligonucleotides were synthesized by Gene Link (Thomwood, N.Y.). All were dissolved at 50 uM in TE (10 mM Tris, pH 8.0/1 mM EDTA) and kept frozen and in the dark until use. PCR products were purified using QIAquick PCR purification kits (Qiagen). In the relevant experiments described in the text, 20% of the product from single wells was used for gel electrophoresis and 40% was used for each sequencing reaction. The primer used for sequencing was 5'-CATTATTTTTATTATAAGGCCTGC-3' (SEQ ID NO: 6). Sequencing was performed using fluorescently-labeled ABI Big Dye terminators and an ABI 377 automated sequencer.

EXAMPLE 4

Principles underlying experiment. The experiment is outlined in FIG. 1A. First, the DNA is diluted into multiwell plates so that there is, on average, one template molecule per two wells, and PCR is performed. Second, the individual wells are analyzed for the presence of PCR products of mutant and WT sequence using fluorescent probes.

As the PCR products resulting from the amplification of single template molecules should be homogeneous in sequence, a variety of standard techniques could be used to assess their presence. Fluorescent probe-based technologies, in the same wells) are particularly well-suited for this application (31, 33-40). We chose to explore the utility of one such technology, involving Molecular Beacons (MB), for this purpose (33,34). MB probes are oligonucleotides with stem-loop structures that contain a fluorescent dye at 40 the 5' end and a quenching agent (Dabcyl) at the 3' end (FIG. 1B). The degree of quenching via fluorescence energy resonance transfer is inversely proportional to the 6th power of the distance between the Dabcyl group and the fluorescent dye. After heating and cooling, MB probes reform a stemloop structure which quenches the fluorescent signal from the dye (41). If a PCR product whose sequence is complementary to the loop sequence is present during the heating/ cooling cycle, hybridization of the MB to one strand of the PCR product will increase the distance between the Dabcyl 50 and the dye, resulting in increased fluorescence.

A schematic of the oligonucleotides used for Digital Amplifications shown in FIG. 1C. Two unmodified oligonucleotides are used as primers for the PCR reaction. Two MB probes, each labeled with a different fluorophore, are used to detect the PCR products. MB-GREEN has a loop region that is complementary to the portion of the WT PCR product that is queried for mutations. Mutations within the corresponding sequence of the PCR product should significantly impede its hybridization to the MB probe (33,34). MB-RED has a loop region that is complementary to a different portion of the PCR product, one not expected to be mutant. It thus should produce a signal whenever a well contains a PCR product, whether that product is WT or mutant in the region queried by MB-GREEN. Both MB 65 probes are used together to simultaneously detect the presence of a PCR product and its mutational status.

Practical Considerations. Numerous conditions were optimized to define conditions that could be reproducibly and generally applied. As outlined in FIG. 1A, the first step involves amplification from single template molecules. Most protocols for amplification from small numbers of template molecules use a nesting procedure, wherein a product resulting from one set of primers is used as template in a second reaction employing internal primers. As many applications of digital amplification are expected to require hundreds or 10 thousands of separate amplifications, such nesting would be inconvenient and could lead to contamination problems. Hence, conditions were sought that would achieve robust amplification without nesting. The most important of these conditions involved the use of a polymerase that was activated only after heating (44,45) and optimized concentrations of dNTP's, primers, buffer components, and temperature. The conditions specified in Examples 1–3 were defined after individually optimizing each of these components and proved suitable for amplification of several different human genomic DNA sequences. Though the time required for PCR was not particularly long (~2.5 hr), the number of cycles used was high and excessive compared to the number of cycles required to amplify the "average" single template molecule. The large cycle number was necessary because the template in some wells might not begin to be amplified until several PCR cycles had been completed. The large number of cycles ensured that every well (not simply the average well) would generate a substantial and roughly equal amount of PCR product if a template molecule were 30 present within it.

The second step in FIG. 1A involves the detection of these PCR products. It was necessary to considerably modify the standard MB probe approach in order for it to function efficiently in Digital Amplification applications. which can be performed on the PCR products "in situ" (i.e., 35 Theoretically, one separate MB probe could be used to detect each specific mutation that might occur within the queried sequence. By inclusion of one MB corresponding to WT sequence and another corresponding to mutant sequence, the nature of the PCR product would be revealed. Though this strategy could obviously be used effectively in some situations, it becomes complex when several different mutations are expected to occur within the same queried sequence. For example, in the c-Ki-Ras gene example explored here, twelve different base substitutions resulting 45 in missense mutations could theoretically occur within codons 12 and 13, and at least seven of these are observed in naturally-occurring human cancers. To detect all twelve mutations as well as the WT sequence with individual Molecular Beacons would require 13 different probes. Inclusion of such a large number of MB probes would raise the background fluorescence and cost of the assay. We therefore attempted to develop a single probe that would react with WT sequences better than any mutant sequence within the queried sequence. We found that the length of the loop sequence, its melting temperature, and the length and sequence of the stem were each important in determining the efficacy of such probes. Loops ranging from 14 to 26 bases and stems ranging from 4 to 6 bases, as well as numerous sequence variations of both stems and loops, were tested during the optimization procedure. For discrimination between WT and mutant sequences (MB-GREEN probe), we found that a 16 base pair loop, of melting temperature (Tm) 50-51°, and a 4 bp stem, of sequence 5'-CACG-3', were optimal. For MB-RED probes, the same stem, with a 19-20 bp loop of Tm 54-56°, proved optimal. The differences in the loop sizes and melting temperatures between MB-GREEN and MB-RED probes reflected the fact that

only the GREEN probe is designed to discriminate between closely related sequences, with a shorter region of homology facilitating such discrimination.

Examples of the ratios obtained in replicate wells containing DNA templates from colorectal tumor cells with mutations of c-Ki-Ras are shown in FIG. 2. In this experiment, fifty genome equivalents of DNA were added to each well prior to amplification. Each of six tested mutants yielded ratios of RED/GREEN fluorescence that were significantly in excess of the ratio obtained with DNA from normal cells (1.5 to 3.4 in the mutants compared to 1.0 in normal DNA; p <0.0001 in each case, Student's t-Test). The reproducibility of the ratios can be observed in this figure. Direct DNA sequencing of the PCR products used for fluorescence analysis showed that the RED/GREEN ratios were dependent on the relative fraction of mutant genes within the template population (FIG. 2). Thus, the DNA from cells containing one mutant c-Ki-Ras allele per every two WT c-Ki-Ras allele yielded a RED/GREEN ratio of 1.5 (Gly12Arg mutation) while the cells containing three mutant 20 c-Ki-Ras alleles per WT allele exhibited a ratio of 3.4 (Gly12Asp). These data suggested that wells containing only mutant alleles (no WT) would yield ratios in excess of 3.0, with the exact value dependent on the specific mutation.

Though this mode is the most convenient for many applications, we found it useful to add the MB probes after the PCR-amplification was complete (FIG. 1). This allowed us to use a standard multiwell plate fluorometer to sequentially analyze a large number of multiwell plates containing pre-formed PCR products and bypassed the requirement for multiple real time PCR instruments. Additionally, we found that the fluorescent signals obtained could be considerably enhanced if several cycles of asymmetric, linear amplification was achieved by including an excess of a single internal primer (primer INT in FIG. 1C) at the time of addition of the MB probes.

25 exhibited ratios ranging from 0.7 to 1.2, identical to those observed in the positive control wells. To determine the nature of the mutant c-Ki-Ras genes in the five positive wells from stool, the PCR products were completely composed of mutant c-Ki-Ras sequence (FIG. 5). The sequence of three of these PCR products revealed Gly12Ala mutations (GGT to GCT at codon 12), while the sequence of the fourth indicated a silent C to T transition at the third position of codon 13. This transition presumably resulted from a PCR error during the first productive cycle of amplification from a WT template. The well with a ratio of 2.1 contained a ~1:1 mix of WT and

EXAMPLE 5

Analysis of DNA from tumor cells. The principles and 40 practical considerations described above were illustrated with DNA from two colorectal cancer cell lines, one with a mutation in c-Ki-Ras codon 12 and the other in codon 13. Representative examples of the MB-RED fluorescence values obtained are shown in FIG. 3. There was a clear biphasic 45 distribution, with "positive" wells yielding values in excess of 10,000 specific fluorescence units (SFU, as defined in Materials and Methods) and "negative" wells yielding values less than 3500 SFU. Gel electrophoreses of 127 such wells demonstrated that all positive wells, but no negative 50 wells, contained PCR products of the expected size (FIG. 3). The RED/GREEN fluorescence ratios of the positive wells are shown in FIG. 4. Again, a biphasic distribution was observed. In the experiment with the tumor containing a Gly12Asp mutation, 64% of the positive wells exhibited RED/GREEN ratios in excess of 3.0 while the other 36% of the positive wells exhibited ratios ranging from 0.8 to 1.1. In the case of the tumor with the Gly13Asp mutation, 54% of the positive wells exhibited RED/GREEN ratios >3.0 while the other positive wells yielded ratios ranging from 0.9 to 1.1. The PCR products from 16 positive wells were used as sequencing templates (FIG. 4). All the wells yielding a ratio in excess of 3.0 were found to contain mutant c-Ki-Ras fragments of the expected sequence, while WT sequence was found in the other PCR products. The presence of 65 homogeneous WT or mutant sequence confirmed that the amplification products were usually derived from single

12

template molecules. The ratios of WT to mutant PCR products determined from the Digital Amplification assay was also consistent with the fraction of mutant alleles inferred from direct sequence analysis of genomic DNA from the two tumor lines (FIG. 2).

Digital Analysis of DNA from stool. As a more practical example, we analyzed the DNA from stool specimens of colorectal cancer patients. A representative result of such an experiment is illustrated in FIG. 5. From previous analyses of stool specimens from patients whose tumors contained c-Ki-Ras gene mutations, we expected that 1% to 10% of the c-Ki-Ras genes purified from stool would be mutant. We therefore set up a 384 well Digital Amplification experiment. As positive controls, 48 of the wells contained 25 genome equivalents of DNA (defined in Materials and Methods) from normal cells. Another 48 wells served as negative controls (no DNA template added). The other 288 wells contained an appropriate dilution of stool DNA. MB-RED fluorescence indicated that 102 of these 288 experimental wells contained PCR products (mean +/-s.d. of 47,000 + -18,000 SFU) while the other 186 wells did not (2600+/-1500 SFU). The RED/GREEN ratios of the 102 positive wells suggested that five contained mutant c-Ki-Ras genes, with ratios ranging from 2.1 to 5.1. The other 97 wells exhibited ratios ranging from 0.7 to 1.2, identical to those observed in the positive control wells. To determine the nature of the mutant c-Ki-Ras genes in the five positive wells from stool, the PCR products were directly sequenced. The four wells exhibiting RED/GREEN ratios in excess of 3.0 were completely composed of mutant c-Ki-Ras sequence (FIG. 5). The sequence of three of these PCR products revealed Gly12Ala mutations (GGT to GCT at codon 12), while the sequence of the fourth indicated a silent C to T transition at the third position of codon 13. This transition productive cycle of amplification from a WT template. The well with a ratio of 2.1 contained a ~1:1 mix of WT and Gly12Ala mutant sequences. Thus 3.9% (4/102) of the c-Ki-Ras alleles present in this stool sample contained a Gly12Ala mutation. The mutant alleles in the stool presumably arose from the colorectal cancer of the patient, as direct sequencing of PCR products generated from DNA of the cancer revealed the identical Gly12Ala mutation (not shown).

References

- Vogelstein & Kinzler, (1998) The Genetic Basis of Human Cancer (MCGraw-Hill, Toronto).
- 2. Lee et al., (1997) Free Radical Biol Med 22, 1259-69.
- 3. Ozawa, T. (1997) Physiol Rev 77, 425-64.
- 4. Sidransky et al., (1991) Science 252, 706-09.
- 5. Sidransky et al., (1992) Science 256, 102-05.
- 6. Smith-Ravin et al., (1995) Gut 36, 81–6.
- 7. Mills et al., (1995) J. Natl Cancer Inst 87, 1056-60.
- 8. Mao et al. (1994) Cancer Res 54, 1634–37.
- 9. Brossart et al., (1995) Caner Res 55, 4065-68.
- 10. Tada et al. (1993) Cancer Res 53, 2472–74.
- 11. Nawroz et al. (1996) Nature Med 2, 1035-37.
- 12. Hayashi et al., (1994) Cancer Res 54, 3853–56.
- 13. Sidransky, (1997) Science 278, 1054-59.
- 14. Koch et al. (1994) Arch Otolaryngol Head Neck Surg 120, 943–47.
- 15. Kumar et al., (1990) Science 248, 1101-04.
- 16. Jonason et al., (1996) Proc Natl Acad Sci USA 93, 14025-29.
- 17. Ananthaswamy et al. (1999) J Invest Dermiatol 112, 763–68.

18. Bar-Eli et al. (1989) Blood 73, 281-83.

19. Collins et al. (1989) Blood 73, 1028-32.

20. Saiki et al. (1986) Nature 324, 163-66.

21. Bos et al. (1987) Nature 327, 293-97.

22. Dicker et al. (1990) Genes Chromosomes Cancer 1, 5 257-69

13

23. Haque et al. (1998) Diagn Mol Pathol 7, 248-52.

24. Haliassos et al. (1989) Nucleic Acids Res 17, 8093-99.

25. Chen et al. (1997) Anal Biochem 244, 191-94.

26. Cha et al. (1992) PCR Methods Appl 2, 14-20.

27. Jiang et al. (1989) Oncogene 4, 923-28.

28. Kahn et al. (1991) Oncogene 6, 1079-83.

29. Kahn et al. (1995) Methods Enzymol 255, 452-64.

30. Laken et al., (1998) Nature Biotechnol 16, 1352-56.

31. Whitcombe et al. (1998) Curr Opin Biotechnol 9, 15 50. Jeffreys et al. (1995) Electrophoresis 16, 1577-85.

32. Day et al. (1999) Nucleic Acids Res 27, 1820-18.

33. Tyagi et al. (1998) Nature Biotechnol 16, 49-53.

34. Tyagi et al. (1996) Nat Biotechnol 14, 303-08.

35. Lee et al. (1993) Nucleic Acids Res 21, 3761-66.

36. Chiang et al. (1996) Genome Res 6, 1013-26.

14

37. Heid et al. (1996) Genome Res 6. 986-94.

38. Paris et al. (1998) Nucleic Acids Res 26, 3789-93.

39. Gibson et al. (1997) Clin Chem 43, 1336-41.

40. Chen et al. (1999) Genome Res 9, 492-98.

41. Szollosi et al. (1998) Cytometry 34, 159-79.

42. Cortopassi et al. (1992) Mutat Res 277, 239-49.

43. Monckton et al. (1991) Genomics 11, 465-67.

44. Chou et al. (1992) Nucleic Acids Res 20, 1717-23. 45. Kellogg et al. (1994) Biotechniques 16, 1134-37.

10 46. Li et al. (1988) Nature 335, 414-17.

47. Schmitt et al. (1994) Forensic Sci Int 66, 129-41.

48. Navidi et al. (1991) Hum Reprod 6, 836-49.

49. Zhang et al. (1992) Proc Natl Acad Sci USA 89, 5847-51.

51. Ruano et al. (1990) Proc Natl Acad Sci USA, 6296–300.

52. Sidransky et al. (1992) Nature 355, 846–47.

53. Parsons et al. (1995) Science 268, 738-40.

54. Lizardi et al. (1998) Nature Genet 19, 225-32.

20 55. Vogelstein (1989) Science 244, 207-11.

26

24

20

27

56. Marras et al. (1999) Genet Anal 14, 151-56.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 15

<210> SEQ ID NO 1

<211> LENGTH: 26 <212> TYPE: DNA

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 1

catgttctaa tatagtcaca ttttca

<210> SEQ ID NO 2

<211> LENGTH: 24 <212> TYPE: DNA

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 2

tctgaattag ctgtatcgtc aagg

<210> SEQ ID NO 3

<211> LENGTH: 20 <212> TYPE: DNA

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 3

tagctgtatc gtcaaggcac

<210> SEQ ID NO 4

<211> LENGTH: 27 <212> TYPE: DNA

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 4

cacgggcctg ctgaaaatga ctgcgtg

<210> SEO ID NO 5 <211> LENGTH: 24

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 5

<212> TYPE: DNA

-continued

cacgggagct ggtggcgta	g cgtg	24
<210> SEQ ID NO 6 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: homo	sapiens	
<400> SEQUENCE: 6		
cattattttt attataagg	c ctgc	24
33	,	
<210> SEQ ID NO 7 <211> LENGTH: 12 <212> TYPE: DNA <213> ORGANISM: homo	sapiens	
<400> SEQUENCE: 7		
gctggtggcg ta		12
<pre><210> SEQ ID NO 8 <211> LENGTH: 12 <212> TYPE: DNA <213> ORGANISM: homo</pre>	sapiens	
<400> SEQUENCE: 8		
gctagtggcg ta		12
<pre><210> SEQ ID NO 9 <211> LENGTH: 12 <212> TYPE: DNA <213> ORGANISM: homo</pre>	sapiens	
<400> SEQUENCE: 9		
gctggtgacg ta		12
<pre><210> SEQ ID NO 10 <211> LENGTH: 12 <212> TYPE: DNA <213> ORGANISM: homo</pre>	sapiens	
<400> SEQUENCE: 10		
gctcgtggcg ta		12
<pre><210> SEQ ID NO 11 <211> LENGTH: 13 <212> TYPE: DNA <213> ORGANISM: homo</pre>	sapiens	
<400> SEQUENCE: 11		
gcttgtggcc gta		13
<210> SEQ ID NO 12 <211> LENGTH: 13 <212> TYPE: DNA <213> ORGANISM: homo	sapiens	
<400> SEQUENCE: 12		
gctgatgggc gta		13
<pre><210> SEQ ID NO 13 <211> LENGTH: 12 <212> TYPE: DNA <213> ORGANISM: homo</pre>	sapiens	
<400> SEQUENCE: 13		

-continued

gctgatggcg ta	12
<210> SEQ ID NO 14 <211> LENGTH: 12 <212> TYPE: DNA <213> ORGANISM: homo sapiens	
<400> SEQUENCE: 14 gctgctggcg ta	12
<210> SEQ ID NO 15 <211> LENGTH: 12 <212> TYPE: DNA <213> ORGANISM: homo sapiens	
<400> SEQUENCE: 15	
gctggtggtg ta	12

What is claimed is:

- 1. A method for determining the ratio of a selected genetic $_{25}$ sequence in a population of genetic sequences, comprising the steps of:
 - diluting nucleic acid template molecules in a biological sample to form a set comprising a plurality of assay samples;
 - amplifying the template molecules within the assay samples to form a population of amplified molecules in the assay samples of the set;
 - analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples 35 which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence;
 - comparing the first number to the second number to ascertain a ratio which reflects the composition of the 40 biological sample.
- 2. The method of claim 1 wherein the step of diluting is performed until at least one-tenth of the assay samples in the set comprise a number (N) of molecules such that 1/N is larger than the ratio of selected genetic sequences to total 45 employs hybridization to at least one nucleic acid probe. genetic sequences required for the step of analyzing to determine the presence of the selected genetic sequence.
- 3. The method of claim 1 wherein the step of diluting is performed until between 0.1 and 0.9 of the assay samples yield an amplification product when subjected to a polymerase chain reaction.
- 4. The method of claim 1 wherein the step of diluting is performed until all of the assay samples yield an amplification product when subjected to a polymerase chain reac- 55 tion and each assay sample contains less than 10 nucleic acid template molecules containing the reference genetic sequence.
- 5. The method of claim 1 wherein the step of diluting is performed until all of the assay samples yield an amplification product when subjected to a polymerase chain reaction and each assay sample contains less than 100 nucleic acid template molecules containing the reference genetic sequence.
- 6. The method of claim 1 wherein the biological sample is cell-free.

- 7. The method of claim 1 wherein the number of assay samples within the set is greater than 10.
- 8. The method of claim 1 wherein the number of assay samples within the set is greater than 50.
- 9. The method of claim 1 wherein the number of assay samples within the set is greater than 100.
- 10. The method of claim 1 wherein the number of assay samples within the set is greater than 500.
- 11. The method of claim 1 wherein the number of assay samples within the set is greater than 1000.
- 12. The method of claim 1 wherein the step of amplifying and the step of analyzing are performed on assay samples in the same receptacle.
- 13. The method of claim 1 wherein a molecular beacon probe is used in the step of analyzing, wherein a molecular beacon probe is an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end.
- 14. The method of claim 1 wherein the step of analyzing employs gel electrophoresis.
- 15. The method of claim 1 wherein the step of analyzing
- 16. The method of claim 1 wherein the step of analyzing employs hybridization to at least two nucleic acid probe.
- 17. The method of claim 13 wherein two molecular beacon probes are used, each having a different photoluminescent dve.
- 18. The method of claim 13 wherein the molecular beacon probe detects a wild-type selected genetic sequence better than a mutant selected genetic sequence.
- 19. The method of claim 1 wherein the step of amplifying employs a single pair of primers.
- 20. The method of claim 1 wherein the step of amplifying employs a polymerase which is activated only after heating.
- 21. The method of claim 1 wherein the step of amplifying employs at least 40 cycles of heating and cooling.
- 22. The method of claim 1 wherein the step of amplifying employs at least 50 cycles of heating and cooling.
- 23. The method of claim 1 wherein the step of amplifying employs at least 60 cycles of heating and cooling.
- 24. The method of claim 1 wherein the biological sample is selected from the group consisting of stool, blood, and lymph nodes.

- 25. The method of claim 1 wherein the biological sample is blood or bone marrow of a leukemia or lymphoma patient who has received anti-cancer therapy.
- 26. The method of claim 1 wherein the selected genetic sequence is a translocated allele.
- 27. The method of claim 1 wherein the selected genetic sequence is a wild-type allele.
- 28. The method of claim 1 wherein the selected genetic sequence is within an amplicon which is amplified during 10 neoplastic development.
- 29. The method of claim 1 wherein the selected genetic sequence is a rare exon sequence.
- **30**. The method of claim **1** wherein the nucleic acid template molecules comprise cDNA of RNA transcripts and ¹⁵ the selected genetic sequence is present on a cDNA of a first transcript and the reference genetic sequence is present on a cDNA of a second transcript.
- 31. The method of claim 1 wherein the selected genetic sequence comprises a first mutation and the reference genetic sequence comprises a second mutation.
- 32. The method of claim 1 wherein the selected genetic sequence and the reference genetic sequence are on distinct chromosomes.
 - 33. A molecular beacon probe comprising:
 - an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 16 base pairs, wherein the loop has a T_m of 50–51° C. and the stem consists of 4 base pairs having a sequence 5'-CACG-3'.
- **34**. The probe of claim **33** wherein the molecular beacon probe detects a wild-type selected genetic sequence better than a mutant selected genetic sequence.
- **35**. The probe of claim **33** wherein the molecular beacon probe detects a mutant genetic sequence better than a wild-type genetic sequence.
 - **36**. A molecular beacon probe comprising:
 - an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 19-20 base pairs, wherein the loop has a T_m of $54-56^\circ$ C. and the stem consists of 4 base pairs having a sequence 5'-CACG-3'.
 - 37. A pair of molecular beacon probes comprising:
 - a first molecular beacon probe which is an oligonucleotide with a stem-loop structure having a first photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 16 base pairs having a T_m of 50–51° C. and the stem consists of 4 base pairs having a sequence 5'-CACG-3'; and
 - a second molecular beacon probe which is an oligonucleotide with a stem-loop structure having a second photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 19–20 base pairs having a T_m of $54-56^{\circ}$ C. and the stem consists of 4 base pairs having a sequence 5'-CACG-3';
 - wherein the first and the second photoluminescent dyes are distinct.
- **38**. A method for determining the ratio of a selected ₆₅ genetic sequence in a population of genetic sequences, comprising the steps of:

- amplifying template molecules within a set comprising a plurality of assay samples to form a population of amplified molecules in each of the assay samples of the set;
- analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence, wherein at least one-fiftieth of the assay samples in the set comprise a number (N) of molecules such that 1/N is larger than the ratio of selected genetic sequences to total genetic sequences required to determine the presence of the selected genetic sequence; comparing the first number to the second number to ascertain a ratio which reflects the composition of the biological sample.
- **39**. The method of claim **38** wherein the number of assay samples within the set is greater than 10.
- **40**. The method of claim **38** wherein the number of assay samples within the set is greater than 50.
- **41**. The method of claim **38** wherein the number of assay samples within the set is greater than 100.
- **42**. The method of claim **38** wherein the number of assay samples within the set is greater than 500.
- **43**. The method of claim **38** wherein the number of assay samples within the set is greater than 1000.
- 44. The method of claim 38 wherein the step of amplifying and the step of analyzing are performed on assay samples in the same receptacle.
- 45. The method of claim 38 wherein a molecular beacon probe is used in the step of analyzing, wherein a molecular beacon probe is an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end.
- **46**. The method of claim **38** wherein the step of analyzing 40 employs gel electrophoresis.
 - 47. The method of claim 38 wherein the step of analyzing employs hybridization to at least one nucleic acid probe.
 - **48**. The method of claim **38** wherein the step of analyzing employs hybridization to at least two nucleic acid probe.
 - **49**. The method of claim **45** wherein two molecular beacon probes are used, each having a different photoluminescent dve.
 - **50**. The method of claim **45** wherein the molecular beacon probe detects a wild-type selected genetic sequence better than a mutant selected genetic sequence.
 - 51. The method of claim 38 wherein the step of amplifying employs a single pair of primers.
 - **52**. The method of claim **38** wherein the step of amplifying employs a polymerase which is activated only after heating.
 - 53. The method of claim 38 wherein the step of amplifying employs at least 40 cycles of heating and cooling.
 - **54**. The method of claim **38** wherein the step of amplifying employs at least 50 cycles of heating and cooling.
 - 55. The method of claim 38 wherein the step of amplifying employs at least 60 cycles of heating and cooling.
 - 56. The method of claim 38 wherein the template molecules are obtained from a body sample selected from the group consisting of stool, blood, and lymph nodes.

- 57. The method of claim 38 wherein the template molecules are obtained from a body sample of a leukemia or lymphoma patient who has received anti-cancer therapy, said body sample being selected from the group consisting of blood and bone marrow.
- **58**. The method of claim **38** wherein the selected genetic sequence is a translocated allele.
- **59**. The method of claim **38** wherein the selected genetic sequence is a wild-type allele.
- **60**. The method of claim **38** wherein the selected genetic sequence is within an amplicon which is amplified during neoplastic development.
- **61**. The method of claim **38** wherein the selected genetic sequence is a rare exon sequence.


22

- 62. The method of claim 38 wherein the nucleic acid template molecules comprise cDNA of RNA transcripts and the selected genetic sequence is present on a cDNA of a first transcript and the reference genetic sequence is present on a cDNA of a second transcript.
- 63. The method of claim 38 wherein the selected genetic sequence comprises a first mutation and the reference genetic sequence comprises a second mutation.
- **64.** The method of claim **38** wherein the selected genetic sequence and the reference genetic sequence are on distinct chromosomes.

* * * * *

EXHIBIT 3

	1.	_	_
	912	Subclass	JE CLASSIFICATION
	585	Classa	ISSUE CLA
· - ·		a	<u>٧</u>





					·· r		;	हा दुवस र १५४४
	APPLICATION NO. 09/613826	CONTIPRIOR	CLASS 435	SUBCLASS	ART UNIT	EKAMINER	74907	
	09/812026	J .		8912	10%	2 agrees		
,	p Bart Vogels Kanneth Kir J	stein nzler	ŧ		1657		. :	, , , , , , , , , , , , , , , , , , ,
age ,	Digital amp	olificati	ion	•				
, k-1	2		,			٠.	,	PTO-2040 12/99

ISSUING CLASSIFICATION								
· ORIGINAL	+		CROSS REFERENCE(S)					
CLASS S	UBCLASS	CLASS	şui	CLASS (O	NE SUBCI	ASS PER	BLOCK)	
435	11.2	.:435	6	7.1	911		,	
INTERNATIONAL CLA	INTERNATIONAL CLASSIFICATION		22.(23.1	છા, ઉ	24.31	24.32	24.33
C12P 19/34	1					ľ		
C(120 1/6°	3							The same of the sa
CO 7 H 21/0:	,	.						
CO7H 21/0	1					<u></u>		
CO7 H 19/0	Ö	1		1	_l Continued	on Issue Slip	Inside File J	acket

	•	~							
TERMINAL	•	DRAWINGS		CLAIMS ALLOWED					
LIDISCLAIMER	Sheets Drwg.	Fige. Drwg.	Print Fig.	Total Claims	Print Claim for O.G.				
	1 7	17	NONE	64	1				
The term of this patent				NOTICE OF ALL	OWANCE MAILED				
subsequent to (date) . has been disclaimed.	(Assistant)	Examiner)	(Dale)	JJ i n	f) a				
The term of this patent shall		•	į	Harch 2	(a) (a) (b) (b) (b) (c) (c) (c) (d) (d) (d) (d) (d) (d) (d) (d) (d) (d				
not extend beyond the expiration date of U.S Patent. No.			•		UE FEE (W				
	700	0	-1 i	Amount Dus	Date Paid				
	Vettle (Primary E	4 Siew	3/19/02	104000	5-21-02				
The terminal months of	MALL		alanka	: ISSUE BA	TCH NUMBER				
this patent have been discialmed.	ACCOMPANION OF	(Edition)	3/200	489	3				
WARNING:	.			•	٠				
The Information disclosed herein may be re- Possession outside the U.S. Petent & Trada	The information disclosed hersin may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title 35, Sections 122, 161 and 366. Possession outside the U.S. Patem & Tradament Office is restricted to authorized employees and contractors only.								
Form PTO-438A (Rev. 6/99)			FILED WITH	The fall of the same of the sa	FICHE CD-ROM				
1551	JE BLE IN	FILE	.63		Attached in pocket on right inside Rep				

Formed Breakings (___shis) and (FACE)

-i .

0% 13826

09/613826

Bruful MOD INITIALS

CONTENTS

	Date Réceived (incl. C. of M.)	•	Date Received (Incl. C. of M.)
	or Date Malfed	1	Deta Maked
1. Applicationpapers.	· ·	42	
2/chie Filing Claim, Dec miss	ing 10-31:10	43,	
3. Dec	03-11-01	44	
a TDS	12-15-00	48	
5. TDS	3-201	46	
6. (ex(3741)	4-12-014	47	
7. 105	7/12/01	46	
a Cente a les libres de	V. 7/12/01	49.	* *
2 Supple. Distant & the	et oikibi	50	
in Goral Rills	01/20/01/9/20		
e RSI	Maylal 900	52.	
12 RSL	9-25-01	53.	
13. Amdt B NE	12-06-01	54.	
12 Adulary actin	·	² -55	
708	1/2/12		
15. Exol-line (2)	2/20/02	56.	
Another files	2/20/02	57	•
16. Interview Summary	3402	58	y
	31102	59	· · · · · · · · · · · · · · · · · · ·
19. RAW SEQ LISTING		60	
20. Interview Summary		61.	
21. Notice of Allowability	3/24/02	, 62. <u> </u>	
22 Dupp Notice of Allows	Flavior	63.	
23. Johnal Wawing	5/21/02	64.	-
24. Ltr Ke Vrawings	1/15/02	65	
25. Formal Drawings (2_shts) 686	7-8-02	66	
26.		67	<u> </u>
27	 	68	
28		69	
20.	,	70	
30.		71	
31		72	
32		73	t,
33. <u>`</u>		74	·
34		75	
35		. 76	<u> </u>
38		77	·
37		78	
38.		79	
39.		80	í
40.			
41.)		82.	
of 1224	(LEFT O		
	/· · · · ·	<i>-</i> ,	

SEARCHED Exmr. Date Sub. Class 4/7/01 Ø 6 435 7.1 91.1 91.2 221 536 23,1 и.3 24.32 24.33 M 9/20/01 (peleta) <u>√√</u> 3/19/02 plated

INTERFERENCE SEARCHED								
Cass	Sub.	Date	Exmr.					
435	6	3/19/02	83					
536	7.1 91.1 91.2 22.1 23.1 24.3-33							

SEARCH NOTES (INCLUDING SEARCH STRATEGY)

(HACTORHAG OFUL	1001 0 . 1		
EAST ALIPB	Date	Exmr.	
STN CAPUS, MEQUAE CANCERLIT, BIOGLS	4/1/01	SH	
CANCERLITIBLE			
SMD			
Reference			
toget single moleculo			
molecula la beccar			
bop hanpin Hem			
1 4			
melting temperate	<u> </u>	1 3	
uptatiel	9/20/01	8	١
politat	3/18/02	27	١
			١
		, 	١
			-
		, [
.)			•
		,	
		,	
1	- 1		

J.

ISSUE SLIP STAPLE AREA (for additional cross references)

POSITION	INITIALS	ID NO.	DATE
FEE DETERMINATION ,	M	· 63480	2/2010
O.I.P.E. CLASSIFIER	PH		7/22
FORMALITY REVIEW	As	551	8-29-00
RESPONSE FORMALITY REVIEW	"为	973	03-22-01

INDEX OF CLAIMS

		¥ /	
Gran Control	Rojected	- N	Non-elected
	Allowed	1	Interference
	(Through numeral) Canceled	Α	Appeal
•	Restricted		Objected

					D-1-	·	District		Date		
Claim	Date	Claim	1	ST	Data	\neg	Claim		Date	TT	-
Final Conginal Congina Conginal Conginal Conginal Congina Congina Congina Congina Co		21 Original	4 5/5/2 A	3300			Final				
E Q 01 V 0	¥		1 VI V.					 	╂╌╂╌┼	++	+
100 3		61 51		50	\dashv		101	 	-1		4-1
1 - 1 - 1 1 1 1	 	5352 5353						┞┼┼	$\vdash \vdash \vdash$	┵╂	4-1
3 3		63,53	1 11 1		\dashv		103	\Box	╎ ╶┤╧┼	╌╁╌	4.
4 4	 	54 54					105	++-	╂╼┼╌┼		+-
6 6	11111	55 55				- - - 	106	-++	 	+	++1
6 6	╇┋┋	56 56		H - I			107	╂╫╂	╂╼╂╾╂		┽╢
7 7	╎╎╸ ┼╾┼╾┼╸	57 57 38 58					108	 	╂┷┼╌┼	-1-⊹	++
g 8 1				╂╂╾┤			109	┼╌┼╌┾╌	┞╌╁╼┼	1	+
9 9	 	<u>හි</u> 59					110	╂╼╂╼	╂╌╏╌╏	-	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$
(O) 10		4 (5) 60 6) 61		-			111	╂╼╂╌╏	╂╾┼╌╂	╌╂╌┼╴	
11 11	╎ ╏┼┼┼╀╌┼╌┞╸	43 62		H			112	 	╂╼╁╌╂		
12 12	╄┼╄╂╇┼╸	23 63 23 63		-	\dashv	-; - - - 	113	 	┼╼╂╌┟		+
13 13	╀┼┼┼	6464	TIMES		├╌╂╌┤		114	╁╌╁╼┼╌	╁╾╁╌╂		$\dashv\dashv$
14 14	╽╸ ┤╶┼╌╀╌┼╌	- 10 A 200	1.1	-	\vdash		115	+++	 	- - -	+1
15 15 1 1 1 1 1 1 1 1	╫╫╫╫		41	-	HH	╼╁╼╁═┨	116	╎╎ ┼┼	╁╌┼╾╂	11	ᅦ
16 18 17 17 17 17 17 17 17 17 17 17 17 17 17	╅╂╅┪		# + #	┢═┼═	\vdash	- - - - ,	1177		+++	.	$\dashv \dashv$
18 18	┼┼┼┼┼		1 1			- - - - 	118		HH		$\neg \neg$
19 19 1	╎┩╸╽╶╏ ╶┪═╏╸		5 10	H^{-}		111	119				\sqcap
	╎ ┥╴╂╾╏╼╏╸╏╌	70		\vdash		1111	120			$\neg \vdash \vdash$	
	╟┼┼┼┼┼	H H		 	\vdash		121	1	+		- -
	╟╶╎╸╏╶╏╸╏	1 72		╁┼	- -		122	1-1-1-	1 1 1	\dashv	$\dashv \dashv$
33 22 1 33 23 1	╟╫╫╫	7					123		1 1	\top	+
CHI CHI THE	╟╸╎╶╏╶╏╸╏╸╏╸	H 7		++			124	 	+	\neg	\top
25 25	╟╶┞┈╎┈ ┼┈┼┈┤┈	- -	_ 1 _	+			125		\Box		\Box
137122 1 1 12 -	╟╫╌╂╌╂═┼╌╂╌╁╌	1 170	6		\sqcap		126				77
27 27	╎╎╶╎╸ ┤ ┈ ┼	7.	7				127				
28 28 31 31 32 32		70		\sqcap			128				
		70	9				129				
3/13/11		8					130	<u> </u>	$\bot \bot$		\perp
8/31		8					131			-	
32 32		8:					132				-
33 33 P		<u> 8</u> :					133	1 4 4	1	-	_
34 34		8		↓↓	\Box		134	++	+++		_
3333 7 3434 8 3435 3439 3539	$H \rightarrow + + + + + + + + + + + + + + + + + + $	8		╀-	 	┝┼┼┼┤	135 136	+++			- -
364 369	 	8		+	- -	┡╌┼╌╂╌┦	137	╂╌╂╌├╌	+	 	- -
30 (S)	 	8		╁╁╌	╁╌├╌	 - - - 	136	╂═╂╌╁╌	+	┝┼┤	
32(39)	$\frac{11}{11}$	8		╁╇╌	┼┼	++++	139	╁┼┼	+	$\vdash \vdash \vdash$	- -
D4(139)]	╫┼╀╇╀╋	- 9		+	-	┝ ╌┼ ╗ ┟┤	140	┼┼┼	╁┼	$\vdash \vdash \vdash$	_
40 40	╫┼┼┼			+	\vdash	┢┪╼┋┨╌╢	140	++-	+	┞╌╂╌┦	-
44 41	+	В		++	 -	╒ ╌┼╌┼╌┦	142	╀╌┼╌	+	┝┼╌	╟┼
40 42	 	9		+-	 		142	╁┼┼	+		
13 43	++++			++-		┣ ╍╂╼╂═╂	144	 	++-	-	
W4 44 1	╫┼┼┼┼		4		┼-	┠╸╏╸ ┼╌┤	145	+++	+	┝┼┤	\dashv
345 45 L	╫┵┼┼┼			+-	┼-├-	╏╸╏╶╿╶	146	+++	++-	$\vdash \vdash \vdash$	
46 46	H + + + +		6	╂┼	╁╌╁╌	 - - - 	147	- - -	+-	$\vdash\vdash\vdash$	
47 47	╢┊╎┤┤ ┼			- -}-	┼┼╴	H = H = H	148	+++	1	┝╌┼╌┨	+
18 48 19 49	╫┼┼┼┼	l 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	9	 - -	┼┼	┡╸╏╸╏ ╶╏╼┩	149	╅╂╂	+	┝┤┷┥	7
149 50 50 (12)	┋ ┼┼┼┼┼		00	++	++	┼┼┼┼┼	150	+++	+-		-
50 50 (12)		ىلال لىل	<u> </u>				1,00		سلساب	لسيهتمسا	

If more than 150 claims or 10 actions staple additional sheet here



 \parallel

United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE
YES AND TRADEMARK OFFICE
YES AND TRADEMARK OFFICE
WWW.uspic.gov

CONFIRMATION NO. 9893

Bib Data Sheet

Verified and Acknowledged ADDRESS 22907

ATTORNEY FILING DATE **GROUP ART UNIT** CLASS SERIAL NUMBER DOCKET NO. 07/11/2000 1632 09/613,826 435 01107.00031 RULE APPLICANTS Berl Vogelstein, Baltimore, MD; Kenneth W. Kinzler, BelAir, MD; CONTINUING DATA THIS APPLN CLAIMS BENEFIT OF 60/146,792 08/02/1999 ** FOREIGN APPLICATIONS ****************** IF REQUIRED, FOREIGN FILING LICENSE ** SMALL ENTITY ** GRANTED ** 08/29/2000 TOTAL INDEPENDENT STATE OR SHEETS 35 USC 119 (a-d) conditions met CLAIMS CLAIMS DRAWING COUNTRY 5 MD 64

TITLE Digital amplification

'IG FEE EIVED 696	FEES: Authority has been given in Paper Noto charge/credit DEPOSIT ACCOUNT Nofor following:
EIVED	Noto charge/credit DEPOSIT ACCOUNT

- All Legs	_
1.16 Fees (Filing)	_
1.17 Fees (Processing Ext. of ime)	
and)	-
1.18 Fees (Issue)	

Other Credit



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OPPICE
WASHINGTON, D.C. 20231
WASHINGTON, D.C. 20231

BIBDATASHEET

CONFIRMATION NO. 9893

BID DE GOT				rannoko reneka kumu viili (1866-1866)	·
SERIAL NUMBE 09/613,826	FILING DATE 07/11/2000 RULE	CLASS 435	GROUP ART 1637	UNII	ATTORNEY DOCKET NO. 01107.00031
APPLICANTS				and the second s	
Bert Vogelstein, B	altimore, MD;				* /
Kenneth W. Kinzie	er, BelAir, MD;				
THIS APPLN CLA	DATA ***********************************	792 08/02/1999			
IF REQUIRED, FO ** 08/29/2000	DREIGN FILING LICENSE	GRANTED ** SMALL	ENTITY **		
Foreign Priority claimed 35 USC 119 (a-d) cond	-	STATE OR	SHEETS	TOTAL	INDEPENDENT
met Verified and Acknowledged	Allowance	COUNTRY MD	DRAWING 7	CLAIMS 64	CLAIMS 5
ADDRESS 22907 BANNER & WITCH 1001 G STREET N SUITE 1100 WASHINGTON, I 20001 TITLE Digital a nplificatio	NW DC				
			Q All F	ees	
				Fees (Filin	
FILING FEE FEES: Authority has been given in Paper No to charge/credit DEPOSIT ACCOUNT 1.17 Fees (Processing Ext. of time)					
RECEIVED Nofor following: Q 1.18 Fees (Iss				Fees (Issu	e)

1 of 2

3/21/02 7:00 AM

5

10

DIGITAL AMPLIFICATION

ABSTRACT

The identification of pre-defined mutations expected to be present in a minor fraction of a cell population is important for a variety of basic research and clinical applications. The exponential, analog nature of the polymerase chain reaction is transformed into a linear, digital signal suitable for this purpose. Single molecules can be isolated by dilution and individually amplified; each product is then separately analyzed for the presence of mutations. The process provides a reliable and quantitative measure of the proportion of variant sequences within a DNA sample.

10

15

20

DIGITAL AMPLIFICATION

This application claims the benefit of U.S. Serial No. 60/146,792, filed August 2, 1999.

The U.S. government retains certain rights in this invention by virtue of its support of the underlying research, supported by grants CA 43460, CA 57345, and CA 62924 from the National Institutes of Health.

TECHNICAL FIELD OF THE INVENTION

This invention is related to diagnostic genetic analyses. In particular it relates to detection of genetic changes and gene expression.

BACKGROUND OF THE INVENTION

In classical genetics, only mutations of the germ-line were considered important for understanding disease. With the realization that somatic mutations are the primary cause of cancer (1), and may also play a role in aging (2,3), new genetic principles have arisen. These discoveries have provided a wealth of new opportunities for patient management as well as for basic research into the pathogenesis of neoplasia. However, many of these opportunities hinge upon detection of a small number of mutant-containing cells among a large excess of normal cells. Examples include the detection of neoplastic cells in urine (4), stool (5,6), and sputum (7,8) of patients with cancers of the bladder, colorectum, and lung, respectively. Such detection has been shown in some cases to be possible at a stage when the primary tumors are still curable and the patients asymptomatic. Mutant sequences from the DNA of neoplastic cells have also been found in the blood of cancer patients (9-11). The detection of residual disease in lymph nodes or surgical margins



10

15

20

25

30

may be useful in predicting which patients might benefit most from further therapy (12-14). From a basic research standpoint, analysis of the early effects of carcinogens is often dependent on the ability to detect small populations of mutant cells (15-17).

Because of the importance of this issue in so many settings, many useful techniques have been developed for the detection of mutations. DNA sequencing is the gold standard for the detection of germ line mutations, but is useful only when the fraction of mutated alleles is greater than ~20% (18,19). Mutant-specific oligonucleotides can sometimes be used to detect mutations present in a minor proportion of the cells analyzed, but the signal to noise ratio distinguishing mutant and wild-type (WT) templates is variable (20-22). The use of mutant-specific primers or the digestion of polymerase chain reaction (PCR) products with specific restriction endonucleases are extremely sensitive methods for detecting such mutations, but it is difficult to quantitate the fraction of mutant molecules in the starting population with these techniques (23-28). Other innovative approaches for the detection of somatic mutations have been reviewed (29-32). A general problem with these methods is that it is difficult or impossible to independently confirm the existence of any mutations that are identified.

Thus there is a need in the art for methods for accurately and quantitatively detecting genetic sequences in mixed populations of sequences.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide methods for determining the presence of a selected genetic sequence in a population of genetic sequences.

It is another object of the present invention to provide molecular beacon probes useful in the method of the invention.

These and other objects of the invention are achieved by providing a method for determining the presence of a selected genetic sequence in a population of genetic sequences. A biological sample comprising nucleic acid template molecules is diluted to form a set of assay samples. The template molecules within the assay samples are amplified to form a population of

1)-

10

15

20

25

30

amplified molecules in the assay samples of the set. The amplified molecules in the assay samples of the set are then analyzed to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence. The first number is then compared to the second number to ascertain a ratio which reflects the composition of the biological sample.

Another embodiment of the invention is a method for determining the ratio of a selected genetic sequence in a population of genetic sequences. Template molecules within a set comprising a plurality of assay samples are amplified to form a population of amplified molecules in each of the assay samples of the set. The amplified molecules in the assay samples of the set are analyzed to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence. The first number is compared to the second number to ascertain a ratio which reflects the composition of the biological sample.

According to another embodiment of the invention, a molecular beacon probe is provided. It comprises an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end. The loop consists of 16 base pairs and has a $T_{\rm m}$ of 50-51°C. The stem consists of 4 base pairs having a sequence 5'-CACG-3'.

A second type of molecular beacon probe is provided in another embodiment. It comprises an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end. The loop consists of 19-20 base pairs and has a T_m of 54-56°C. The stem consists of 4 base pairs having a sequence 5'-CACG-3'.

Another embodiment provides the two types of molecular beacon probes, either mixed together or provided in a divided container as a kit.

d

10

15

25

30

The invention thus provides the art with the means to obtain quantitative assessments of particular DNA or RNA sequences in mixed populations of sequences using digital (binary) signals.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Schematic of experimental design. (A) The basic two steps involved: PCR on diluted DNA samples is followed by addition of fluorescent probes which discriminate between WT and mutant alleles and subsequent fluorometry. (B) Principle of molecular beacon analysis. In the stem-loop configuration, fluorescence from a dye at the 5' end of the oligonucleotide probe is quenched by a Nabcyl group at the 3' end. Upon hybridization to a template, the dye is separated from the quencher, resulting in increased fluorescence. Modified from Marras et al. . (C) Oligonucleotide design. Primers F1 and R1 are used to amplify the genomic region of interest. Primer INT is used to produce single stranded DNA from the original PCR products during a subsequent asymmetric PCR step (see Materials and Methods). MB-RED is a Molecular Beacon which detects any appropriate PCR product, whether it is WT or mutant at the queried codons. MB-GREEN is a

Fig. 2. Discrimination between WT and mutant PCR products by Molecular Ten separate PCR products, each generated from ~50 genome equivalents of DNA of cells containing the indicated mutations of c-Ki-Ras, were analyzed with the Molecular Beacon probes described in the text. Representative examples of the PCR products used for Molecular Beacon analysis were purified and directly sequenced. In the cases with Gly12Cys and Gly12Arg mutations, contaminating non-neoplastic cells within the tumor presumably accounted for the relatively low ratios. In the cases with Gly12Ser and Gly12Asp, there were apparently two or more alleles of mutant c-Ki-Ras for every WT allele; both these tumors were aneuploid.

Molecular Beacon which preferentially detects the WT PCR product.

Fig. 3. Detecting Dig-PCR products with MB-RED. Specific Fluorescence /Units of representative wells from an experiment employing colorectal cancer

Page 42 of 1224

15

20

25

cells with Gly12Asp or Gly13Asp mutations of the *c-Ki-Ras* gene. Wells with values >10,000 are shaded yellow. Polyacrylamide gel electrophoretic analyses of the PCR products from selected wells are shown. Wells with fluorescence values <3500 had no PCR product of the correct size while wells with fluorescence values >10,000 SFU always contained PCR products of 129 bp. Non-specific products generated during the large number of cycles required for Dig-PCR did not affect the fluorescence analysis. M1 and M2 are molecular weight markers used to determine the size of fragments indicated on the left (in base pairs).

FIG. 4. Discriminating WT from mutant PCR products obtained in Dig-PCR. RED/GREEN ratios were determined from the fluorescence of MB-RED and MB-GREEN as described in Materials and Methods. The wells shown are the same as those illustrated in Fig. 3. The sequences of PCR products from the indicated wells were determined as described in Materials and Methods. The wells with RED/GREEN ratios >3.0 each contained mutant sequences while those with RED/GREEN ratios of ~1.0 contained WT sequences.

EIG. 5. Dig-PCR of DNA from a stool sample. The 384 wells used in the experiment are displayed. Those colored blue contained 25 genome equivalents of DNA from normal cells. Each of these registered positive with MB-RED and the RED/GREEN ratios were 1.0 +/- 0.1 (mean +/- 1 standard deviation). The wells colored yellow contained no template DNA and each was negative with MB-RED (i.e., fluorescence <3500 fluorescence units.). The other 288 wells contained diluted DNA from the stool sample prepared by alkaline extraction. (Rubeck et al., 1998, BioTechniques 25:588-592.) Those registering as positive with MB-RED were colored either red or green, depending on their RED/GREEN ratios. Those registering negative with MB-RED were colored white. PCR products from the indicated wells were used for automated sequence analysis.

DETAILED DESCRIPTION OF THE INVENTION

The method devised by the present inventors involves separately amplifying small numbers of template molecules so that the resultant products have a proportion of the analyte sequence which is detectable by the detection means chosen. At its limit, single template molecules can be amplified so that the products are completely mutant or completely wild-type (WT). The homogeneity of these amplification products makes them trivial to distinguish through existing techniques.

The method requires analyzing a large number of amplified products simply and reliably. Techniques for such assessments were developed, with the output providing a digital readout of the fraction of mutant alleles in the analyzed population.

The biological sample is diluted to a point at which a practically usable number of the diluted samples contain a proportion of the selected genetic sequence (analyte) relative to total template molecules such that the analyzing technique being used can detect the analyte. A practically usable number of diluted samples will depend on cost of the analysis method. Typically it would be desirable that at least 1/50 of the diluted samples have a detectable proportion of analyte. At least 1/10, 1/5, 3/10, 2/5, 1/2, 3/5, 7/10, 4/5, or 9/10 of the diluted samples may have a detectable proportion of analyte. The higher the fraction of samples which will provide useful information, the more economical will be the overall assay. Over-dilution will also lead to a loss of economy, as many samples will be analyzed and provide no signal. A particularly preferred degree of dilution is to a point where each of the assay samples has on average one-half of a template. The dilution can be performed from more concentrated samples. Alternatively, dilute sources of template nucleic acids can be used. All of the samples may contain amplifable template molecules. Desirably each assay sample prior to amplification will contain less than a hundred or less than ten template molecules.

Digital amplification can be used to detect mutations present at relatively low levels in the samples to be analyzed. The limit of detection is defined by the number of wells that can be analyzed and the intrinsic mutation rate of the polymerase used for amplification. 384 well PCR plates are

gh,

25

5 .

10

15

20

10

15

20

25

30

commercially available and 1536 well plates are on the horizon, theoretically allowing sensitivities for mutation detection at the ~0.1% level. It is also possible that Digital Amplification can be performed in microarray format, potentially increasing the sensitivity by another order of magnitude. This sensitivity may ultimately be limited by polymerase errors. The effective error rate in PCR as performed under our conditions was <0.3%, i.e., in control experiments with DNA from normal cells, none of 340 wells containing PCR products exhibited RED/GREEN ratios >3.0. Any individual mutation (such as a G- to C- transversion at the second position of codon 12 of c-Ki-ras) is expected to occur in <1 in 50 polymerase-generated mutants (there are at least 50 base substitutions within or surrounding codons 12 and 13 that should yield high RED/GREEN ratios). Determining the sequence of the putative mutants in the positive wells, by direct sequencing as performed here or by any of the other techniques, provides unequivocal validation of a prospective mutation: a significant fraction of the mutations found in individual wells should be identical if the mutation occurred in vivo. Significance can be established through rigorous statistical analysis, as positive signals should be distributed according to Poisson probabilities. Moreover, the error rate in particular Digital Amplification experiments can be precisely determined through performance of Digital Amplification on DNA templates from normal cells.

Digital Amplification is as easily applied to RT-PCR products generated from RNA templates as it is to genomic DNA. For example, the fraction of alternatively spliced or mutant transcripts from a gene can be easily determined using photoluminescent probes specific for each of the PCR products generated. Similarly, Digital Amplification can be used to quantitate relative levels of gene expression within an RNA population. For this amplification, each well would contain primers which are used to amplify a reference transcript expressed constitutively as well as primers specific for the experimental transcript. One photoluminescent probe would then be used to detect PCR products from the reference transcript and a second photoluminescent probe used for the test transcript. The number of wells in

S

10

15

20

25

30

which the test transcript is amplified divided by the number of wells in which the reference transcript is amplified provides a quantitative measure of gene expression. Another group of examples involves the investigations of allelic status when two mutations are observed upon sequence analysis of a standard DNA sample. To distinguish whether one variant is present in each allele (vs. both occurring in one allele), cloning of PCR products is generally performed. The approach described here would simplify the analysis by eliminating the need for cloning. Other potential applications of Digital Amplification are listed in Table 1. When the goal is the quantitation of the proportion of two relatively common alleles or transcripts rather than the detection of rare alleles, techniques such as those employing TaqMan and real time PCR provide an excellent alternative to use of molecular beacons. Advantages of real time PCR methods include their simplicity and the ability to analyze multiple samples simultaneously. However, Digital Amplification may prove useful for these applications when the expected differences are small, (e.g., only ~2-fold, such as occurs with allelic imbalances (55)),

The ultimate utility of Digital Amplification lies in its ability to convert the intrinsically exponential nature of PCR to a linear one. It should thereby prove useful for experiments requiring the investigation of individual alleles, rare variants/mutations, or quantitative analysis of PCR products.

In one preferred embodiment each diluted sample has on average one half a template molecule. This is the same as one half of the diluted samples having one template molecule. This can be empirically determined by amplification. Either the analyte (selected genetic sequence) or the reference genetic sequence can be used for this determination. If the analysis method being used can detect analyte when present at a level of 20%, then one must dilute such that a significant number of diluted assay samples contain more than 20% of analyte. If the analysis method being used requires 100% analyte to detect, then dilution down to the single template molecule level will be required.

To achieve a dilution to approximately a single template molecule level, one can dilute such that between 0.1 and 0.9 of the assay samples yield

()

10

15

20

25

30

an amplification product. More preferably the dilution will be to between 0.1 and 0.6, more preferably to between 0.3 and 0.5 of the assay samples yielding an amplification product.

The digital amplification method requires analysis of a large number of samples to get meaningful results. Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. As in any method, the accuracy of the determination will improve as the number of samples increases, up to a point. Because a large number of samples must be analyzed, it is desirable to reduce the manipulative steps, especially sample transfer steps. Thus it is preferred that the steps of amplifying and analyzing are performed in the same receptacle. This makes the method an *in situ*, or "one-pot" method.

The number of different situations in which the digital amplification method will find application is large. Some of these are listed in Table 1. As shown in the examples, the method can be used to find a tumor mutation in a population of cells which is not purely tumor cells. As described in the examples, a probe for a particular mutation need not be used, but diminution in binding to a wild-type probe can be used as an indicator of the presence of one or more mutations. Chromosomal translocations which are characteristic of leukemias or lymphomas can be detected as a measure of the efficacy of therapy. Gene amplifications are characteristic of certain disease states. These can be measured using digital amplification. Alternatively spliced forms of a transcript can be detected and quantitated relative to other forms of the transcript using digital amplification on cDNA made from mRNA. Similarly, using cDNA made from mRNA one can determine relative levels of transcription of two different genes. One can use digital amplification to distinguish between a situation where one allele carries two mutations and one mutation is carried on each of two alleles in an individual. Allelic imbalances often result from a disease state. These can be detected using digital amplification.

Q

Biological samples which can be used as the starting material for the analyses may be from any tissue or body sample from which DNA or mRNA can be isolated. Preferred sources include stool, blood, and lymph nodes. Preferably the biological sample is a cell-free lysate.

¥ .

	Table 1. Potential Applications of Dig-PCR	us of Dig-PCR	
Application	Ехапріе	Probe 1 Detects:	Probe 2 Detects:
Base substitution	Cancer gene mutations in stool, blood, lymph	mutant or WT alleles	WT PCR products
mutations	nodes		
Chromosomal	Residual leukemia cells after therapy (DNA or	normal or translocated	translocated allele
translocations	RNA)	alleles	
Gene amplifications	Determine presence or extent of amplification	sequence within amplicon	sequence from another part of
			same chromosome arm
Alternatively spliced	Determine fraction of alternatively spliced	minor exons	ccomon exons
products	transcripts from same gene (RNA)		
Changes in gene	Determine relative levels of expression of two	first transcript	reference transcript
expression	genes (RNA)		
Allelic discrimination	Two different alleles mutated vs. one mutation	first mutation	second mutation
	in each of two alleles		
Allelic imbalance	Quantitative analysis with non-polymorphic	marker from test	marker from reference
	markers	спотоготе	ситотоготе

family family

10

15

20

25

30

Molecular beacon probes according to the present invention can utilize any photoluminescent moiety as a detectable moiety. Typically these are dyes. Often these are fluorescent dyes. Photoluminescence is any process in which a material is excited by radiation such as light, is raised to an excited electronic or vibronic state, and subsequently re-emits that excitation energy as a photon of light. Such processes include fluorescence, which denotes emission accompanying descent from an excited state with paired electrons (a "singlet" state) or unpaired electrons (a "triplet" state) to a lower state with the same multiplicity, i.e., a quantum-mechanically "allowed" transition. Photoluminescence also includes phosphorescence which denotes emission accompanying descent from an excited triplet or singlet state to a lower state of different multiplicity, i.e., a quantum mechanically "forbidden" transition. Compared to "allowed" transitions, "forbidden" transitions are associated with relatively longer excited state lifetimes.

The quenching of photoluminescence may be analyzed by a variety of methods which vary primarily in terms of signal transduction. Quenching may be transduced as changes in the intensity of photoluminescence or as changes in the ratio of photoluminescence intensities at two different wavelengths, or as changes in photoluminescence lifetimes, or even as changes in the polarization (anisotropy) of photoluminescence. Skilled practitioners will recognize that instrumentation for the measurement of these varied photoluminescent responses are known. The particular ratiometric methods for the analysis of quenching in the instant examples should not be construed as limiting the invention to any particular form of signal transduction. Ratiometric measurements of photoluminescence intensity can include the measurement of changes in intensity, photoluminescence lifetimes, or even polarization (anisotropy).

Although the working examples demonstrate the use of molecular beacon probes as the means of analysis of the amplified dilution samples. other techniques can be used as well. These include sequencing, get

10

15

20

25

TaqMan[™] (dual-labeled fluorogenic) probes (Perkin Elmer Corp./Applied Biosystems, Foster City, Calif), pyrene-labeled probes, and other biochemical assays.

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention.

EXAMPLE 1

Step 1: PCR amplifications. The optimal conditions for PCR described in this section were determined by varying the parameters described in the Results. PCR was performed in 7 ul volumes in 96 well polypropylene PCR plates (Marsh Biomedical Products, Rochester, NY). composition of the reactions was: 67 mM Tris, pH 8.8, 16.6 mM NH₄SO₄ 6.7 mM MgCl_2 , $10 \text{ mM }\beta$ -mercaptoethanol, 1 mM dATP, 1 mM dCTP, 1mM dGTP, 1 mM TIP, 6% DMSO, 1 uM primer F1, 1 uM primer R1, 0.05 units/ul Platinum Taq polymerase (Life Technologies, Inc.), and "one-half genome equivalent" of DNA. To determine the amount of DNA corresponding to one-half genome equivalent, DNA samples were serially diluted and tested via PCR. The amount that yielded amplification products in half the wells, usually ~1.5 pg of total DNA, was defined as "one-half genome equivalent" and used in each well of subsequent Digital Amplification experiments. Fifty ut light mineral oil (Sigma M-3516) was added to each well and reactions performed in a HybAid Thermal cycler at the following temperatures: denaturation at 94° for one min; 60 cycles of 94° for 15 sec, 55° for 15 sec., 70° for 15 seconds; 70° for five minutes. Reactions were read immediately or stored at room temperature for up to 36 hours before fluorescence analysis.

10

15

20

25

EXAMPLE 2

Step 2: Fluorescence analysis. 3.5 ul of a solution with the following composition was added to each well: 67 mM Tris, pH 8.8, 16.6 mM NH₄SO₄ 6.7 mM MgCl₂, 10 mM β-mercaptoethanol, 1 mM dATP, 1 mM dCTP, 1 mM dGTP, 1 mM TTP, 6% DMSO, 5 uM primer INT, 1 uM MB-GREEN, 1 uM MB-RED, 0.1 units/ul Platinum Taq polymerase. The plates were centrifuged for 20 seconds at 6000 g and fluorescence read at excitation/emission wavelengths of 485 nm/530 nm for MB-GREEN and 530 nm/590 nm for MB-RED. The fluorescence in wells without template was typically 10,000 to 20,000 fluorescence "units", with about 75% emanating from the fluorometer background and the remainder from the MB probes. The plates were then placed in a thermal cycler for asymmetric amplification at the following temperatures: 94° for one minute; 10 - 15 cycles of 94° for 15 sec, 55° for 15 sec., 70° for 15 seconds; 94° for one minute; and 60° for five minutes. The plates were then incubated at room temperature for ten to sixty minutes and fluorescence measured as described above. Specific fluorescence was defined as the difference in fluorescence before and after the asymmetric amplification. RED/GREEN ratios were defined as the specific fluorescence of MB-RED divided by that of MB-GREEN. RED/GREEN ratios were normalized to the ratio exhibited by the positive controls (25 genome equivalents of DNA from normal cells, as defined above in Example 1). We found that the ability of MB probes to discriminate between WT and mutant sequences under our conditions could not be reliably determined from experiments in which they were tested by hybridization to relatively short complementary single stranded oligonucleotides, and that actual PCR products had to be used for validation.

EXAMPLE 3

Oligonucleotides and DNA sequencing. Primer F1:

5'-CATGTTCTAATATAGTCACATTTTCA-3'; Primer R1:

5'-TCTGAATTAGCTGTATCGTCAAGG-3'; Primer INT:

10

15

20

25

5'-TAGCTGTATCGTCAAGGCAC-3'; MB-RED: 5'-Cy3-CACGGGCCTGCTGAAAATGACTGCGTG-Dabcyl-3'; E N R E M В G 5'-Fluorescein-CACGGGAGCTGGTGGCGTAGCGTG-Dabcyl-3'. Molecular Beacons (33,34) were synthesized by Midland Scientific and other oligonucleotides were synthesized by Gene Link (Thornwood, NY). All were dissolved at 50 uM in TE (10 mM Tris, pH 8.0/1 mM EDTA) and kept frozen and in the dark until use. PCR products were purified using QIAquick PCR purification kits (Qiagen). In the relevant experiments described in the text, 20% of the product from single wells was used for gel electrophoresis and 40% was used for each sequencing reaction. The sequencing was primer used for 5'-CATTATTTTTATTATAAGGCCTGC-3'. Sequencing was performed using fluorescently-labeled ABI Big Dye terminators and an ABI 377 automated sequencer.

EXAMPLE 4

Principles underlying experiment. The experiment is outlined in Fig. 1A. First, the DNA is diluted into multiwell plates so that there is, on average, one template molecule per two wells, and PCR is performed. Second, the individual wells are analyzed for the presence of PCR products of mutant and WT sequence using fluorescent probes.

As the PCR products resulting from the amplification of single template molecules should be homogeneous in sequence, a variety of standard techniques could be used to assess their presence. Fluorescent probe-based technologies, which can be performed on the PCR products "in situ" (i.e., in the same wells) are particularly well-suited for this application (31, 33-40). We chose to explore the utility of one such technology, involving Molecular Beacons (MB), for this purpose (33,34). MB probes are oligonucleotides with stem-loop structures that contain a

fluorescent dye at the 5' end and a quenching agent (Dabcyl) at the 3' end (Pig. 1B). The degree of quenching via fluorescence energy resonance transfer is inversely proportional to the 6th power of the distance between the Dabcyl group and the fluorescent dye. After heating and cooling, MB probes reform a stem-loop structure which quenches the fluorescent signal from the dye (41). If a PCR product whose sequence is complementary to the loop sequence is present during the heating/cooling cycle, hybridization of the MB to one strand of the PCR product will increase the distance between the Dabcyl and the dye, resulting in increased fluorescence.

A schematic of the oligonucleotides used for Digital Amplifications

10

5

shown in Fig. 1C. Two unmodified oligonucleotides are used as primers for the PCR reaction. Two MB probes, each labeled with a different fluorophore, are used to detect the PCR products. MB-GREEN has a loop region that is complementary to the portion of the WT PCR product that is queried for mutations. Mutations within the corresponding sequence of the PCR product should significantly impede its hybridization to the MB probe (33,34). MB-RED has a loop region that is complementary to a different portion of the PCR product, one not expected to be mutant. It thus should produce a signal whenever a well contains a PCR product, whether that product is WT or mutant in the region queried by MB-GREEN. Both MB probes are used together to simultaneously detect the presence of a PCR product and its mutational status.

20

15

Practical Considerations. Numerous conditions were optimized to define conditions that could be reproducibly and generally applied. As outlined in Fig. 1A, the first step involves amplification from single template molecules. Most protocols for amplification from small numbers of template molecules use a nesting procedure, wherein a product resulting from one set of primers is used as template in a second reaction employing internal primers. As many applications of digital amplification are expected to require hundreds or thousands of separate amplifications, such

30

10

15

20

25

30

nesting would be inconvenient and could lead to contamination problems. Hence, conditions were sought that would achieve robust amplification without nesting. The most important of these conditions involved the use of a polymerase that was activated only after heating (44,45) and optimized concentrations of dNTP's, primers, buffer components, and temperature. The conditions specified in Examples 1-3 were defined after individually optimizing each of these components and proved suitable for amplification of several different human genomic DNA sequences. Though the time required for PCR was not particularly long (~2.5 hr), the number of cycles used was high and excessive compared to the number of cycles required to amplify the "average" single template molecule. The large cycle number was necessary because the template in some wells might not begin to be amplified until several PCR cycles had been completed. The large number of cycles ensured that every well (not simply the average well) would generate a substantial and roughly equal amount of PCR product if a template molecule were present within it.

The second step in Fig 1A involves the detection of these PCR products. It was necessary to considerably modify the standard MB probe approach in order for it to function efficiently in Digital Amplification applications. Theoretically, one separate MB probe could be used to detect each specific mutation that might occur within the queried sequence. By inclusion of one MB corresponding to WT sequence and another corresponding to mutant sequence, the nature of the PCR product would be revealed. Though this strategy could obviously be used effectively in some situations, it becomes complex when several different mutations are expected to occur within the same queried sequence. For example, in the c-Ki-Ras gene example explored here, twelve different base substitutions resulting in missense mutations could theoretically occur within codons 12 and 13, and at least seven of these are observed in naturally-occurring human cancers. To detect all twelve mutations as well as the WT sequence with individual Molecular Beacons would require 13 different probes. Inclusion of such a large number of MB probes would raise the background

10

15

20

25

30

fluorescence and cost of the assay. We therefore attempted to develop a single probe that would react with WT sequences better than any mutant sequence within the queried sequence. We found that the length of the loop sequence, its melting temperature, and the length and sequence of the stem were each important in determining the efficacy of such probes. Loops ranging from 14 to 26 bases and stems ranging from 4 to 6 bases, as well as numerous sequence variations of both stems and loops, were tested during the optimization procedure. For discrimination between WT and mutant sequences (MB-GREEN probe), we found that a 16 base pair loop, of melting temperature (Tm) 50-51°, and a 4 bp stem, of sequence 5'-CACG-3', were optimal. For MB-RED probes, the same stem, with a 19-20 bp loop of Tm 54-56°, proved optimal. The differences in the loop sizes and melting temperatures between MB-GREEN and MB-RED probes reflected the fact that only the GREEN probe is designed to discriminate between closely related sequences, with a shorter region of homology facilitating such discrimination.

Examples of the ratios obtained in replicate wells containing DNA templates from colorectal tumor cells with mutations of c-Ki-Ras are shown in Fig. 2. In this experiment, fifty genome equivalents of DNA were added to each well prior to amplification. Each of six tested mutants yielded ratios of RED/GREEN fluorescence that were significantly in excess of the ratio obtained with DNA from normal cells (1.5 to 3.4 in the mutants compared to 1.0 in normal DNA; p < 0.0001 in each case, Student's t-Test). The reproducibility of the ratios can be observed in this figure. Direct DNA sequencing of the PCR products used for fluorescence analysis showed that the RED/GREEN ratios were dependent on the relative fraction of mutant genes within the template population (Fig. 2). Thus, the DNA from cells containing one mutant c-Ki-Ras allele per every two WT c-Ki-Ras allele yielded a RED/GREEN ratio of 1.5 (Gly12Arg mutation) while the cells containing three mutant c-Ki-Ras alleles per WT allele exhibited a ratio of 3.4 (Gly12Asp). These data suggested that wells

containing only mutant alleles (no WT) would yield ratios in excess of 3.0, with the exact value dependent on the specific mutation.

Though this mode is the most convenient for many applications, we found it useful to add the MB probes after the PCR-amplification was complete (Fig. 1). This allowed us to use a standard multiwell plate fluorometer to sequentially analyze a large number of multiwell plates containing pre-formed PCR products and bypassed the requirement for multiple real time PCR instruments. Additionally, we found that the fluorescent signals obtained could be considerably enhanced if several cycles of asymmetric, linear amplification were performed in the presence of the MB probes. Asymmetric amplification was achieved by including an excess of a single internal primer (primer INT in Fig. 1C) at the time of addition of the MB probes.

EXAMPLE 5

The principles and practical

Analysis of DNA from tumor cells.

20

25

15

5

10

considerations described above were illustrated with DNA from two colorectal cancer cell lines, one with a mutation in c-Ki-Ras codon 12 and the other in codon 13. Representative examples of the MB-RED fluorescence values obtained are shown in Fig. 3. There was a clear biphasic distribution, with "positive" wells yielding values in excess of 10,000 specific fluorescence units (SFU, as defined in Materials and Methods) and "negative" wells yielding values less than 3500 SFU. Gel electrophoreses of 127 such wells demonstrated that all positive wells, but no negative wells, contained PCR products of the expected size (Fig. 3). The RED/GREEN fluorescence ratios of the positive wells are shown in Fig. 4. Again, a biphasic distribution was observed. In the experiment with the tumor containing a Gly12Asp mutation, 64% of the positive wells exhibited RED/GREEN ratios in excess of 3.0 while the other 36% of the

19

positive wells exhibited ratios ranging from 0.8 to 1.1. In the case of the

5

15

tumor with the Gly13Asp mutation, 54% of the positive wells exhibited RED/GREEN ratios >3.0 while the other positive wells yielded ratios ranging from 0.9 to 1.1. The PCR products from 16 positive wells were used as sequencing templates (Fig. 4). All the wells yielding a ratio in excess of 3.0 were found to contain mutant c-Ki-Ras fragments of the expected sequence, while WT sequence was found in the other PCR The presence of homogeneous WT or mutant sequence products. confirmed that the amplification products were usually derived from single template molecules. The ratios of WT to mutant PCR products determined from the Digital Amplification assay was also consistent with the fraction of mutant alleles inferred from direct sequence analysis of genomic DNA from the two tumor lines (Fig. 2).

Digital Analysis of DNA from stool. As a more practical example, we analyzed the DNA from stool specimens of colorectal cancer patients. A representative result of such an experiment is illustrated in Fig. 5. From previous analyses of stool specimens from patients whose tumors contained c-Ki-Ras gene mutations, we expected that 1% to 10% of the c-Ki-Ras genes purified from stool would be mutant. We therefore set up a 384 well Digital Amplification experiment. As positive controls, 48 of the wells contained 25 genome equivalents of DNA (defined in Materials and Methods) from normal cells. Another 48 wells served as negative controls (no DNA template added). The other 288 wells contained an appropriate dilution of stool DNA. MB-RED fluorescence indicated that 102 of these 288 experimental wells contained PCR products (mean +/- s.d. of 47,000 +/- 18,000 SFU) while the other 186 wells did not (2600 +/- 1500 SFU). The RED/GREEN ratios of the 102 positive wells suggested that five contained mutant c-Ki-Ras genes, with ratios ranging from 2.1 to 5.1. The other 97 wells exhibited ratios ranging from 0.7 to 1.2, identical to those observed in the positive control wells. To determine the nature of the mutant c-Ki-Ras genes in the five positive wells from stool, the PCR products were directly sequenced. The four wells exhibiting RED/GREEN ratios in excess of 3.0 were completely composed of mutant c-Ki-Ras

30

10

sequence (Fig. 5). The sequence of three of these PCR products revealed Gly12Ala mutations (GGT to GCT at codon 12), while the sequence of the fourth indicated a silent C to T transition at the third position of codon 13. This transition presumably resulted from a PCR error during the first productive cycle of amplification from a WT template. The well with a ratio of 2.1 contained a ~1:1 mix of WT and Gly12Ala mutant sequences. Thus 3.9% (4/102) of the c-Ki-Ras alleles present in this stool sample contained a Gly12Ala mutation. The mutant alleles in the stool presumably arose from the colorectal cancer of the patient, as direct sequencing of PCR products generated from DNA of the cancer revealed the identical Gly12Ala mutation (not shown).

References

- 1. Vogelstein & Kinzler, (1998) The Genetic Basis of Human Cancer (MCGraw-Hill, Toronto).
- 15 2. Lee et al., (1997) Free Radical Biol Med 22, 1259-69.
 - 3. Ozawa, T. (1997) Physiol Rev 77, 425-64.
 - 4. Sidransky et al., (1991) Science 252, 706-09.
 - 5. Sidransky et al., (1992) Science 256, 102-05.
 - 6. Smith-Ravin et al., (1995) Gut 36, 81-6.
- 7. Mills et al., (1995) J. Natl Cancer Inst 87, 1056-60.
 - 8. Mao et al. (1994) Cancer Res 54, 1634-37.
 - 9. Brossart et al., (1995) Caner Res 55, 4065-68.
 - 10. Tada et al. (1993) Cancer Res 53, 2472-74.
 - 11. Nawroz et al. (1996) Nature Med 2, 1035-37.
- 25 12. Hayashi et al., (1994) Cancer Res 54, 3853-56.
 - 13. Sidransky, (1997) Science 278, 1054-59.
 - 14. Koch et al. (1994) Arch Otolaryngol Head Neck Surg 120, 943-47.

- 15. Kumar et al., (1990) Science 248, 1101-04.
- 16. Jonason et al., (1996) Proc Natl Acad Sci USA 93, 14025-29.
- 17. Ananthaswamy et al. (1999) J Invest Dermatol 112, 763-68.
- 18. Bar-Eli et al. (1989) Blood 73, 281-83.
- 5 19. Collins et al. (1989) Blood 73, 1028-32.
 - 20. Saiki et al. (1986) Nature 324, 163-66.
 - 21. Bos et al. (1987) Nature 327, 293-97.
 - 22. Dicker et al. (1990) Genes Chromosomes Cancer 1, 257-69.
 - 23. Haque et al. (1998) Diagn Mol Pathol 7, 248-52.
 - 24. Haliassos et al. (1989) Nucleic Acids Res 17, 8093-99.
 - 25. Chen et al. (1997) Anal Biochem 244, 191-94.
 - 26. Cha et al. (1992) PCR Methods Appl 2, 14-20.
 - 27. Jiang et al. (1989) Oncogene 4, 923-28.
 - 28. Kahn et al. (1991) Oncogene 6, 1079-83.
- 29. Kahn et al. (1995) Methods Enzymol 255, 452-64.
 - 30. Laken et al., (1998) Nature Biotechnol 16, 1352-56.
 - 31. Whitcombe et al. (1998) Curr Opin Biotechnol 9, 602-08.
 - 32. Day et al. (1999) Nucleic Acids Res 27, 1820-18.
 - 33. Tyagi et al. (1998) Nature Biotechnol 16, 49-53.
- 20 34. Tyagi et al. (1996) Nat Biotechnol 14, 303-08.
 - 35. Lee et al. (1993) Nucleic Acids Res 21, 3761-66.
 - 36. Chiang et al. (1996) Genome Res 6, 1013-26.
 - 37. Heid et al. (1996) Genome Res 6, 986-94.
 - 38. Paris et al. (1998) Nucleic Acids Res 26, 3789-93.

ČI.

Page 61 of 1224

10

- 39. Gibson et al. (1997) Clin Chem 43, 1336-41.
- 40. Chen et al. (1999) Genome Res 9, 492-98.
- 41. Szollosi et al. (1998) Cytometry 34, 159-79.
- 42. Cortopassi et al. (1992) Mutat Res 277, 239-49.
- 5 43. Monckton et al. (1991) Genomics 11, 465-67.
 - 44. Chou et al. (1992) Nucleic Acids Res 20, 1717-23.
 - 45. Kellogg et al. (1994) Biotechniques 16, 1134-37.
 - 46. Li et al. (1988) Nature 335, 414-17.
 - 47. Schmitt et al. (1994) Forensic Sci Int 66, 129-41.
 - 48. Navidi et al. (1991) Hum Reprod 6, 836-49.
 - 49. Zhang et al. (1992) Proc Natl Acad Sci USA 89, 5847-51.
 - 50. Jeffreys et al. (1995) Electrophoresis 16, 1577-85.
 - 51. Ruano et al. (1990) Proc Natl Acad Sci USA, 6296-300.
 - 52. Sidransky et al. (1992) Nature 355, 846-47.
- 15 53. Parsons et al. (1995) Science 268, 738-40.
 - 54. Lizardi et al. (1998) Nature Genet 19, 225-32.
 - 55. Vogelstein (1989) Science 244, 207-11.
 - 56. Marras et al. (1999) Genet Anal 14, 151-56.

Callery

CLAIMS

5

10

15

20

25

A method for determining the ratio of a selected genetic sequence in a population of genetic sequences, comprising the steps of:

diluting nucleic acid template molecules in a biological sample to form a set comprising a plurality of assay samples;

amplifying the template molecules within the assay samples to form a population of amplified molecules in the assay samples of the set;

analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence;

comparing the first number to the second number to ascertain a ratio which reflects the composition of the biological sample.

- 2. The method of claim 1 wherein the step of diluting is performed until at least one-tenth of the assay samples in the set comprise a number (N) of molecules such that 1/N is larger than the ratio of selected genetic sequences to total genetic sequences required for the step of analyzing to determine the presence of the selected genetic sequence.
- 3. The method of claim 1 wherein the step of diluting is performed until between 0.1 and 0.9 of the assay samples yield an amplification product when subjected to a polymerase chain reaction.
- 4. The method of claim 1 wherein the step of diluting is performed until all of the assay samples yield an amplification product when subjected to a polymerase chain reaction and each assay sample contains less than 10 nucleic acid template molecules containing the reference genetic sequence.

24

performed until all of the assay samples yield an amplification product when subjected to a polymerase chain reaction and each assay sample contains less than 100 nucleic acid template molecules containing the reference genetic sequence.

6. The method of claim 1 wherein the biological sample is cell-free.

7. The method of claim 1 wherein the number of assay samples within the set is greater than 10.

5.

5

10

15

20

25

The method of claim 1 wherein the step of diluting is

- 8. The method of claim 1 wherein the number of assay samples within the set is greater than 50.
 - The method of claim 1 wherein the number of assay samples within the set is greater than 100.
 - 10. The method of claim 1 wherein the number of assay samples within the set is greater than 500.
 - 11. The method of claim 1 wherein the number of assay samples within the set is greater than 1000.
 - 12. The method of claim 1 wherein the step of amplifying and the step of analyzing are performed on assay samples in the same receptacle.
 - 13. The method of claim 1 wherein a molecular beacon probe is used in the step of analyzing, wherein a molecular beacon probe is an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end.
 - 14. The method of claim 1 wherein the step of analyzing employs gel electrophoresis.
 - 15. The method of claim 1 wherein the step of analyzing employs hybridization to at least one nucleic acid probe.

10

15

20

25

- The method of claim 1 wherein the step of analyzing employs hybridization to at least two nucleic acid probe.
- 17. The method of claim 13 wherein two molecular beacon probes are used, each having a different photoluminescent dye.
- 18. The method of claim 13 wherein the molecular beacon probe detects a wild-type selected genetic sequence better than a mutant selected genetic sequence.
- The method of claim 1 wherein the step of amplifying employs a single pair of primers.
- 20. The method of claim 1 wherein the step of amplifying employs a polymerase which is activated only after heating.
- The method of claim 1 wherein the step of amplifying employs at least 40 cycles of heating and cooling.
- 22. The method of claim 1 wherein the step of amplifying employs at least 50 cycles of heating and cooling.
- 23. The method of claim 1 wherein the step of amplifying employs at least 60 cycles of heating and cooling.
- 24. The method of claim 1 wherein the biological sample is selected from the group consisting of stool, blood, and lymph nodes.
- 25. The method of claim 1 wherein the biological sample is blood or bone marrow of a leukemia or lymphoma patient who has received anticancer therapy.
- 26. The method of claim 1 wherein the selected genetic sequence is a translocated allele.
- 27. The method of claim 1 wherein the selected genetic sequence is a wild-type allele.

- 28. The method of claim. I wherein the selected genetic sequence is within an amplicon which is amplified during neoplastic development.
- The method of claim 1 wherein the selected genetic sequence 29. is a rare exon sequence.

The method of claim 1 wherein the nucleic acid template 30. molecules comprise cDNA of RNA transcripts and the selected genetic sequence is present on a cDNA of a first transcript and the reference genetic sequence is present on a cDNA of a second transcript.

- The method of claim 1 wherein the selected genetic sequence 31. comprises a first mutation and the reference genetic sequence comprises a second mutation.
- The method of claim 1 wherein the selected genetic sequence 32. and the reference genetic sequence are on distinct chromosomes.
 - A molecular beacon probe comprising:

an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 16 base pairs, wherein the loop has a T_m of 50-51 °C and the stem consists of 4 base pairs having a sequence 5'-CACG-3'.

- The probe of claim 33 wherein the molecular beacon probe detects a wild-type selected genetic sequence better than a mutant selected genetic sequence.
- 35. The probe of claim 33 wherein the molecular beacon probe detects a mutant genetic sequence better than a wild-type genetic sequence.
- an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at

A molecular beacon probe comprising:

15

5

10

20

10

15

20

25

the opposite 5' or 3' end, wherein the loop consists of 19-20 base pairs, wherein the loop has a T_m of 54-56°C and the stem consists of 4 base pairs having a sequence 5'-CACG-3'.

A pair of molecular beacon probes comprising:

a first molecular beacon probe which is an oligonucleotide with a stem-loop structure having a first photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 16 base pairs having a T_m of 50-51°C and the stem consists of 4 base pairs having a sequence 5'-CACG-3'; and

a second molecular beacon probe which is an oligonucleotide with a stem-loop structure having a second photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 19-20 base pairs having a $T_{\rm m}$ of 54-56°C and the stem consists of 4 base pairs having a sequence 5'-CACG-3';

wherein the first and the second photoluminescent dyes are distinct.

38. A method for determining the ratio of a selected genetic sequence in a population of genetic sequences, comprising the steps of:

amplifying template molecules within a set comprising a plurality of assay samples to form a population of amplified molecules in each of the assay samples of the set;

analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence, wherein at least one-fiftieth of the assay samples in the set comprise a number (N) of molecules such that 1/N is larger than the ratio of selected genetic sequences to total genetic sequences required to determine the presence of the selected genetic sequence;

39

10

15

25

comparing the first number to the second number to ascertain a ratio which reflects the composition of the biological sample.

- 39. The method of claim 38 wherein the number of assay samples within the set is greater than 10.
- 40. The method of claim 38 wherein the number of assay samples within the set is greater than 50.
 - 41. The method of claim 38 wherein the number of assay samples within the set is greater than 100.
 - 42. The method of claim 38 wherein the number of assay samples within the set is greater than 500.
 - 43. The method of claim 38 wherein the number of assay samples within the set is greater than 1000.
 - 44. The method of claim 38 wherein the step of amplifying and the step of analyzing are performed on assay samples in the same receptacle.
 - 45. The method of claim 38 wherein a molecular beacon probe is used in the step of analyzing, wherein a molecular beacon probe is an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' ends.
- 20 46. The method of claim 38 wherein the step of analyzing employs gel electrophoresis.
 - 47. The method of claim 38 wherein the step of analyzing employs hybridization to at least one nucleic acid probe.
 - 48. The method of claim 38 wherein the step of analyzing employs hybridization to at least two nucleic acid probe.
 - 49. The method of claim.45 wherein two molecular beacon probes are used, each having a different photoluminescent dye.

29

10

15

20


25

- 50. The method of claim 45 wherein the molecular beacon probe detects a wild-type selected genetic sequence better than a mutant selected genetic sequence.
- The method of claim 38 wherein the step of amplifying employs a single pair of primers.
- 52. The method of claim 38 wherein the step of amplifying employs a polymerase which is activated only after heating.
- 53. The method of claim 38 wherein the step of amplifying employs at least 40 cycles of heating and cooling.
- 54. The method of claim 38 wherein the step of amplifying employs at least 50 cycles of heating and cooling.
- 55. The method of claim 38 wherein the step of amplifying employs at least 60 cycles of heating and cooling.
- 56. The method of claim 38 wherein the template molecules are obtained from a body sample selected from the group consisting of stool, blood, and lymph nodes.
- 57. The method of claim 38 wherein the template molecules are obtained from a body sample of a leukemia or lymphoma patient who has received anti-cancer therapy, said body sample being selected from the group consisting of blood and bone marrow.
- 58. The method of claim 38 wherein the selected genetic sequence is a translocated allele.
- 59. The method of claim 38 wherein the selected genetic sequence is a wild-type allele.
- 60. The method of claim 38 wherein the selected genetic sequence is within an amplicon which is amplified during neoplastic development.

10

- 61. The method of claim 38 wherein the selected genetic sequence is a rare exon sequence.
- 62. The method of claim 38 wherein the nucleic acid template molecules comprise cDNA of RNA transcripts and the selected genetic sequence is present on a cDNA of a first transcript and the reference genetic sequence is present on a cDNA of a second transcript.
- 63. The method of claim 38 wherein the selected genetic sequence comprises a first mutation and the reference genetic sequence comprises a second mutation.
- 64. The method of claim 38 wherein the selected genetic sequence and the reference genetic sequence are on distinct chromosomes.

(Maga,



[3:

na <u>inaggap</u>

₩MB-Green

% MB-Red


::

Queried Codons

8


Page 72 of 1224

Red/Green



i Ö

Fig. 3



ræ.

Fig. 4





Fig. 5





2.

NEW UNITED STATES UTILITY PATENT APPLICATION under 37 C.F.R. 1.53(b)



Atty. Decket No. 01107.00031

Assistant Commissioner of Patents Box Patent Applications Washington, D.C. 20231

Enclosed herewith is a new patent application and the following papers:

First Named Inventor (or application identifier):	Kenneth W. Kinzler
---	--------------------

Title of Invention: DIGITAL AMPLIFICATION

1.		Specification	32 pages (including specification, claims, abstract) / 64 claims (5 independent
----	--	---------------	---

	attached in the regular manner.
\$00E	MOT included but deferred under 37 CHD R 1 53(f)

- MOT included, but deferred under 37 C.F.R. § 1.53(f).
- 3. ☐ ☐ Distinct sheets of ☐ Formal ☐ Informal Drawings

Declaration/Power of Attorney is:

- 4. Preliminary Amendment.
- 5. Information Disclosure Statement
 - Form 1449
 A copy of each cited prior art reference
- 6. Assignment with Cover Sheet.
- 7. Priority is hereby claimed under 35 U.S.C. § 119 based upon the following application(s):

Country	Application Number	Date of Filing (day, month, year)
US	60/146,792	August 2, 1999

8.	Priority document(s).
9.	Statement Claiming Small Entity Status.
10.	Microfiche Computer Program (Appendix).
11.	Nucleotide and/or Amino Acid Sequence Submission. ☐ Computer Readable Copy. ☐ Paper Copy (identical to computer copy). ☐ Statement verifying identity of above copies.

NEW UNITED STATES UTILITY PATENT APPLICATION under 37 C.F.R. 1.53(b)

Pege 2

Atty. Docket No. 01107.00031

12. Calculation of Fees:

BESFOR	EXCESS CLAIMS	FEE	AMOUNT DUB
Basic Filing Fee (37 C.F.R. § 1.16(a))			\$690.00
Total Claims in Excess of 20 (37 C.F.R. § 1.16(c))	44	18.00	\$792.00
Independent Claims in Excess of 3 (37 C.F.R. § 1.16(b))	2	78.00	\$156.00
Multiple Dependent Claims (37 C.F.R. § 1.16(d))	<u> </u>	260.00	\$0,00
Subtotal - Filing Fee Due			\$1,638.00
	REDI	UCE BY (%)	(\$)
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)	0		\$819.00
TOTAL FILING FEE DUE		Variation of the second of the	\$819.00
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))	0	40.00	\$0.00
ZGRAND TOTAL DUE			\$819.00

- 13. PAYMENT is:
 - included in the amount of the GRAND TOTAL by our enclosed check. A general authorization under 37 C.F.R. § 1.25(b), second sentence, is hereby given to credit or debit our Deposit Account No. 19-0733 for the instant filing and for any other fees during the pendency of this application under 37 C.F.R. §§ 1.16, 1.17 and 1.18.
 - not included, but deferred under 37 C.F.R. § 1.53(f).
- 14. All correspondence for the attached application should be directed to:

Banner & Witcoff, Ltd. 1001 G Street, N.W. Washington, D. C. 20001-4597 Telephone: (202) 508-9100 Facsimile: (202) 508-9299

15.	Other:	
		DAN Mar Va
Date:	July 11, 2000	By: MUN WURNGOL
2-0	the same of the sa	Sarah A. Kagan
		Reg. No. 32,141

SAK/ama



United States Patent and Trademark Office

#2

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
VAUNDATION, D.C. 20 231
WWW.LEPOOGO

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/613,826

07/11/2000

Kenneth W. Kinzler

01107.00031

FORMALITIES LETTER

ETTER Karana mengananan

OC00000005521419

Banner & Witcoff Ltd 1001 G Street N W Washington, DC 20001-4597

Date Mailed: 11/01/2000

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.63(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The Item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a pelition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
 Applicant must submit \$ 690 to complete the basic filing fee and/or file a small entity statement claiming such status (37 CFR 1.27).
- Total additional claim fee(s) for this application is \$948.
 - \$792 for 44 total claims over 20.
 - \$156 for 2 independent claims over 3.
- The oath or declaration is missing.
 A property signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing Items Identified in this letter.
- The balance due by applicant is \$ 1768.

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 3 - OFFICE COPY

Page 2 of 2

SECTOR

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit:

Examiner:

Docket No. 01107.00031

Serial No. 09/613,826

In re Application of

Bert Vogelstein et al.

Filed: July 11, 2000

FOR: DIGITAL AMPLIFICATION

SUBMISSION OF EXECUTED DECLARATION FOR PATENT APPLICATION AND FILING FEES

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Attached is an executed Declaration for Patent Application in compliance with the Notice to File Missing Parts of Application (copy enclosed), mailed November 1, 2000. Accordingly, it is respectfully submitted that this application is entitled to a filing date of July 11, 2000, the date upon which the specification and drawings were received by the U.S. Patent and Trademark Office. Applicants claims small entity status.

Please charge \$896.00 for filing fees to our Deposit Account No. 19-0733. The calculation is as follows:

Basic Fee (total claims = 64)	\$355.00
Total Claims in Excess (44)	396.00
Independent Claims over Three (2)	80.00
Surcharge for subsequent filing	65.00
of executed Declaration	

TOTAL FILING FEE \$896.00

Page 81 of 1224

In the event any variance exists between the amount enclosed and the Patent Office charges, please charge or credit any difference to our Deposit Account No. 19-0733.

Respectfully submitted,

Date: December 12, 2000

y: Diah U

Sarah A. Kagan

Registration No. 32,141

Banner & Witcoff, Ltd. 1001 G Street, N.W., Eleventh Floor Washington, D.C. 20001-4597

(202) 508-9100 SAK/ama

LARATION FOR PATENT APP. CATION



	d inventor, we hereby de	eclare that:		5 200
Our reside	t office address and citiz		ow next to our names;	TEMPLE
was file applica was file No We hereby state including the claims, as	e the original, first and join vention entitled DIGITAL med hereto. ed on July 11, 2000 as Appliable). ed under the Patent Coopera filed	AMPLIFICATION, the ication Serial Number of the ication Treaty (PCT) and it, and amended on the ication treferred to above.	e specification of white of the specification of white of the above identification of the specification of the spe	nended on (if Application (if any). entified specification,
Title 37, Code of Federa	il-Regulations, §1.56(a).	·	•	
for patent or inventor's	Prior Font for foreign priority benefits und certificate listed below and wing a filing date before that	have also identified be	ites Code, §119 of any low any foreign appli	cation(s) for patent or
Country	Application No.	Date of Filing (day month year)	Date of Issue (day month year)	Priority Claimed Under 35 U.S.C. §119
				<u> </u>

Prior United States Provisional Application(s)

We hereby claim priority benefits under Title 35, United States Code, §119(e)(1) of any U.S. provisional application listed below:

U.S. Provisional Application No.	Date of Filing (day month year)	Priority Claimed Under 35 U.S.C. § 119(e)(1)
60/146,792	02 August 1999	Yes

Prior United States Application(s)

We hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Date of Filing (Day, Month, Year)	Status — Patented, Pending, Abandoned

Attorney Docket No. 01107.00031 Page 1

Power of Attorney

*		and severally, as our attorney			
this applica		e Patent and Trademark Offic	e connected herewi	th the following attorneys and	agents, their
registration numbers	heir nan	nes:	10	P E	
ALTHERR, Robert F.		HOSCHEIT, Dale H.	19,090	PATEI Binal J. PATHAS Ajay S. PANE, Stephen S.	42,065
BANNER, Donald W.		IWANICKI, John P.	34,628	PATHAR Ajay S.	38,266
BANNER, Mark T.		JACKSON, Thomas H.	29.80 EC 1	PANE Stephen S.	35,316
BANNER, Pamela I.		KAGAN, Sarah A.			30,969
BECKETT, William W.	18,262	KATZ, Robert S.	36,402	POTEMA, Joseph M.	28,175
BODNER, Jordan	42,338	KLEIN, William J.	43,719	PRAKA, Thomas K.	37,210
BUROW, Scott A.	42,373	KRAUSE, Joseph P.	32,578 RADI	EKENK, Christopher J.	33,761
CALLAHAN, James V.	20,095	LINEK, Ernest V.	29.822	PETERSON, Thomas L. POTENS'A, Joseph M. PRAST, Thomas K. EMENK, Christopher J. RESIS, Robert H. PIVARD, Poul M.	32,168
CHANG, Steve S	42,402	MALONE, Dale A.	32,155	RIVARD, Paul M.	43,446
COHAN, Gregory J.	40,959	MANNAVA, Asbok K.	45,301	SCHAD, Steve P.	32,550
COOPERMAN, Marc S.	34,143	McDERMOTT, Peter D.	29,411	SHANAHAN, Michael H.	24,438
CURTIN, Joseph P.	34,571	McKEE, Christopher L.	32,384	SHIFLEY, Charles W.	28,042
DAWSON, John R.	39,504	McKIE, Edward F.	17,335	SKERPON, Joseph M.	29,864
DEMOOR, Laura J.	39,654	MEDLOCK, Nina L.	29,673	STOCKLEY, D. J.	34,257
EVANS, Thomas L.	35,805	MEECE, Timothy C.	38,553	VAN ES, J. Pieter	37,746
FEDOROCHKO, Gary D.	35,509	MEEKER, Frederic M.	35,282	WITCOFF, Sheldon W.	17,399
FISHER, William J.	32,133	MILLER, Charles L.	43,805	WOLFFE, Franklin D.	19,724
GLEMBOCKI, Christopher		MITRIUS, Janice V.	43,808	WOLFFE, Susan A.	33,568
HANLON, Brian E.	40,449	MORENO, Christopher P.		WRIGHT, Bradley C.	38,061
HEMMENDINGER, Lisa		NELSON, Jon O.	24,566	,	,
HONG, Patricia E.	34,373	NIEGOWSKI, James A.	28,331		
	• • •	•	·		
All corresponden		mmunications should be add			
	Banner & Witco		Customer Num		
	1001 G Street, N		Tel: (202) 508-		
	Washington, D.C	J. 20001-4597	Fax: (202) 508	-9239	
We hereby declar	e that all statement	s made herein of our own kno	wledge are true and	d that all statements made on	information
and belief are believed to be	e true: and further (hat these statements were ma	de with the knowled	dge that willful false statemen	its and the
like so made are nunishable	by fine or impriso	nment, or both, under Section	1001 of Title 18 of	f the United States Code and	that such
willful false statements may	vicopardize the val	idity of the application or any	patent issuing ther	eon.	
	, ,		-		
/ / /	-110			/ / /	
	$(1 1 \times 1)$			/ ulapla	
Signature	NIX		Da	16 11 20 19	
Full Name of First Inventor		Vogelstein	Bert		
	· Y)	Family Name	First Given Name	Second Given Nar	ne
Residence Balamore Mi	aryland		Citizenship_U	nited States	
Post Office Address 37	M Breton Way, Ba	ltimore, Maryland 21208			
, .	4			_	
	411			11/201	
	1/ 1/4	V . ~ l.	. D.	11120100	
Signature	W V V	Kinzle	De	110	
Full Name of Second Inver	104	Family Name	First Given Name	Second Given Nar	ne
Residence RelAir, Mary	iand	venus Manne	Citizenship_U		
Post Office Address14	03 Halkirk Way D.	elAir Maryland 21015	Cinamin D	MANAGE MA	
LOST OTHER UNITES TA	THE PERSON NAMED IN PORT OF TH	EXCENSES TAXABLE TO A STATE OF THE STATE OF	., ,		

BANNER & WITCOFF, LTD.

Attorney Docket No. 01107.00031 Page 2



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 2023

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/613,826

07/11/2000

Kenneth W. Kinzler

01107.00031

Banner & Witcoff Ltd 1001 G Street N W Washington, DC 20001-4597



FORMALITIES LETTER OC000000005521418

Date Mailed: 11/01/2000

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.63(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
 Applicant must submit \$ 690 to complete the basic filing fee and/or file a small entity statement claiming such status (37 CFR 1.27).
- · Total additional claim fee(s) for this application is \$948.
 - a \$792 for 44 total claims over 20.
 - s \$166 for 2 independent claims over 3.
- The oath or declaration is missing. A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

The balance due by applicant is \$ 1768.	09613826		•
A copy of this notice MUST be returned with the rep	h/451		
Thhan	26000000	8888 8888 8888	
Customer Service Center Initial Patent Examination Division (703) 308-1202 PART 2 - COPY TO BE RETURNED WITH RESPONSE	SAME	MTMT	
file-//C-\APD\$\PnoFivom\correspondence\? B rm!	12/19/2000	22 FC 202 22 FC 202 23 FC 202 24 FC 202 25 FC	10/31 <i>/</i> /

file://C:\APPS\PreExam\correspondence\2_B.xml

10/31/00

44/52

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Bert Vogelstein et al.

Serial No. 09/613,826

Filed: July 11, 2000

) Attn: Application Branch

Atty. Dkt. No. 01107.00031

For: DIGITAL AMPLIFICATION

INFORMATION DISCLOSURE STATEMENT

The Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, enclosed is a PTO Form-1449 listing documents for consideration by the Examiner during the prosecution of the subject application and a copy of each of the identified documents. It is believed no fee is required to make this a complete and timely filing. However, if a fee is required, please charge our Deposit Account No. 19-0733.

Consideration of this information is respectfully requested.

Respectfully submitted,

Date: December 12, 2000

Registration No. 32,141

Banner & Witcoff, Ltd. 1001 G Street, N.W., Eleventh Floor Washington, D.C. 20001-4597 (202) 508-9100 SAK/ama

Page 86-of-1224 -

File History Report

Paper number is missing from the United States Patent
Trademark Office's copy of the file History. No additional information is
available.
W.1 01100-1-0.
The following page(s) 1 of 2 PTO -1449 of paper number 4 is/are
missing from the United States Patent and Trademark Office's original
copy of the file history. No additional information is available
The following checked item(s) below of paper number
is/are missing from the United States Patent and Trademark Office's
original copy of the file history. No additional information is available
1
PTO 1449
□ PTO 892
<u>□</u> PTO 948
TO 1474
Assignment
Cover page
Additional comments:

本人

	transporter to the second section of the se			7		Sheet 2 of	
. :	PTO-1449 (Modified)		ATTY. DOCKET NO. 01107.00031	SERIAL N	UMBER 09/613,826		
	PARTMENT OF COM		APPLICANT O I P			omon no Propagation - and Op	
			Bert Vogelstein et (7)	ත්			
INFORMAT	TION DISCLOSURE 5 BY APPLICANT	TATEMENT	FILING DATE GROUP ART UNIT				
			July 11, 2000	\$ 1637			
		U	S. PATENT DOCUMENTS		· · · · · · · · · · · · · · · · · · ·		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE	
				_			
				_			
		-	Annual Control of Cont				
		 					
		<u> </u>					
		<u> </u>				<u> </u>	
EXAMINER	DOCUMENT		EIGN PATENT DOCUMENTS	Cr. Lag	SUB	TRAHELATECH ONSERV	
INITIAL	NUMBER	DATE	COUNTRY	CLASS	CLASS		
~~~~ ~~~						_	
·							
			a rich rable				
			W.				
			N.				
Secretary of the second	Commence of the Commence of th	Action Company of the		No.		and the same of th	
	отне	S DOG IMPNITS	Uncluding Author, Title, Date, Pertinent Pa	pes. Etc.)			
<i>ර</i> ්	Lisadi et al. "Mulati	es detection and	(Including Author, Title, Date, Pertinent Pa		hpiineanon"	रिकाकाट	
<i>8</i> 5	Lizardi et al. "Mutati Gazatics, Vol. 10 pa Schmitt et al. "High number of tandean re	en-detection and gas-225-32- sensitive DNA-ty- peats (VATR) am	single-molecule counting using Yeatherman in ping-approaches for the analysis of forening philipation and a short tandem repeats (STR	Olling-circle at	parison of ne	sted-variable	
8	Lissediret al. "Mutati Gancties, Vol. 10 pe Schmitt et al. "High number of tenden no international 66 (199	ion detection and gas 225-32* sensitive DNA-ty peats (VATR) am 4) pages 129-141	single-molecule counting using Yeatherman in ping-approaches for the analysis of forening philipation and a short tandem repeats (STR	olling-circle at evidence; com) polymorphisi	parison of ne n'' Porensio	sted variable Seience	
85	Lizardi et al. "Mutati Ganetics, Vol. 10. pa Schmitt et al. "High: numbes of tandem re international 66 (199 Li "Amplification as 29, 1958 pages vive	ion detection and gas 225-32- sensitive DMA-typeats (VNTR) am 4) pages 129-141 d coalysis of DN, 117	ningle-molecule counting using Yeathermal f ping-approaches for the Englysis of foreign philosnion and a short tandem repeats (STR	olling-circle at evidence: com) polymorphisi bid cells "Nat	parison of ne n" Poressio me Voi. 335	stod variable Gelence September	
35	Lisardi et al. "Mutati Genetics, Vol. 19. pa Schmitt et al. "High: number of tandem re international 66 [199 Li "Amplification an 29, 1958 pages 414-	ion detection and gas 225-32- sensitive DMA-typeats (VNTR) am 4) pages 129-141 d coalysis of DN, 117	single-molecule counting using 'sothermal r sing approaches for the snalysis of foreign philosition and a short tandem repeats (3TR A sequences in single human sperm and the	olling-circle at evidence: com) polymorphisi bid cells "Nat	parison of ne n" Poressio me Voi. 335	stod variable Gelence September	
35]	Lisardi et al. "Mutati Genetics, Vol. 19. pa Schmitt et al. "High: number of tandem re international 66 [199 Li "Amplification an 29, 1958 pages 414-	ion detection and gas 225-32- sensitive DMA-typeats (VNTR) am 4) pages 129-141 d coalysis of DN, 117	single-molecule counting using 'sothermal r sing approaches for the snalysis of foreign philosition and a short tandem repeats (3TR A sequences in single human sperm and the	olling-circle at evidence: com) polymorphisi bid cells "Nat	parison of ne n" Poressio me Voi. 335	stod variable Gelence September	
SS S S S S S S S S S	Lisardi et al. "Mutati Genetics, Vol. 19. pa Schmitt et al. "High: number of tandem re international 66 [199 Li "Amplification an 29, 1958 pages 414-	on detection and gas 225-32* sensitive DMA by peats (WYRK) on 4) pages 129-141 ad analysis of DM, 117	single-molecule counting using Yeatherman in ping approaches for the analysis of forengo philosopon and a short tandem repeats (STR A sequences in single human aperm and the from a single cell: Implications for genetic a	olling-circle at evidence: com) polymorphisi bid cells "Nat	parison of ne n" Poressio me Voi. 335	stod variable Gelence September	

4501

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	•
Bert Vogelstein, et al.	Ź	Group Art No. 1632
Serial No.: 09/613,826	}	Examiner: TBA
Filed: July 11, 2000)	Docket No. 01107.00031

INFORMATION DISCLOSURE STATEMENT

RECEIVED

MAR 0 8 2001

Assistant Commissioner for Patents Washington, D.C. 20231

DIGITAL AMPLIFICATION

TECH CENTER 1600/2900

Sir:

Pursuant to 37 C.F.R. §1.56 and in compliance with 37 C.F.R. §1.97, Applicants submit herewith a Form PTO-1449 identifying information for consideration by the Examiner. A copy of each of the items of information is enclosed.

Applicants do not waive any rights to take appropriate action to establish patentability over the listed documents should they be applied as a reference against the claims of the present application.

Consideration of the cited information and making the same of record in the prosecution of the above-noted application are respectfully requested. Should the Patent and Trademark Office determine that a fee is required, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.

Sarah A. Kagan Registration No. 32,141

1001 G Street, N.W. Washington, D.C. 20001-4597 (202) 508-9100 Dated: 03-05-0

Page 89 of 1224

					Direct	т.ы.т	-	
	PTO-1449 (Modifie	d)	ATTY, DOCKET NO.	SERIALN	iumber (09613926]	
	EPARTMENT OF CO		01107.00031	TRA		RECE	IVED	
	IT AND TRADEMAR TION DISCLOSURE		APPLICANTS Bert Vogelstein, et al.				8 2001	
INFORMA	BY APPLICANT	<i>%</i>	FILING DATE	GROUP A	RT UNIT			
	(a MAR	9 7 2001 E	July 11, 2000	-788A*/	637 637	CH CENTE	R 1600/2900	
	To have	-1 CE U	S. PATENT DOCUMENTS			A.		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE		
<i>S</i> 8	5,670,325	9/1997	Lapidus, et al.	CLASS	CLASS	DATE		
(4 02R 97A	7/1000	T middie int at	-				
					_			
SS				سينتي				
U		, , , , , , , , , , , , , , , , , , ,		nges Etc.)			ļ.	
X	Danes G. MONCK	TON, et al., "Minis	atellite "Isoallele" Discrimination in Pasus	(CA CALORDON	by Single M	olecule PCR]	
85	Gualbarin BIIANO	et al "Hankhama	Multiple Polymorphisms Baselyad by E	nzymatic Ampl	ification of S	ingle DNA		
83			1	Human Reprodu	ction, Vol. 6	, No. 6, pp.		
85	Hongus Ll, et al., "A Vol. 335, September	Amplification and A	nalysis of DNA Sequences in Single Hum	an Sperm and D	iploid Cells	", Nature,		
S			epair Deficiency in Phenotypically Norms	il Human Celis"	, Science, V	ol. 268,		
9 3	Lin ZHANG, et al., Science USA, Vol. i	"Whole Genome A 19, pp. 5847-5851, J	mplification from a Single Cell; Implication 1992	ons for Genetic	Analysis', Pr	oc. National		
84	David SIDRANSKY - Nature, February 27	, et al., "Cional Exp 1992 vol. 353	pansion of p53 Mutant Cells is Associated , 우 해수 역약기 홍	with Brain Tur	nour Progress	ilon",		
85	Alec J. Jeffreys, et a	I, "Mutation Proces	ses at Human Minisatellites", Electophore	sis, pp. 1577-1:	585, 1995			
S.928,870 7/1999 Lapidus, et al.								
25	Paul M. LIZARDI, a	t al., "Mutation Det	ection and Single-Molecule Counting Usi 9, July 1998 p.o. 225-232	ng Isothermal R	olling-Circle			
25			-	luman Reprodu	ction, Vol. 6	1001		
H	Honghus El, et al.," Vol. 135, Soptomber	Amplification and a 29, 1988	tnelysis of DNA Sequences in Single Hur	nan Sperm and	Diploid Cein	त्र सिंबामा ल ्		
EXAMINER	Jeffry 8	rei	DATE CONSIDERED 4	15/01				
EXAMINER: I considered. In	initial citation if refere clude copy of this form	nce was considered. with next commun	Draw line through citation if not in confe ication to applicant.	ormance to MPE	P 609 and n	ot		



UNITED STATE. EPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Weshington, D.C. 20231

AP	PLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	OTTA	RNEY DOCKET NO.
t	09/613,	826 07/11	(/00	VOGELSTEIN	E	01107.0003
_	022907			HM22/0412 🗀	EXAM	MINER
Į.	BANNER & WITCOFF 1001 G STREET N W			VII 122/22 5/-7/11/22	SIEW,	J
	SUITE 1				ART UNIT	PAPER NUMBER
		TON DC 2001	1.0		1656	6
					DATE MAILED:	04/12/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

1- File Copy

		Application No.	Applicant(s)
		09/613,826	VOGELSTEIN ET AL.
	Office Action Summary	Examiner	Art Unit
	,	Jeffrey Slew	1656
	The MAILING DATE of this communication	n appears on the cover sheet with	the correspondence address
eriod fo	• •	DENIVIO CETTO EVDIDE 2 MO	NTU(S) EDOM
THE I - Exter exter - If the - If NO - Fallu - Anyr	DRTENED STATUTORY PERIOD FOR MAILING DATE OF THIS COMMUNICAT issues of time may be available under the provisions of 37 K(6) MONTHS from the massing date of this communic period for reply especified above, he stees than thirty (30) days period for reply is especified above, the maximum statutos to reply within the set or extended period for reply within the set or extended period for reply with, eply received by the Office later than three months after the distance of the set of	FION. CFR 1.136 (a). In no event, however, may a rejulion. Journal of the statutory minimum of thirty is period will apply and will expire SIX (8) MONT) whether cause the conficients on the SIX (8) MONT).	ply be timely filed (30) days with be considered timely. -15 from the mailting date of this communication. -NOONEO 15 U.S.C.\$ 139).
1)🛛	Responsive to communication(s) filed	on <u>07 March 2001</u> .	
2a)	This action is FINAL. 2b)	☑ This action is non-final.	
3)□	Since this application is in condition for closed in accordance with the practice	allowance except for formal mattunder Ex parte Quayle, 1935 C.D	ers, prosecution as to the merits is . 11, 453 O.G. 213.
Dispositi	on of Claims		
	Claim(s) 1-64 is/are pending in the app		
	4a) Of the above claim(s) is/are v	ithdrawn from consideration.	
5)	Claim(s)is/are allowed.		
6)⊠	Claim(s) <u>1-64</u> is/are rejected.		
,	Claim(s) is/are objected to.		
8)□	Claims are subject to restriction	and/or election requirement.	
Applicati	on Papers		
9)🛛	The specification is objected to by the E	xaminer.	i
	The drawing(s) filed on is/are ob		
	The proposed drawing correction filed of		disapproved.
12)	The oath or declaration is objected to b	y the Examiner.	
Priority (ınder 35 U.S.C. % 119		
13)	Acknowledgment is made of a claim for	foreign priority under 35 U.S.C. 🛭	119(a)-(d) or (f).
-	□ All b)□ Some * c)□ None of:		
-	1. Certified copies of the priority do		•
	2. Certified copies of the priority do		
an y	Copies of the certified copies of tapplication from the Internation see the attached detailed Office action for	onal Bureau (PCT Rule 17.2(8)).	
14)	Acknowledgement is made of a claim for		
لسالة	*	*	
	-ut-ab		
Attachmen	R(s) lice of References Cited (PTO-892)	18) 🔲 Interview	Summary (PTO-413) Paper No(s)
18) TI No	ice of Draftsperson's Patent Drawing Review (PTG)-948) 19) Notice of	Informal Patent Application (PTO-152)
17) 🛛 inf	ormation Disclosure Statement(s) (PTO-1449) Pap	er No(s) <u>4 & 6</u> . 20) 🔯 Other: na	нсв то сотрлу .
S. Patent and TO-326 (R	frademark Office	Office Action Summery	Pert of Paper No. 6

Art Unit: 1656

Page 2

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

DETAILED ACTION

APPLICANT IS GIVEN THE RESPONSE PERIOD SET FORTH IN THIS OFFICE

ACTION IN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825.

Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response. The application is not in compliance for the reason(s) set forth on the attached Notice to Comply With the Sequence Rules or CRF Diskette Problem Report.

Information Disclosure Statement

2. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609 A(1) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless

Art Unit: 1656

Page 3

the references have been cited by the examiner on form PTO-892, they have not been considered.

Specification

- 3. In the Brief Description of the Drawings Figure 1 is referred to but no Figure 1 exists in the Drawings. The specification should be amended to recite the actual figures in the drawings i.e. Figure 1A, 1B and 1C.
- 4. Moreover, the specification contains nucleotide sequences which require Sequence identifiers (see page 14 line 30 & 31). Appropriate correction is required (see also Notice to comply).

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-64 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Page 94 of 1224

Art Unit: 1656

Page 4

- A) Claims 1-32 & 38-64 lack rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted steps are; serially diluting to form a set of assay samples and testing by PCR. The specification provides guidance as to determining the analyte concentration in which the samples are serially diluted and the concentration is determined by PCR (see page 13 line19). It appears that the initial concentration of sample at the start of the assay is essential to the invention. Such a step would be critical because it is unclear as to how otherwise the initial concentration would be achieved without testing by PCR.
- B) Claims 1-32 & 38-64 lack rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted steps are: linear amplification by PCR. The step of linear amplification appears essential to the invention (see page 14 line 18).
- C) The use of the term consists" is confusing in claims 33, 36 & 37 rendering claims 33-37 indefinite. It cannot be determined whether the claim intends open or closed language for the limitation of the sequence. Proper Markush language is required.
- D) Claim 2 is confusing because it is unclear as to whether each sample of the fraction of one out ten are to contain N molecules.

Page 95 of 1224

Art Unit: 1656

Claim Rejections - 35 USC § 103

Page 5

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c)

and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1,3,4-11,14-16 & 19-32 are rejected under 35 U.S.C. 103(a) as being unpatentable
 over Lapidus et al (US5,928,870 July 27, 1999) in view of Ruano et al (PNAS vol. 87 pp. 6296-

63000 August 1990).

Art Unit: 1656

Lapidus et al teach a method of determining the subpopulation of genomically transformed cells such as in stool samples by enumerating number molecules of a target sequence and comparing with a number of molecules of a reference genomic sequence (see whole doc. esp. col.2 lines 58-66). They teach statistical difference leads to differences in genomic sequence (see col. 2 lines 8-10). They teach that the reference and target are different genetic loci (see col. 7 lines 63-65). They perform amplification by PCR and detect by probing (see col. 11 lines18-51 & 40-45). They teach that one probe is to wild type genome (see col.. 5 lines 40-46). They test malignant cells and the method would be useful for precancerous cells in humans and colorectal cancer (see col. 5 line30-35). They teach that method would be useful for studying patients (see col. 6 line 17-20).

Page 6

Lapidus et al do not teach dilution to one half genomic equivalent in samples.

Ruano et al teach single molecule dilution (SMD) in which genomic DNA concentration is one haploid equivalent per aliquot (see whole doc. esp. pp. 6296 & Fig. 3).

One of ordinary skill would have been motivated to apply Ruano et al SMD method to Lapidus et al's comparison method in order to determine actual allele concentration ratios.

Ruano et al state that SMD method avoids the empirical optimization of amplification conditions and allows resolution of ambiguous arrangement of polymorphic markers by isolating into definitive haplotypes. It would have been prima facie obvious to apply Ruano et al's dilution method to Lapidus et al's method in order to accurately determine allele ratios.

Moreover, it would have been <u>prima facie</u> obvious to further optimize the assay conditions as in the increasing the number of PCR cycles or increasing the dilution schema to achieve single molecule dilution in order to effectively amplify from haploid equivalent.

Page 97 of 1224

Art Unit: 1656

Page 7

Claims 12,13,17 & 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over
 Lapidus et al (US5,928,870 July 27, 1999) in view of Ruano et al (PNAS vol. 87 pp. 6296-63000
 August 1990) in further view of Tyagi et al (US5,925,517 July 20, 1999).

The teachings and suggestions of Lapidus and Ruano et al are described previously. Lapidus et al do not teach molecular beacons.

Tyagi et al teach molecular beacons (see whole doc. & Fig. 3). They teach that the probe allows monitoring of progress of reactions that produce nucleic acids with either linear or exponential kinetics. They provide sensitive detection (see col. 4 lines 22-40).

One of ordinary skill would have been motivated to apply Tyagi et al's molecular beacons to the combined invention of Lapidus and Ruano et al's enumeration method in order to accurately monitor detection over real time. It would have been prima facie obvious to apply Tyagi et al's probes which would allow detection of the different sequences in Lapidus and Ruano et al's method in order to achieve accurate quantification.

SUMMARY

Claims 33-37 are free of the prior art but rejected under 112 second paragraph. There is no prior art that teach or suggest a molecular beacon probe that has a loop consisting of 16 base pairs and having a Tm of 50-51C and the stem consisting of CACG sequence.

Art Unit: 1656

Page 8

The closest prior art is Tyagi et al (US5,925,517) who teach a molecular beacon which has 15 base pair loop but a Tm of approximately 40C (Tm=[(A+T)x2C + (G+C) x4C](see PCR essential Data page 53 1995) and the stem is GCGAG (see col. . Tyagi et al (US6,037,130) teach molecular beacon with a stem comprising CACG (see col. 11 probe 3) but with a loop of Tm 65C (see col. 28 line 54). Moreover, the prior art has been focused on the Tm of the stem which relates to the functioning of the opening and closing of the hairpin during hybridization.

Claims 2 & 38-64 is free of the prior art but rejected under 112 second paragraph.

Applicant is directed to 112 second paragraph rejections concerning these claims as the lack clarity of the claims may prove a barrier to allowability. There is no prior art that teach that one tenth or one fiftieth of samples in a set comprise N molecules such that 1/N is larger than the ratio of selected genetic sequence to total genetic sequences required for the step of analyzing to determine presence of selected genetic sequence.

CONCLUSION

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Siew whose telephone number is (703) 305-3886 and whose e-mail address is Jeffrey. Siew@uspto.gov. However, the office cannot guarantee security through the e-mail system nor should official papers be transmitted through this route. The examiner can best be reached on Monday through Thursday from 6:30 a.m. to 4 p.m. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703)-308-1152.

Art Unit: 1656

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist for Technology Center 1600 whose telephone number is

(703) 308-0196.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Center numbers for Group 1600 are Voice (703) 308-3290 and Fax (703) 308-4556 or (703) 308-4242.

Jeffy Sur Jeffrey Siew

Page 9

April 7, 2001

an Aggreen St.		P. 20 M	- 04 - 1	Applic 09/61	cation/Cont 3,828	rol No.	Applicant(s)/Pat Reexamination VOGELSTEIN		
		Notice of Reference	s Cited	Exam			Art Unit	Page '	l of 1
				Jeffre	y Siew		ASSE 1637		
				U.S. PATENT I	DOCUMENT	`\$			
		Document Number Country Code-Number-Kind Code	Date MM-YYYY			Name		Classi	lication
1	A	US-5,926,517 -A	07-1999	Tyagi et al				435	6
7	В	US-6,037,130-A	03-2000	Tyagi et al				435	6
1	С	US	<u> </u>						
7	D	US							ļ
	E	US							
7	F	U\$							
7	G	US-							ļ
7	н	U\$							ļ
٦	ı	US							ļ
	J	US							<u> </u>
	К	US							}
	L	US-						٠	
_	М	US							<u> </u>
!				FOREIGN PATE	NT DOCUM	ENTS			
rk		Document Number Country Code-Number-Kind Code	MM-YYYY	Country		Nan	16	Class	ification
	N								
	0		-	<u> </u>	\rightarrow				
	Р		<u> </u>	<u> </u>	-+				}
	a			<u> </u>		\			
	R								
	8								+
	Т	-		<u> </u>		· · · · · · · · · · · · · · · · · · ·			1
				NON-PATEN			ne, Pertinent Pages)		
*	├			e: Aunor, Thie D	ale, Publish	et, Edinari or void	ite, i djanoni i agosy		<u> </u>
	U	Newton Esssential PCR pp.	11-01 1890						
	V			•					
	w								
	×	1						 	
- 2		this reference is not being furnished wit M-YYYY format are publication dates. C	h this Office action	i. (See MPEP § 707.	.05(a).)				

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 1 2 2001

In re Application of

Bert Vogelstein et al.

Serial No. 09/613,826

Filed: July 11, 2000

For: DIGITAL AMPLIFICATION

) Attn: Application Branch

) Atty. Dkt. No. 01107.00031

INFORMATION DISCLOSURE STATEMENT

The Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, enclosed is a PTO Form-1449 listing documents for consideration by the Examiner during the prosecution of the subject application and a copy of each of the identified documents. It is believed no fee is required to make this a complete and timely filing. However, if a fee is required, please charge our Deposit Account No. 19-0733.

Consideration of this information is respectfully requested.

Respectfully submitted,

Date: December 12, 2000

Sarah A. Kagan Registration No. 32,141

Banner & Witcoff, Ltd. 1001 G Street, N.W., Eleventh Floor Washington, D.C. 20001-4597 (202) 508-9100 SAK/ama

Page 102 of 1224

PATENT

пимвек 6/3826 01107,0003 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE APPLICANT JUL 1 2 2001 Bert Vogelstein et al INFORMATION DISCLOSURE STATEMENT THADESARY ROUP ART UNIT FILING DATE BY APPLICANT July 11, 2000 163 U.S. PATENT DOCUMENTS EXAMINER SÚB FILING DOCUMENT NITIAL 95 DATE NAME CLASS CLASS DATE NUMBER 5,928,970 7/27/1999 Lapidus et ill. 9/23/1997 Lapidus et al. 5,670,323 Lapidus et al. 6,020,137 FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER SUB TRANSLATION EXAMINER COUNTRY CLASS DATE MITIAL OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Jeffreys et al. "Mutation processes of human minisarelines" Electrophoresis 1995, 16 pages 1577-1585 Rusno et al. "Haplotype of multiple polymorphisms resolved by constraint emplification of single DNA molecules" Proc. Natl. Acad. Sci. USA Vol. 87, pages 6296-6300, August 1990 Persons et al. "Mismatch Repair Deficiency in Phonotypically Normal Human Cells" Science, Vol. 268 May 5, 1995 pages 738-740 Monekton et al. "Missestellite. "Isosficte" Discrimination in Vseudohomologiques by Single Mulecule PCR and Variant Repeat Mapping" Genomics, Vol. 11, 1991 pages 465-467 Sidnansky et al. "Cloud-expension of p53 naturant cells is associated with historium pages 846-847 1992 Navidies at "Licing PCR in preimplamation genetic disease disgnosts" Ruman reproduction Vol. 6, No. 6, pages 836-849 DATE CONSIDERED EXAMINER EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.

ATTY. DOCKET NO.

PTO-1449 (Modified)

SERIAL NUMBER

Page 103 of 1224

ATTY. DOCKET NO. 01107.00031 09/613,826 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE APPLICANT Bert Vogelstein et al. INFORMATION DISCLOSURE STATEMENT BY APPLICANT GROUP ART UNIT FILING DATE 1637 July 11, 2000 U.S. PATENT DOCUMENTS EXAMINER INITIAL SUB FILING DOCUMENT CLASS NAME CLASS DATE DATE NUMBER JUL 1 2 2001 C.PRADEMARY OF FOREIGN PATENT DOCUMENTS DOCUMENT SUB MINTARHART DIAZEY EXAMINER CLASS NUMBER DATE COUNTRY CLASS INITIAL OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Lizardi et al. "Mutation detection and single-molecule counting using isothermat rolling-circle amplification" Nature Genetics, Vol. 19 pages 225-32 Schmitt et al. "High sensitive D14A typing approaches for the analysis of foreistic evidence: comparison of nested variable number of tandem repeats (VNTR) amplification and a short tandem repeats (STR) polymorphism" Forensic Science International 66 (1994) pages 129-141 Li "Amplification and muniysts of DNA sequences in single human sperm and diploid cells" Nature Vol. 335 September 29, 1988 pages 414-417 Zhang "Whole genome amplification from a single cell: Implications for genetic analysis" Proc. Natl. Acad. Sc. USA., Vol. 89 pages 3847-3851 July 1992 DATE CONSIDERED EXAMINER EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.

PTO-1449 (Modified)

Sheet 2 of 2

SERIAL NUMBER



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Bert Vogelstein, et. al.

Serial No. 09/613,826

Filing Date: July 11, 2000

Group Art Unit: 1656

) Examiner: J Siew

) Docket No. 01107,00031

For: DIGITAL AMPLIFICATION

AMENDMENT

RECEIVED

JUL 1 7 2001

Assistant Commissioner for Patents Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

In response to the Office Action mailed April 12, 2001, applicants request entry of the following amendments and request reconsideration of the claims. Claims 1-64 are pending in the application. Claims 2 and 38-64 are allowable over the prior art. If any additional fee is due please change our Deposit Account No. 19-0733.

IN THE CLAIMS

Please add new claims 65-69.

65. (New)

A molecular beacon probe comprising:

an oligonucleotide comprising a stemland a loop structure and having a

1

0

photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop comprises 16 base pairs and has a Tm of 50-51°C, and wherein the stem comprises 4 base pairs having a sequence 5'-CACG-3'.

- 66. (New) The molecular beacon probe of claim 65, wherein the probe detects a wild-type nucleic acid better than a mutant nucleic acid.
- 67. (New) The molecular beacon probe of claim 65, wherein the probe detects a mutant nucleic acid better than a wild-type nucleic acid.
- 68. (New) A molecular bradon probe comprising:

 an oligonucleotide comprising a stem and a loop structure and having a

 photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5'

 or 3' end, wherein the loop comprises 19-20 base pairs and has a Tm of 54-56°C, and

 wherein the stem comprises 4 base pairs having a sequence 5'-CACG-3'.
- 69. (New) A pair of molecular beacon probes comprising:

 a first oligonucleotide comprising a first stem and a first loop structure and having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the first loop comprises 16 base pairs and has a Tm of 50-51°C, and wherein the first stem comprises 4 base pairs having a sequence 5'-CACG-3'; and a second oligonucleotide comprising a second stem and a second loop structure

Qi Cond and having a phototraginescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the second loop comprises 19-20 base pairs and has a Tm of 54-56°C, and wherein the second stem comprises 4 base pairs having a sequence 5'-CACG-3'.

IN THE SPECIFICATION

Please replace the paragraph beginning on page 4, line 5, with the following paragraph.

FIG. 1A, 1B, 1C. Schematic of experimental design. (A) The basic two steps involved: PCR on diluted DNA samples is followed by addition of fluorescent probes which discriminate between WT and mutant alleles and subsequent fluorometry. (B) Principle of molecular beacon analysis. In the stem-loop configuration, fluorescence from a dye at the 5' end of the oligonucleotide probe is quenched by a Dabcyl group at the 3' end. Upon hybridization to a template, the dye is separated from the quencher, resulting in increased fluorescence. Modified from Marras et al. (C) Oligonucleotide design. Primers F1 and R1 are used to amplify the genomic region of interest. Primer INT is used to produce single stranded DNA from the original PCR products during a subsequent asymmetric PCR step (see Materials and Methods). MB-RED is a Molecular Beacon which detects any appropriate PCR product, whether it is WT or mutant at the queried codons. MB-GREEN is a Molecular Beacon which preferentially detects the WT PCR product.

 $\alpha^{\mathcal{V}}$

3

37

1

Please replace the paragraph beginning on page 14, line 29 with the following paragraph.

Oligonucleotides and DNA sequencing. Primer F1:

5'-CATGTTCTAATATAGTCACATTTTCA-3' (SEQ ID NO: 1); Primer R1:

5'-TCTGAATTAGCTGTATCGTCAAGG-3' (SEQ ID NO: 2); Primer INT:

5'-TAGCTGTATCGTCAAGGCAC-3' (SEQ ID NO: 3); MB-RED:

5'-Cy3-CACGGGCCTGCTGAAAATGACTGCGTG-Dabcyl-3' (SEQ ID NO: 4);

MB-GREEN: 5'-Fluorescein-CACGGGAGCTGGTGGCGTAGCGTG-Dabcyl-3' (SEQ

ID NO: 5). Molecular Beacons (33,34) were synthesized by Midland Scientific and other

oligonucleotides were synthesized by Gene Link (Thornwood, NY). All were dissolved

at 50 uM in TE (10 mM Tris, pH 8.0/1 mM EDTA) and kept frozen and in the dark until

use. PCR products were purified using QIAquick PCR purification kits (Qiagen). In the

relevant experiments described in the text, 20% of the product from single wells was used

for gel electrophoresis and 40% was used for each sequencing reaction. The primer used

for sequencing was 5'-CATTATTTTTATTATAAGGCCTGC-3' (SEQ ID NO: 6).

Sequencing was performed using fluorescently-labeled ABI Big Dye terminators and an

ABI 377 automated sequencer.

SEQUENCE LISTING

Please enter the enclosed paper copy of the Sequence Listing after the claims. A computer readable copy of the Sequence Listing is also enclosed herewith to comply with 37 § CFR 1.821(e). The content of the paper and computer readable copy of the

4

35

U

Sequence Listing, submitted in accordance with 37 CFR § 1.821 (c) and (e), respectively, are identical. The submitted Sequence Listing, filed in accordance with 37 CFR § 1.821 (g) herein does not include new matter.

REMARKS

The Invention

The invention is directed to a method for determining the ratio of a selected genetic sequence in a population of genetic sequences. Nucleic acid template molecules in a biological sample are diluted to form a set comprising a plurality of assay samples. The diluted nucleic acid template molecules are amplified to form a population of amplified molecules in the assay samples of the set. The amplified molecules are analyzed to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence. The first number and the second number are compared to ascertain a ratio that reflects the composition of the biological sample (claim 1).

The invention is also drawn to a method for determining the ratio of a selected genetic sequence in a population of genetic sequences. Template molecules within a set which comprises a plurality of assay samples are amplified to form a population of amplified molecules in each of the assay samples of the set. The amplified molecules in the assay samples of the set are analyzed to determine a first number of assay samples which contain the selected genetic sequence and a second umber of assay samples which contain a reference genetic sequence. At least one-fiftieth of the assay samples in the set

comprise a number (N) of molecules such that 1/N is larger than the ratio of selected genetic sequences to total genetic sequences required to determine the presence of the selected genetic sequence. The first number is compared to the second number to ascertain a ratio which reflects the composition of the biological sample (claim 38).

The invention is also drawn to molecular beacon probes. The molecular beacon probe comprises an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end. The loop consists of 16 base pairs and has a T_m of 50-51°C. The stem consists of 4 base pairs and has a sequence 5'-CACG-3' (claim 33). The loop of the molecular beacon probe may alternatively consist of 19-20 base pairs and have a T_m of 54-56°C (claim 36).

The invention also is drawn to a pair of molecular beacon probes comprising a first and second probe. This first probe comprises an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' and 3' ends and a quenching agent at the opposite 5' or 3' end. The loop consists of 16 base pairs and has a T_m of 50-51°C. The stem consists of 4 base pairs and has a sequence 5'-CACG-3'. The second probe comprises an oligonucleotide that has a stem-loop structure having a photoluminescent dye at one of the 5' and 3' ends and a quenching agent at the opposite 5' or 3' end. The loop consists of 19-20 base pairs and has a T_m of 54-56°C. The stem consists of 4 base pairs and has a sequence 5'CACG-3' (claim 37).

Information Disclosure Statement

The Office Action asserts that the listing of references in the specification is not a

proper information disclosure statement (IDS). The listing of references in the specification is not intended as the IDS for the application. Applicants have made two submissions on Form PTO-1449, in compliance with 37 CFR 1.98(b) on December 15, 2000 and March 7, 2001. A copy of each IDS submitted is attached along with the postcard receipts, at Tabs A and B. Clearly the PTO received at least one sheet of PTO-1449, as this has been returned to applicant, albeit entirely crossed out. No explanation is provided for the failure to consider the references. A new set of references is included in case these were lost in PTO handling. Li et al. is not included with this response, but will be sent in a separate mailing. Applicants recognize that the two lists of references are almost identical but for the Brown patent which was only listed on the March 7, 2001 submission. Applicants request an initialed copy of the PTO-1449 indicating consideration of each reference.

Objections to the Specification

The Office Action has objected to the specification for reciting "Figure 1" in the Brief Description of the Drawings, while no Figure 1 exists in the drawings. The specification has been amended to properly recite Figure 1A, 1B, 1C in the Brief Description of the Drawings.

The specification was further objected to for improper disclosure of nucleotide sequences. The sequences referenced in the Office Action (at page 14, lines 30 and 31, as well as sequences not referenced in the Office Action at page 15, lines 1, 2, 4, and 13 of the specification) were entered into a Sequence Listing as they appear in the

application, and thus contain no new matter. A paper and computer readable form of the Sequence Listing are submitted with this amendment.

The Rejection of Claims 1-64 under 35 U.S.C. § 112

Claims 1-64 have been rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the applicant regards as his invention.

A. The rejected claims are allegedly incomplete for omitting essential steps. The Office Action identifies the omitted steps as "serially diluting to form a set of assay samples and testing by PCR." (Page 4, lines 3-4.) Applicants respectfully traverse.

Claim 1 recites both a diluting step and an amplifying step at lines 3 and 5, respectively. Claim 38 recites an amplifying step at line 3. Thus the only step that could possibly be missing is diluting in claim 38. However, this step is neither essential nor required. Claim 38 requires a certain concentration of template which may, but need not, be achieved by dilution. If samples are initially sufficiently dilute, no dilution is required. Thus dilution is not a necessary step.

The Office Action points to the specification at page 13, lines 17-19, to demonstrate that claims 1-32 and 38-64 omit the essential steps of serially diluting and testing via PCR. The citation is to example 1. The examples, however, are provided "for purposes of illustration only, annd are not intended to limit the scope of the invention." (Page 13, lines 6-7.) Nothing in the example indicates that dilution is essential, and as discussed above, it is not.

B. The Office Action asserts that the claims omit linear amplification by PCR, which is allegedly a critical step of the invention. The PTO supports this assertion by citing the specification at page 14, line 18 where an example of sample analysis is disclosed in which linear amplification is used to enhance the signal provided by molecular beacon probes. Applicants respectfully traverse.

Claim 1 recites:

analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence.

Claim 38 recites:

analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected genetic sequence and a second umber of assay samples which contain a reference genetic sequence, wherein at least one-fiftieth of the assay samples in the set comprise a number (N) of molecules such that 1/N is larger than the ratio of selected genetic sequences to total genetic sequences required to determine the presence of the selected genetic sequence.

In each claim, the amplified molecules in the assay samples of the set are analyzed, but a particular analysis method is not required.

Linear amplification can be performed as part of the step of analyzing but it need not be. The specification teaches that: "Although the working examples demonstrate the use of molecular beacon probes as the means of analysis of the amplified dilution samples, other techniques can be used as well." (Emphasis added, page 12, lines 29-31.) Since linear amplification was taught to enhance the signal of molecular beacon probes,

which are not essential, clearly linear amplification is not essential either. Therefore, the claimed method does not require linear PCR.

Nothing in the specification indicates that linear amplification by PCR is essential. Rather, linear amplification by PCR is disclosed as an <u>enhancement</u> to the analysis step when molecular beacon (MB) probes are used. The specification states, "fluorescent signals obtained could be considerably enhanced if several cycles of asymmetric, linear amplification were performed in the presence of the MB probes." (Page 19, lines 9-11.) Thus linear amplification is not essential to the method of the invention.

C. The Office Action asserts that the use of the term "consists" is confusing because "[i]t cannot be determined whether the claim intends open or closed language for the limitation of the sequence. Proper Markush language is required." (Page 4, lines 14-15.) Applicant's respectfully traverse.

Each of claims 33, 36, and 37 recite "the stem consists of 4 base pairs having a sequence 5'-CACG-3." "When the phrase 'consists of' appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause." Manesmann Demag Corp. v. Engineered Metal Products Co., 793 F.2d 1279, 230 USPQ 45 (Fed. Cir. 1986). Therefore, the term "consists" is closed. The stem contains the four recited base pairs 5'-CACG-3' and no others. No Markush group is present in claims 33, 36, and 37.

D. The Office Action asserts that "[c]laim 2 is confusing because it is unclear as to whether each sample of the fraction of one out ten (sic) are to contain N molecules."

(Page 4, lines 16-17.) Applicant's respectfully traverse.

The claim recites, "at least one-tenth of the assay samples in the set comprise a number (N) of molecules." (Claim 2, lines 2-3.) The claim positively recites that at least one out of ten of the assay samples in the set have a number (N) molecules. The claim is not confusing or unclear. The language of the claim affirmatively answers the question of the Office Action. Each of the 1/10 fraction of samples comprise a number (N) molecules. N is defined so that 1/N is larger than the ratio of selected genetic sequences to total genetic sequences. Thus all of the 1/10 samples need not have the same number of molecules, but a number that fits the definition. Nonetheless, if samples are formed by dilution, as in claim 2, the samples should have roughly identical numbers of molecules.

Withdrawal of the 35 U.S.C. §112 rejection of claims 1-64 is respectfully requested as all claims are clear and definite.

Rejection of claims 1 and 3-32 under 35 U.S.C. §103(a)

Lapidus (U.S. 5,928,870) and Ruano (P.N.A.S., vol. 87, pp. 6296-6300, August 1990) in combination are cited as teaching the invention of claims 1, 3, 4-11, 14-16, and 19-32. Tyagi (U.S. 5,925,517) is further combined to allegedly teach the invention of claims 12, 13, 17, and 18. These rejections are respectfully traversed.

It is axiomatic that all elements of a claim must be taught or suggested by the prior art for a *prima facie* case of obviousness to be proper. MPEP §2143. The present rejection fails to fulfill this "all elements" rule and thus fails to present a *prima facie* case.

Claim 1 requires four steps: diluting, amplifying, analyzing, and comparing.

Neither Lapidus nor Ruano teach the step of analyzing or the step of comparing as specified in claim 1. Claim 1, steps 3 and 4, recite:

analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence;

comparing the first number to the second number to ascertain a ratio which reflects the composition of the biological sample.

Emphasis added. The Office Action fails to point to any portion in either Lapidus or Ruano which teach these two steps. Lapidus does not teach determining a number of assay samples containing genetic sequences. Lapidus instead teaches determining concentration. The Office Action refers to this teaching of Lapidus as "enumerating number molecules of a target," citing col. 2, lines 58-66. This, however, is different from determining the <u>number</u> of <u>assay samples</u> containing a genetic sequence. Since the numbers of assay samples are not determined according to Lapidus, neither are the numbers compared, as required in step 4.

This difference leads to an advantage of the present invention over Lapidus.

Digital amplification, as claimed, converts "the intrinsically exponential nature of PCR to a linear one." Specification at page 8, lines 17-18. Thus the present invention eliminates the quantitative bias which exponential amplification introduces into a nucleic acid sample. Since neither Lapidus nor Ruano teach these elements of the claims, the *prima facte* case must fail.

Tyagi teaches molecular beacon probes. Tyagi is cited in combination with Lapidus and Ruano to allegedly render claims 12, 13, 17 and 18 obvious. (Claim 12 does not employ a molecular beacon probe at all, so its inclusion in this rejection is improper.)

Like the primary references, Tyagi does not teach the element of "determining a first number of assay samples" nor of comparing the first and second numbers. Thus Tyagi does not remedy the defect of the primary references. Again, the *prima facie* case fails to teach all elements of the claimed invention and must therefore be withdrawn as improper.

A speedy allowance of all pending claims is respectfully requested.

Respectfully submitted,

Date: July 12, 2001

Sarah A. Kagan Registration No. 32,141

BANNER & WITCOFF, LTD. 1001 G STREET, NW WASHINGTON, DC 20001 202-508-9100

Ü

MARKED UP VERSION TO SHOW CHANGES MADE

Replacement paragraph beginning on page 4, line 5.

FIG. 1A, 1B, 1C. Schematic of experimental design. (A) The basic two steps involved: PCR on diluted DNA samples is followed by addition of fluorescent probes which discriminate between WT and mutant alleles and subsequent fluorometry. (B) Principle of molecular beacon analysis. In the stem-loop configuration, fluorescence from a dye at the 5' end of the oligonucleotide probe is quenched by a Dabcyl group at the 3' end. Upon hybridization to a template, the dye is separated from the quencher, resulting in increased fluorescence. Modified from Marras et al. (C) Oligonucleotide design. Primers F1 and R1 are used to amplify the genomic region of interest. Primer INT is used to produce single stranded DNA from the original PCR products during a subsequent asymmetric PCR step (see Materials and Methods). MB-RED is a Molecular Beacon which detects any appropriate PCR product, whether it is WT or mutant at the queried codons. MB-GREEN is a Molecular Beacon which preferentially detects the WT PCR product.

Replacement paragraph beginning on page 14, line 29.

Oligonucleotides and DNA sequencing. Primer F1:

5'-CATGTTCTAATATAGTCACATTTTCA-3' (SEO ID NO; 1); Primer R1:

5'-TCTGAATTAGCTGTATCGTCAAGG-3' (SEO ID NO: 2); Primer INT:

5'-TAGCTGTATCGTCAAGGCAC-3' (SEO ID NO: 3); MB-RED:

5'-Cy3-CACGGGCCTGCTGAAAATGACTGCGTG-Dabcyl-3' (SEQ ID NO: 4);
MB-GREEN: 5'-Fluorescein-CACGGGAGCTGGTGGCGTAGCGTG-Dabcyl-3' (SEQ ID NO: 5). Molecular Beacons (33,34) were synthesized by Midland Scientific and other oligonucleotides were synthesized by Gene Link (Thornwood, NY). All were dissolved at 50 uM in TE (10 mM Tris, pH 8.0/ 1 mM EDTA) and kept frozen and in the dark until use. PCR products were purified using QIAquick PCR purification kits (Qiagen). In the relevant experiments described in the text, 20% of the product from single wells was used for gel electrophoresis and 40% was used for each sequencing reaction. The primer used for sequencing was 5'-CATTATTTTTATTATAAGGCCTGC-3' (SEQ ID NO: 6).
Sequencing was performed using fluorescently-labeled ABI Big Dye terminators and an ABI 377 automated sequencer.

20/01 FRI 10:12 FAY 70 08 02648 JUL 1 2 7001

GP 1800 FAX MACHIN.

⊠002

Application No.: 09/613 826

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE PRODUCT AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

Ø	1. This application clearly falls to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
N	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
X	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other.
Apı	plicant Must Provide:
N	An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".
Ø	An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
N.	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(a) or 1.821(f) or 1.821(g) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, cali (703) 308-4216 CRF Submission Help, call (703) 308-4212 entin Software Program Support Technical Assistance
	To Purchase Patentin Software703-306-2600
	PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Page 120 of 1224

.

Page 121 of 1224

C1



MATERIT - DECICAL - DUD-5	1001 00031 0000 \$17101
PATENT □ DESIGN B&W Ref. □ HAND CARRY Group/Section □	Pida Rm
HAND CARRY Group/Section	ANGE SAVISE
Serial/Patent No. D4/1/13,8216	Ally/Sec Dis-19-19
Inventor VDGSLSTSIN ALL.	Client Jours Honard
Title DIGITAL AMPLIBICATIONS	
The following has been received in the U.S. Parent	and Trademark Office on the date stamped hereon.
Dtotal pp Soec., including : # of Claims	□ Sequence Listing : □ Diskette □ Paper
(# of independent claims); DAbstract	D Amendment D Response : OA dtd
Denvisor : O Formal O Information	CPA DRCE D W/Ext of Time : OA did
Drawings: Dramal Information of distinct sheets Figs	D Petition for Extension of Time until
	Request for Approval of Drawing Changes
O Assignment w/PTO Cover Steet MAR 0 7 200	O Notice of Appeal & Fee
O Small Entity Declaration	
Small Entity Declaration IDS w/PTO 1449 References Sw/Fee Control Preliminary Amendment Description of U.S.Prov Bank ADEMAN	© Request for Oral Hearing
O Preliminary Amendment	Dissue Fee D Adv Patent Copies (#ordered)
D Priority Claim (Foreign or U.S.Prov BandADEM)	Notice of Allowance did
Country Appl 8 Uste	☐ Amendment under 37 CFR 1.312
D w/Foreign Priority Document(s)	☐ Request for Certificate of Correction
□ Application: □ CIP □ Continuation □ Divisional	□ Check # for \$
Parent Ser No B&W#	□ Check # for \$
U.S. Provisional pp Spec/Clms, Cover Sht	D
D Response to Missing Parts/Romts, did	4
☐ Request for Expedited Foreign Filing License	ρ 7
☐ Request for Corrected : ☐ Filmp Rec ☐ Assignment	P BRM HEL JOHOC
☐ Response to Restriction/Election Requirement \	BEW REC 1000

q

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Bert Vogelstein, et al.

Serial No.: 09/613,826

Filed: July 11, 2000

Caroup Art No. 1632

Examiner: TBA

Docket No. 01107.00031

For: DIGITAL AMPLIFICATION

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56 and in compliance with 37 C.F.R. §1.97, Applicants submit herewith a Form PTO-1449 identifying information for consideration by the Examiner. A copy of each of the items of information is enclosed.

Applicants do not waive any rights to take appropriate action to establish patentability over the listed documents should they be applied as a reference against the claims of the present application.

Consideration of the cited information and making the same of record in the prosecution of the above-noted application are respectfully requested. Should the Patent and Trademark Office determine that a fee is required, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.

Sarah A. Kagan

Registration No. 32,141

1001 G Street, N.W. Washington, D.C. 20001-4597 (202) 508-9100 Dated:

	PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT		ATTY, DOCKET NO.	SERIAL NUMBER		
			01107.00031	TEAR 09/613826		1890
			APPLICANTS Ben Vogelstein, et al.			
INFORMA			FILING DATE	GROUP A	GROUP ART UNIT	
			July 11, 2000	TRA	1637	
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
SS	5,670,325	9/1997	Lapidus, et al.			
	5,928,870	7/1999	Lapidus, et al.			
	6,020,137	2/2000	Lapidus, et al.			
\$ <u></u>	6,143,496	11/2000	Brown, et al.	<u> </u>	<u> </u>	
U	OTHER	DOCUMENTS (including Author, Title, Date, Pertinent Pa	ges, Etc.)		
	Darren G. MONCKTO and Varient Repeat Ma	N, et al "Minisa	tellite "Isoallele" Discrimination in Pseud s 11, pp. 465-467, 1991	ohomozygotes	by Single M	olecule PCR
85	Gualberto RUANO, et al., "Haplotype of Multiple Polymorphisms Resolved by Enzymatic Amplification of Single DNA Molecules", Proc. National Science USA, 1990					
		,	ndla katios Gendlic Discase Diagnosis", H	uman Reprodu	ction, Vol. 6	, No. 6, pp.
	Hongus Ll, et al., "Amplification and Analysis of DNA Sequences in Single Human Sperm and Diploid Cells", Nature Vol. 335, September 29, 1988			, Nature,		
	Ramon PARSONS, et al., "Mismatch Repair Deficiency in Phenotypically Normal Human Cells", Science, Vol. 268, May 5, 1995			i. 268,		
	Lin ZHANG, et al., "Whole Genome Amplification from a Single Cell: Implications for Genetic Analysis", Proc. National Science USA, Vol. 89, pp. 5847-5851, July 1992					
	David SIDRANSKY, et al., "Clonal Expansion of p53 Mutant Cells is Associated with Brain Tumour Progression", Nature, February 27, 1992					
	Alec J. Jestreys, et al., "Mutation Processes at Human Minisatellites, Electophoresis, pp. 1577-1585, 1995					
	C. SCHMITT, et al., "High Sensitive DNA Typing Approaches for the Analysis of Forensic Evidence: Comparison of Nested Variable Number of Tandem Repeats (VNTR) Amplification and Short Tandem Repeats (STR) Polymorphism", Forensic Science International, Vol. 66, pp. 129-141, 1994					
	Paul M. LIZARDI, et al., "Mutation Detection and Single-Molecule Counting Using Isothermal Rolling-Circle Amplification", Nature Genetics, Vol. 19, July 1998					
	W. NAVIDI, et al., "Using PCR in Preimplantation Genetic Disease Diagnosis", Human Reproduction, Vol. 6, 1991					
86	Honghua Ll, et al., "Ar Vol. 335, September 29		unalysis of DNA Sequences in Single Hum	an Sperm and	Diploid Cells	"Nature,
00	1			\		
EXAMINER	· Jeklon &	luy,	DATE CONSIDERED 3	123/0	2	,
	Initial citation if reference clude copy of this form w		Draw line through citation if not in conforcation to applicant.	mance to MPE	P 609 and n	ú

В

Page 125 of 1224

Ó



Patent/Design	O PATENT	
☐ HAND CARRY Group/Section _ Serial No. C.9 c/3 5.34c B&W # C 1 C 7.5.503;	Bldg	Rm
Serial No. C9 16 3 536 B&W # 6110 7.00031	Alty/Sec 51 Consc. D	late iulisics
Inventor Catalian Title Digital Amprilantes	Client THE	·
Title Vicitory HINDRIGHTON		
The following has been received in the U.S. Patent a	nd Trademark Office on the date st	amped hereon:
n total pp Spec., including : # of Claims	O Claim for Priority w/Priority Doc	olov Appl 8 and Dale
(# of independent claims); □ Abstract	O Petition for Extension til	
☐ Foreign Priority on	□ Amendment □ Response : OA	dtď
	O Request for Approval of Drawing	
O Priority on U.S. ProvB&W#	□ CPA Request □ w/Ext of Time	
□ Application : □ CIP □ Continuation □ Divisional Parent Ser. No	☐ Notice of Appeal & Fee	
Provisional App pp Spec/Clms; Cover Sht.	□ Brief : □ Appeal & Fee	O Reply
- management	Propert for Oral Hearing	
Patent/Design		□ DESIGN
☐ HAND CARRY Group/Section	Bldg	Rm
Senal No. (1/2/3) 144 B&W # CNG7 (203	J Atty/Sec (G / A / M/)	Date 12/15/C2
Inventor Structure	Client_3 hTd	
Inventor Courter		,
The following has been received in the U.S. Patent	and Trademark Office on the date	stamped hereon:
total pp Spec., including: # of Claims	Claim for Priority w/Priority Do	oc -
f# of independent claims); □ Abstract		Country, Appl # and Date
Country, Appl # and Date	Petition for Extension til	
O Priority on U.S. Prov B&W#	☐ Amendment ☐ Response : C	
□ Application : □ CIP □ Continuation □ Divisional	□ Request for Approval of Drawi	
Parent Ser. No B&W#	□ CPA Request □ w/Ext of Tin □ Notice of Appeal & Fee	16 : UA 010
Provisional App pp Spec/Clms; Cover Sht.	Brief: Appeal & Fee	□ Reply
Q Declaration/PoA : D Executed Unexecuted	(I)Request for Oral Hearing	о керу
O Drawings: O Formal O Informal PE	D Issue Fee : Allowance dtd	
 # of distinct sheats; Figs 	☐ Advance Patent Copies : # ord	lared
☐ Assignment w/PTO Cover Sheet	Sheck#for	E
9 Small Entity Declaration g DEC 1 5 2000	Check# for	*
DIDS w/PTO 1449 Prior Art O w/fee	<i>A</i>	Y
☐ Preliminary Amendment		
Response : Missing Parts did		
Request for Expedited Foreign Filing License	o (VX)	
☐ Request for Corrected Filing Receipt		BEVV Rev 4/99

Box Seg/ 1656

PTO/SB/21 (08-00) Approved for use through 10/31/2002. OMB 0651-0031
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to respond to a collection of information unless it displays a valid OMB control number. Please type a plus sign (+) inside this box -> [+] Under the Paperwork Reduction Act of 1995, no persons are required Application Number 09/613,826 TRANSMITTAL Filing Date July 11, 2000 **FORM** VOGELSTEIN, et al. First Named Inventor 2001 (to be used for all correspondence after initial filing) **Group Art Unit** 1656 J. SIEW Examiner Name TECH CENTER 1800/2900 01107.00031 Attorney Docket Number Total Number of Pages in This Submission ENCLOSURES (check all that apply) After Allowance Communication to Assignment Papers
(for an Application) Fee Transmittal Form Group Appeal Communication to Board of Appeals and Interferences Drawing(e) Fee Attached Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Licensing-related Papers Amendment / Response Petition Routing Slip (PTO/SB/89) and Accompanying Petition Proprietary information After Finel Petition to Convert to a Status Letter Affidavita/declaration(s) Provisional Application Power of Attorney, Revocation Other Enclosure(s)
(please Identity below): Change of Correspondence Address Extension of Time Request Sequence Listing; Diskette Terminal Disclaimer Containing Sequence Listing; Express Abandonment Request Copy of Notice to Comply; copies of 2 previously submitted IDS's; copies of references cited Request for Refund Information Disclosure Statement CD, Number of CD(s) pages of references are in addition to Total Number of pages World Certified Copy of Priority Remarks Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Serah A. Kagan Reg. No. 32,14 or Individual name Signature July 12, 2001 Date CERTIFICATE OF MAILING I hereby cartify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to; Assistant Commissioner for Patents, Washington, D.C. 20231 on this dete: Typed or printed name Date Signature Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Tredemark Office, Weshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Weshington, DC 20231.

406795-1

Page 127 of 1224

<210> 5
<211> 24
<212> DNA
<213> homo sapiens
<400> 5
cacgggagct ggtggcgtag cgtg
24
<210> 6
<211> 24
<212> DNA
<212> DNA
<213> homo sapiens
<400> 6
cuttatttt attataaggc ctgc
24

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Bert Vogelstein, et. al. Serial No. 09/613,826

Filing Date: July 11, 2000

) Group Art Unit: 1656) Examiner: I Siew

) Docket No. 01107,00031

RECEIVED

JUL 1 9 2001 TECH CENTER 1600/2900

For: DIGITAL AMPLIFICATION

SUPPLEMENTAL SUBMISSION

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In applicants' response to the Office Action mailed July 12, 2001 copies of two previously filed Information Disclosure Statements (IDS) were supplied. A new set of references was also included in case the original set of references was lost in PTO handling. A copy of Li, et al. (Nature, 1988, (335):414-417) however was missing. The reference is enclosed herewith.

No fee is believed due. If any additional fee is due please change our Deposit Account No. 19-0733.

Respectfully submitted,

July 17, 2001 Date:

Registration No. 47,660

BANNER & WITCOFF, LTD. 1001 G STREET, NW WASHINGTON, DC 2000 I 202-508-9100

lease type a plus sign (+) incide this box ->>

Approved for use through 10/31/2002, OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paparwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Please type a plus sign (+) incide this box -> [+]

GIPA		Application Number	09/613,826	profile
TRANSMITTAL	•	Filing Date	July 11, 2000	RECEIVED
JUL 1 7 201 (1) FORM	FORM		VOGELSTEIN et al.	JUL 1 9 2001
be used for all correspondence after la	itlaf filing)	Group Art Unit	1656	TECH CENTER 1600/290
MADEMA		Examiner Name	J. SIEW	ובטת טבויו בוו וטטטוצטט
Total Number of Pages in This Submission	6	Attorney Docket Number	01107.00031	
	ENCL	OSURES (check all that apply)		
Fee Transmittel Form		ment Papers Application)	After Allowance Comm Group	unication to
Fee Attached	☐ Drawlr	g(s)	Appeal Communication Appeals and Interferen	ices
Amendment / Response		ing-related Papers	Appeal Communication (Appeal Notice, Brief, Rep	
After Final		n Routing Silp (PTO/SB/89) ccompanying Petition	Proprietary Information	1
Affidavite/declaration(s)		n to Convert to a Ional Application	Status Letter	
Extension of Time Request		of Attornay, Revocation ge of Correspondence Address	Other Enclosure(s) (please identify below):	
Express Abandonment Request		nal Disclaimer set for Refund	Supplemental Sul Copy of TRAG	
Information Disclosure Statement	CD, N	umber of CD(e)		
Certified Copy of Priority Document(s)	Certified Copy of Priority Rema			
Response to Missing Parts/ incomplete Application				
Response to Missing Parts under 37 CFR 1.52 or 1.53				nessence angles angles and an analysis a
sign/	TURE OF	APPLICANT, ATTORNEY, O	R AGENT	
Firm Michelle Holmes- or Individual name Reg. No. 47,680	Son			
Signature MichOu	when	m don		
Date July 17, 2001		, and the second se		
		RTIFICATE OF MAILING	1.	
I hereby cartify that this correspondence				in an envelope
addressed to: Assistent Commissioner f	addressed to: Assistant Commissioner for Patanta, Wa		ite:	
Typed or printed name				
Signeture			Date	
Burden Hour Statement: This form is estimated comments on the amount of time you are required. Washington, DC 20231. DO NOT SI Patents, Washington, DC 20231.	ed to take 0.2 ulred to compl END FEES Of	hours to complete. Time will visit die ete this form should be send to the C R COMPLETED FORMS TO THIS A	thing upon the needs of the little information Officer, U.S. Par DERESS. SEND TO: Assisten	ndividusi casa. Any tant and Trademark I Commissioner for

407556-1



UNITED STATE EPARTMENT OF COMMERCE Patent and Tradeniark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231 //

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 09/613,826 07/11/00 VOGELSTEIN Ľ 01107.00033 EXAMINER 022907 HM12/0920 BANNER & WITCOFF ARY UNIT 1001 G STREET N W SUITE 1100 PAPER NUMBER WASHINGTON DC 20001 10 1656 DATE MAILED; 09/20/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Tredemarks

PTC-69C (Rev. 2/85) "U.S. GPO: 2000-473-000/44602 1- File Copy

أمون

		Application No.	Applicant(s)		
Afflan Bation Cummany		09/813,626	VOGELSTEIN ET AL.		
	Office Action Summary	Examiner	Art Unit		
		Jeffrey Siew	1656		
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply				
THE II - Extensifier: - If the - If NO - Fallur - Any o	A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extansions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is teen than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If the period for reply is a pecified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Fallure to reply within the set or extended period for reply will, by alsatuta, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office leter than three months effect the making date of this communication, even if timely filed, may reduce any examed patent term adjustment. See 37 CFR 1.1704(b).				
1)	Responsive to communication(s) filed on 12.	hilv 2004			
2a) 🛛	· · · · · · · · · · · · · · · · · · ·	ils action is non-final.			
3)	Since this application is in condition for allow closed in accordance with the practice under	ance except for formal matters, p	rosecution as to the merits is 453 O.G. 213,		
Dispositi	on of Claims				
·	Claim(s) 1-69 is/are pending in the application	1.			
, –	4a) Of the above claim(s) is/are withdra				
l .	Claim(s) 1-64 is/are allowed.				
8)□	Claim(s) 65-69 is/are rejected.				
7)□	Claim(s) is/are objected to.				
	Claim(s) are subject to restriction and/o	r election requirement.			
Applicati	on Papers				
9) ☐ The specification is objected to by the Examiner.					
10)□ 1	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1,85(a).					
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12)☐ The oath or declaration is objected to by the Examiner.					
Priority 4	mder 35 U.S.C. §§ 119 and 120		· ·		
13)	Acknowledgment is made of a claim for foreig	n priority under 35 U.S.C, § 119(a	a)-(d) or (f).		
a)[☐ All b)☐ Some * c)☐ None of:				
	1. Certified copies of the priority document	s have been received.			
	2. Certified copies of the priority document				
. 6	 Copies of the certified copies of the pricapplication from the International Business that a continuous pricapplication for a list see the attached detailed Office action for a list 	reau (PCT Rule 17.2(a)).			
	acknowledgment is made of a claim for domest				
a	☐ The translation of the foreign language pro	ovisional application has been rec	ceived.		
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)					
2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(e) (PTO-1449) Paper No(e) ഉ	5) Notice of Informal	Patent Application (PTO-152)		
US Patent and T PTO-328 (Re		ction Summary	Part of Paper No. 10		

Application/Control Number: 09/613,826

Art Unit: 1656

Page 2

DETAILED ACTION

Information Disclosure Statement

1. The IDS filed 12/15/00 was one page and IDS filed March 7,2001 was one page. Both were signed and intended to be mailed to applicant. Apparently the IDS of 12/15/00 was only received. The references on this IDS were crossed out because they are duplicates of references on IDS March 7, 2001. Moreover, all the references in newly submitted IDS July 12, 2001 were contained in the IDS of March 7, 2001. It is unclear as to the purpose applicant's resubmission of these references but as the office has reviewed the references per IDS March 7, 2001 and signed the PTO-1449 it is deemed adequately considered. A copy of signed IDS March 7, 2001 will be resent with this mailing.

THE FOLLOWING IS A NEW GROUND OF REJECTION NECESSITATED BY THE AMENDMENT

Claim Rejections - 35 USC § 112

2. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 65-69 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one

Application/Control Number: 09/613,826

Art Unit: 1656

Page 3

skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The specification describes molecular probes that are consisting of 16 base pairs with a Tm of 50-51°C and a stem consisting of 4 base pairs or one with a loop consisting of 19-20 base pairs and Tm of 54-56°C and stem consisting of 4 base pairs. The specification lacks support for molecular beacon that has a loop greater than 16 base pairs with Tm of 50-51°C and stem comprising 4 base pairs nor a molecular beacon that a loop comprising 19-20 base pairs and Tm of 54-56°C and stem comprising of 4 base pairs.

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 68 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A) The term comprising 19-20 renders claim 68 unclear. As the term is open it is unclear as to whether the loop is to be greater than 19 or greater than 20 base pairs.

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

Page 4

Application/Control Number: 09/613,826 Art Unit: 1656

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

Claim 65-67 are rejected under 35 U.S.C. 102(e) as being anticipated by Tyagi et al (US5,925,517 March 14, 2000).

Tyagi et al who teach a molecular beacon with a stem <u>comprising CACG</u> (see col. 11 probe 3) but with a loop of Tm 50 Tm=[(A+T)x2C + (G+C) x4C] (see col. 12 SEQ ID NO:3).

Claims 66 & 67 refer to a property that is drawn to the intended use of the probe.

Upon recalculation of the loop for Tyagi et al's probe 3, it appears that the Tm is within the claimed range. However, in referring to original claim 33 probe 3 does not have the limitation of stem of only 4 base pairs.

SUMMARY

5. Claims 33-37 are allowable. There is no prior art that teach or suggest a molecular beacon probe that has a loop consisting of 16 base pairs and having a Tm of 50-51C and the stem consisting of CACG sequence. The closest prior art is Tyagi et al (US6,037,130) teach molecular beacon with a stem comprising CACG (see col. 11 probe 3) but with a loop of Tm 50C. Moreover, the prior art has been focused on the Tm of the stem which relates to the functioning of the opening and closing of the hairpin during hybridization.

Application/Control Number: 09/613,826

Art Unit: 1656

Claims 1-32 & 38-64 is allowable. There is no prior art that teach or suggest diluting a nucleic acid template in a sample to a plurality of sample and amplifying the template molecule in the samples and analyzing amplified molecules to determine the first number of samples containing the selected genetic sequence and second number assay samples which contain a reference genetic sequence and comparing the two numbers. Moreover, there is no prior art that teach or suggest that one tenth or one fiftieth of samples in a set comprise N molecules such that 1/N is larger than the ratio of selected genetic sequence to total genetic sequences required for the step of analyzing to determine presence of selected genetic sequence. The closest prior art is Lapidus et al who teach a reference and target nucleic acid amplification and concentration determination. However, his determination of concentration is within a sample and they do not teach or suggest a dilution.

CONCLUSION

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

Application/Control Number: 09/613,826

Art Unit: 1656

Page 6

final action.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Siew whose telephone number is (703) 305-3886 and whose email address is Jeffrey.Siew@uspto.gov. However, the office cannot guarantee security through the e-mail system nor should official papers be transmitted through this route. The examiner is on flex-time schedule and can best be reached on weekdays from 6:30 a.m. to 3 p.m. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703)-308-1152.

however, will the statutory period for reply expire later than SIX MONTHS from the date of this

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist for Technology Center 1600 whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Center numbers for Group 1600 are Voice (703) 308-3290 and Fax (703) 308-4556 or (703) 308-4242.

Iffy steen

Jeffrey Siew

September 20, 2001

	Application No.	Applicant(s)
Interview Summary	09/613,826	VOGELSTEIN ET AL.
merview Summary	Examiner	Art Unit
	Jeffrey Slew	1656
All participants (applicant, applicant's representative, PTO I	personnel):	
(1) <u>Jeffrey Siew</u> .	(3)	
(2) Michelle Holmes-Son.	(4)	
Date of Interview:		
Type: a)☐ Telephonic b)☐ Video Conference c)☐ Personal [copy given to: 1)☐ applicant 2	e)☐ applicant's representativ	Θ]
Exhibit shown or demonstration conducted: d) Yes If Yes, brief description:	e) <u>□</u> No.	
Claim(s) discussed: <u>None</u> .		
Identification of prior art discussed;		
Agreement with respect to the claims $\mathfrak{H}igotimes$ was reached.	g) was not reached. h)	N/A.
Substance of Interview Including description of the general reached, or any other comments: applicant did not receive considered IDS (A fuller description, if necessary, and a copy of the amend allowable, if available, must be attached. Also, where no considered is available, a summary thereof must be attached in the intervention of the intervention of the paragraph above has been checked. THE FOR MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW action has already been filed, APPLICANT IS GIVEN ONE STATEMENT OF THE SUBSTANCE OF THE INTERVIEW reverse side or on attached sheet.	iments which the examiner agony of the amendments that wit.) sperate record of the substance MAL WRITTEN REPLY TO T . (See MPEP Section 713.04 MONTH FROM THIS INTER	submitted signed elready reed would render the claims would render the claims be of the interview(if box is HE LAST OFFICE ACTION). If a reply to the last Office VIEW DATE TO FILE A
Examiner Note: You must sign this form unless it is an Attachment to a signed Office action. U.S. Palant and Trademark Office PTO-413 (Rev. 03-98) Intervi		nature, if required Paper No. :

Paper No. 10.

Page 139 of 1224

OIPE

RAW SEQUENCE LISTING PATENT APPLICATION: UB/09/613,826

DATE: 07/24/2001 TIME: 11:12:16

Input Set : A:\sequencelist.ST25.txt
Output Set: N:\CRF3\07242001\I613826.raw

3	<110> APPLICANT: Vogelstein, Bert	
4	Kinzler, Kenneth W.	parties (5
6	<120> TITLE OF INVENTION: DIGITAL AMPLIFICATION	ENTERES
8	<130> FILE REFERENCE: 01107.00031	ENIE III
10	<140> CURRENT APPLICATION NUMBER: 09/613,826	
11	<141> CURRENT FILING DATE: 2000-07-11	
13	<150> PRIOR APPLICATION NUMBER: US 60/146,792	
14	<151> PRIOR FILING DATE: 1999-08-02	_
16	<160> NUMBER OF SEQ ID NOS: 6	
	<170> SOFTWARE: PatentIn version 3.0	
	<210> SEQ ID NO: 1	
21	<211> LENGTH: 26	
	<212> TYPE: DNA	
	<213> ORGANISM: homo sapiens	
	<400> SEQUENCE; 1	26
26	catgttctaa tatagtcaca ttttca	26
29	<210> SEQ ID NO: 2	
	<211> LENGTH: 24	
31	<212> TYPE: DNA	
32	<213> ORGANISM: homo sapiens	
34	<400> SEQUENCE: 2	0.4
35	totgaattag otgtatogto aagg	24
38	<210> SEQ ID NO: 3	
39	<211> LENGTH: 20	
40	<212> TYPE: DNA	
41	<213> ORGANISM: homo sapiens	
	<400> SEQUENCE: 3	. 20
	tagctgtatc gtcaaggcac	20
	<210> SEQ ID NO: 4	
	<211> LENGTH: 27	
49	<212> TYPE: DNA	
	<213> ORGANISM: homo sapiens	
	<400> SEQUENCE: 4	. 27
53	cacgggcctg ctgaaaatga ctgcgtg	. .
56	<210> SEQ ID NO: 5	
57	<211> LENGTH: 24	
58	<212> TYPE: DNA	
	<213> ORGANISM: homo sapiens	
	<400> SEQUENCE: 5	24
62	cacgggaget ggtggcgtag cgtg	2.4
65	<210> SEQ ID NO: 6	
	5 <211> LENGTH: 24	
	/ <212> TYPE: DNA	•
	<213> ORGANISM: homo sapiens	
70	<400> SEQUENCE: 6	24
71	cattatttt attataaggc ctgc	. 24

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/613,826

DATE: 07/24/2001 TIME: 11:12:17

Input Set : A:\sequencelist.ST25.txt
Output Set: N:\CRF3\07242001\1613826.raw


7/24/01

File History Report

Paper number is missing from the United States Patent Trademark Office's copy of the file History. No additional information is available.
The following page(s) 3 of 3 of paper number 11 is/are missing from the United States Patent and Trademark Office's original copy of the file history. No additional information is available
The following checked item(s) below of paper number is/are missing from the United States Patent and Trademark Office's original copy of the file history. No additional information is available PTO 1449 PTO 948 PTO 1474 Assignment Cover page
Additional comments:

Siew 5.

Renon



RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/613,826

DATE: 09/20/2001 TIME: 17:06:04

Input Set : A:\sequencelist.ST25.txt
Output Set: N:\CRF3\09202001\1613026.raw

RECEIVED

SEP 2 8 2001

3 <110> APPLICANT: Vogelstein, Bert 4 Kinzler, Kenneth W. 6 <120> TITLE OF INVENTION: DIGITAL AMPLIFICATION TECH CENTER 1600/2900 8 <130> FILE REFERENCE: 01107.00031 10 <140> CURRENT APPLICATION NUMBER: 09/613,826 ENTERED 11 <141> CURRENT FILING DATE: 2000-07-11 13 <150> PRIOR APPLICATION NUMBER: US 60/146,792 14 <151> PRIOR FILING DATE: 1999-08-02 16 <160> NUMBER OF SEQ ID NOS: 6 18 <170> SOFTWARE: PatentIn version 3.0 20 <210> SEQ ID NO: 1 21 <211> LENGTH: 26 22 <212> TYPE: DNA 23 <213> ORGANISM: homo sapiens 25 <400> SEQUENCE: 1 26 26 catgitictaa tatagicaca tittica 29 <210> SEQ ID NO: 2 30 <211> LENGTH: 24 31 <212> TYPE: DNA 32 <213> ORGANISM: homo sapiens 34 <400> SEQUENCE: 2 24 35 totgaattag otgtatogto aagg 38 <210> SEQ ID NO: 3 39 <211> LENGTH: 20 40 <212> TYPE: DNA 41 <213> ORGANISM: homo sapiens 43 <400> SEQUENCE: 3 20 44 tagctgtatc gtcaaggcac 47 <210> SEQ ID NO: 4 48 <211> LENGTH: 27 49 <212> TYPE: DNA 50 <213> ORGANISM: homo sapiens 52 <400> SEQUENCE: 4 27 53 cacgggcctg ctgaaaatga ctgcgtg 56 <210> SEQ ID NO: 5 57 <211> LENGTH: 24 58 <212> TYPE: DNA 59 <213> ORGANISM: homo sapiens 61 <400> SEQUENCE: 5 24 62 cacgggaget ggtggcgtag cgtg 65 <210> SEQ ID NO: 6 66 <211> LENGTH: 24 67 <212> TYPE: DNA 68 <213> ORGANISM: homo sapiens 70 <400> SEQUENCE: 6 24 71 cattatttt attataaggc ctgc

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/613,826

DATE: 09/20/2001 TIME: 17:06:05

Input Set : A:\sequencelist.ST25.txt
Output Set: N:\CRF3\09202001\I613826.raw

RECEIVED

SEP 2 8 2001

TECH CENTER 1600/2900

9/20/01

Page 3 of 3

STATISTICS SUMMARY

DATE: 09/20/2001 TIME: 17:06:05

PATENT APPLICATION: US/09/613,826

Input Set : A:\sequencelist.ST25.txt
Output Set: N:\CRF3\09202001\1613826.raw

Application Serial Number: US/09/613,826 Alpha or Numeric: Numeric Application Class: Application File Date: 07-11-2000

Art Unit: OIPE

Software Application: PatentIn Total Number of Sequences: 6 Total Nucleotides: 145

Total Amino Acids: 0 Number of Errors: 0

Number of Warnings: 0 Number of Corrections: 0

MESSAGE SUMMARY

9/20/01



PATENT

TECH CENTER 1600/2900 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of) Group Art Unit: 1656 Bert Vogelstein, et. al.) Examiner: J Siew) Box AF Serial No. 09/613,826) Docket No. 01107.00031 Filing Date: July 11, 2000

DIGITAL AMPLIFICATION For:

AMENDMENT AFTER FINAL REJECTION

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Final Office Action mailed September 20, 2001, applicants request entry of the following amendments and request reconsideration of the claims. Claims 1-69 are pending in the application. Claims 1-64 are allowed, and claims 65-69 are rejected. No fees are believed due to make this response filed timely. If any fee is due please change our Deposit Account No. 19-0733.

IN THE CLAIMS

Please amend claims 33, 36-37, 65, and 68-69.

1

33. (Amended) A molecular beacon probe comprising:

an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 16 bases, wherein the loop has a T_m of 50-51°C and the stem consists of 4 base pairs having a sequence 5'-CACG-3'.

36. (Amended) A molecular beacon probe comprising:

an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 19-20 bases, wherein the loop has a T_m of 54-56°C and the stem consists of 4 base pairs having a sequence 5'-CACG-3'.

37. (Amended) A pair of molecular beacon probes comprising:

a first molecular beacon probe which is an oligonucleotide with a stem-loop structure having a first photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 16 bases having a T_m of 50-51°C and the stem consists of 4 base pairs having a sequence 5'-CACG-3'; and

a second molecular beacon probe which is an oligonucleotide with a stem-loop structure having a second photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 19-20 bases having a T_m of 54-56°C and the stem consists of 4 base pairs having a sequence 5'-CACG-3';

wherein the first and the second photoluminescent dyes are distinct.

65. (Amended) A molecular beacon probe comprising:

an oligonucleotide comprising a stem and a loop structure and having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 14-26 bases and has a Tm of 50-51°C, and wherein the stem consists of 4 base pairs having a sequence 5'-CACG-3'.

68. (Amended) A molecular beacon probe comprising:

an oligonucleotide comprising a stem and a loop structure and having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 14-26 bases and has a Tm of 54-56°C, and wherein the stem consists of 4-6 base pairs comprising a sequence 5'-CACG-3'.

69. (Amended) A pair of molecular beacon probes comprising:

a first oligonucleotide comprising a first stem and a first loop structure and having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the first loop consists of 14-26 bases and has a Tm of 50-51°C, and wherein the first stem consists of 4 base pairs having a sequence 5'-CACG-3'; and

a second oligonucleotide comprising a second stem and a second loop structure and having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the second loop consists of 14-26 bases and has a Tm

of 54-56°C, and wherein the second stem consists of 4-6 base pairs comprising a sequence 5'-CACG-3'.

REMARKS

The Invention

The invention is directed to methods for determining the ratio of a selected genetic sequence in a population of genetic sequences.

The invention is also drawn to molecular beacon probes. The molecular beacon probes can be used to execute the methods of the invention. The molecular beacon probes comprise an oligonucleotide comprising a stem and a loop structure and have a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' ends.

The Amendments

Claims 33, 36-37, 65, and 68-69 have each been amended to recite that the loops of the molecular beacon probes consist of a specified number of "bases" instead of "base pairs." The amendments are supported by the specification and drawings of the application as filed. The specification supports this amendment where it discloses the sequence of two example molecular beacon probes: "MB-RED: 5'-Cy3'-CACGGGCCTGCTGAAAATGACTGCGTG-Dabcyl-3'; MB-GREEN: 5'-Fluorescein-CACGGGAGCTGGTGGCGTAGCGTG-Dabcyl-3'." (Page 15, lines 1-3.) Each of the molecular beacon probes has a 5' terminal sequence, 5'-CACG-3', which base pairs with

the 3' terminal sequence, 5'-CGTG-3', to form the stem of the probe. The intervening sequence of each probe forms the loop. The loop of each probe is not self-complementary and therefore does not form base pairs. Thus the loop is measured in bases rather than base pairs. Figure 1b is a further disclosure that the loop of the molecular beacon probes is not base paired. Figure 1b is an illustration of the stem-loop structure of a molecular beacon probe. The stem portion of the structure, or bottom half, is base paired. The loop, above the stem and at the top half of the probe, is not base paired. Therefore the drawings also support that the loop should be measured in bases, not base pairs. Thus the amendment to the claims is supported by the application. The amendments do not introduce new matter and do not require a new search. The amendments also clarify the claims and do not narrow the scope of the claims. The amendments were not earlier introduced, as applicants were just became of this inadvertent mistake.

Claim 65 has been amended to recite that the loop of the molecular beacon probe "consists of 14-26 bases" instead of "comprises 16 base pairs." Claim 65 has also been amended to recite that the stem of a molecular beacon probe "consists of 4 base pairs" instead of "comprises 4 base pairs." These amendments are supported by the specification where it is disclosed, "Loops ranging from 14 to 26 bases and stems ranging from 4 to 6 bases, as well as numerous sequence variations of both stems and loops, were tested during the optimization procedure." (Page 18, lines 6-8.) Thus, molecular beacon probes with loops consisting of 14-26 bases and stems consisting of 4 base pairs are supported in the specification. The amendments therefore introduce no new matter and

do not require a new search. The amendments to claim 65 were not made earlier as it is a newly entered claim and applicants have first been made aware of its alleged insufficiencies in the final rejection. The amendments are also believed to place the claims in condition for allowance or better condition for appeal.

Claim 68 has been similarly amended to recite the loop of the molecular beacon probe "consists of 14-26 bases" instead of "comprises 19-20 base pairs." Claim 68 has also been amended to recite the stem of the molecular beacon probe "consists of 4-6 bases" instead of "comprises 4 base pairs." These amendments are also supported by the specification where it is disclosed, "Loops ranging from 14 to 26 bases and stems ranging from 4 to 6 bases, as well as numerous sequence variations of both stems and loops, were tested during the optimization procedure." (Page 18, lines 6-8.) Thus, molecular beacon probes with loops consisting of 14-26 bases and stems consisting of 4 to 6 base pairs are supported in the specification. The amendments therefore introduce no new matter and do not require a new search. The amendments to claim 68 were not made earlier as it is a newly entered claim and applicants have first been made aware of its alleged insufficiencies in the final rejection. The amendments also are believed to place the claims in condition for allowance or better condition for appeal.

Claim 69 has been similarly amended to recite that the first oligonucleotide of a pair of molecular beacon probes has a first loop that "consists of 14-26 bases" instead of "comprises 16 base pairs" and a first stem that "consists of 4 base pairs" instead of "comprises 4 base pairs." Claim 69 has also been amended to recite that the second oligonucleotide of the pair of molecular beacon probes has a second loop that "consists of

14-26 bases" instead of "comprises 19-20 base pairs" and a stem that "consists of 4-6 base pairs" instead of "comprises 4 base pairs." This amendment is also supported by the specification at page 18, lines 6-8. Thus, molecular beacon probes with loops consisting of 14-26 bases and stems consisting of 4 to 6 base pairs are supported in the specification. The amendments to claim 68 therefore introduce no new matter and do not require a new search. These amendments were not made earlier as it is a newly entered claim and applicants have first been made aware of its alleged insufficiencies in the final rejection. These amendments to claim 68 are also believed to place the claim in condition for allowance or in better condition for appeal.

The Rejection of Claims 65-69 under 35 U.S.C. § 112

Claims 65-69 have been rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonable convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Specifically, the Office Action alleges that the "specification lacks support for molecular beacon that has a loop greater than 16 base pairs with Tm of 50-51°C and stem comprising 4 base pairs nor a molecular beacon that a loop comprising 19-20 base pairs and Tm of 54-56°C and stem comprising of 4 base pairs." (Paper 10, page 3, lines 5-7.) Applicants respectfully traverse.

To satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can

reasonably conclude that the inventor had possession of the claimed invention. Vas-Cath, Inc. v. Mahurkar, 935 F.2d. at 1563. Amended claims 65-69 are described in the specification such that one of skill in the art would conclude that the inventors had possession of the invention.

Claims 65, 68, and 69 have been amended to recite molecular beacon probes that have a loop that "consists of 14-26 bases." Claims 65, 68, and 69 have each also been amended to recite that the molecular beacon probes have a stem that "consists of 4 base pairs" or "consists of 4-6 base pairs." The inventors clearly had possession of the invention as recited in the amended claims. The specification discloses that "[1]oops ranging from 14 to 26 bases and stems ranging from 4 to 6 bases, as well as numerous sequence variations of both stems and loops, were tested during the optimization procedure." (Page 18, lines 6-8.) Thus the specification discloses that molecular beacon probes with loops consisting of 14 to 26 bases and stems consisting of 4-6 bases are of the lengths that are optimum in probe design. Clearly the inventors had possession of the invention as it is claimed. Withdrawal of this rejection to claims 65, 68, 69 and dependent claims 66-67 is respectfully requested.

The Rejection of Claim 68 under 35 U.S.C. § 112

Claims 65-69 have been rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Specifically, the Office Action asserts that the phrase "comprising 19-20" renders claim 68 unclear. Claim 68 has been amended to

recite "consists of 14-26" in place of "comprises 19-20." Thus the rejection is rendered moot.

Rejection of Claims 65-67 under 35 U.S.C. §102(e)

Claims 65-67 are rejected under 35 U.S.C. §102(e) as being anticipated by Tyagi et al. (U.S. 5,925,517 March 14, 2000).

The Office Action asserts that Tyagi et al. teaches a molecular beacon probe with a stem comprising CACG (see col. 11 probe 3) and a loop of Tm 50 (see SEQ ID NO: 3 at column 12). (Paper 10, page 4, lines 8-9.) Applicants respectfully traverse.

Applicants are unable to locate the cited molecular beacon probe in Tyagi et al. (U.S. 5,925,517). However, Tyagi et al., U.S. 6,037,130, issued March 14, 2000, does teach a molecular beacon probe (probe 3) at column 11. Applicants will discuss molecular beacon probe 3 disclosed in Tyagi et al., U.S. 5,925,517 in this response.

To reject a claim under 35 U.S.C. § 102, each element must be taught or inherently described in the prior art reference. "A claim is anticipated only if each and every element as set forth in the claim is found, either expressly or inherently described, in a single prior art reference." Verdegaal Bros. v. Union oil Co. of California, 814 F.2d 628, (Fed. Cir. 1987). Tyagi et al. do not teach each element as set forth in claims 65-67.

Claim 65 has been amended to recite a molecular beacon probe "wherein the loop consists of 14-26 bases and has a Tm of 50-51°, and wherein the stem consists of 4 base pairs having a sequence 5'-CACG-3." (Emphasis added.) Tyagi et al. do not teach a molecular beacon probe with the limitation of a stem consisting of 4 base pairs. Tyagi et

al. teach a molecular beacon probe of SEQ ID NO: 3 that has the sequence "TMR-5'-CCACGT-fluorescein-TCTTGTGGGTCAACCCCGTGG-3'-DABSYL." (Column 11 through column 12, line 40, emphasis in reference.) Thus Tyagi et al. teach a molecular beacon probe with a stem loop of 5 base pairs comprising the sequence CACG. Thus Tyagi et al. do not teach all the limitations of claim 65. Tyagi et al. do not teach a molecular beacon probe with a stem consisting of 4 base pairs. Withdrawal of this rejection to claims 65 and dependent claims 66-67 is respectfully requested.

Respectfully submitted,

Date: December 6, 2001

Michelle Holmes-Son Registration No. 47,660

Banner & Witcoff, Ltd. 1001 G Street, NW Washington, DC 20001 202-508-9100

MARKED UP VERSION OF THE CLAIMS TO SHOW CHANGES MADE

33. (Amended) A molecular beacon probe comprising:

an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 16 bases [pairs], wherein the loop has a T_m of 50-51°C and the stem consists of 4 base pairs having a sequence 5'-CACG-3'.

36. (Amended) A molecular beacon probe comprising:

an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 19-20 bases [pairs], wherein the loop has a T_m of 54-56°C and the stem consists of 4 base pairs having a sequence 5'-CACG-3'.

37. (Amended) A pair of molecular beacon probes comprising:

a first molecular beacon probe which is an oligonucleotide with a stem-loop structure having a first photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 16 bases [pairs] having a T_m of 50-51°C and the stem consists of 4 base pairs having a sequence 5'-CACG-3'; and

a second molecular beacon probe which is an oligonucleotide with a stem-loop structure having a second photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 19-20 bases

[pairs] having a T_m of 54-56°C and the stem consists of 4 base pairs having a sequence 5'-CACG-3';

wherein the first and the second photoluminescent dyes are distinct.

65. (Amended) A molecular beacon probe comprising:

an oligonucleotide comprising a stem and a loop structure and having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop [comprises 16] consists of 14-26 bases [pairs] and has a Tm of 50-51°C, and wherein the stem [comprises] consists of 4 base pairs having a sequence 5'-CACG-3'.

68. (Amended) A molecular beacon probe comprising:

an oligonucleotide comprising a stem and a loop structure and having a photohuminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop [comprises 19-20] consists of 14-26 bases [pairs] and has a Tm of 54-56°C, and wherein the stem [comprises] consists of 4-6 base pairs [having] comprising a sequence 5'-CACG-3'.

69. (Amended) A pair of molecular beacon probes comprising:

a first oligonucleotide comprising a first stem and a first story structure and having a photoluminescent dye at one of the 5' or 3' ends and a queries agent at the opposite 5' or 3' end, wherein the first loop [comprises 16] consists of the bases [pairs] and has

a Tm of 50-51°C, and wherein the first stem [comprises] consists of 4 base pairs having a sequence 5'-CACG-3'; and

a second oligonucleotide comprising a second stem and a second loop structure and having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the second loop [comprises 19-20] consists of 14-26 bases [pairs] and has a Tm of 54-56°C, and wherein the second stem [comprises] consists of 4-6 base pairs [having] comprising a sequence 5'-CACG-3'.

AF/1656

(فسند

	Please type a plus sign	n (1) Incluia this hav	> [i]		Annrove	d for use throw	PTO/S gh 10/31/2002. ON	SB/21 (08-00) AB 0851-0031
		•			S. Patent and Trademar apond to a collection of infor	Coffice: U.S. D	EPARTMENT OF	COMMERCE
PE	<u> </u>		Alam of the Stript Tolks and other	Y-	ation Number	09/613,826		
0, (为 TRAN	SMITTAL		Filing	Date	July 11, 20	000	
DEC 067	n a E	ORM		Firet N	lamed inventor	Bert Voge	Istein, et. 😜	- m
4 100	(je ps used for all con	espondence after in	itial filing)	Group	Art Unit	1656	8	80
DART & TRACE	Miles			Exami	ner Name	J. Slew	á	e m
-	Total Number of Pages	in This Submission	13	Attorne	ey Docket Number	01107.000)31	23
			ENCL	OSURES	(check all that apply)		- 2	i a m
	Fee Transmittal Fo	orm		ment Pap Application		After All Group	lowance Commig	Acation to
	Fee Attached		Drawir	ng(e)			Communication t s and interference	
'	Amendment / Res	ponse	Licens	Ing-relate	d Papers		Communication t Notice, Brief, Reply	
!	After Final				Slip (PTO/SB/69) ring Petition	☐ Proprie	tery Information	
	Affidavits/deci	eration(s)		n to Conv Ional App		☐ Status	Letter	
	Extension of Time	Request			ey, Revocation espandence Address	Other I	Enclosure(s) Identify below):	
			Termin	nal Discla	lmer			(
	Express Abandon	ment Request	☐ Request for Refund					
	Information Disclo	sure Statement	CD, N	umber of	CD(s)			
	Certified Copy of I	Priority	Rema	arks				
	Response to Miss Incomplete Applic							
·	Response to Parts under 3 1.52 or 1.53							
		SIGNA	TURE OF	APPLIC	ANT, ATTORNEY, O)R AGENT		
	Firm or Individual name	Michelle Holmes-S	Son, Registr	ation No.	47,680		•	
	Signature	Michell)e UL	olnu	0-An			
	Date	December 6, 200	I					
			CE	RTIFIC	ATE OF MAILING			V marine and a second
	I hereby certify that the	ils correspondance	ia baing dap	osited wit	h the United States Pos	tal Service es	first class mail in	an envelope
	addressed to: Assist	ant Commissioner fo	or Patents, V	Vashingto	n, D.C. 20231 on this d	ate:		
	Typed or printed nam	18				- Company		
	Signature			and the second section and the second		Date		
		nt of time you are raqu C 20231, DO NOT SE			omplete. Time will vary de m should be send to the t ETEO FORMS TO THIS			

Page 159 of 1224



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE Unled States Petent and Trademark Office Address. COMMESCORE OF PATENTS AND TRADEMARKS Washington, D.C. FOM:

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO.
09/613,826	07/11/2000	Bert Vogelstein	01107,00031	9893
22907	7590 12/12/2001			
BANNER &	WITCOFF		EXAM	NER
1001 G STRE	ET N W		SIEW, JE	FFREY
SUITE 1100				
WASHINGTO	ON, DC 20001		ART UNIT	PAPER NUMBER
			1656	14
			DATE MAILED: 12/12/2001	

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-90C (Rev. 07-01)

**		<i></i>	9P12-
	Application No.	.4pplicant(s)	U
Advisory Action	09/613,826	VOGELSTEIN ET AL.	
Mansory Metron	Examiner	Art Unit	
	Definition of the final rejection. Definition of the correspondence address of the standard o		
-The MAILING DATE of this communication	appears on the cover sheet w	Ith the correspondence addres	\$
Therefore, further action by the applicant is required	to avoid abandonment of this or: (1) a timely filed amendme opeal (with appeal fee); or (3)	s application. A proper reply to ent which places the application	્થ nin
		b)]	
a) X The period for reply expires 3 months from the mailing	g date of the final rejection.		
no event, however, will the statutory period for reply ex ONLY CHECK THIS BOX WHEN THE FIRST REPLY 708.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). fee have been filed is the date for purposes of determining the periods.	xpire later than SIX MONTH'S from 'WAS FILED WITHIN TWO MONT . The date on which the petition un- plied of extension and the correspon- ate of the shortened statutory perior to Office later than three months att	the mailing date of the hinal rejection. HS OF THE FINAL REJECTION. Settler 37 CFR 1.136(a) and the appropriating amount of the fee. The appropriation was a set in the final Officer and continuations at in the final Officer.	e MPEP ate extension late extension ce action: or
1. A Notice of Appeal was filed on Appell 37 CFR 1.192(a), or any extension thereof (37	lant's Brief must be filed with 7 CFR 1.191(d)), to avoid dis	in the period set forth in missal of the appeal.	
2. The proposed amendment(s) will not be enter	ed because:		
(a) X they raise new issues that would require	further consideration and/or	search (see NOTE below);	
(b) they raise the issue of new matter (see N	lote below);		
(c) they are not deemed to place the application issues for appeal; and/or	tion in better form for appeal		lifying the
(d) they present additional claims without ca	anceling a corresponding nun	nber of finally rejected claims.	
NOTE: the limitation to consisting of 14-26	would require new search and	consideration.	
3. Applicant's reply has overcome the following re	ejection(s): <u>See Continuation :</u>	<u>Sheat</u> .	
* *			nendment
5. The a) effidavit, b) exhibit, or c) reque application in condition for allowance because	st for reconsideration has be	en considered but does NOT p	place the
The affidavit or exhibit will NOT be considered raised by the Examiner in the final rejection.	d because it is not directed S		
7 El For sumposes of Anneal the proposed amend	iment(s) a)∏ will not be ent∈ ms would be rejected is provi	ored ar b) Will be entered and ided below or appended.	i en
The status of the claim(s) is (or will be) as foll	lows:		
Claim(s) allowed: 1-64.			
Claim(s) objected to:			
Claim(s) rejected: 65-69.			
Claim(s) withdrawn from consideration:			
8. The proposed drawing correction filed on	is a) [] approved or b) [disapproved by the Examine	r.
9. Note the attached Information Disclosure Sta	itement(s)(PTO-1449) Papa	r No(s)	
10. ☐ Other:			
10. <u>1.</u> Julioi			
İ			

Page 1670 1072 20 20 101)

Advisory Action

Part of Paper No. 14

Continuation Sheet (PTO-303)

Application No. 09/613,826

Continuation of 3. Applicant's reply has overcome the following rejection(s): the proposed amendment would over ocmver the 112 first written description and second paragraph rejections. The office would like to thank applicant to bringing attention the inadvertent oversight of 102(e) rejection over Tyagi US6,037,130. The 102(e) rejection appears overcome by the new amendment.

Jeffry bur 3/23/02 copy filed 12/13/01

JAN 2 3 2007 E

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Ap	oplication of:)	THE SOLL
Bert VO	GELSTEIN et al.)) Group Art Unit: 1656	SOUTH THE THE THE THE THE THE THE THE THE T
Serial No	o. 09/613,826) Examiner: J. Siew	B
Filed:	July 11, 2000) Box: AF	
For:	DIGITAL AMPLIFICATION) Attorney Docket No. 01107.0003	1

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. § 1.56 and in compliance with 37 C.F.R. § 1.97(d), Applicants herewith submit Form PTO 1449 listing references for consideration in connection with the above-identified application. A copy of each reference is provided herewith.

Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

01/28/2002 NACHAWA1 00000149 190733 09613826 01 FC:126 180.00 CH

Serial No. 09/613,826

Applicants respectfully request that the Examiner consider and enter these documents into the file of the above-identified application. A fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p) is enclosed herewith to ensure consideration and entry of the cited documents by the Examiner. If any additional fee is deemed necessary, the Commissioner is authorized to charge our Deposit Account No. 19-0733.

Respectfully submitted,

Date: January 23, 2002

Michelle L. Holmes-Son Registration No. 47,660

BANNER & WITCOFF, LTD 1001 G Street, N.W. Eleventh Floor Washington, D.C. 20001-4597 (202) 508-9100

												المل
					U.S. Paten	Appro and Tradem	ve 1: ark v 100	so thr s: U.S	ough DEF	10/31/2002. OMB	08A (10-01) 0651-0031 DMMERCE	~{\l
	Underti	ne Paperwork Reduction Act of 1995.	no persons are	required to	prespond to a	CORECTOR OF A	University	H PEROLE	II CUIT	WILLS OF VEST CAME OF	una univoer	ı
Substitute	for form '	1449A/PTO	Ĺ				Comple	_		wn e		
INFO	RMA	TION DISCLOSE	RE	Applica	illon Numbe	ır	09/61	3,82	6		2	m
		NT BY APPLRA		Filing C	Date		July 1	1, 2	300		<u>5</u> 5	
SIAI	CIVIE	MIDIAPPLICA	" G	First No	nevni bema	tor	Bert \	/oge	Istei	n et al.	7	
		1 100 0	18		Art Unit		1656		11.	37	哥	o M
	luea ae	many sheets as (1900ssary)	3 2002		ner Neme		J. Sle				50	X)
	1	of len	- 3		y Docket N	umhar	01107	-	131		8	
Sheet	1	1.736		11101110	,, 000,0111		COMPTON TO SERVICE	-	COLOR COLORS		3	8 III
	mand to a second	18.204	EMP.	Maria, m	Cation.	MYC	TO STREET OF THE PARTY OF THE P		IODA NA	And the second s	ম্ভ	
		1	U.S. PAT			etantes or App	icant of					
Examiner	Cita	Occument Number	Publication MM-DD-Y	Dale YYY	""	ited Document		Pe	ges, C	olumna, Lines, Where Repeages or Relever Figures Appear	Relevant nt	
initials *	No.1	Number - Kind Code ² (# known)					(الملايا	900	Figures Appear		
$X \subset X$	<u> </u>	US-5,804,383	09-08-1			rueneri et al.		1	듸			
RR_	<u> </u>	US- 5,658,663	01-12-1	999		Nisson et al.		-	-			
U	<u> </u>	US-			-			\vdash	Н			
		US-			 			-	\vdash			
	ļ	US-						-	\vdash	*		
		US-			-		-		Н			
		US-			l				\Box			
	 	US-		-					П			
	}	US-							\prod			
	<u> </u>	US-]
		US-							Ш			ĺ
		US-						<u>. </u>				ĺ
		US-		.,				<u> </u>	+-			
		US-	ļ					├	╀			
		US-			 			├	╁	1		ĺ
		U\$-			 			├	╫	1		
	ļ	US-	 		 			-	╁	 		
		US-	 		+			-	╁	 		
Marie Inc.		U3-				**************************************					and photographic and a second	1
gast addardanses e un			FOREIGN I	PATEN	T DOCU	MENTS	W					1
	T	Foreign Patent Dos	ument		hilasilas	Nama of Po	lentee or		ages N	, Columns, Lines, here Relevant		l
Examiner Initials*	Cite No.	Country Code ² - Number ⁵ - Kind	Code ⁶ (# known		ibilcation Date -DD-YYYY	Applicant Docum	of Clad		Pass KF	nere Relevant ages or Relevant pures Appear	T⁰	
R		WO 95/1339	9	05-	18-1995	il	75	٧,	7		ļ	1
4	1	EP 0643140	Α	03-	15-1995	VI	//	-	- -	-	1	l

Exeminer Signature Jeffy Sier EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered, include copy of this form with next communication to applicant.

Date Considered

3/23/02

03-18-1999

WO 99/13113

Burdan Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Weshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Petents, Weshington, DC 20231.

Applicant's unique citation designation number (options)). Sas Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

Senter Office that feaued the document, by the two-latter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. Applicant is to place a check mark here if English tanguage Translation is effected.

PTC/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent end Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB comparison. Complete if Known Application Number 09/613,826 July 11, 2000 Filing Date Bert Vogelstein et al. First Named Inventor 1000 (/97

J. Siew

of 2 Attorney Docket Number 01107.00031 OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. T 2 Cite No. Initials ' A. PIATEK et al., "Molecular Beacon Sequence Analysis for Detecting Drug Resistance in Mycobecterium Tuberculosis", Nature Biotechnology, April 1993, pp. 359-363, Vol. 18, No. 4 S. TYAGI et al., "Multicolor Molecular Beacone for aliale discrimination", Nature Biotechnology, pp. 303-308, January 1998, Vol. 16, No. 1 J. A.M. VET et al., "Multilex Detection of Four Pathogenic Retroviruses Using Molecular Beacons", Proceedings of the National Academy of Sciences of the United States", May 25, 1999, pp. 6394-6399, Vol. 96, No. 11 S. TYAGI et al., "Molecular Beacons: probes that Fluoresce" Upon Hybridization", Nature Biotechnology, 1996, pp. 303-308, Vol. 14, No. 3 W. P. HALFORD et al., "The Inherent Quantitative Capacity of the Reverse Transcription-Polymerase Chain Reaction", Analytical Biochemistry, January 15, 1899, prg. 181-191, Vol. 268, No. 2 B. VOGELSTEIN et al., "Digital PCR", Proceedings of the National Academy of Sciences of the United States, August 3, 1869, pp. 9236-9241, Vol. 98, No. 16 K. D.E. EVERETT et et, "identification of nine species of the Chlemydiacese Using PCR-RFLP", April 1999, pp. 803-813, Vol. 49, No. 2

Group Art Unit

Examiner Name

(F	- 11' A	Date	7 / 4	
Examiner Signature	Jehrnbour	Considered	3/18/60	-
Signature		The second secon		Constitution of the last of th

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP.809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademerk Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Weshington, DC 20231.

Substitute for form 1449A/PTO

STATEMENT BY APPLICANT

many sheets as necessary)

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is ettached,

Approved for use through 10.0717/0.0000 (10.0000)

Approved for use through 10.0717/0000, 0.000 0651-0032

These Tibes T

Under the Peperwork Reduction Act of 1.

Banamanatika	-FF	a kana a kana p	TRA	INS	M	TT	14	-				Complete if Known	
	(d 12mm							Appl	callon Nu	mbar	08/6	13,826	T)
		T	or t	-Y 2	UU	(``	√ .	Po Filing	Date		July	11,2000	Till I
						/0	-המ	15 (SI	Named Ir	vantor	Bert'	Vogelstein et al.	
		Pelent	feas are s	subject to a	บากบลไ	nevision.	13 m	Edan	iner Nan	1e	J. Sa	aw Z	Es []
							7411 5 3 AM	19/0U	p / Art Ur	ilt	1658	TO TO	OD ,
TOTA	L AMC	DUNT ()F PAY	MENT	(\$)		Correspondent	12	ney Dock	et No.	0110	7,00031	18
	M	ETHOD	OF PAY	WENT (che	ck all	that apply	Simon		Charles and the		EEE C	ALCULATION (continued)	1
	-	of the contract of the contrac	terrent in the court of	· ·	ئىلتى خىسىب	وبرواسي وهداويهم		3. AD	DITIONAL	L FEEB		ALCOLATION (CONTINUED)	<u> </u>
☐ Chao	k 🛘	Credit	ard [Money Order		her 🔲	None	l	Large Entity		Small Entity		6
⊠ Dep	osli Acc	ount:		Cider				Fee	Pea	Fee	Fee	Fee Dascription	Fee
Depo	tien							Code 105	(%) 130	Code 205	(B) 65	Surcherge - late filing fee or ceth	Paid
Acce	ount	Ban	nor & Wild	coff, Ltd.			1	127	50	227	25	Surcharge - late provisional filing fee	H
Num	Det	L						139	***	470	400	or cover sheet.	
Dapo								147	130 2,520	139 147	130 2,620	Non-English specification For filing a request for reexamination	\vdash
Acco Nam		19-0	733				1	112	920*	112	920	Requesting publication of SIR prior to	
The Con	nmiseid			ed to: (chi				113	1,840*	113	1,840*	Examiner action Requesting publication of SIR after	\vdash
				/ 🗵 Cred			nents e application	1			·	Examineraction	
☐ Chan	ge fee(9) Indical	ed below	, except i	or the	filing fe	p Depresentation	115	110	215	55	Extension for reply within first month	
to the ab	ove-lde	ntified d	ASSESSED VALUE OF THE PARTY OF				شروع سم ربيوستم <u>بي مسمور</u> ه	116	400	216	200	Extension for reply within second month	1 1
	ag and Since on complete to	CODE CONTRACT	FEE C	ALCULAT	TON	20	Don't District Day of the second	117	920	217	480	Extension for reply within third month	
1. E Lengs		ILING F	Enuly Enuly					118	1,440	218	720	Extension for reply within fourth month	
Fee	Fee	Fea	Fes	Fee Deec	ription)		128	1,960	226	980	Extension for reply within fifth month	
Code	(\$)	Code	(\$)				Fee Pald	119	320	219	160	Notice of Appeal	
101	740 330	201 208	370 165	Utility film Daeign fü	-			120	320	220	160	Filing a brief in support of an appeal	
107	510	200	255	Plant filing	-			121	280	221	140	Request for oral hearing	
108	740	208	370	Reissue f		1		138	1,510	138	1,510	Patition to institute a public use proceeding	1 1
114	160	214	60	Provision	el filling	fea		140	110	240	55	Petitlon to revive - unavoldable	
			UBTOTA				(6) A	141	1,260	241	640	Petition to revive - unintentional	
			UB IU IA	L [1]		1	(\$)0	142	1,280	242	640	Utility issue fee (or release)	\vdash
2. EXTR	A CLA	M FEE	\$					143	460	243	230	Design lesue fee	
				Extra		ee from	Fee	144	620 130	244 122	310 130	Plent Issue fee Petitions to the Commissioner	
otal Cleim	10 F	7.2	.0 ** =	Claims 0	٦x٢	alow]	□ Pald	123	50 .	123	50	Processing fee under 37 CFR 1.17 (q)	
dependen talms			3 ** □	o] x		- 0	128	180	126	180	Submission of Information Disclosure Simt	180
fulliple	_			L	χĹ	==	-	581	40	581	40	Recording each patent assignment per properly (times number of	\vdash
Lange Lange	Entit	y Smal	/ Enti	ty	~ L		اــــــا	(properties)	
Fee Gode	Fea (\$)	Fea Code	Fee (\$)	-	escript	lon		148	740	248	370	Filing a submission after that rejection (37 CFR § 1.128(a))	
103	18	203	9			ssa of 20	- -	149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
102 104	84 280	202 204	42 140				xcess of 3 n, if not paid	178	740	270	370	Request for Continued Exemination (RCE)	
109	84	209	42		aua Ind	lependent	claims over	169	900	169	900	Request for expedited exemination of a design application	
110	18	210	9		eue cla	ima in exc	ces of 20 and	}				er Rei Jahramannei	
				UBTOTAL		(\$) 0		Other I	ica (speci	y)			
			E	OBIUIAL	· (*/	(9)0			and be D	iòla E30-	n Een P	old GURTATAL 193	
°°Cf nur	mber pro	eviously	pald, if g	reater, Fo	r Reis	093,99US	above	-Kegt	iced by Ba	wic Lill	A LEG L	aid 8UBTOTAL (3) (8) 180	
SUBMIT	ED BY											Complete (if applicable)	
		- 1				1			1		- 1	(

Name (Prin/Type) Milchelle L. Holmas-Son Registration No. Attorney/Agent) 47,680 Telephone 202-508-4100

Signature Date January 23, 2002

WARNING: Information on this form may become public. Credit eard information should not be Included on this form. Provide credit card information and authorization on PTO-3038.

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the encount of time you are required to complete this form should be sent to the Chief Information Office, V.S. Patient and Tredewark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

165-6 A

ease type a plus sign (+) inside this box -> + Approved for use through 10/31/2002. OMB 0531,6031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1895, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Please type a plus sign (+) inside this box -> + 09/613.826 **Application Number** TRANSMITTAL Filing Date July 11, 2000 **FORM** Bert Vogelstein et al. First Named Inventor (to be used for all corresponder Group Art Unit 1656 Examiner Name J. Siew Total Number of Pages In This Submiss Attorney Docket Number 01107.00031 ENCLOSURES (check all that apply) After Allowance Communication to Assignment Papers Fee Transmittal Form (for an Application) Group Appeal Communication to Board of Fee Altached Drawing(s) Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Amendment / Response Licensing-related Papers Petition Proprietary Information After Final Petition to Convert to a Status Letter Affidavits/declaration(s) Provisional Application Power of Attorney, Revocation Change of Correspondence Address Other Enclosure(s)
(please (dentity below): Extension of Time Request PTO-1449 (w/references) Terminal Disclaimer Express Abandonment Request Request for Refund Information Disclosure Statement CD, Number of CD(s) Certifled Copy of Priority Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Flm Michelle L. Holmes-Son, Registration No. 47,660 individual name Signature January 23, 2002 Date CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: Typed or printed name

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Weshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissionar for Patents, Washington, DC 20231.

Date

Signature

Approved for U.S. Palant and Trademark Ct Under the Papelwork Reduction Act on 1995, no persons are required to respond to a collection of information un.

PTO/SB/22 (10-00)
rough 10/31/2002. OMB 0651-0031
s. DEPARTMENT OF COMMERCE
s.s & digplays a valid OMB option Impher,
Docket Number (Optional)
091107.00031

M

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)

VIDE OF	\		in re Application of I	Bert VOGELSTE	IN, et a.	Ĭ
·	<u>"</u>		Application Number	09/613,826	Filed July 11, 2000	强
LEO 5 0 5005			For Digital Amplific	ation		西
TRADEMA	7		Group Art Unit 1656	Examiner Jeffrey Siew		<u>5</u>
& TRAULE	This is	a request under the provisio			eriod for filing a	TER 1600/290
	•	se in the above Identified ap	•			8
		uested extension and appro time period desired):	opdate non-small-enti	ty fee are as folio	awd	
		One month (37 CFR	: 1.17(a)(1))		\$	ĺ
		Two months (37 CF)	R 1.17(a)(2))		\$ <u>400.00</u>	6
		☐ Three months (37 C	FR 1.17(a)(3))		\$	ĺ
		Four months (37 Ci	FR 1.17(a)(4))	•	\$	
		Five months (37 CF			\$	
	X	Applicant claims small entit			e, the fee amount shown	
:	П	above is reduced by one-h A check in the amount of ti		ee is: \$ <u>200.00</u> .		Î
		Payment by credit card. For		ched.		1
•	⊠	The Commissioner has aire			this	Į
:		application to a Deposit Ac				
	×	The Commissioner is here!				Į
•		or credit any overpayment		Number <u>19-0/33</u>	•	
_	I am the	I have enclosed a duplicat i D applicant/inventor.	e copy or this sheet.			
		assignee of record of the	ne entire Interest. Sec	37 CFR 3.71]
		Statement under 37 (SB/96).	ļ
		attorney or agent of rec	• •	•	-	
		attorney or agent under				
ľ			ting under 37 CFR 1.34(a).	·		1
	WAR	VING: Information on this	form may become p	ublic. Credit ce	rd Information should	not
•	be inc	cluded on this form. Provi	de credit card infon	nauon ang auti	ionzagon on P1U-2036.	·
~		February 20, 2002		Mel	hala Alenas-a	In_
		Date		• 1	Signature]
-C 127206€ AVOHDA	1 00000064	190733 69613626		N	fichelle L. Holmes-Son,	1
10:216	200.00 CH				Reg. No. 47,660	
				ן	Typed or printed name	ļ
	NOTE: Stano	itures of all the inventors or assigne	es of record of the entire fol	erest or their represer	ntative(s) are required. Submit i	multiple
	forms if more	then one alguature is required, see	below*.			
	I I I STAIN	hadimunin and according				R

Burden Hour Statement: This form is estimated to take 0.1 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademerk Officer, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approve 4 or use through 10/31/2002 OMB 6651-0032
U.S. Petent and Trademr
ersons are required to respond to a collection of information

List displays a valid OMB control number.

Under the Paperwork Reduction Act of 189

Application Number 00/04/13, 928 1/19 1/19 2000 1/19 1/19 2000 1/19 1/19 2000 1/19 1/19 2000 1/19 1/19 2000 1/19 1/19 2000 1/19 1/19 2000 1/19 1/19 2000 1/19 1/19 2000 2000 1/19 2000 1/19 2000 1/19 2000 1/19 2000 1/19 2000 1/19 2000 1/19 2000 1/19 2000 1/19 2000 1/19 2000 1/19 2000 1/19 2000 1/19 2000 1/19 2000 1/19 2000 1/19 2000 1/19 2000 1/19 2000	THE PARTY OF THE RESERVE	A B B B B B B B B B B B B B B B B B B B					Authore it without and	
Chack Credit card Money Other None None Credit card Money Other None None Credit card Money Other None None Credit Money Other None None Credit None Non	CALE IKANS	SWILL AL	Applic	ation Mur	mber	09/81	3,826	
Check Credit card Money Other None Credit (a) (b) Card (b) Suchtage - Intel filling fee or color None Credit (card (car	or FY 2	2002	Filing	Date		July 1	1, 2000	
Check Credit card Money Other None Credit (s) Card (t) Sucharge- lete Prevalent (s) Sucharge- lete Prevale	CER 2 0 2002 E		First I	iamed In	ventor	Bert \	OGELSTEIN, et el	
Chack Credit cerd Money Other None Other Other None Other	m. Fille to a community at the		Exam	iner Nami	8	Jeffre	y Siew	-
Chack Credit card Money Other None Order	Town and the second		Group	Art Uni	t	1858		-C7
Chack Credit card Money Other None Order	TOTAL ABOUNT OF BAVESENT	(%) 200	1			00110	D7 00031	8
Chack Credit card Money Other None Code Chack Credit card Money Other None Code Chack Chac			- Ami	IDY DOCKE	ot NO.			سيد
Check Gredit card Money Other None Order Deposit Account: Page Code	METHOD OF PAYMENT (c)	heck all that apply)		DITIONAL	2E CO	FEE C/	ALCULATION (continued)	ware the state of
Daposit Dapo	Order			Larga Entity		Entity	_	F4.
Account Number 19-0733 19-0733 127 50 227 25 Surchargo- Intel provisional Ring fee or cover sheet. Non-English specification 139 130 13	Deposit Account:		Code	(8)	Code	(8)	•	Paid
Deposit Account Benner & Whooff, Ltd 139 130 130 130 Non-English specification 147 2,520 147 2,520 For filling a request for reasonihablion 147 2,520 147 2,520 For filling a request for reasonihablion 147 2,520 147 2,520 For filling a request for publication of ISIR prior to Examiner action 147 250 147 2,520 For filling a request for publication of ISIR prior to Examiner action 148 148 153 1,840 153 154 153	Account 19-0733						Surcharge - Iste provisional filing fee	-
Deposit Account Request Park Vificuifi, Lid 112 620 112 820 For filing a request for reasymbation account. 112 620 112 820 Requesting publication of SIR prior to Examiner action Distance of the special publication of SIR prior to Examiner action Distance of Six provided Park Park Park Park Park Park Park Park	Rembel		139	130	139	130		<u> </u>
Name The Commissioner is suthorized to: (check all that supply) Charge res(e) indicated below □ Credit any overpayments The Commission of the provided in the provised in the provided in the provised in t								
□ Charge fee(s) Indicated below □ Credit any overpayments □ Charge fee(s) Indicated below except for the filling fee			2	830*	112	920*	Requesting publication of SIR prior to	
Charge fee(s) indicated below, except for the filling fee of the ebove-identified deposit account.	Charge fee(s) indicated below Cr	redit any overpayments	113	1,840*	113	1,840*	Exeminer action	
116 200 217 217 200 217 217 200 217 217 200 217 217 200 217 217 200 217 217 200 217 217 200 217 217 200 217 217 200 217 217 200 217 217 200 217 217 200 217 217 200 217 217 200 217 217 200 217 217 200 217 217 200 217 217 200 217	⊠ Charge any additional ree(s) during tr □ Charme fasés) indicated below, except	ns pendency of this approach of for the filles fee	115				and the second s	ļ
BASIC FILING FEE 118 1,440 218 720 Extension for reply within flourith month mont	o the above-identified deposit account.		116	400	216	200		200.00
Page	FEE CALCUL	AYION	117	920	217	460	Extension for reply within third month	
19 20 20 18 19 20 21 18 18 19 18 19 18 19 18 18			118	1,440	218		month	<u></u>
101 740 201 370 Utility filing fee 120 320 220 160 Filing a briter in support of an eppart 121 260 221 140 Request for cral hearing 122 260 221 140 Request for cral hearing 123 124 125	es Fee Fee Fee Do		1					
121 260 221 140 Requisit for oral hearing 121 260 221 140 Requisit for oral hearing 121 122 1230 123 1	(1)							
138 1,510 139 1,510 1,510 1,510 1,510 1,510 1,510 1,510 1,510 1,510 1,510 1,510 1,510 1,510 1,510 1,510 1,510 1,510	•		4					
BUSTOTAL (1) EXTRA CLAIM FEES Extra Fee from Fee Ped Claims Fee from Ped Description Substantial Entity Small Entity Fee Fee Pee Fee Fee Fee Fee Fee Fee Fee	107 610 207 255 Plant fi	iling fee	1				Pelition to institute a public use	
BUBTOTAL (1) (3) 0 141 1,280 241 640 Petition to revive — unfortentional 42 1,280 242 640 Utility issue fec (or relasue) 143 480 243 230 Design issue fee 144 820 244 310 Plant issue fee 144 820 244 310 Plant issue fee 145 180 123 50 Processing fee under 37 CFR 1.17 (q) 146 180 123 50 Processing fee under 37 CFR 1.17 (q) 147 180 180 180 180 180 Submission of Information Disclosure Simit 148 180 180 180 Submission of Information Disclosure Simit 149 180 180 Submission of Information Disclosure Simit 140 180 180 180 Submission of Information Disclosure Simit 140 180 180 180 Submission of Information Disclosure Simit 140 180 180 180 Submission of Information Disclosure Simit 140 180 180 180 Submission after final rejection (37 CFR § 1.128(s)) 140 180 180 180 180 Submission after final rejection (37 CFR § 1.128(s)) 140 180 180 180 180 180 Submission Submiss			140	110	240	65		
Extra Fee from Fee Claims Fees from Fee Description Extra Fee from Fee Ped Leg Fees Fees Fees Fees Fees Fees Fees Fe	114 100 214 00 110188			1,280	241	640		
Extra Fee from Fee from Paid 124 820 244 310 Plant leaue fee	SUBTOTAL (1)	(\$) 0	142	1,280	242	640	Utility issue fee (or release)	
Lettra Fee from Fee claims below Paid 122 130 122 130 Patticus to the Commissioner 123 50 Processing fee under 37 CFR 1.17 (q) 125 150 123 50 Processing fee under 37 CFR 1.17 (q) 126 150 123 50 Processing fee under 37 CFR 1.17 (q) 127 128 150 129 150 150 Processing fee under 37 CFR 1.17 (q) 128 150 129 150 129 150 Processing fee under 37 CFR 1.17 (q) 129 150 129 150 129 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 129 150 150 Processing fee under 37 CFR 1.17 (q) 127 128 150 129 150 Processing fee under 37 CFR 1.17 (q) 128 150 129 150 150 150 Processing fee under 37 CFR 1.17 (q) 129 150 129 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 128 150 129 150 150 150 Processing fee under 37 CFR 1.17 (q) 129 150 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 150 150 Processing fee under 37 CFR 1.17 (q) 120 150 150 150 150 150 150 150 150 150 15	L EXTRA CLAIM FEES		100					
chal Claims -20 ** = 0 X = 0 123 50 Proceasing fee under 37 CFR 1.17 (q) 126 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Disclosure sins 128 180 128 180 Submission of information Submission of information Disclosure sins 128 180 128	Extre		b.					
targe entity 8mail Entity Fee Fee Pee Fee Pee (8) Claims in excess of 20 independent claims in excess of 30 independent c								
Autible pendant X = 0 581 40 581 40 per properly (fines number of properlies) Large Entity Small Entity Fee	dependent		į.				Submission of Information Disclosure	
Large Entity Small Entity Fee	uliigle	X 0	581	40	581	40	Recording each patent assignment per properly (%nes number of	
Code [8] Code [9] For each additional invention to be examined (37 CFR § 1.126(b)) 102 84 202 42 Independent claims in excess of 3 Multiple dependent claims in excess of 3 Multiple dependent claims in excess of 3 For each additional invention to be examined (37 CFR § 1.126(b)) 109 84 209 42 Independent claims in excess of 3 For each additional invention to be examined (37 CFR § 1.126(b)) 109 84 209 42 Independent claims in excess of 3 For each additional invention to be examined (37 CFR § 1.126(b)) 109 84 209 42 Independent claims in excess of 3 For each additional invention to be examined (37 CFR § 1.126(b)) 109 84 209 42 Independent claims in excess of 3 For each additional invention to be examined (37 CFR § 1.126(b)) 109 84 209 42 Independent claims in excess of 3 For each additional invention to be examined (37 CFR § 1.126(b)) 109 600 169 600 169 600 Request for expedited examination of a deep examined (37 CFR § 1.126(b)) 110 18 210 9 Order for expedited examination of a deep examined (37 CFR § 1.126(b)) 109 600 169 600 169 600 Request for expedited examination of a deep examined (37 CFR § 1.126(b))	fee Fee Fee Fee Fee	a Description	146	740	246	370	Filing a automission after final rejection	
102 B4 202 42 Independent claims in excess of 3 104 200 204 140 Multiple dependent cleim, if not paid 109 84 209 42 original pattent 110 19 210 9 Redsaus craims in excess of 20 and over original pattent 110 19 210 9 Other fee (apacity)	Code (8) Gode (\$)		149	740	249	370	For each additional invention to be	
109 84 209 42 original patent of a design application of a design application of a design application of a design application or a design application of a design application			179	740	279	370	Request for Continued Examination (RCE)	
110 19 210 9 "Relatus cleims in excess of 20 and over original patent	*** ** *** *** *** *** *** *** *** ***		169	600	169	800		
SUBTOTAL (2) (6) 0 Other fee (apacity)								
	eustor	TAL (2) (8) 0	Other	fee (apaci	ły)	~		<u></u>
**or number previously paid, If greater; For Reissues, see above **or number previously paid, If greater; For Reissues, see above **or number previously paid, If greater; For Reissues, see above	°°or number previously paid, If greater;	For Reissues, see above	*Red	uced by Bi	aalc Filla	tg Fee P	zid SUBTOTAL (3) (9) 200	
				trouble and our of the		**************************************		/A
SUBMITTED BY Complete (# applicable)				· · · · · · · · · · · · · · · · · · ·		- nomonnasie	Complete (# socilcahia)	avecus - Port

(202) 508-9100 Michelia L. Holmes-Son Registration No. Attorney/Agent) 47,860 Nama (Print/Typa) Telephone Name (Print/Type) Michelle L. Holmes-Son Registration No. Attorney/Agenty 47,960 Telephone (202) 908-9100

Signeture Date February 20, 2002

WARNING! Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2018.

Burden Hour Statement: This form is settimated to take 0.2 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are registred to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Weshington, DC 20231

Page 170 of 1224

Pietas type a plus sign Under the Paperwork Re			U.S. Patent and Trademerk	PTO/SB/21 (08-00) d for use through 10/31/2002. OMB 0651-9934 t Office: U.S. DEPARTMENT OF COMME
(to be used for all come		itial filing)	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name	09/613,826 July 11, 2000 Bert VOGELSTEIN, et al. 1656 Jeffrey Siew
Total Number of Pages	in This Submission		Attorney Docket Number	001107.00031
Fee Transmittal Fo Fee Attached Amendment / Resp After Final Affidavits/decta Extension of Time Express Abandonn Information Disclost Certified Copy of P Document(s) Response to Missis Incomplete Application Response to M Parts under 37 1.52 of 1.53	conse aration(s) Request ment Request sure Statement Priority ng Perts/ Allon Alissing	Assign (for en. (for en. (for en.) Drawin Ucens Petitio Provis Power Chang Termin Reque	ing-related Papers n n to Convert to a lonal Application of Attorney, Revocation je of Correspondence Addrese nal Disclaimer sat for Refund umber of CD(s)	After Allowance Communication to Group Appeal Communication to Board of Appeals and interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Sequence Listing Computer Readable Disk
Firm or Individual name Signature Data	Michelle L. Holmes Michelle L. Holmes February 20, 2002	S-Son, Reg.	RTIFICATE OF MAILING :	(a) Service es first class mail in an envelopé
Typed or printed name	8		Vashington, D.C. 20231 on this dis-	Upon the needs of the individual case. Any Conscision Officer, U.S. Patent and Trademark CONCESS. SEND TO. Assistant Commissioner for



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Bert Vogelstein, et. al.

Serial No. 09/613,826

Filing Date: July 11, 2000

For: DIGITAL AMPLIFICATION

) Group Art Unit: 1656

) Examiner: J Siew

) Box AF

) Docket No. 01107.00031



AMENDMENT AFTER FINAL REJECTION

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Final Office Action mailed September 20, 2001, applicants request entry of the following amendments. Claims 1-64 are pending in the application and are allowed. A petition for a two-month extension of time is enclosed herewith. No other fees are believed due to make this response filed timely. If any additional fee is due please change our Deposit Account No. 19-0733.

IN THE CLAIMS

Please cancel claims 65-69.

1

(1 x

Page 172 of 1224 --- -

SEQUENCE LISTING

Please replace the sequence listing in the application with the accompanying substitute sequence listing. A computer readable form and paper copy of the substitute sequence listing are enclosed. They are believed to be identical in content. The substitute sequence listing introduces no new matter.

IN THE SPECIFICATION

The paragraph beginning page 4, line 19.

Fig. 2. Discrimination between WT and mutant PCR products by Molecular Beacons. Ten separate PCR products, each generated from ~25 genome equivalents of genomic DNA of cells containing the indicated mutations of *c-Ki-Ras*, were analyzed with the Molecular Beacon probes described in the text. Representative examples of the PCR products used for Molecular Beacon analysis were purified and directly sequenced. In the cases with Gly12Cys (SEQ ID NO: 11) and Gly12Arg (SEQ ID NO: 10) mutations, contaminating non-neoplastic cells within the tumor presumably accounted for the relatively low ratios. In the cases with Gly12Ser (SEQ ID NO: 8) and Gly12Asp (SEQ ID NO: 12), there were apparently two or more alleles of mutant *c-Ki-Ras* for every WT allele (SEQ ID NO: 7); both these tumors were aneuploid. Analysis of the Gly13Asp mutation is also shown (SEQ ID NO: 9).

The paragraph beginning page 5, line 10.

34

Fig. 4. Discriminating WT from mutant PCR products obtained in Dig-PCR. RED/GREEN ratios were determined from the fluorescence of MB-RED and MB-GREEN as described in Materials and Methods. The wells shown are the same as those illustrated in Fig. 3. The sequences of PCR products from the indicated wells were determined as described in Materials and Methods. The wells with RED/GREEN ratios >3.0 each contained mutant sequences while those with RED/GREEN ratios of ~1.0 contained WT sequences. WT *c-Ki-Ras* (SEQ ID NO: 7), Gly12Asp (SEQ ID NO: 13), and Gly13Asp (SEQ ID NO: 9) were analyzed.

The paragraph beginning page 5, line 17.

Fig. 5. Dig-PCR of DNA from a stool sample. The 384 wells used in the experiment are displayed. Those colored blue contained 25 genome equivalents of DNA from normal cells. Each of these registered positive with MB-RED and the RED/GREEN ratios were 1.0 +/- 0.1 (mean +/- 1 standard deviation). The wells colored yellow contained no template DNA and each was negative with MB-RED (i.e., fluorescence <3500 fluorescence units.). The other wells contained diluted DNA from the stool sample. Those registering as positive with MB-RED were colored either red or green, depending on their RED/GREEN ratios. Those registering negative with MB-RED were colored white. PCR products from the indicated wells were used for automated sequence analysis. The sequence of WT c-Ki-Ras in well K1 (SEQ ID NO: 7), and mutant c-Ki-Ras in wells C10, E11, M10, and L12 (SEQ ID NO: 14), and well F21 (SEQ ID NO: 15) were analyzed.

n 3

REMARKS

The Amendments

The specification has been amended to enter a substitute sequence listing. The substitute sequence listing includes sequences that were not present in the prior sequence listing. The additional sequences are disclosed in Figures 2, 4, and 5 of the drawings.

The paragraph beginning at page 4, line 19 has been amended to disclose the sequence identifier of each of the wildtype or mutant *ras* sequences shown in Figure 2.

The paragraph beginning at page 5, line 10 and the paragraph beginning at page 5, line 17 have each been amended to disclose the sequence identifier for each of the wildtype or mutant ras sequences shown in Figures 4 and 5, respectively.

These amendments were not made earlier as applicants only first became aware of this oversight after the final rejection was mailed. Rejected claims 65-69 have been canceled without prejudice to their future prosecution in continuation applications. A notice of allowance is respectfully requested.

Respectfully submitted,

Date: February 20, 2002

: MULUDE HA Michelle Holmes-Son Registration No. 47,660

Banner & Witcoff, Ltd. 1001 G Street, NW Washington, DC 20001 202-508-9100 MARKED UP VERSION TO SHOW CHANGES MADE

The paragraph beginning page 4, line 19.

Fig. 2. Discrimination between WT and mutant PCR products by Molecular Beacons. Ten separate PCR products, each generated from ~25 genome equivalents of genomic DNA of cells containing the indicated mutations of *c-Ki-Ras*, were analyzed with the Molecular Beacon probes described in the text. Representative examples of the PCR products used for Molecular Beacon analysis were purified and directly sequenced. In the cases with Gly12Cys (SEQ ID NO: 11) and Gly12Arg (SEQ ID NO: 10) mutations, contaminating non-neoplastic cells within the tumor presumably accounted for the relatively low ratios. In the cases with Gly12Ser (SEQ ID NO: 8) and Gly12Asp (SEQ ID NO: 12), there were apparently two or more alleles of mutant *c-Ki-Ras* for every WT allele (SEQ ID NO: 7); both these tumors were aneuploid. Analysis of the Gly13Asp mutation is also shown (SEQ ID NO: 9).

The paragraph beginning page 5, line 10.

Fig. 4. Discriminating WT from mutant PCR products obtained in Dig-PCR. RED/GREEN ratios were determined from the fluorescence of MB-RED and MB-GREEN as described in Materials and Methods. The wells shown are the same as those illustrated in Fig. 3. The sequences of PCR products from the indicated wells were determined as described in Materials and Methods. The wells with RED/GREEN ratios >3.0 each contained mutant sequences while those with RED/GREEN ratios of ~1.0

contained WT sequences. WT c-Ki-Ras (SEQ ID NO: 7), Gly12Asp (SEQ ID NO: 13), and Gly13Asp (SEQ ID NO: 9) were analyzed.

The paragraph beginning page 5, line 17.

Fig. 5. Dig-PCR of DNA from a stool sample. The 384 wells used in the experiment are displayed. Those colored blue contained 25 genome equivalents of DNA from normal cells. Each of these registered positive with MB-RED and the RED/GREEN ratios were 1.0 +/- 0.1 (mean +/- 1 standard deviation). The wells colored yellow contained no template DNA and each was negative with MB-RED (i.e., fluorescence <3500 fluorescence units.). The other wells contained diluted DNA from the stool sample. Those registering as positive with MB-RED were colored either red or green, depending on their RED/GREEN ratios. Those registering negative with MB-RED were colored white. PCR products from the indicated wells were used for automated sequence analysis. The sequence of WT c-Ki-Ras in well K1 (SEO ID NO: 7), and mutant c-Ki-Ras in wells C10, E11, M10, and L12 (SEO ID NO: 14), and well F21 (SEO ID NO: 15) were analyzed.

```
107.31.ST25
                                     SEQUENCE LISTING
          Vogelstein, Bert
Kinzler, Kenneth W.
 <110>
<120>
          DIGITAL AMPLIFICATION
<130> 01107.00031
          09/613,826
2000-07-11
 <140>
 <141>
<150> US 60/146,792
<151> 1999-08-02
 <160> 15
<170> Patentin version 3.1
<210> 1
<211> 26
<212> DNA
<213> homo sapiens
 <400> 1
catgitictaa tatagicaca tittca
                                                                                                      26
<210> 2
<211> 24
<212> DN/
<213> hor
          DNA
homo sapiens
<400> 2
tctgaattag ctgtatcgtc aagg
                                                                                                      24
<210> 3
<211> 20
<212> DNA
<213> homo sapiens
<400> 3 tagctgtarc gtcaaggcac
                                                                                                      20
<210>
<211>
 <212> DNA
<213> homo sapiens
<400> 4 cacgggcctg ctgaaaatga ctgcgtg
                                                                                                      27
<210> 5
<211> 24
<212> DNA
<213> homo sapiens
<400> 5 cacgggagct ggtggcgtag cgtg
```

Page 1

:--/-)

107.31.ST25

<210> <211> <212> <213>	6 24 DNA homo sapiens	
<400> cattat	6 Ettt attataaggc ctgc	24
<210> <211> <212> <213>	7 12 DNA homo sapiens	
	7 ggcg ta	12
<210> <211> <212> <213>	8 12 DNA homo sapiens	
<400> gctagt	8 ggcg ta	12
<210> <211> <212> <213>	9 12 DNA homo sapiens	
<400> gctggt	gacg ta	12
<210> <211> <212> <213>	10 12 DNA . homo sapiens	
<400> gctcgt	10 ggcg ta	12
<210> <211> <212> <213>	11 13 DNA homo sapiens	
<400> gcttgt	11 ggcc gta	13
<210> <211> <212> <213>	12 13 DNA homo sapiens	
<400> gctgat	12 gggc gta	13

Page 2

·)(·

107.31.ST25

<400> gctgat	13 ggcg ta	12
<211> <212>	14 12 DNA homo sapiens	
<400> gctgct	14 ggcg ta	12
	15 ggtg ta	12

Page 3

311

7000 4 considered median to consider proposal consideration and the constraints of the co	Application No.	Applicant(s)	
	09/613,828	VOGELSTEIN ET AL.	
Interview Summary	Examiner	Art Unit	
	Jeffrey Slew	1656	
All participants (applicant, applicant's representative, P	TO personnel);		
1) <u>Jeffrey Slew</u> .	(3)		
2) <u>Michelle Holmes-Son</u> .	(4)		
Date of Interview: 04 March 2002			
Type: a)⊠ Telephonic b)☐ Video Conference c)☐ Personal [copy given to: 1)☐ applican	nt 2) applicant's repres	entative]	
Exhibit shown or demonstration conducted: d) Yes if Yes, brief description:	s e)⊡ No.		
Claim(s) discussed: <u>1-64</u> .			
Identification of prior art discussed:			
Agreement with respect to the claims f)☐ was reach	ned. g)⊠ was not reache	d. h)□ N/A.	
Substance of interview including description of the ger reached, or any other comments: <u>discussed newly dis</u>	neral nature of what was agi sclosed prior art	eed to if an agreement was	
(A fuller description, if necessary, and a copy of the an allowable, if available, must be attached. Also, where allowable is available, a summary thereof must be attached.	no copy of the amendment	ner agreed would render the c s that would render the claims	lalm
 It is not necessary for applicant to provide checked). 	a separate record of the su	bstance of the interview(if box	ls
Unless the paragraph above has been checked, THE MUST INCLUDE THE SUBSTANCE OF THE INTERVaction has already been filed, APPLICANT IS GIVEN STATEMENT OF THE SUBSTANCE OF THE INTERVeverse side or on attached sheet.	ONE MONTH FROM THIS	INTERVIEW DATE TO FILE A	
	Sol	Gysiew 3/4/02	

Page 182-of 1224 --- ··

Paper No. 18.

#19

RECEIVED

MAR 1 4 2002

TECH CENTER 1600/2900

ENTERED

1637

RAW SEQUENCE LISTING PATENT APPLICATION: US/09/613,826A

DATE: 03/01/2002 TIME: 15:29:37

Input Set : A:\107.31.8T25.txt
Output Set: N:\CRF3\03012002\1613826A.raw

3 <110> APPLICANT: Vogelstein, Bert Kinzler, Kenneth W. 6 <120> TITLE OF INVENTION: DIGITAL AMPLIFICATION 8 <130> FILE REFERENCE: 01107.00031 10 <140> CURRENT APPLICATION NUMBER: 09/613,826A 11 <141> CURRENT FILING DATE: 2000-07-11 RECEIVED 13 <150> PRIOR APPLICATION NUMBER: US 60/146,792 14 <151> PRIOR FILING DATE: 1999-08-02 MAR 1 4 2002 16 <160> NUMBER OF SEQ ID NOS: 15 18 <170> SOFTWARE: PatentIn version 3.1 **TECH CENTER 1600/2900** 20 <210> SEQ ID NO: 1 21 <211> LENGTH: 26 22 <212> TYPE: DNA 23 <213> ORGANISM: homo sapiens 25 <400> SEQUENCE: 1 26 26 catgitictaa tatagicada tittca - 29 <210> SEQ ID NO: 2 30 <211> LENGTH: 24 31 <212> TYPE: DNA 32 <213> ORGANISM: homo sapiens 34 <400> SEQUENCE: 2 24 35 totgaattag otgtatogto aagg 38 <210> SEQ ID NO: 3 39 <211> LENGTH: 20 40 <212> TYPE: DNA 41 <213> ORGANISM: homo sapiens 43 <400> SEQUENCE: 3 20 44 tagctgtatc gtcaaggcac 47 <210> SEQ ID NO: 4 48 <211> LENGTH: 27 49 <212> TYPE: DNA 50 <213> ORGANISM: homo sapiens 52 <400> SEQUENCE: 4 27 53 cacgggcctg ctgaaaatga ctgcgtg 56 <210> SEQ ID NO: 5 57 <211> LENGTH: 24 58 <212> TYPE: DNA 59 <213> ORGANISM: homo sapiens 61 <400> SEQUENCE: 5 62 cacgggaget ggtggcgtag cgtg 65 <210> SEQ ID NO: 6 66 <211> LENGTH: 24

3/1/02

67 <212> TYPE: DNA

RAW SEQUENCE LISTING

DATE: 03/01/2002 TIME: 15:29:37

PATENT APPLICATION: US/09/613,826A

Input Set : A:\107.31.ST25.txt
Output Set: N:\CRF3\03012002\I613826A.raw

```
68 <213> ORGANISM: homo sapiens
 70 <400> SEQUENCE: 6
                                                                              24
 71 cattatttt attataaggc ctgc
 74 <210> SEQ ID NO: 7
 75 <211> LENGTH: 12
 76 <212> TYPE: DNA
 77 <213> ORGANISM: homo sapiens
 79 <400> SEQUENCE: 7
                                                                              12
 80 gctggtggcg ta
 83 <210> SEQ ID NO: 8
84 <211> LENGTH: 12
 85 <212> TYPE: DNA
 86 <213> ORGANISM: homo sapiens
 88 <400> SEQUENCE: 8
                                                                              12
 89 gctagtggcg ta
 92 <210> SEQ ID NO: 9
 93 <211> LENGTH: 12
 94 <212> TYPE: DNA
 95 <213> ORGANISM: homo sapiens
 97 <400> SEQUENCE: 9
                                                                              12
 98 gctggtgacg ta
 101 <210> SEQ ID NO: 10
 102 <211> LENGTH: 12
103 <212> TYPE: DNA
 104 <213> ORGANISM: homo sapiens
 106 <400> SEQUENCE: 10
                                                                               1.2
 107 gctcgtggcg ta
 110 <210> SEQ ID NO: 11
. 111 <211> LENGTH: 13
 112 <212> TYPE: DNA
 113 <213> ORGANISM: homo sapiens
 115 <400> SEQUENCE: 11
                                                                               13
 116 gcttgtggcc gta
 119 <210> SEQ ID NO: 12
 120 <211> LENGTH: 13
 121 <212> TYPE: DNA
 122 <213> ORGANISM: homo sapiens
 124 <400> SEQUENCE: 12
                                                                                13
 125 gctgatgggc gta
 128 <210> SEQ ID NO: 13
 129 <211> LENGTH: 12
  130 <212> TYPE: DNA
  131 <213> ORGANISM: homo sapiens
  133 <400> SEQUENCE: 13
                                                                                12
  134 gctgatggcg ta
  137 <210> SEQ ID NO: 14
  138 <211> LENGTH: 12
  139 <212> TYPE: DNA
  140 <213> ORGANISM: homo sapiens
```

...

Page 3 of 5

RAW SEQUENCE LISTING DATE: 03/01/2002 PATENT APPLICATION: US/09/613,826A TIME: 15:29:37

Input Set : A:\107.31.ST25.txt
Output Set: N:\CRF3\03012002\1613826A.raw

142 <400> SEQUENCE: 14

143 getgetgggg ta

146 <210> SEQ ID NO: 15

147 <211> LENGTH: 12

148 <212> TYPE: DNA

149 <213> ORGANISM: homo sapiens

151 <400> SEQUENCE: 15

152 getggtggtg ta

12

Page 4 of 5

VERIFICATION SUMMARY PATENT APPLICATION: US/09/613,826A

DATE: 03/01/2002 TIME: 15:29:38

Input Set : A:\107.31.ST25.txt
Output Set: N:\CRF3\03012002\1613826A.raw

3/1/02

File History Report

Paper number is missing from the United States Patent Trademark Office's copy of the file History. No additional information is available.
The following page(s) 5 of 5 of paper number 19 is/are missing from the United States Patent and Trademark Office's original copy of the file history. No additional information is available
The following checked item(s) below of paper number is/are missing from the United States Patent and Trademark Office's original copy of the file history. No additional information is available PTO 1449 PTO 892 PTO 948 PTO 1474 Assignment Cover page

Additional comments:

Application No. Applicant(s) TAKESHITA ET AL. 09/613,829 Interview Summary Examiner Art Unit Jeffrey Slew 1656 All participants (applicant, applicant's representative, PTO personnel): (1) Jeffrey Siew. (2) Michelle Holmes Son. Date of Interview: 19 March 2002. Type: a) ☐ Telephonic b) ☐ Video Conference c) Personal [copy given to: 1) applicant 2) applicant's representative] Exhibit shown or demonstration conducted: d) Yes e) No. If Yes, brief description: _ Claim(s) discussed: 1-64. identification of prior art discussed: _ Agreement with respect to the claims f) was reached. g) was not reached. h) N/A. Substance of interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: <u>discussed that newly cited prior art do not read on the prior art. For example,</u>
<u>Halford while performing dilutions and amplifications, the claimed invention is performing a dilution which results in aa</u> first number of samples which contain selected genetic sequence and second number of assay samples which contain a reference and comparing to ascertain a ratio . (A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.) i) It is not necessary for applicant to provide a separate record of the substance of the interview (if box is checked). Unless the paragraph above has been checked, THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet. Examiner Note: You must sign this form unless it is an Examiner's signature, if required Attachment to a signed Office action.

U.S. Patent and Trademark Office PTO-413 (Rev. 03- 98)

Application No. Applicant(s) Delivation Delivatio				
Notice of Allowability Examiner Jeffrey Slow Art Unit Je566	b	Application No.	Applicant(s)	
Notice of Allowability Examiner Jeffrey Slow Art Unit Je566		09/813 829	TAKESHITA ET AL	
	Notice of Allowability			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address—All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application, if not included herewith for previously mailtor), a Notice of Allowano (PTOL-89) or other appropriate communication will be malled in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. 1. □ This communication is responsive to (Int. 3/19/02). 2. □ The allowed claim(s) Island 1.324. 3. □ The drawings filled on 11.3/W.2000 are accepted by the Examiner. 4. □ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 118(e)-(d) or (f). 3. □ The drawings filled on priority documents have been received. 2. □ Certified copies of the priority documents have been received in Application No. □ International Bureau (PCT Rule 17.2(a)). 3. □ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). 4. □ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). (a) □ The translation of the foreign language provisional application has been received. 4. □ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 120 and/or 121. 4. □ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 120 and/or 121. 4. □ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). (a) □ The translation of the foreign language provisional application has been received. 5. □ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 120 and/or 121. 4. □ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 120 and/or 121. 4. □ Acknowledgment is made of a claim for domestic		Infference Closes	1656	
All claims being allowable, PROSECUTION ON THE MERTIS IS (OR REMAINS) (CLUSED in the application. The inherentity for previously malled), a Notice of Allowance (PTCL-86) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. 1. ☑ This communication is responsive to Int. 3/19/02. 2. ☑ The drawings filled on I1_UNIV_2000 are accepted by the Examiner. 4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 118(e)-(d) or (f). a) ☐ All b) ☐ Some* (a) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No				
2. ☑ The drawings field on 11. July 2000 are accepted by the Examiner. 3. ☑ The drawings field on 11. July 2000 are accepted by the Examiner. 4. ☐ Acknowledgment to made of a claim for foreign priority under 35 U.S.C. § 118(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Cartified copies of the priority documents have been received. 2. ☐ Cartified copies of the priority documents have been received in Application No 3. ☐ Copies of the cartified copies of the priority documents have been received in this national stage application from the International Burseu (PCT Rule 17.2(a)). * Cartified copies not received: 1. ☐ Cartified copies not received: 5. ☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 118(e) (to a provisional application). (a) ☐ The translation of the foreign language provisional application has been received. 3. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 120 and/or 121. Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 7. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(e) why the oath or declaration is deficient. 8. ☑ CORRECTED DRAWINGS must be submitted. (a) ☑ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) ☑ hereto or 2) ☐ to Paper No (b) ☐ including changes required by the proposed drawing correction filed which has been approved by the Examiner. (c) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No (d) ☐ Including changes required by the proposed drawing correction filed which has been approved by the Examiner's comment regarding	All claims being allowable, PROSECUTION ON THE MERITS herewith (or previously mailed), a Notice of Allowance (PTOL-INCOME) AND A GRANT OF PATENT	IS (OR REMAINS) CLUS 86) or other appropriate of RIGHTS. This applicati	SED in this application, it not inclu- communication will be mailed in du	e course, THIS
3. ☑ The drawings filed on 11 July 2000 are accepted by the Examiner. 4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(e)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the Intermetional Burseu (PCT Rule 17.2(a)). * Certified copies not received: 5. ☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). (a) ☐ The translation of the foreign lenguage provisional application has been received. 6. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Fallure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 7. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the certification is deficient. 8. ☑ CORRECTED DRAWINGS must be submitted. (a) ☑ Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) ☑ hereto or 2) ☐ to Paper No Including changes required by the stacked Examiner's Amendment / Comment or in the Office action of Paper No Identifying Indicis such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmittel latter addressed to the Official Draftsperson. 9. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note' the attached Examiner's Comment	1. This communication is responsive to int 3/19/02.			
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 118(e)-(d) or (f). a) ☐ All b) ☐ Some* o) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Burseu (PCT Rule 17.2(a)). **Certified copies not received: 5. ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). (a) ☐ The translation of the foreign language provisional application has been received. 6. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 7. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 8. ☒ CORRECTED DRAWINGS must be submitted. (a) ☒ Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) ☒ heristo or 2) ☐ to Paper No (b) ☐ including changes required by the stitached Examiner's Amendment / Comment on the drawings in the top margin (not the beck) of each abest. The drawings should be filed as a separate per with a transmitted later addressed to the Official Draftsperson. 9. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Altachment(s) 1☐ Notice of References Cited (PTO-982) 3☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 4☐ Ex	2. The allowed claim(s) is/are 1-64.			ļ
a)	3. The drawings filed on 11 July 2000 are accepted by the	Examiner.	5411-346	
1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). **Certified copies not received: **Certified copies of the priority documents have been received in this national stage application. The provisional application has been received. **Certified copies of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application. **Certified copies of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application. **Certified copies of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application. **Certified copies of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application. **Certified copies of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application. **Certified copies of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application. **Certified copies of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application in the provisional application of the provisional application in the provisional application of Teature notation. **This THREE-MONTH PERIOD IS NOT Extended Examiner's Amendment / Comment or Intended Examiners in the top margin (not the beach) of including changes required by the Notice of Parather's Amendment / Comment or In the Office action of Paper No	4. Acknowledgment is made of a claim for foreign priority	under 35 U.S.C. § 119(a)-(d) or (f).	
2. ☐ Cartifled copies of the priority documents have been received in Application No	a) All b) Some* c) None of the:			
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bursau (PCT Rule 17.2(a)). ** Certified copies not received: ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐	 Certified copies of the priority documents h 	ave been received.	-Hil 61-	
* Certified copies not received:	Certified copies of the priority documents h	ave been received in Ap	pression No	antian from the
5.			aceined in this liatiousi stage abbiid	Sandi inoni ine
(a) ☐ The translation of the foreign language provisional application has been received. 6. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 7. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 8. ☑ CORRECTED DRAWINGS must be submitted. (a) ☑ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) ☑ hereto or 2) ☐ to Paper No (b) ☐ including changes required by the proposed drawing correction filed, which has been approved by the Exeminer. (c) ☐ including changes required by the attached Exeminer's Amendment / Comment or in the Office action of Paper No Identifying Indicis such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmittel letter addressed to the Official Draftsperson. 9. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Aftachment(s) 1☐ Notice of References Cited (PTO-892) 3[☑ Notice of Draftperson's Patent Drawing Review (PTO-948) 5[☐ Information Disclosure Statements (PTO-1449), Paper No 6[☐ Examiner's Amendment/Comment of Reasons for Allowance	* Certified copies not received:			
6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 8. CORRECTED DRAWINGS must be submitted. (a) Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2 to Paper No. (b) Including changes required by the proposed drawing correction filed which has been approved by the Examiner. (c) Including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. Including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. Including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. Including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. Including changes required by the attached Examiner's Amendment / Comment or the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmitted latter addressed to the Official Draftsperson. 9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding Requirement for Deposit Attachment(s) 1. Notice of Informal Patent Application (PTO-152) 4. Interview Summary (PTO-413), Paper No. 5. Examiner's Amendment/Comment 5. Examiner's Amendment/Comment 6. Examiner's Comment of Reasons for Allowance	5. Acknowledgment is made of a claim for domestic priorit	ly under 35 U.S.C. § 119	(e) (to a provisional application).	
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 8. CORRECTED DRAWINGS must be submitted. (a) Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No (b) including changes required by the proposed drawing correction filed, which has been approved by the Examiner. (c) Including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No Identifying Indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmittel letter addressed to the Official Draftsperson. 9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Aftachment(e) 1 Notice of References Citad (PTO-892) 3 Whotice of Draftperson's Patent Drawing Review (PTO-948) 5 Information Disclosure Statements (PTO-1449), Paper No 5 Examiner's Amendment/Comment of Reasons for Allowance	(a) The translation of the foreign language provision	al application has been t	aceived.	
below. Failure to timely comply will result in ABANDONMENT of this application. 7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 8. CORRECTED DRAWINGS must be submitted. (a) Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No. (b) Including changes required by the proposed drawing correction filed which has been approved by the Examiner. (c) Including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. Identifying Indicia such as the application number (see 37 GFR 1.84(c)) should be written on the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmitted letter addressed to the Official Draftsperson. 9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1 Notice of References Cited (PTO-892) 3 Notice of Patiperson's Patent Drawing Review (PTO-948) 5 Notice of Informal Patent Application (PTO-152) 4 Notice of Informal Patent Application (PTO-152) 5 Notice of Patiperson's Patent Drawing Review (PTO-948) 5 Notice of Patiperson's Patent Drawing Review (PTO-948) 6 Notice of Patiperson's Amendment Comment Regarding Requirement for Deposit	6. Acknowledgment is made of a claim for domestic priorit	ly under 35 U.S.C. 99 12	u ano/or 121.	
INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the data of decision is decision. 8.	Applicant has THREE MONTHS FROM THE "MAILING DATE below. Fallure to timely comply will result in ABANDONMENT	e" of this communication of this application. This	to file a reply complying with the res S THREE-MONTH PERIOD IS NO	quirements noted TEXTENDABLE.
(a) ☑ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) ☑ hereto or 2) ☐ to Paper No (b) ☐ including changes required by the proposed drawing correction filed, which has been approved by the Examiner. (c) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No, Identifying Indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmittel letter addressed to the Official Draftsperson. 9. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(e) 1☐ Notice of References Cited (PTO-892) 3☐ Whotice of Draftperson's Patent Drawing Review (PTO-948) 5☐ Information Disclosure Statements (PTO-1449), Paper No 6☐ Examiner's Amendment/Comment 8☐ Examiner's Statement of Ressons for Allowance	7. A SUBSTITUTE OATH OR DECLARATION must be a INFORMAL PATENT APPLICATION (PTO-152) which gives in	ubmitted. Note the attack reason(s) why the oath o	ned EXAMINER'S AMENDMENT or r declaration is deficient.	r NOTICE OF
(b) including changes required by the proposed drawing correction filed, which has been approved by the Examiner. (c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No, Identifying Indicia such as the application number (see 37 GFR 1.84(c)) should be written on the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmittel letter addressed to the Official Draftaperson. 9. In DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1. Notice of References Cited (PTO-892) 3. Notice of Informal Patent Application (PTO-152) 4. Interview Summary (PTO-413), Paper No, 5. Information Disclosure Statements (PTO-1449), Paper No, 7. Examiner's Comment Regarding Requirement for Deposit 2. Notice of Informal Patent Application (PTO-152) 4. Interview Summary (PTO-413), Paper No, 5. Examiner's Amendment/Comment 8. Examiner's Statement of Ressons for Allowance	(a) including changes required by the Notice of Drafts	person's Patent Drawing	Review (PTO-948) attached	
(c) Including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No	1) 🛭 hereto or 2) 🔲 to Paper No		and to the	- F
Identifying Indicia such as the application number (see 37 GFR 1.84(c)) should be written on the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmittel letter addressed to the Official Draftsperson. 9.	(b) including changes required by the proposed draw	ing correction filed	_, which has been approved by the	e Examiner.
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1 Notice of References Cited (PTO-892) 3 Notice of Draftperson's Patent Drawing Review (PTO-948) 5 Information Disclosure Statements (PTO-1449), Paper No 7 Examiner's Comment Regarding Requirement for Deposit 2 Notice of Informal Patent Application (PTO-152) 4 Interview Summary (PTO-413), Paper No 5 Examiner's Amendment/Comment 8 Examiner's Statement of Reasons for Allowance	(c) Including changes required by the attached Exam	iner's Amendment / Com	ment or in the Office action of Pap	ar No,
Attachment(s) 1 Notice of References Cited (PTO-892) 3 Notice of Draftperson's Patent Drawing Review (PTO-948) 5 Information Disclosure Statements (PTO-1449), Paper No 7 Examiner's Comment Regarding Requirement for Deposit Attachment(s) 2 Notice of Informal Patent Application (PTO-152) 4 Interview Summary (PTO-413), Paper No 6 Examiner's Amendment/Comment 8 Examiner's Statement of Reasons for Allowance	identifying Indicia such as the application number (see 37 Ci of each sheet. The drawings should be filed as a separate p	FR 1.84(c)) should be writt aper with a transmittel lett	en on the drawings in the top margir er addressed to the Official Draftspe	ı (not the back) rson.
1 Notice of References Cited (PTO-892) 3 Notice of Draftperson's Patent Drawing Review (PTO-948) 5 Information Disclosure Statements (PTO-1449), Paper No 7 Examiner's Comment Regarding Requirement for Deposit	DEPOSIT OF and/or INFORMATION about the dattached Examiner's comment regarding REQUIREMENT FOR A STATE OF THE PROPERTY OF	eposit of BIOLOGICAL OR THE DEPOSIT OF BI	_MATERIAL must be submitted OLOGICAL MATERIAL.	I. Note the
1 Notice of References Cited (PTO-892) 3 Notice of Draftperson's Patent Drawing Review (PTO-948) 5 Information Disclosure Statements (PTO-1449), Paper No 7 Examiner's Comment Regarding Requirement for Deposit	Attachment(s)			•
3 Notice of Draftperson's Patent Drawing Review (PTO-948) 5 Information Disclosure Statements (PTO-1449), Paper No 7 Examiner's Comment Regarding Requirement for Deposit 8 Examiner's Statement of Reasons for Allowance	4ET Notice of References Clied (PTO-892)		lotice of informal Patent Application	n (PTO-152)
5 Information Disclosure Statements (PTO-1449), Paper No 5 Examiner's Comment Regarding Requirement for Deposit 7 Examiner's Comment Regarding Requirement for Deposit 5 Examiner's Statement of Reasons for Allowance 7 Examiner's Comment Regarding Requirement for Deposit 7 Examiner's Comment Regarding Regard	2004 Aletton of Draffmarson's Patent Drawing Review (PTO-94	8) 42	nterview Summary (PTO-413), Par	er No. <i>[06*29</i> /
/ L Examiner & Comment Regarding Reduction of the Property of	Later Information Disclosure Statements (PTO-1449), Paper N	io old s	:xaminers Amendmenv.comment Evaminers Statement of Ressons f	or Allowance
	7 Examiner's Comment Regarding Requirement for Depos	HC OEST		and a start pape
U.S. Patent and Tredemark Office				

PTO-37 (Rev. 04-01)

Notice of Allowability

The state of the s

Part of Paper No. 20 .

Page 2

Application/Control Number: 09/613,829

Art Unit: 1656

REASONS FOR ALLOWANCE

1. The following is an examiner's statement of reasons for allowance:

Claims 33-37 are allowable. There is no prior art that teach or suggest a molecular beacon probe that has a loop consisting of 16 base pairs and having a Tm of 50-51C and the stem consisting of CACG sequence. The closest prior art is Tyagi et al (US6,037,130) teach molecular beacon with a stem comprising CACG (see col. 11 probe 3) but with a loop of Tm 50C. Moreover, the prior art has been focused on the Tm of the stem which relates to the functioning of the opening and closing of the hairpin during hybridization.

Claims 1-32 & 38-64 is allowable. There is no prior art that teach or suggest diluting a nucleic acid template in a sample to a plurality of sample and amplifying the template molecule in the samples and analyzing amplified molecules to determine the first number of samples containing the selected genetic sequence and second number assay samples which contain a reference genetic sequence and comparing the two numbers. Moreover, there is no prior art that teach or suggest that one tenth or one fiftieth of samples in a set comprise N molecules such that 1/N is larger than the ratio of selected genetic sequence to total genetic sequences required for the step of analyzing to determine presence of selected genetic sequence. The closest prior art is Lapidus et al who teach a reference and target nucleic acid amplification and concentration determination. However, his determination of concentration is within a sample and they do not teach or suggest a dilution.

Page 3

Application/Control Number: 09/613,829 Art Unit: 1656

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

CONCLUSION

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Siew whose telephone number is (703) 305-3886 and whose e-mail address is Jeffrey Siew@uspto.gov. However, the office cannot guarantee security through the e-mail system nor should official papers be transmitted through this route. The examiner is on flex-time schedule and can best be reached on weekdays from 6:30 a.m. to 3 p.m. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (703)-308-1119.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist for Technology Center 1600 whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal

Application/Control Number: 09/613,829

Art Unit: 1656

Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Center numbers for Group 1600 are Voice (703) 308-3290 and Before Final FAX (703) 872-9306 or After Final FAX (703) 30872-9307.

Jeffrey Siew

Page 4

March 19, 2002

Page 192 of 1224



United States Patent and Trademark Office

03/24/2002

UNITED STATESH DEPARTMENT OF COMMERCE United States Patent and Tradeshark Office Athers COMMENSIONER OF PATENTS AND TRAIRM ARX Windington, D.C. 2000)

NOTICE OF ALLOWANCE AND FEE(S) DUE

22907 7590 BANNER & WITCOFF 1001 G STREET N W

SUITE 1100 WASHINGTON, DC 20001 EXAMINER

SIEW, JEFFREY

ART UNIT

CLASS-SUBCLASS

1637

435-006000

DATE MAILED; 03/24/2002

APPLICATION NO.	FILINO DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO	
00/613 P26	07/11/2000	Bert Vugelstein	01107 00031	9893	

TITLE OF INVENTION: DIGITAL AMPLIFICATION

FOTAL CLAIMS	APPLN, TYPE	SMALL ENTITY	issue pee	PUBLICATION FEE	TOTAL FEE(S) DUE	DATL DUI;
64	nonprovisional	YES	\$640	20	\$640	06/24/2002

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1,313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above. If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

B. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.

 Applicant claims SMALL ENTITY status. See 37 CFR 1.27.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

Page 1 of 3

PTOL-85 (REV. 07-01) Approved for use through 01/31/2004.

garat v · · · · · · · · · · · · · · · · · ·						
PART B - FEE(S) TRANSMITTAL						
				Box ISSUE FEE Assistant Commi Washington, D.C	ssioner for Patents	
maintenance les notificado	ns.		CONT. Company of the Control of the	PUBLICATION FEE on of maintenance fees rrespondence address;	(if required). Blocks I throw will be mailed to the curren and/or (b) indicating a sepa	
CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections: 22907 7590 03/24/2002 BANNER & WITCOFF 1001 G STREET N W SUITE 1100 WASHINGTON, DC 20001			Blook 1)		of mailing below can on papers. Each additional papers. Each additional papers bush awards own contificate of Contificate of Mailing this Fec(s) Transmittel is Service with sufficient posta to the Box Issue Fee ud	being deposited with the go for first class mail in a dress above on the date
				All property of the second	otalista esta anticolor de la constantica della	(Верация) нап
						(Oin
APPLICATION NO.	FILING DATE	FIRS	ST NAMED INVEN	FOR	ATTORNEY DOCKET NO	CONFIRMATION NO
09/613,826	07/11/2000		Bert Vogelstein		01107,00031	9893
TITLE OF INVENTION: E	OIGITAL AMPLIFICATION					
TOTAL CLAIMS	APPLN. TYPE 6M	IALL ENTITY	ISSUE FEE	PUBLICATION FE	E TOTAL FEE(S) DUB	DATE DUE
64	nonprovisional	YES	\$640	\$0	\$640	06/24/2002
EXAMI	NER	ART UNIT	CLASS-SUBCL	ASS		
O Change of correspond Address form PTO/SB/1 U "Pue Address" indicate PTO/SB/47) atteched 3. ASSIGNEE NAME AND PLEASE NOTE; Unless a been previously submitted		Correspondence tion form E PRINTED ON THE w, no assignee data wi bmitted under separate	the names of up or agents OR, single firm (he attorney or age registered paten is listed, no nam PATENT (print or ill appear on the p cover. Completio	atent, Inclusion of assi n of this form is NOT a	Entroneys Inenies of a registered f up to 2 f on name 3 gaec data is only appropriate substitute for filing an assig	c when an assignment has
(A) NAME OF ASSIGNE Please check the appropriate 4a. The following foe(s) are	e assignee category or catego	ries (will not be printed	,	and STATE OR COU	NTRY) orporation or other private gr	oup untily U government
☐ Isauc Fee				of the fee(s) is enclose	d,	
O Publication Fee				l. Parm PTO-2038 is a		
Advance Order - # of C	Сортав	☐ The Deposi	Commissioner is I it Account Number	ereby authorized by ch	iarge the required fec(s), or c nclose an extra copy of this f	redit any overpayment, to omn).
The COMMISSIONER OF application identified above		ARKS is requested to s	apply the Issue Fee		fany) or to re-apply any pre	
(Authorized Signature) NOTE: The issue Fee an other than the applicant; interest as shown by the re	d Publication Fee (if require a registered anomy or as coords of the United States Personal Publication of the Coords of the United States Personal Publication of the Coords of the Coo	(Date) ed from anyone or other party in ffice. Time will vary of time required ed States Patent COMPLETIED Box Issue Fee,				
	eduction Act of 1995, no inless it displays a valid OM			annin de la companya	2004 (<u>1111) </u>	

TRANSMIT THIS FORM WITH FEE(S)

PTOL-85 (REV, 07-01) Approved for use through 01/31/2004, OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE Butted Series Patent and Trademerk Office Aktonic, COMMERCIONER OF PAYENTS AND TRADEMACK Workington, D.C. 198331

APPLICATION NO	FIL	ING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/613,826	09/613,826 07/11/2000		Bert Vogelstein	tert Vogelstein 01107.0003f	
22907	7590	03/24/2002		EXAMIN	<u>C</u> R
BANNER &			-	SIEW, JEF	TREY
1001 G STREE SUITE 1100			<u> </u>	ART UNIT	PAPER NUMBER
WASHINGTO	N, DC 2000	11		1637	21
			DA	TE MAILED: 03/24/2002	aci

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The patent term adjustment to date is 0 days. If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the term adjustment will be 0 days.

If a continued prosecution application (CPA) was filed in the above-identified application, the filing date that determines patent term adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system. (http://pair.uspto.gov)

Page 3 of 3

PTOL-85 (REV. 07-01) Approved for use through 03/31/2004.

		•	
0 1 11	Application No.	Applicant(s)	
Supolemental)	09/613,829	TAKESHITA ET A	l_
Notice of Allowability	Examiner	Art Unit	
	Jeffrey Slew	1656	
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS Is herewith (or previously malled), e Notice of Allowance (PTOL-86 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT I of the Office or upon petition by the applicant. See 37 CFR 1.3	S (OR REMAINS) CLOSED 5) or other appropriate com RIGHTS. This application i) in this application. If not inclu munication will be mailed in du	ded e course, THIS
1. X This communication is responsive to int 3/19/02.			
2. The allowed claim(s) is/are 1-64.			
3. \(\times \) The drawings filed on \(\frac{11 \text{ July 2000}}{11 \text{ acknowledgment is made of a claim for foreign priority units.} \)	examiner. nder 35 U.S.C. & 119(a)-(d	or (f).	
a) ☐ All b) ☐ Some° c) ☐ None of the:	100, 00 0.0.0. 8 110(0) (0)	(-),-	
1. Certified copies of the priority documents ha	ve been received.		
2. T Certified copies of the priority documents ha	ve been received in Applica	ition No	
 Copies of the certified copies of the priority of International Bureau (PCT Rule 17.2(a)). 	locuments have been recel	ved in this national stage appli	cation from the
Certified conies not received:			
5. Acknowledgment is made of a claim for domestic priority	under 35 U.S.C. § 119(e) (to a provisional application).	
(a) The translation of the foreign language provisional	application has been recei	ved.	
6. Acknowledgment is made of a claim for domestic priority	under 35 U.S.C. 99 120 an	0/01 121.	
Applicant has THREE MONTHS FROM THE "MAILING DATE" below. Failure to timely comply will result in ABANDONMENT or	of this communication to file of this application. THIS T	e a reply complying with the re HREE-MONTH PERIOD IS NO	quirements noted TEXTENDABLE.
7. A SUBSTITUTE OATH OR DECLARATION must be sul INFORMAL PATENT APPLICATION (PTO-152) which gives re	omitted. Note the attached ason(s) why the oath or de	EXAMINER'S AMENDMENT o claration is deficient.	r NOTICE OF
8. X CORRECTED DRAWINGS must be submitted.			
(a) X including changes required by the Notice of Draftsp	erson's Patent Drawing Re	view (PTO-948) attached	
1) (I hereto or 2) (A to Paper No			- 5tage
(b) Including changes required by the proposed drawin	g correction filed, v	hich has been approved by the	e Examiner.
(c) including changes required by the attached Examin	er's Amendment / Comme	it or in the Olitce action of Esp	91 I4O
Identifying indicia such as the application number (see 37 CFF of each aheet. The drawings aboutd be filed as a separate par	(1.64(c)) should be written c per with a transmittel letter a	n the drawings in the top margi iddressed to the Official Draftape	r (not the back) reon.
DEPOSIT OF and/or INFORMATION about the delattached Examiner's comment regarding REQUIREMENT FOR	posit of BIOLOGICAL Ma THE DEPOSIT OF BIOLO	ATERIAL must be submitted OGICAL MATERIAL.	i. Note the
Attachment(s)			
1 Notice of References Cited (PTO-892)		e of Informal Patent Applicatio	n (PTO-152)
3 Motice of Draftperson's Patent Drawing Review (PTO-946) 5 ☐ Information Disclosure Statements (PTO-1449), Paper No		view Summary (PTO-413), Pap niner's Amendment/Comment	101 IAO TOA COA
5 ☐ Information Disclosure Statements (PTO-1949), Paper NO 7 ☐ Examiner's Comment Regarding Requirement for Deposit		niner's Statement of Reasons i	or Allowance
of Biological Material	9∏ Othe	r , ,	
			44
U.S. Patent and Trademark Office	Notice of Allowability		Part of Paper No 22

Page 2

Application/Control Number: 09/613,829

Art Unit: 1656

REASONS FOR ALLOWANCE

1. The following is an examiner's statement of reasons for allowance:

Claims 33-37 are allowable. There is no prior art that teach or suggest a molecular beacon probe that has a loop consisting of 16 base pairs and having a Tm of 50-51C and the stem consisting of CACG sequence. The closest prior art is Tyagi et al (US6,037,130) teach molecular beacon with a stem comprising CACG (see col. 11 probe 3) but with a loop of Tm 50C. Moreover, the prior art has been focused on the Tm of the stem which relates to the functioning of the opening and closing of the hairpin during hybridization.

Claims 1-32 & 38-64 is allowable. There is no prior art that teach or suggest diluting a nucleic acid template in a sample to a plurality of sample and amplifying the template molecule in the samples and analyzing amplified molecules to determine the first number of samples containing the selected genetic sequence and second number assay samples which contain a reference genetic sequence and comparing the two numbers. Moreover, there is no prior art that teach or suggest that one tenth or one fiftieth of samples in a set comprise N molecules such that 1/N is larger than the ratio of selected genetic sequence to total genetic sequences required for the step of analyzing to determine presence of selected genetic sequence. The closest prior art is Lapidus et al who teach a reference and target nucleic acid amplification and concentration determination. However, his determination of concentration is within a sample and they do not teach or suggest a dilution.

Page 3

Application/Control Number: 09/613,829

Art Unit: 1656

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

CONCLUSION

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Siew whose telephone number is (703) 305-3886 and whose e-mail address is Jeffrey. Siew@uspto.gov. However, the office cannot guarantee security through the e-mail system nor should official papers be transmitted through this route. The examiner is on flex-time schedule and can best be reached on weekdays from 6:30 a.m. to 3 p.m. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (703)-308-1119.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist for Technology Center 1600 whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal

Application/Control Number: 09/613,829

Art Unit: 1656

Page 4

Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Center numbers for Group 1600 are Voice (703) 308-3290 and Before Final FAX (703) 872-9306 or After Final FAX (703) 30872-9307.

Jeffrey Siew

March 19, 2002

File History Report

Paper number is missing from the United States Patent Trademark Office's copy of the file History. No additional information is available.
The following page(s) <u>PTO - 948</u> of paper number <u>22</u> is/are missing from the United States Patent and Trademark Office's original copy of the file history. No additional information is available
The following checked item(s) below of paper number

Additional comments:

* corrected Copy +



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERC'S United States Patent and Tradomark Office Addition COMMISSIONS OF PATENTS AND CRADEMARKS Wishington, D.C. 2023 www.usptc.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

22907 7190

BANNER & WITCOFF 1001 G STREET N W SUITE 1100 WASHINGTON, DC 20001 03/26/2002

SIEW, JEFFREY

ART UNIT CLASS-SUHCLASS

1637 415-006000

DATE MAILED: 03/26/2002

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/613 826	07/11/2000	Bert Vogelstein	01107.00031	9893	

TITLE OF INVENTION, DIGITAL AMPLIFICATION

		1 1				
TOTAL CLAIMS	APPLN, TYPE	SMALL ENTITY	18SUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
L	laional	VES	\$640	\$0	\$640	06/26/2002

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION, THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above. If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

B. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.

 Applicant claims SMALL ENTITY status. Sec 37 CFR 1.27.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications flied on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

Page 1 of 3

PTOL-85 (REV. 07-01) Approved for use through 01/31/2004.

PART B - FEE(S) TRANSMITTAL

Complete and n	nail this form, togethe	er with applicable t				ner for Patents 231			
MAILING INSTRUCT where appropriate. All indicated unless correc maintenance fee notific	IONS: This form should be further correspondence included below or directed other ations.	e used for transmitting t ding the Patent, advance wise in Block 1, by (a)	he ISSUE FEE and orders and notification specifying a new co						
CURRENT CORRESPOND 22907 BANNER & V	DENCE ADDRESS (Note: Legibly in 7590 03/26/20 WITCOFF	• •	se Black I)	or formal d	lawing, must he	IVE HS OWN CONTINCATE O	ly be used for domestic te cannot be used for any or, such as an assignment f mailing.		
1001 G STREE SUITE 1100 WASHINGTO				l hereby c United State envelope a indicated b	ertify that this es Postal Servi addressed to the	Certificate of Mailing Fec(s) Transmittal is to with sufficient postage Box Issue Fcc ad	being deposited with the ge for first class mail in an dress above on the date		
							(Depositor's nume)		
							(Signature)		
							(Date)		
APPLICATION NO	FILING DATE	T F	IRST NAMED INVEN	OR .	ATT	ORNEY DOCKET NO	CONFIRMATION NO		
09/613,826	07/11/2000	and transfer and the same	Bert Vogelstein	· · · · · · · · · · · · · · · · · · ·		01107.00031	9893		
TOTAL CLAIMS	APPLN, TYPE	SMALL ENTITY	ISSUE FEE	PUBLIC	CATION FEE	TOTAL FEE(S) DUE	DA'IE DUE		
64	nonprovisional	YES	\$640		02	\$640	06/26/2002		
EX	AMTNER	ART UNIT	CLASS-SUBCL	ASS					
	, JEFFREY	1637	435-00600						
but not required. Change of corresp Address form PTO	CFR 1.363). Use of PTO form(s) and Customer Number are recommended, but not required. Cl Change of correspondence address (or Change of Correspondence address form PTO/SB/122) attached.				printing on the patent front page, list (1) mes of up to 3 registered patent attorneys ats OR, alternatively, (2) the name of a firm (having as a member a registered y or agent) and the names of up to 2 red patent attorneys or agents. If no name 1, no name will be printed.				
PLEASE NOTE: Unit been previously subm (A) NAME OF ASSIG		below, no assignee data ng aubmitted under acpa (日)	will appear on the pate cover. Completion RESIDENCE: (CITY	atent, Inclus n of this fon and STAT	E OR COUNTR				
	riate essignee category or c			- indiv	аля стесогра	ation or other private g	roup entity Q government		
4a, The following fee(s) nie enciozeor,		Payment of Fee(s): check in the amount	of the feets) is enclosed.				
Issue FeePublication Fee			ayment by credit can			ed.			
Q Advance Order - #	of Capies	Q.T	he Commissioner is posit Account Numbe	ereby autho	rized by charge	the required fee(s), or see an extra copy of this	redit any overpayment, to		
-									
The COMMISSIONER application identified a	OF PATENTS AND TRAI bove.	DEMARKS is requested	to apply the issue re	and Public	illon rec (ii an)	or to te-apply any pro-	eviously paid issue fee to the		
(Authorized Signature)		(Date)				,			
Contract of the second	e and Publication Fee (if and ant; a registered attorney the records of the United State). This form is estimated to	a tales fi 2 house to govern	lata Time wall were				•		
to complete this form and Trademark Office FORMS TO THIS	int: Ints form is estimated to de of the individual case. An in should be sent to the Chi- e, Washington, D.C. 20231 ADDRESS. SEND FEES ner for Patents, Washington.	ef Information Officer, to DO NOT SEND FEES AND THIS FORM TO D.C. 20231	Juited States Patent OR COMPLETED O: Box Issue Fee,						
	1. D. A A C 1005		ad to respond to a	1					

TRANSMIT THIS FORM WITH FEE(S)

U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Page 202 of 1224

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTOL-85 (REV. 07-01) Approved for use through 01/31/2004, OMB 0651-0033

CO L	SUJO	ites Patent Unium	AND TRADEMARK OFFICE	United State Address CUM Wast	KTES DEPARTMENT OF CYL 88 Patons and Trudenurk Of BISHLYNKKOP PATENTS AND T INGOL. DC 30231 uspto gre	Rea
APPLICATION NO.	Fil	ING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO	CONFIRMATION NO
09/613,826	0	7/11/2000	Bert Vagelatein		01107.00031	9893
22907	7590	03/26/2002			EXAMIN	E R
BANNER & '	WITCOFF	03/20/2002		L	SIEW, JEF	FREY
SUITE 1100	SI IN WY			Γ	ART UNIT	PAPER NUMBER
WASHINGTO	N, DC 2000	1		D 4.5	1637	22

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The patent term adjustment to date is 0 days. If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the term adjustment will be 0 days.

If a continued prosecution application (CPA) was filed in the above-identified application, the filing date that determines patent term adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system. (http://pair.uspto.gov)

Page 3 of 3

	MAY 2 1 232 -3)	Y PART D	- Pee(s) trap	ISMIT	TAL		
Complete and in	il this form, to be the	r with applicable		Assists	SUE FEE int Commission agton, D.C. 26	aer for Patents 231	
MAILING INSTRUCTA where appropriate. All fu- indicated unless correcto maintenance fee notificat	ONS: This form should be riker correspondence inclu- d below or directed other	used for transmitting sing the Palent, advanc vise in Block 1, by (a			-		h 4 should be completed orrespondence address as the "FEE ADDRESS" for
	PACE ADDRESS (NAS: Leght) and 1590 09/24/20 TTCOFF 'N W		ross Black 1)	Note: mailing other a or form I harek United envelop	The certificate of ps of the Fee(s) Traccompanying paper al drawing, must be try certify that this Biates Postal Service ps addressed to the ps addressed to the ps addressed to the ps addressed to the ps addressed to the ps ps addressed to the ps addressed to the ps ps addressed to the ps ps addressed to the ps ps ps ps ps ps ps ps ps ps	mailing below can only memital. This certificate s. Each additional paper save its own certificate of Certificate of Melling Fee(s) Transmittal is be- ce with sufficient postago to Box Issue Fee addition	be used for domestic cannot be used for any such as an assignment nating. ling deposited with the for first class shall be an ass above on the date
	•		ļ	indicati	ed below.		(Deptekto/a cases)
							(Lignoun)
							(Dase)
APPLICATION NO.	FILING DATE		FIRST NAMED INVEN	TOR	ITA	ORNEY DOCKET NO.	CONFIRMATION NO.
09/613,826	07/11/2000	Comment Description of the Comment o	Bert Vogalateln			01107.00031	9893
HILE OF IMAEMION	: DIGITAL AMPLIFICAT	ĮON					
TOTAL CLAB48	APPLN. TYPE	BMALL ENTITY	BEUE PES	FU	BLICATION FEE	TOTAL PEE(S) DUE	DATE DUE
64	nenprovisional	YES	\$640		\$40	\$640	06/26/2002
EKA	MINER	ART UNIT	CLA98-SUBC]		
SIEW,	JEFFREY	1637	435-00600	10			
Dut not required. Change of correspond	dence address er kudication O form(a) and Customer No andence address (or Change 3/122) amached. estion (or "Fee Address" in	of Correspondence	or agents OR, single firm (be attorney or ag	p to 3 re elternati eving ea ent) and et estope	stork front page, I rgistered patent essent vely, (2) the resent a member a regi the names of up ye or agents. If no a printed	stered 2 Bariner	Witcoff, Ltd.
may part where the part of the		V			- primou		mayoring and model build in the forming
	ND RESIDENCE DATA 1 in an amignes is identified ted to the USPTO or is beli NEE	de submitted under sep		petent, fr on of this	chales of assigned form is NOT a sub ATE OR COUNTS	e data la only appropriate stituto for filing an ataign tY)	when an assignment has most
Johns Hopk	ins University	r	Baltimore,	Mary	yland		
Hearo check the sensoon	iato antigane category or cr	nagories (will not be p	cinavd on the patent)	OE	adividuat Micorpo	ration or other private gro	upentity Opverament
4a. The following fre(s)	ON THE RESIDENCE AND THE PROPERTY OF THE PERSONS ASSESSMENT OF THE PER		, Payment of Pen(s):			Control of the Contro	40.000
M Issue Pes			A check in the emoun			4	
O Publication For M Advance Order - 4 c	of Conless 10		Payment by credit ear (The Commissioner is			ecu. o the required fee(s), or on se an extra copy of this fo	odii say overpayment, to
	OF PATENTS AND TRAC			_	-		
		MA A (DIB)		Ī	•		*
(Authorized Signature)) Michelle Holms NOTE: The Laser For other than \$40 sepplies	E-BOIL, Reg. West and Poblication Fee (if you are records of the United Smith This form is essentiated by	o. 47,660 equired) will not be a or agent; or the assign	Mary 21, 200 ccepted from enyone nee or other party in		75/22/2002 TDE	MARIE 60604060 1507	i (Mine
depending on the secon to complete this form and Trademark Office, FORMS TO THIS A Assistant Commission	s of the individual case. An should be sent to the Chis . Weshingson, D.C. 2021; . DDRESS. SEND FEES to for Panents, Washington,	y comments on the art if information Officer, DO NOT SEND FEE AND THIS FORM D.C. 20231	sount of time required United States Patent is OR COMPLETED TO: Box Issue Pec,)1 FC:242 32 FC:351	640.00 CH 30.00 CH	•
Under the Paperwork collection of informatic	Reduction Act of 1995, on redess is displays a valid	aper ou enous pro required to the control of the co	ived to respond to a				
	Approved for use through	TRANSMI	T THIS FORM WITH	• • •	ed Trademark Offic	a; U.S. DEPARTMENT (OF COMMERCE

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re A	pplication of:)
Ben VC	OGELSTEIN et al.)) Group Art Unit: 1656
Serial N	o. 09/613,826)
) Examiner: J. Siew
Filed:	July 11, 2000) Box: AF
For:	DIGITAL AMPLIFICATION) Attorney Docket No. 01107.00031

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. § 1.56 and in compliance with 37 C.F.R. § 1.97(d), Applicants herewith submit Form PTO 1449 listing references for consideration in connection with the above-identified application. A copy of each reference is provided herewith.

Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Serial No. 09/613,826

Applicants respectfully request that the Examiner consider and enter these documents into the file of the above-identified application. A fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p) is enclosed herewith to ensure consideration and entry of the cited documents by the Examiner. If any additional fee is deemed necessary, the Commissioner is authorized to charge our Deposit Account No. 19-0733.

Respectfully submitted,

Date: January 23, 2002

Michelle L. Holmes-Son Registration No. 47,660

BANNER & WITCOFF, LTD 1001 G Street, N.W. Eleventh Floor Washington, D.C. 20001-4597 (202) 508-9100

		Under the Pages work	(Fischer	Son Act of 1885, no possona.	U.C. Deland and Trail	proved use through 10/31/2002. OMB 0961-0031 embly Crifes: U.S. DEPARTNEM OF COMMERCE Hinkometin unless tronteins a telid CAB control number.			
Budgitudo for form 1449A/PTO				Complete If Known					
	INFORMATION DISCLOSURE				Application Number 09/613,826				
	STATEMENT BY APPLICANT		Filing Date	July 11, 2000					
	SIAI	EMENID	I PAI	PLICATE	Fire! Named Inventor	Bert Vogelstein ei al.			
					Group Art Unit	1656			
(use as many shocta as nacessary)					Examiner Name	J. Slaw			
۲-	Sheet	1	OT.	2	Attorney Dockel Number	01107-00031			

			U.B. PATENT	TOPOMEN 12	
Esseniner Initigle	Cities No.	Document Number	Publication Date Mid-DD-YYYY	Perior of Palentee or Applicant of Ched Document	Pages, Columns, Linos, White Resevent Pages god of Resevent Co. St. C. Glorder Appear
Initials *	No."	Hearthey - Kind Gode ^b (Flatown)			Cha sub Charges Appear
X		US-6,804,383	09-08-1998	Gruenart et et.	
21X		US- 5,858,653	.01-12-1999	Nisson et al.	
7	T	Us-		J	
		US-			
- Salanian	1	US-			
		US-			
-	1	US-			
	1	US-			
		U8-			
	1	US-			<u> </u>
		Ųs-		1	
		U\$-			
		ับร-			
	J	Us-			
-		บละ			
		UÐ-			
		US-			<u> </u>
		US-			
		บร-			
	1	UB-			

		FOREIGN PA	ATENT DOCU	MENTS		
Example: Initiate	Cita No.	Foreign Patent Document Country Code* - Number* - Kind Code* (# Intern)	Pubsesson Doto MM-DD-YYYY	Name of Patenties or Applicant of Cited Document	Pagas, Columns, Lines, Where Refevent Pagages or Religional Conference Sension	T ⁰
X	1	WQ 98/13399	05-18-1995			
57		EP 0843140 A	03-15-1995		- -	
98		WQ 99/13113	03-18-1999			
			ļ			
					J	

government to the same of the				A STATE OF THE PARTY OF THE PAR
Examiner	Makin	Date	in the day	
Signature	How bur	Considered	1 9//5/07	
	1 //7/19			

EXAMINES: hitigit reference considered, whether or not challen is in conformance with MPEP 609, threw line through clinical front in on in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.trapis.cogy</u> or MPEP 901.04, ⁴ Enter Office that leaved the document, by the two-totter code (MIPO Standard ST.), ⁴ For Japaness patent documents, the indication of the year of the ratin of the Emperor must precede the seriel number of the postent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if postable. ⁶ Applicant is to place a check mark here if English hurguage Translation is altoched.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Throw will very expending upon the hoode of the individual case, Any comments on the around of time you are required to complete this form should be sent to the Chail Information Officer, U.S. Patant and Vradamark Officer, Weekington, OC 20231. DO NOT BEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Palanta, Weekington, DC 20231.

] of] 2

Under the Preservon's Reduction Act of 1985, no persons a	H O Dalant and Tends	PTO/SB/068(10-01) proved for use through 19/31/200/. OMB 0851-0331 emerk Office: U.S. DEPARTMENT OF COMMERCE Officemetics priess it contains a valid Civili contain surder	Đ
Subsidias for form 144PAPTO	}	Complete If Known	1
	Application Number	09/613,826	
INFORMATION DISCLOSURE	Filing Date	July 11, 2000	Ì
STATEMENT BY APPLICANT	First Named Inventor	Bert Vogelstein et al.	
	Group Art Unit	1656	•
4	Europa ar blama	1 Slote	ļ

Allomey Docket Number 01107.00031

	- c-Engine - character	OTHER PRIDR ART – NON PATENT LITERATURE DOCUMENTS	
Examinar Initiota *	Cite No.	Include name of the bulbor (in CAPITAL LETTERS), it is of the article (when appropriate), this of the item (book, magazine, journal, serial, symposkim, catalog, etc.), date, page(e), vokuma-issue number(e), publisher, city and/or country where published.	T.
SS	To and the	A. PIATEK et et., "Motecular Beacon Sequence Analysis for Delecting Drug Resistence in Mycobacterium Tubertrufesis", Neture Ballechnology, April 1996, pp. 393-363, Vol. 16, No. 4	
Í		5. TYAGI et al., "Mullicotor Molecular Beacutes for eliele discrimination", Nature Biolochnology, pp. 303-308, Journey 1988, Vol. 18, No. 1	
		J. A.M., VET at al., "Muliflax Detection of Four Patrogenia Ratrovituses Uning Molecular Bascons", Proceedings of the National Academy of Sciences of the United States", May 25, 1989, pp. 8384-0399, Vol. 96, No. 11	
1		S. TYAGI et al., "Molecular Bostona: probes that Fibreson Upon Hyteridization", Nature Biotechnology, 1985, pp. 303-308, Vol. 14, No. 3	
		W. P. HALFORD et el., 'The inherent Quantite(ive Capacity of the Revotee Transcriptun-Polymentser Chelry Reaction', Analytical Electronistry, Jenuary 15, 1989, pg. 181-191, Vol. 288, No. 2	
	<u> </u>	B. VOGELSTEIN of pl., "Digital PCR", Proceedings of the National Academy of Sciences of the United States, August 3, 1988, pp. 9238-9241, Vol. 95, No. 16	
}		K, D.E. EVERETT of pl, "Identification of nine species of the Chiamydecape Using PCR-RFLP", April 1988, pp. 803-818, Vol. 49, No. 2	
	<u> </u>		
	+		

A STATE OF THE PARTY OF THE PAR		OCCUPATION OF STREET,	
	(f) A.	Date	1. 1. 1
Examinar	Alla bin	เทตเธ	U I . mla
		Considered	9/15/0)
Signature	JAM Sen	I COURTON I	1 1111111111111111111111111111111111111
0.8110		name to the particular and the first feet from the particular and the first feet feet from the particular and the first feet feet feet feet from the particular and the first feet feet feet feet feet feet feet fe	

EXAMPLE Initial if relatence considered, whomes or not obtain is in conformance with MPEP 609. Draw the through ediation if not in conformance and not considered, include copy of this form with next communication to applicant.

^{*} Unique citation designation number (epitonet). * Applicant to to peece a check mark here II English tempospe Transfelion is edisched.

Eurdan Hour Statement: This form is restinged to take 2.0 hours to complete. This will vary doopeding your this reside of the fiction of complete. This will vary doopeding your this reside of the finite comments on the enguest of the regular discrete comments on the enguest of the regular discrete form should be sont to the Chof information Officer, LLS. Petent and Tredemark Officer, LLS. Petent an

U.B. Potent and Trader's Too U.B. Potent and Trader's Too U.B. Potent and Trader's Too U.B. Potent and Trader's Too U.B. Potent and Trader's Too U.B. Potent or COMMERCAL ON C Complete If Known

FEE TRANS	MITTAL	Applica	iton Nun	aber	09/61	3,826	
for FY 2		Films Date July 11, 2000				Ì	
			amed In	mntor	Reft\	logelalain ol el.	
Palant fees are subject to	nament emitten	-	nor Name		J. Sie		
Sensin Land 61 A Worker to	multiple s de marie	oli-		200	-		1
		Grond	/ Art Uni	<u> </u>	1658		
TOTAL AMOUNT OF PAYMENT	(\$) 180	Allorn	y Docks	MO.	0110	7.00031	
METHOD OF PAYMENT (ch	eck all that each)			and the same	FEE C.	ALEULATION (condinued)	
		3. ADI	MINORIAL	Fres	enen		
☐ Chack ☐ Credit card ☐ Money Order	C Other C Mous)	គ្នបព្តវុំ ក្រសិង		Entity		Fee
🗵 Doposii Account:		Fee Code	Fed (II)	Fee Code	Pag (8)	Fee Description	Fald
Dapesil		103	120	208	0/5	Euronemps - Isla Billy fes on cells	
Account Genrer & Wilcolf, LVd. Number	1	127	69	227	26	Eurofrango - teta provinternal (Plog fee) or cover shoot.	
14419241		138	130	130	150	Non-English specification	
Deposit 19-0735	}	167	2,820	147	2,620	For living a request for ruoscarination	
Approximit 16-0735		112	920 *	112	<u>₽20°</u>	Requireding publication of GIR pater to Exempleor estate	
The Commissioner is sutherized to: (d Charge issis) indicated below (iii Cra	tinemy greens vine file	112	1,840°	113	1,640*	Roquesting publication of SIR allor Examiner action	
Charge any additional foc(s) theing the Charge fee(s) indicated before, except	e pandency of this application	115	110	215	65	Extension for reply within first month	
to the spove-identified deposit scoours.		110	400	216	300	Extension for copty within succend month	
FER CALCULA	TION	1117	920	217	460	Extension for raphy whiten third month	
1. BASIC PILING FEE	The second secon	116	1,440	216	720	Extension for reply within fourth	
Large Entity Small Entity Fee Fee Fee Fee Fee Der		128	1,630	225	230	Extension for rooty within Mich month	
(Fee Fee Fee Fee Fee Des Code (8) Code (6)	respuen Fee Paid	110	320	219	160	Nation of Account	
101 740 201 270 Usely 13	brog lises	120	820	220	160	Filing a brief in support of an eppeal	
103 250 200 165 Design (lling lea	121	260	221	140	Frequent for oral hearing	
107 610 207 258 Fame 65	ng feo Mag lee	128	1.610	138	1.51D	Petalen to instante a public use processing	
1	nal Minu fee	140	110	240	86	Petition to revive - unavoidable	
		162	1.260	241	84D	Petition to ravive – unintentional	
CUBTOTAL (4)	1310	143	1,580	242	640	LHUTY bace fee (or relicate)	
2. EXTRA CLAM FEES		143	460	243	230	Design issue iso	
Éidra	Fog from Feb	148	630	244	240	Plant terro feet	
Colors	X PERMIT IN FRANCE	122	130	133	130	Palitions to the Commissioner	
Lottel Clayura -50 0	╡^╞══╣╶╞╩═╣	123	Ø	123	60	Processing for under 37 CFR 1.17 (q)	
Claire -2 - a G	x = 0	128	160	129	180	Butministra of Internation Disconurs Strik	180
radiole Oxpaniera	X O	881	40	591	40	Recording each palent assignment per property (times runder of properties)	
Lergo Eniky Smell Eniky For Fee Fee Fee Fee	Description	146	740	243	370	Filing a submission effer final rejection (37 CFR § 1.129(a))	
(5) (5) Ce2a (6) (103 16 203 9 Cale	ra in success of 20	142	740	349	370	For each additional invention to be examined (37 CFR § 1.129(b))	
	pandera cisisso he orcpes of 9 No concentration of the 15 and mild	176	760	ध्यक	210	Request for Continued Examination (RCE)	
100	(16 dependent deim, E not peld Prove ledependent deims over	189	600	159	E00	Request for experient exemination	\vdash
109 BA 209 42 polytic	ud patent					di e detign epplication]
	issue sixins in exects of 20 and original palent						
, systoti	म छ। (छ)व	1	ao (speci		-		
		*Floreda	cad by Bu	Nation File	y Fee P	64 (E) LATOTAL (3) (3) 160	
"or number previously palet, if probler, i	of Lorswins, next House				ويودمني		2017/7 Annual 2002

SUBSTITED BY				Çşn	giala (d'applicable)
Name (Pdol/Type)	udchelle L. Holmer-Sco	Registration No. Allomay/Agent)	47,650	Yelsphone	202-502-9100
Signatura	Mibiles	KALLAND Da		Date	January 23, 2012

WARRING: Information on this term may be come public. Credit card information and the information and the information and the information and authorization and FITA USS.

Button More Balance: This form is estimated to text 0.2 hours to complete. Then and vary depending upon the needs of the training out on any are the complete of th

Received from < > 21 4/15/02 10:19:34 AM [Eastern Daylight Time]

Γħ	an	9/	n	מים

04/18/02	: 00:	79 F	AX

Please type a plus sign (+) incide this box - Under the Paperwork Raduction Act of 1995, no p	-> († STEGNET ESC 18		PTO/SB/21 (08-00) if for use birough 10/31/2002, OARS 0551-0/31 Office: U.S. DEPARTMENT OF COMMERCE ration unless it displays a vaid OARS control number.
	1990 man 1990 m	Application Humber	09/613,826
TRANSMITTAL		Filling Date	July 11, 2000
FORM		First Named Inventor	Berl Vogeletsin et al.
to be used for all correspondence after in	lei filing)	Group Art Unit	1656
,		Examiner Name	J. Siew
otal Number of Pages in This Submission	1	Attorney Docket Number	01107.00031
	ENCL	OSURES (check all that apply)	
Fee Trensmittel Form	Assign	rmant Papera Application)	After Allowance Communication to Group
Foo Alloched	Drawli	ng(b)	Appeal Communication to Board of Appeals and Intellectors
Amendment / Response	Licena	Ing-related Pepers	Appeal Communication to Group (Appeal Notice, Erial, Reply Eriel)
After Final	Peliffo	n	Proprietary information
Affideviks/declaration(a)	Petition to Convert to a Provisional Application		Scalus Letter
Extension of Time Request	Power of Attorney, Revocation Change of Correspondence Address		Other Enclosure(a) (please leantify below):
		nei Digcielmer	PTO-1449 (w/references)
Dipress Abandonmeni Request	_	ssi for Refund	
Information Disclosure Statement	CD, Number of CD(s)		
Carillied Copy of Priority Rems		11/03	
Response to Missing Perts/ Incomplete Application			
Response to Missing Parts under 37 CFR 1,52 or 1,53			
	TURE OF	APPLICANT, ATTORNEY, C	R AGENT
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm or Michelle L. Holmes-Son, Registration No. 47,880			
Signeture UMINGG X XVIIII			
Dele January 23, 2002			
	CE	RTIFICATE OF MAILING	
I hereby certify that this correspondence is	pajug dab	osited with the United States Pop	bil Garvice as first class mall in an envelope
sudressed to: Assistant Commissioner for Palants, Washington, D.C. 20231 on this date:			
Typed or printed name			
Signature			; Data

Received from < > at 415/02 10:19:34 AM [Eastern Daylight Time]



1001 G STREET, N.W. WASHINGTON, D.C. 20001-4597

TEL: 202,508,9100 FAX: 202,508,9299 www.bannerwitcoff.com

	FACSIMILE TF	ANSMITTAL SHEET		
To:		FROM:		
Jeffrey Sle	we	Michelle L. Holmes-Son		
COMPANY:		DATE:		
United States Patent and Trademark Office		April 15, 2002		
FAX NURBER:		Total No. of Pages:		
(703)-746-	5179	7, Including this cover sheet		
TE:		Our Reference No.:		
U.S. Serial Number: 09/613,826		01107.00031		
If you do I	not receive all page(s) or have any p	roblems receiving this transmission, please call:		
NAME:	Michelle L. Halmes-Son	PHONE: 1-202-508-9220		
Сомием	ģ d			

Pursuant to our telephone conversation of this morning, attached please find a copy of our information disclosure statement filed January 23, 2002. Please return by fax after you are satisfied with your review of the document.

Yours truly.

Michelle L. Holmes-Son (47,660)

IMPORTANT/CONFIDENTIAL: This message is intended only for the use of the individual or entity to whom it is addressed. This message contains information from the law time of BANNER & WITCOFF, LTD. whilch may be privileged, confidential or exempt from dischaire funder applicable law. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, retention, archiving, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately at our telephone number listed above. We will be happy to arrange for the return of this message to our offices at no cost to you.

CHICAGO

WASHINGTON, D.C.

BOSTON

PORTLAND, OR

Received from < > at 411502 10:10:34 AM (Cestern Daylight Time)



#23 Johnal

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Bert Vogelstein, et. al.

Serial No. 09/613,826

Filing Date: July 11, 2000

) Group Art Unit: 1637

) Examiner: Jeffrey Siew

) Docket No. 01107.00031

DIGITAL AMPLIFICATION

SUBMISSION OF FORMAL DRAWINGS

Assistant Commissioner of Patents Washington, D.C. 20231 Attn: Box ISSUE FEE

Dear Sir:

Attached hereto for filing in the United States Patent and Trademark Office are seven (7) sheets of formal drawings (FIGS. 1 A-C, 2-5) for the above-identified patent application.

Please charge any fee in connection with the filing of these drawings to our Deposit Account No. 19-0733 and forward the recorded document to the undersigned. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: May 21, 2002

By:

Michelle L. Holmes-Son Registration No. 47,660


Banner & Witcoff, Ltd. 1001 G Street, N.W., Eleventh Floor Washington, D.C. 20001-4597 (202) 508-9100

1


8440708

FIG. 1A DNA

DILUTE TO ~ 1/2 COPY/ STEP 1 **WELL PCR**





ADD FLUORESCENT PROBES **FLUOROMETRY**




-) = NO PCR PRODUCT
- = WILD TYPE PCR PRODUCT
- = MUTANT PCR PRODUCT

FLUORESCENT NON-FLUORESCENT FLUORÉSCENT QUENCHER DYE +











FIG. 5



Page 219 of 1224

E PATENT DESIGN BAWRET 01107.0001 Date May 21, 200	2
TI HAND CARRY Groun/Section Bldg Rm	- A
Serial/Patent No. 09/6/3, 826 Any/Sec SAL MHS/Sel O	<u>~</u>
Inventor Bert Vage/stein etal client THY	SUUS @
IMA Z	
The following has been received in the U.S. Patent and Trademark Office on the date stamped hereon:	THE PARTY OF
(8 of independent claims) Abstract	O Comment
Drawings: September 1 informal	
☐ Declaration/Power of Attorney: ☐ Executed ☐ Unexecuted ☐ Request for Approval of Drawing Changes	
☐ Assignment w/PTO Cover Sheet ☐ Notice of Appeal & Fee ☐ IDS w/PTO 1449 ☐ References ☐ w/Fee ☐ Brief: ☐ Appeal & Fee ☐ Reply	
☐ Preliminary Amendment ☐ Request for Oral Hearing	
Priority Claim (Foreign or U.S. Provisional, B&W #	<u> </u>
Rountry Appl. 4 Date ☐ Amendment under 37 CFR 1.312	
☐ WiForeign Priority Document(s) ☐ Request for Cartificate of Correction ☐ Application : ☐ CIP ☐ Continuation ☐ Divisional	11 4 1
Parent Sor. No. B&W# Continued of Mailton	JOSH AUCI.
U.S. Provisionalpp Spec/Claims; Cover Sheet	
Baseonse to Missing Parts/Requirements do Submission of forme	<u>!</u>
Response to Notice to File Corrected Appin. Papera and Drawing S Request for Expedited Foreign Filing License Request for Expedited Foreign Filing License	
LI Request for Corrected: Li Faing Receipt Li Assignment	
Response to Restriction/Election Requirement	DAM Far 501
(B)	

Page 220 of 1224

#24 DI 7115 K

Please type a plus sign (+) ir Under the Poperwork Reduction			.U en at berlup	S Patent and Trademark	Office: U.S. D	PTO/SB/21 (08-00) gh 10/31/2002. OMB 0851-0031 EPARTMENT OF COMMERCE lisplays a veild OMB control number.		
The second secon		www.compressor.com	Applic	ation Number	09/613,82			
TRANSM	IITTAL		Filing	Date	July 11, 20	000		
FOR	M		First N	amed Inventor	Bert Voge	Istein		
(to be used for all correspondence after initial filling)		Group Art Unit		1637				
,		Examiner Name		Jeffrey Slew				
Total Number of Pages In Thi	s Submission	T	Attorne	ey Docket Number	001107.00031			
		ENCLO	SURES	(check all that apply)	Control of the Contro			
Fee Transmittal Form			ment Pap		After Allowance Communication to Group			
Fee Attached			g(s) 7 sl 3, 4, and	neets (Figs. 1A, 1B, 5)		Communication to Board of and Interferences		
Amendment / Response		Licensi	ng-relate	d Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)			
☐ After Final		Petition	1		Proprie	tary Information		
Affidavits/declaration	n(s)	Pelition to Convert to a Provisional Application		Submission of Formal Drawings				
Extension of Time Requ	est	Power of Attorney, Revocation Change of Correspondence Address		Other Enclosure(s) (please Identity below):				
Express Abandonment F	teeupe?	Terminal Disclaimer		rec	py of date-stamped filing elpt and Submission of mei Drawings deted May 21,			
☐ Information Disclosure S	Statement				EIVEC	p ²		
Certified Copy of Priority Document(s)	′	Remarks			8 2002	•		
Response to Missing Pa	nts/			milion at Pat	ent Publicati	OF)		
Incomplete Application Response to Missing		Disactor's Office						
Parts under 37 CFR 1.52 or 1.53				Control of the Contro				
	SIGNA	TURE OF	APPLIC	ANT, ATTORNEY, O	R AGENT	the state of the s		
Film or Mich	elle Holmes-S	ion, Reg. No	. 47,660	ı		•		
Signature	A = A + A + A + A + A + A + A + A + A +							
Date July	Date July 8, 2002							
		CE	RTIFIC	ATE OF MAILING				
						first class mail in en envelope		
addressed to: Assistent Commissioner for Patents, Washington, D.C. 20231 on this date:								
Typed or printed name								
Signature					Date			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time with vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Weshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO. Assistant Commissioner for Petents, Weshington, DC 20231.

-i-25 **DOI**-PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)) Group Art Unit: 1637
Bert Vogelstein, et. al.) Examiner: Jeffrey Siew
Serial No. 09/613,826)
Filing Date: July 11, 2000) Docket No. 01107.00031

For: DIGITAL AMPLIFICATION

SUBMISSION OF FORMAL DRAWINGS

Assistant Commissioner of Patents Washington, D.C. 20231 Attn: Box ISSUE FEE

Dear Sir:

Attached hereto for filing in the United States Patent and Trademark Office are seven (7) sheets of formal drawings (FIGS. 1 A-C, 2-5) for the above-identified patent application.

Please charge any fee in connection with the filing of these drawings to our Deposit Account No. 19-0733 and forward the recorded document to the undersigned. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: May 21, 2002

Ву:

Michella L. Holmes-Son Registration No. 47,660

Banner & Witcoff, Ltd. 1001 G Street, N.W., Eleventh Floor Washington, D.C. 20001-4597 (202) 508-9100

ì

File History Report

Paper number is missing from the United States Patent Trademark Office's copy of the file History. No additional information is available.
The following page(s) of paper number is/are missing
from the United States Patent and Trademark Office's original copy of the
file history. No additional information is available
The following checked item(s) below of paper number
is/are missing from the United States Patent and Trademark Office's
original copy of the file history. No additional information is available
PTO 1449
PTO 892
T PTO 948
T PTO 1474
Assignment
Cover nage

Additional comments: Paper #25 same as Paper #23



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
WWW.USDIO.GOV

Fax Cover Sheet

īc: Michelle L Holmes-Son	From: Jeffrey Slew
Upplication/Control Number: 09/613,826	Art Units 1656
"mx No.: (202) 508-9299	Phone No.: 703-305-3886
/elco No.i (202) 508-9100	Return Fex No.: 703-308-4556
Res	CC:
Urgent For Review For Com	ment For Reply Fer Your Request

STATEMENT OF CONFIDENTIALITY

This facsimile transmission is an Official U.S. Government document which may contain information which is privileged and confidential. It is intended only for use of the recipient named above. If you are not the intended recipient, any dissemination, distribution or copying of this document is strictly prohibited. If this document is received in error, you are requested to immediately notify the sender at the above indicated telephone number and return the entire document in an envelope addressed to: addressed to:

Assistant Commissioner for Patents Washington, DC 20231



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES FATENT AND TRADEMARK DIFFICE
VASHIKOTON, D.C. SOEDIN
WARKEPOLID

Fax Cover Sheet

Dester 20 Jan 2001

managed with 4 Wings 1	
Tox Ms. Holmason	Press Jeffley Slow
Application/Control Number 09/613,626	Art Unite 1656 .
Fax No. (202) 508-9299	Phone No.: 703-305-3888
Volce No.: (202) 508-9100	Return Fix No.s 703-308-4558
Re	ca
Urgant For Review Fer Comme	and For Reply Fer Your Request
Constraints Per your request a copy of the notice to comply for officers.	ce action 4/12/01
thenks	•
Jeffrey Slew	



Commissioner for Patents United States Patent and Trademark Office Washington, D.C. 2023] www.usblo.gov

Fax Cover Sheet

Deates 29 Jun 2001 From Jeffrey Siew To: Ms. Holmeson Art Units 1656 Application/Control Number: 09/613,826 Fax No.s (202) 508-9299 Phone No.: 703-305-3886 Refum Fax No.: 703-308-4556 Voice No.: (202) 508-9100 CC: Res For Comment For Reply Per Your Request **Urgent** For Review Comments: Per your request a copy of the notice to comply for office action 4/12/01 thanks

00

Number of pages $\frac{2}{2}$ including this page

STATEMENT OF CONFIDENTIALITY

This fecsimile transmission is an Official U.S. Government document which may contain information which is privileged and confidential. It is intended only for use of the recipient named above. If you are not the intended recipient, any dissemination, distribution or copying of this document is strictly prohibited. If this document is received in error, you are requested to immediately notify the sender at the above indicated telephone number and return the entire document in an envelope addressed to:

Assistant Commissioner for Patents

Application No.: 09/613 \$ 26

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly falls to comply with the requirements of 37 C.F.R. 1.621-1.625. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
7. Other:Applicant Must Provide:
Applicant Must Provide:
Applicant Must Provide:
Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry
Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or
Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

I mis form is for INTERNAL PTO USE ONLY It does NOT get mailed to the applicant.

NOTICE OF FILING / CLAIM FEE(S) DUE (CALCULATION SHEET)

APPLICATION NUMBER: UN1613824

Total Fee Calculation

	F Ça.*-	र १६३ इ.स.च्या	Ausber Erri	٠,	F : +	f:-		<u> 7484</u>
	3=. L ;			•	್ಷ ಪ್ರವರ್ಣ	L; Estin		; ;
Busic Filizi; Foo	<u> 291 101 </u>	4. 1	. 1. 1			690		;
الا≤ داد العدار العدار	20000	5 :1-	119	×		792	-	
الا يعين المنابعة الم	112001	_5_ ·i-	1	У		134	-	
Mult. Cop Claim Princis	<u>194, 194</u>					130	-	
Signaturge	29.122						•••	
Ezglish Trasslation	113							·
TOTAL FLE CALGIL	VT0-201							1768
Fees due upon filia;	de apploiet es							
Total Filing Fees Dus	:= S	17	68		<i>}</i>			
Less Filing Fees Subs	mines - 5					-		:
BALANCE DUE		/7	168			-		=
Office of Initial Passes	K Examination	and the second s				•	•	
FORM OPERAMAL (R	ier. (277)	F	gurë 7 -		=			•

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY OF TO: BANNER & WITCOFF, LTD. Attn. KAGAN, Sarah A. 1001 G Street. N.W. JAN 3-	NOTIFICATION OF TRANSMITTAL OF
1001 G Street, N.W. Eleventh Floor Washington, DC 20001-4597 UNITED STATES OF AMERICA	OR THE DECLARATION 2002 (PCT Rule 44.1)
	Date of malling (day/month/year) 21/12/2001
Applicant's or agent's file reference 01107.00030	FOR FURTHER ACTION See peregraphs 1 and 4 below
Internetional application No. PCT/US 00/20740	International filing date (day/month/year) 31/07/2000
Applicant	
THE JOHNS HOPKINS UNIVERSITY et al.	
1. X The applicant is hereby notified that the international Se-	arch Report has been established and is transmitted herewith.
Filing of amendments and statement under Article 19. The applicant is entitled, if he so wishes, to amend the c	eims of the International Application (see Rule 46):
When? The time limit for filing such amendments is no international Search Report; however, for more	maily 2 months from the date of transmittat of the details, see the notes on the accompanying sheet.
Where? Directly to the International Bureau of WIPO 34, chemin des Cotombettes 1211 Geneva 20, Switzerland Fascimile No.: (41–22) 740.14	
For more detailed instructions, see the notes on the a	ccompanying sheet
2. The applicant is hereby notified that no international Ser Article 17(2)(a) to that effect is transmitted herewith.	arch Report will be established and that the declaration under
3. With regard to the protest against payment of (an) add	ditional fee(s) under Rule 40.2, the applicant is notified that:
the protest together with the decision thereon has i	peen transmitted to the international Bureau together with the protest and the decision thereon to the designated Offices.
no decision has been made yet on the protest; the	applicant will be notified as eoon as a decision is made.
4. Further action(s): The applicant is reminded of the following	g;
Shortly after 18 months from the priority date, the internations if the applicant wishes to evoid or postpone publication, a no priority claim, must reach the international. Bureau as provic completion of the technical preparations for international pul	dice of withdrawal of the international application, or of the led in Rules 90 <i>bis</i> , 1 and 90 <i>bis</i> , 3, respectively, before the
Within 19 months from the priority date, a demand for interna wishes to postpone the entry into the national phase until 30	tional preliminary examination must be filed if the applicant months from the priority date (in some Offices even later).
Within 20 months from the priority data, the applicant must pe before all designated Offices which have not been elected i priority date or could not be elected because they are not bo	n the damand or in a later election within 19 months from the
Name and mailing address of the International Searching Authorit	y Authorized officer
European Patent Office, P.B. 5818 Patentiaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fay: (-31-70) 340-3018	Catherine Humbert

Form PCT/ISA/220 (July 1998)

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Tresty, the Regulations and the Administrative instructions under that Tresty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WiPC.

In these Notes, "Article", "Pulle", and "Section" reter to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international assists report, one opportunity to amend the claims of the international application, it should however be emphasized that, since all parts of the international application (claims, description and crawings) may be amended during the international preliminary examination procedure, there is usually no need to the amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection of has another reason for amending the claims before international physicians. Furthermore, it should be emphasized that provisional protection is evallable in some States only.

What peris of the International application may be exceeded?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the international Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the international Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittel of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the international Bureau after the expiration of the applicable time kimit but before the completion of the technical preparations for international publication (Fulle 45.1).

Where not to the the emendments?

The emerciments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been in filed, see below.

How?

Either by cencelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as fixed.

A replacement sheet must be submitted for each cheet of the disine which, on account of an amendment or amendment, differs from the sheet originally field.

All the claims appearing on a replacement sheet must be numbered in Arabic numerate. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The emendments must be made in the language in which the international application is to be published.

What documents mustimey accompany the amendments?

Letter (Section 205(b)):

The emendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims, it should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant, However, If the language of the international application is English, the letter must be in English; if the tanguage of the international application is French, the letter must be in French.

Notes to Form PCTASA/220 (first sheet) (Jenuary 1994)

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in peritoder, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be groupsd), whether

- (i) the claim is unchanged;
- (ii) the claim is carealled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying latter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
 Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added.
- (Where originally there were 15 claims and after amendment of all claims there are 11): Claims 1 to 15 replaced by amended claims 1 to 11."
- 3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims): "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added," or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- Where various kinds of amendments are made):
 Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claims 15, 16 and 17; new claims 20 and 21 added.

"Statement under article 19(1)" (Rule 40.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which carried be amended under Article 19(1)).

The eleterment will be published with the international epphication and the amended claims.

il must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 600 words if in English or If translated into English.

It should not be confused with and does not replace the latter indicating the differences between the claims as Ried and as amended, it must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary exemination has paready been filed

It, at the time of filing any amendments under Article 18, a demand for international preliminary examination has already been authoritied, the applicant must preferably, at the same time of filing the amendments with the tritemational Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with request to translation of the international application for entry into the national phase

The applicant's attention is cream to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further datails on the requirements of each designated/elsoled Office, see Volume II of the PCT Applicant's Guide.

Notes to Form PCT/ISA/220 (second sheet) (January 1994)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

opplicants or agent's lile reference	(Form PCT/IS	on of Transmittat of International Search Report (A/220) as well as, where applicable, Ilem 5 below.
1107.00030	ACTION	(Earliest) Priority Date (day/month/year)
iternational application No.	International filing date (day/month/year)	
CT/US 00/20740	31/07/2000	02/08/1999
pplicani		
	a carrie I 9	
HE JOHNS HOPKINS UNIVERSI	IY et al.	
This international Search Report has been according to Article 18. A copy is being tra	prepared by this international Searching namitted to the international Bureau.	Authority and is transmitted to the applicant
This International Search Report consists It is also accompanied by	of a total of <u>5</u> sheets. a copy of each prior art document cited in	ihls report.
1. Basis of the report	AND THE RESERVE OF THE PROPERTY OF THE PROPERT	
a. With regard to the language, the l	nternational search was carried out on the ses otherwise indicated under this item.	e basis of the international application in the
		of the International application furnished to this
Authority (Rule 23.1(b)).		
 With regard to any nucleotide an was carried out on the basis of the 	i/or emino acid sequence disclosed in il	he international application, the international search
	nal application in written form.	
	mational application in computer readable	form.
	this Authority in written form.	
	this Authority in computer readble form.	
the statement that the sub	sequently furnished written sequence list	ing does not go beyond the disclosure in the
international application a		ed ash gratell consupes netthw ent ot isotinebi at mx
furnished		· · ·
2. Certain claims were fou	nd unecarcheble (See Box I).	•
3. Unity of Invention is lac	king (see Box II).	
4. With regard to the title,		
X the text is approved as su	bmitted by the applicant.	
the text has been establis	hed by this Authority to read as follows:	
	,	•
With regard to the abstract,		
TXT the text is enproved as su	ibmitted by the applicant.	at the same to prove the province with a same to the
the text is approved as su	had according to Dulo 20 20ht by this As	ubority as it appears in Box III. The applicant may, th report, submit comments to this Authority.
The lext is approved as su	shed, according to Rule 38.2(b), by this Au a date of mailing of this international searc	n febout, sushing confinents to any Madonity.
the text is approved as an the text has been established within one month from the	thed, according to Rule 38.2(b), by this Au adate of mailing of this international search lished with the abstract is Figure No.	uthority as it appears in Box III. The applicant may, the report, submit comments to this Authority. X None of the figures.
the text is approved as au the text has been established within one month from the 6. The figure of the drawings to be pub	thed, according to Rule 38,2(b), by this At date of mailing of this international searc tished with the abstract is Figure No. icant.	n febout, sushing confinents to any Madonity.

Internetional Application No PCT/US 00/20740

X VET JACQUELINE A M ET AL: "Multiplex detection of four pathogenic retroviruses 15-19, 21-24, 21-24, 21-24, 21-24, 30,32, 32-34,			PC	T/US 00/20740
Disconnected other than minimum documentation to the autent that such obcumentation is included in the fields searched	A. CLASSI IPC 7	FICATION OF SUBJECT MATTER C12Q1/68	And the second s	
PRINCE SEARCHED Minimum documentation opalem tollowed by classification systects Price		and the second s	-Washing and IPA	
Further documental are listed in the centinuation of box C. X Patent family members are listed in time. Page 15	2000			
Electronic data base consulted during the International search (name of data base and, where precicled, search terms used) EPO—Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE, MEDLINE, SCISEARCH C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Televant to claim it detection of four pathogenic retroviruses using molecular beacons." PROCEDINGS of THE MATIONAL ACADEMY OF 30,32, SCIENCES OF THE UNITED STATES, Vol. 96, no. 11, 25 May 1999 (1999–05-25), pages 6394–6399, XPOU2145609 May 25, 1999 ISSN: 0027–8424 the whole document The whole document The whole document The whole document The definition in general state of the art which is no considered to be of pericular retwoence The definition of the process of the state of the stat	Minimum do	cumentation searched (classification system followed by classif	ication symbols)	
EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE, MEDLINE, SCISEARCH C.DOCUMENTS CONSIDERED TO BE RELEVANT C.DIdiction of occurrent, with indication, where appropriate, of the relevant passages VET JACQUELINE A M ET AL: "Multiplex detection of four pathogenic retroviruses 15-19, using molecular beacons." PROCEEDINGS OF THE WINTED STATES, vol. 96, no. 11, 25 May 1999 (1999–05-25), pages 6394-6399, XP002145609 May 25, 1999 ISSN: 0027-8424 the whole document / *Special categories of cited documents **Gocument delining the general state of the art which is no considered to be of particular relevance of the state of the considered to be of particular relevance in special considered to be of particular relevance in considered to be organized from the problem of the considered not be organized relevance in considered to be organized relevance in considered to the considered not be consi	Documental	ion searched other than minimum documentation to the extent if	net such documents are included	in the fields searched
Collegory* Citation of document, with indication, where appropriate, of the relevant passages VET JACQUELINE A M ET AL: "Multiplex detection of four pathogenic retroviruses 15-19, using molecular beacons." 21-24, Proceedings of the NATIONAL ACADEMY OF 30,32, SCIENCES OF THE UNITED STATES, Vol. 96, no. 11, 25 May 1999 (1999-05-25), pages 6394-6399, XP002145609 May 25, 1999 ISSN: 0027-8424 the whole document / Ye predict calegories of caled documents: "" occument dathing the general state of the art which is not considered to be of perfecular relevance." "" focument dathing the general state of the art which is not considered to be of perfecular relevance." "" occument which may throw doubt on a priorty claim(a) or which is not considered to be of perfecular relevance. "" occument which may throw doubt on a priorty claim(a) or which is not considered to be of perfecular relevance. "" occument which may throw doubt on a priorty claim(a) or which is not considered to be of perfecular relevance. "" occument which may throw doubt on a priorty claim(a) or which is not considered in our or an article of the state of transition of the procedit reason (he specified) "" occument aftering to en oral disclosure, use, exhibition or other reports to the international titing date but liter than the proofly date claimed "" occument published prior to the international titing date but liter than the proofly date claimed The actual completion of the international search 10 December 2001 Name and making advised of the ISA European Patent Office, P.B. 5818 Petentiban 2	Electronic d	ste base consulted during the international search (name of dat	s base and, where practical ses	rch terms used)
X VET JACQUELINE A M ET AL: "Multiplex detection of four pathogenic retroviruses 15-19, using molecular beacons." PROCEEDINGS OF THE MATIONAL ACADEMY OF 30, 32, SCIENCES OF THE UNITED STATES, vol. 96, no. 11, 25 May 1999 (1999–05-25), pages 6394–6399, XP002145609 May 25, 1999 ISSN: 0027-8424 the whole document	EPO-In	ternal, WPI Data, PAJ, BIOSIS, CH	EM ABS Data, EMBA	SE, MEDLINE, SCISEARCH
VET JACQUELINE A M ET AL: "Multiplex detection of four pathogenic retroviruses 15-19, using molecular beacons." 21-24, PROCEEDINGS OF THE NATIONAL ACADEMY OF 30, 32, SCIENCES OF THE UNITED STATES, Vol. 96, no. 11, 25 May 1999 (1999–05-25), pages 6394-6399, XP002145609 May 25, 1999 ISSN: 0027-8424 the whole document -/ *Special categories of cited documents:/ **Governent defining the general state of the sit which is not consistent to be of particular reviewence to the particular reviewence of the property desired on or after the International fifting date or of the regard at the published on date of sinchler station or other people is lesson (as specified) or the regard of the published of the sit which is not consistent to the or priority date and not in conflict with the application but clied to understand the principle or theory underlying the variation or other special research (as specified to the site of particular reviewence in the started invention or other research as pecified or date or other property date calmed or other search as pecified to entire the property date calmed or other search as pecified to entire the calmed invention or other many laws or designed and the proof of the search of particular reference; the claimed invention of particular reference in the calmed invention of the international search to the country of particular reference; the claimed invention of particular reference the calmed invention and the proof of particular reference the calmed invention of particular reference; the claimed invention of particular reference; the claimed invention and the proof of particular reference; the claimed invention and the proof of particular reference; the claimed invention of particular reference; the claimed invention and the proof of particular reference; the claimed invention and the proof of particular reference; the claimed invention and the particular reference; the claimed invention and the proof of particular reference; the claimed invention and the proof of particular r	C. DOCUM			
detection of four pathogenic retroviruses using molecular beacons." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 11, 25 May 1999 (1999–05–25), pages 6394–6399, XP002145609 May 25, 1999 ISSN: 0027–8424 the whole document -/ *Special categories of cited documents -/ *Cocument defining the general state of the art which is not considered to be of particular relevance -/ *Special categories of cited documents -/ *Cocument defining the general state of the art which is not considered to be of particular relevance -/ *To take document published reliev the international filing data *It' document by published on or affer the international filing data of another catalon or other special reason (as specified) *Cocument published prior to the international filing data but later than the purphy data citation of other such documents cannot be considered to involve an inventive step when the document is combined with one of more other such documents combined with one of more other such documents combined with one of more other such documents combined with one of more other such documents. Such combined with one of more other such documents. Such combined with one of more other such documents. Such combined with one of more other such documents. Such combined with one of more other such documents. Such combined with one of more other such documents. Such combined with one of more other such documents. Such combined with one of more other such documents. Such combined with one of more other such documents. Such combined with one of more other such documents. Such combined with one of more other such documents. Such combined with one of more other such documents. Such combined with one of more other such documents. Such combined with on	Calegory *	Citation of document, with indication, where appropriate, of th	e rolevani passages	Relevant to dalm No.
*Special categories of cited documents: *A' document defining the general state of the art which is not considered to be of perticular relevance *C' earlier document but published on or after the International fling date *C' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another qualion or other special reason (as specified) *C' document referring to an oral disclosure, use, exhibition or other means *P' document published prior to the international state than the proxy's date claimed *Date of the actual completion of the international search *December 2001 *T' tater document published after the international date of the art which is or principle or theory underlying the creation or principle or theory underlying the claimed invention *Coursent of particular relevance; the claimed invention cannot be considered to involve as hivenibre attention or other such document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *2.* document member of the same petent family Date of the actual completion of the international search **December 2001 **Notice and not in conflict with the application but cled to understand the principle or theory underlying the invention **Y document of particular relevance; the claimed invention cannot be considered to involve as hivenibre action to a considered to involve as hivenibre attention of the combined with one or more other such documents, such combination being obvious to a person skilled in the art. **2.* document member of the same petent family Date of making of the international search report **2.* document member of the same petent family	x	detection of four pathogenic rusing molecular beacons." PROCEEDINGS OF THE NATIONAL ACSCIENCES OF THE UNITED STATES, vol. 96, no. 11, 25 May 1999 (pages 6394-6399, XP002145609 May 25, 1999 ISSN: 0027-8424	etroviruses ADEMY OF 1999-05-25),	15-19, 21-24, 30,32, 38-45, 47-51, 53-56,
**L* document which may throw doubts on priority clear(s) or which is etide to establish the publication date of enrollies or etide to establish the publication date of enrollies of enrol	*Special ca *A* docume consid *E* earlier	ategories of cited documents : ent defining the general state of the srt which is not dered to be of perticular relevance document but published on or after the International	"T" later document publishs or priority date and no cled to understand the invention." "X" document of particular is	od efter the International filing date in conflict with the application but principte or theory underlying the valevance; the claimed invantion
Date of the actual completion of the international search 10 December 2001 Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentian 2	"L" docume which citatio "O" docum other "P" docum	shi which may inrow doubte on priority cleim(e) or is cited to establish the publication date of another nor other special reason (as apactised) which the property of the pro	involve an inventive st "Y" document of particular in cannot be considered document is combined ments, such combined in the art.	ep when the document is taken alone relevance; the claimed invention to involve an inventive step when the lwith one or more other such docu- on being obvious to a person skilled
Name and making address of the ISA European Patent Office, P.B. 5818 Patentian 2			Date of mailing of the	nlarnational search report
European Palent Office, P.B. 5818 Petentiaan 2	1	O December 2001	21/12/200	1
Tel. (431-70) 340-2040, Tx 31 651 epo nl, Gabriels, J	Name and	European Patent Office, P.B. 5818 Patentiaan 2 NL - 2260 HV Rijawiik		

Form PCT/ISA/210 (second sheet) (July 1992)

International Application No PCT/US 00/20740

	PC1/US 00/20/40
Citation of document, with indication, where appropriate, of the relevant passages	Relevent to claim No.
PIATEK AMY S ET AL: "Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis." NATURE BIOTECHNOLOGY, vol. 16, no. 4, April 1998 (1998-04), pages 359-363, XP000891876 ISSN: 1087-0156	1-13, 15-19, 21-24, 26,27, 30,32, 38-45, 47-51, 53-56, 58,59, 62,64
the whole document	
TYAGI SANJAY ET AL: "Multicolor molecular beacons for allele discrimination." NATURE BIOTECHNOLOGY, vol. 16, no. 1, January 1998 (1998-01), pages 49-53, XP002143901 ISSN: 1087-0156	1-13, 15-19, 21-24, 26,27, 30,32, 38-45, 47-51, 53-56, 58,59, 62,64
the whole document	
TYAGI SANJAY ET AL: "Molecular beacons: Probes that fluoresce upon hybridization." NATURE BIOTECHNOLOGY, vol. 14, no. 3, 1996, pages 303-308, XP002914999 ISSN: 1087-0156 the whole document	1-19, 21-23, 30, 38-51, 53-55,62
WO 99 13113 A (KRAMER FRED R ;ALLAND DAVID (US); PIATEK AMY (US); TYAGI SANJAY (U) 18 March 1999 (1999-03-18) page 7, line 32 -page 9, line 3; claims 1-14; example 2	1-19, 21-23, 30, 38-51, 53-55,62
HALFORD WILLIAM P ET AL: "The inherent quantitative capacity of the reverse transcription-polymerase chain reaction." ANALYTICAL BIOCHEMISTRY, vol. 266, no. 2, 15 January 1999 (1999-01-15), pages 181-191, XP000791527 ISSN: 0003-2697 the whole document	1-12, 38-44
EP 0 643 140 A (CANON KK) 15 March 1995 (1995-03-15) page 1-3	1-12, 38-44
	sequence analysis for detecting drug resistance in Mycobacterium tuberculosis." NATURE BIOTECHNOLOGY, Vol. 16, no. 4, April 1998 (1998-04), pages 359-363, XP000891876 ISSN: 1087-0156 the whole document TYAGI SANJAY ET AL: "Multicolor molecular beacons for allele discrimination." NATURE BIOTECHNOLOGY, Vol. 16, no. 1, January 1998 (1998-01), pages 49-53, XP002143901 ISSN: 1087-0156 the whole document TYAGI SANJAY ET AL: "Molecular beacons: Probes that fluoresce upon hybridization." NATURE BIOTECHNOLOGY, Vol. 14, no. 3, 1996, pages 303-308, XP002914999 ISSN: 1087-0156 the whole document WO 99 13113 A (KRAMER FRED R ;ALLAND DAVID (US); PIATEK AMY (US); TYAGI SANJAY (U) 18 March 1999 (1999-03-18) page 7, line 32 -page 9, line 3; claims 1-14; example 2 HALFORD WILLIAM P ET AL: "The inherent quantitative capacity of the reverse transcription-polymerase chain reaction." ANALYTICAL BIOCHEMISTRY, Vol. 266, no. 2, 15 January 1999 (1999-01-15), pages 181-191, XP000791527 ISSN: 0003-2697 the whole document EP 0 643 140 A (CANON KK) 15 March 1995 (1995-03-15) page 1-3

Form PCT/ISA/210 (continuetion of second sheet) (July 1992)

International Application No PCT/US 00/20740

		PC1/US 00/20/40
Centinu	Mion) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to cistin No.
Κ	WO 95 13399 A (NEW YORK HEALTH RES INST)	33-37
	18 May 1995 (1995-05-18) claims 1,2	
A	US 5 804 383 A (GRUENERT DIETER C ET AL) 8 September 1998 (1998-09-08) claim 1	25,28, 57,60
A	US 5 858 663 A (NISSON PAUL E ET AL) 12 January 1999 (1999-01-12) claim 1	25,28, 57,60
A	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 1999 (1999-04) EVERETT KARIN D E ET AL: "Identification of nine species of the Chlamydiaceae using PCR-RFLP." Database accession no. PREV199900271658 XP002185145 abstract & INTERNATIONAL JOURNAL OF SYSTEMATIC BACTERIOLOGY, vol. 49, no. 2, April 1999 (1999-04), pages 803-813, ISSN: 0020-7713	20,52
P,X	VOGELSTEIN BERT ET AL: "Digital PCR." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 16, 3 August 1999 (1999-08-03), pages 9236-9241, XP002185144 Aug. 3, 1999 ISSN: 0027-8424 the whole document	1-64
		,

Information on patent family members

International Application No PCT/US 00/20740

				101700	00/20/40
Patent document cited in search report		Publication date	A-114,111	Palent family member(s)	Publication date
WO 9913113	A	18-03-1999	AU	9484698 A	29-03-1999
10 3010120	•		EP	1012344 A1	28-06-2000
			JP	2001515734 T	25-09-2001
			WO	9913113 A1	18-03-1999
EP 0643140	Α	15-03-1995	JP	7163399 A	27-06-1995
			ΑT	207966 T	15-11-2001
			CA	2126391 A1	14-03-1995
			DE	69428855 D1	06-12-2001
			EP	0643140 A1	15-03-1995
			US	5670315 A	23-09-1997
			AT	206210 T	15-10-2001
			DE	69330818 D1	31-10-2001
			EP	1052291 A2	15-11-2000
			ĒΡ	0603783 A1	29-06-1994
			ĴΡ	9040661 A	10-02-1997
			JP	7174759 A	14-07-1995
			SG	65577 A1	22-06-1999
			us	5624798 A	29-04-1997
			ÜS	6022961 A	08-02-2000
W0 9513399	Α	18-05-1995	AU	697841 B2	15-10-1998
NO 2020011	•-		AU	1292195 A	29-05-1995
			CA	217634B A1	18-05-1995
			EP	0728218 A1	28-08-1996
			JP	9504950 T	20-05-1997
			WO	9513399 A1	18-05-1995
			ÜS	6103476 A	15-08-2000
			US	5925517 A	20-07-1999
US 5804383	Α	08-09-1998	US	6010908 A	04-01-2000
			AU	5087193 A	15-03-1994
			EP	0656747 A1	14-06-1995
			WO	9404032 A1	03-03-1994
			AU	7262696 A	30-04-1997
			WO	9713869 A1	17-04-1997
US 5858663	A	12-01-1999	us	5547838 A	20-08-1996

	PATENT A			ETERMINATION OF 29, 1999	ON RECO	RD	A	pplication	or Do	ocket Num	ber ·
CONTRACTOR OF STREET			S FILED - Column 1)	PART I (Colu	mn 2)		SMALL I	ENTITY	OR	OTHER SMALL	-,,-
FO	R	NUMB	ER FILED	NUMBER	EXTRA		PATE	FEE		RATE	FEE
BA	SIC FEE		10	Ţ.				345.00	OR		690.00
TO	TAL CLAIMS	1/2	/ minus 2	20= 1 4	W		X\$ 9≃		OR	X\$18=	797
IND	EPENDENT CL	AIMS 5	minus	3 = 0	2	1	X39=		OR	X78=	15%
MU	LTIPLE DEPEN	DENT CLAIM F	PRESENT	or the second	, , , , , , , , , , , , , , , , , , , ,	ŀ	460			.000	107
4 17 (lhe difference	in column 1 is	less than 78	ro, enter "0" in c	olumn 2	L	+130=		OR	+260=	0.00
•r							TOTAL		OR	TOTAL	77.28
	C	LAIMS AS ((Column 1)	AMENUEU	(Column 2)	(Column 3)		SMALL	ENTITY	OR	OTHER SMALL!	
ENT A		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE	ADDI- TIONAL FEE		RATE	ADDI- TIONA FEE
MENDMENT	Total	•	Minus	94	21		X\$ 9=		OR	X\$18=	
ME	Independent	t .	Minus	650	F		X39=		OR	X78=	
⋖	FIRST PRESE	NTATION OF N	AULTIPLE DEF	PENDENT CLAIM			+130=			+260=	
							TOTAL		OR	TOTAL	
		(0-1		(Onkon Ó)	(Calumn D)	A	DDIT. FEE		OR	ADDIT. FEE	
		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE	ADDI- TIONAL FEE		RATE	ADDI- TIONA FEE
AMENDMENT	Total		Minus	. 65	-		X\$ 9=		OR	X\$18=	
	Independent	*	Minus	ess	z		X39=		OR	X78;=	
	FIRST PRESE	NTATION OF I	AULTIPLE DEI	PENDENT CLAIM		1	+130=		OR	+260=	
						L	TOTAL		AD.	TOTAL	
		/O-4: 41		(Calina ()	(Column 3)	-	DDIT. FEE		J-n	ADDIT. FEE	Ly
EMIC	l de	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE	ADDI- TIONAL FEE		RATE	ADDI- TIONA FEE
	Total	* .	Minus	20	=		X\$ 9= ·	, ree	OR.	X\$18=	
AMENDA	Independent	*	Minus	4 tr e	E		X39=			X78=/	/
₹	FIRST PRESE	NTATION OF	MULTIPLE DE	PENDENT CLAIM	Man I con Man I con Man I sugar		You	napropaganite and the	OR		
+130= OR +260=											
00 800	if the "Highest Nu "If the "Highest Nu	mber Previously ember Previously	Peld For IN TH	amn 2, write "0" in co IS SPACE is less the IS SPACE is less the Ir Independent) is the	en 20, enter "20. en 3. enter "3." ´		101AL DÓIT. FEE rd in the ap	propriate bo		TOTAL ADDIT, FEE Jumn 1.	
	M PTO-875 12/99)					Pater	nt and Trade;	nark Office, U		PARTMENT O	

EXHIBIT 4



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NUMBER PATENT NUMBER GROUP ART UNIT FILE WRAPPER LOCATION 60/146,792 92001 | 0041 | 061 | 05

Correspondence Address/Fee Address Change

The following fields have been set to Customer Number 11332 on 10/24/2011 Correspondence Address

The address of record for Customer Number 11332 is:

11332 Banner & Witcoff, Ltd. Attorneys for client 001107 1100 13th Street N.W. Suite 1200 Washington, DC 20005-4051



PTO/SB/16 (6-95)
Approved for use through 04/11/98. OMB 0651-0037
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION COVER SHEET

This is a request for filing a PROVIS	SIONAL APPLICA	ATION under 37 CFR 1.	53(c)(2). /	/
·		01107.81418	Type a plus sign (+) inside this box →	+

							inside this box →	+	
INVENTOR(s)/APPLICANT(s)									
LAST NAME FIRST NAME M.I. RESIDENCE (CITY and eith							Y and either STATE o	r COUNTRY)	
VOGELSTEIN Bert KINZLER Kenn			ert enneth	w.		Baltimore, Maryland Belair, Maryland			
		Т	TITLE OF THE I	NVENTI	ON (28		<u>o</u>		
DIGITAL AMPLIFICATION									
CORRESPONDENCE ADDRESS									
BANNER & WITCOFF, LTD. Eleventh Floor 1001 G Street, N.W.									
STATE Washington, D.C. ZIP 20001-4597 COUNTRY USA									
ENCLOSED APPLICATION PARTS (check all that apply)									
х	X Specification Number of Pages 28 Small Entity Statement								
Х	Drawings	Numbe	er of Sheets	8.00	х_	Other (specify) CLAIMS	64	
METHOD OF PAYMENT (check one)									
	A check or money order is enclosed to cover the Provisional filing fee								
	The Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number.				3	PROVISIONAL FILING FEE AMOUNT (\$)	-		

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

NO X YES, the name of the U.S. Government agency and the Go	overnment contract number are: _	National Institute of
Health CA 43460		
Respectfully submitted, August 2, 1999		
TYPED or PRINTED NAME Sarah A. Kagan	REG. NO. (if appropriate)	32,141

____ Additional inventors are being named on separately numbered sheets attached hereto

PROVISIONAL APPLICATION FILING ONLY

20

DIGITAL AMPLIFICATION

The U.S. government retains certain rights in this invention by virtue of its support of the underlying research, supported by grants CA 43460, CA 57345, and CA 62924 from the National Institutes of Health.

TECHNICAL FIELD OF THE INVENTION

This invention is related to diagnostic genetic analyses. In particular it relates to detection of genetic changes and gene expression.

BACKGROUND OF THE INVENTION

In classical genetics, only mutations of the germ-line were considered important for understanding disease. With the realization that somatic mutations are the primary cause of cancer, and may also play a role in aging, new genetic principles have arisen. These discoveries have provided a wealth of new opportunities for patient management as well as for basic research into the pathogenesis of neoplasia. However, many of these opportunities hinge upon detection of a small number of mutant-containing cells among a large excess of normal cells. Examples include the detection of neoplastic cells in urine, stool, and sputum of patients with cancers of the bladder, colorectum, and lung, respectively. Such detection has been shown in some cases to be possible at a stage when the primary tumors are still curable and the patients asymptomatic. Mutant sequences from the DNA of neoplastic cells have also been found in the blood of cancer patients. The detection of residual disease in lymph nodes or surgical margins may be useful in predicting which patients might benefit most from further therapy. From a basic research standpoint,

10

analysis of the early effects of carcinogens is often dependent on the ability to detect small populations of mutant cells.

Because of the importance of this issue in so many settings, many useful techniques have been developed for the detection of mutations. DNA sequencing is the gold standard for the detection of germ line mutations, but is useful only when the fraction of mutated alleles is greater than ~20%. Mutant-specific oligonucleotides can sometimes be used to detect mutations present in a minor proportion of the cells analyzed, but the signal to noise ratio distinguishing mutant and wild-type (WT) templates is variable. The use of mutant-specific primers or the digestion of polymerase chain reaction (PCR) products with specific restriction endonucleases are extremely sensitive methods for detecting such mutations, but it is difficult to quantitate the fraction of mutant molecules in the starting population with these techniques. Other innovative approaches for the detection of somatic mutations have been reviewed. A general problem with these methods is that it is difficult or impossible to independently confirm the existence of any mutations that are identified.

Thus there is a need in the art for methods for accurately and quantitatively detecting genetic sequences in mixed populations of sequences.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide methods for determining the presence of a selected genetic sequence in a population of genetic sequences.

It is another object of the present invention to provide molecular beacon probes useful in the method of the invention.

These and other objects of the invention are achieved by providing a method for determining the presence of a selected genetic sequence in a population of genetic sequences. A biological sample comprising nucleic acid template molecules is diluted to form a set of assay samples. The template molecules within the assay samples are amplified to form a population of amplified molecules in the assay samples of the set. The amplified molecules in the assay samples of the set are then analyzed to determine a first number

10

30

of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence. The first number is then compared to the second number to ascertain a ratio which reflects the composition of the biological sample.

Another embodiment of the invention is a method for determining the ratio of a selected genetic sequence in a population of genetic sequences. Template molecules within a set comprising a plurality of assay samples are amplified to form a population of amplified molecules in each of the assay samples of the set. The amplified molecules in the assay samples of the set are analyzed to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence. At least one-fiftieth of the assay samples in the set comprise a number (N) of molecules such that 1/N is larger than the ratio of selected genetic sequences to total genetic sequences required to determine the presence of the selected genetic sequence. The first number is compared to the second number to ascertain a ratio which reflects the composition of the biological sample.

According to another embodiment of the invention, a molecular beacon probe is provided. It comprises an oligonucleotide with a stem-loop structure having a fluorescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end. The loop consists of 16 base pairs which has a T_m of 50-51 °C. The stem consists of 4 base pairs having a sequence 5'-CACG-3'.

A second type of molecular beacon probe is provided in another embodiment. It comprises an oligonucleotide with a stem-loop structure having a fluorescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end. The loop consists of 19-20 base pairs and has a T_m of 54-56°C. The stem consists of 4 base pairs having a sequence 5'-CACG-3'.

Another embodiment provides the two types of molecular beacon probes, either mixed together or provided in a divided container as a kit.

The invention thus provides the art with the means to obtain quantitative assessments of particular DNA or RNA sequences in mixed populations of sequences using digital (binary) signals.

10

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Schematic of experimental design. (A) The basic two steps involved: PCR on diluted DNA samples is followed by addition of fluorescent probes which discriminate between WT and mutant alleles and subsequent fluorometry. (B) Principle of molecular beacon analysis. In the stem-loop configuration, fluorescence from a dye at the 5' end of the oligonucleotide probe is quenched by a Dabcyl group at the 3' end. Upon hybridization to a template, the dye is separated from the quencher, resulting in increased fluorescence. Modified from Marras *et al.*. (C) Oligonucleotide design. Primers F1 and R1 are used to amplify the genomic region of interest. Primer INT is used to produce single stranded DNA from the original PCR products during a subsequent asymmetric PCR step (see Materials and Methods). MB-RED is a Molecular Beacon which detects any appropriate PCR product, whether it is WT or mutant at the queried codons. MB-GREEN is a Molecular Beacon which preferentially detects the WT PCR product.

FIG. 2. Discrimination between WT and mutant PCR products by Molecular Beacons. Ten separate PCR products, each generated from ~25 genome equivalents of genomic DNA of cells containing the indicated mutations of *c-Ki-Ras*, were analyzed with the Molecular Beacon probes described in the text. Representative examples of the PCR products used for Molecular Beacon analysis were purified and directly sequenced. In the cases with Gly12Cys and Gly12Arg mutations, contaminating non-neoplastic cells within the tumor presumably accounted for the relatively low ratios. In the cases with Gly12Ser and Gly12Asp, there were apparently two or more alleles of mutant *c-Ki-Ras* for every WT allele; both these tumors were aneuploid.

FIG. 3. Detecting Dig-PCR products with MB-RED. Specific Fluorescence Units of representative wells from an experiment employing colorectal cancer cells with Gly12Asp or Gly13Asp mutations of the *c-Ki-Ras* gene. Wells with values >10,000 are shaded yellow. Polyacrylamide gel electrophoretic analyses of the PCR products from selected wells are shown. Wells with

30

25

25

fluorescence values <3500 had no PCR product of the correct size while wells with fluorescence values >10,000 SFU always contained PCR products of 129 bp. Non-specific products generated during the large number of cycles required for Dig-PCR did not affect the fluorescence analysis. M1 and M2 are molecular weight markers used to determine the size of fragments indicated on the left (in base pairs).

FIG. 4. Discriminating WT from mutant PCR products obtained in Dig-PCR. RED/GREEN ratios were determined from the fluorescence of MB-RED and MB-GREEN as described in Materials and Methods. The wells shown are the same as those illustrated in Fig. 3. The sequences of PCR products from the indicated wells were determined as described in Materials and Methods. The wells with RED/GREEN ratios >3.0 each contained mutant sequences while those with RED/GREEN ratios of ~1.0 contained WT sequences.

FIG. 5. Dig-PCR of DNA from a stool sample. The 384 wells used in the experiment are displayed. Those colored blue contained 25 genome equivalents of DNA from normal cells. Each of these registered positive with MB-RED and the RED/GREEN ratios were 1.0 +/- 0.1 (mean +/- 1 standard deviation). The wells colored yellow contained no template DNA and each was negative with MB-RED (i.e., fluorescence <3500 fluorescence units.). The other wells contained diluted DNA from the stool sample. Those registering as positive with MB-RED were colored either red or green, depending on their RED/GREEN ratios. Those registering negative with MB-RED were colored white. PCR products from the indicated wells were used for automated sequence analysis.

DETAILED DESCRIPTION OF THE INVENTION

The method devised by the present inventors involves separately amplifying small numbers of template molecules so that the resultant products have a proportion of the analyte sequence which is detectable by the detection means chosen. At its limit, single template molecules can be amplified so that

10

the products are completely mutant or completely wild-type (WT). The homogeneity of these amplification products makes them trivial to distinguish through existing techniques.

The method requires analyzing a large number of amplified products simply and reliably. Techniques for such assessments were developed, with the output providing a digital readout of the fraction of mutant alleles in the analyzed population.

The biological sample is diluted to a point at which a practically usable number of the diluted samples contain a proportion of the selected genetic sequence (analyte) relative to total template molecules such that the analyzing technique being used can detect the analyte. A practically usable number of diluted samples will depend on cost of the analysis method. Typically it would be desirable that at least 1/50 of the diluted samples have a detectable proportion of analyte. At least 1/10, 1/5, 3/10, 2/5, 1/2, 3/5, 7/10, 4/5, or 9/10 of the diluted samples may have a detectable proportion of analyte. The higher the fraction of samples which will provide useful information, the more economical will be the overall assay. Over-dilution will also lead to a loss of economy, as many samples will be analyzed and provide no signal. A particularly preferred degree of dilution is to a point where each of the assay samples has on average one-half of a template. The dilution can be performed from more concentrated samples. Alternatively, dilute sources of template All of the samples may contain amplifable nucleic acids can be used. template molecules. Desirably each assay sample prior to amplification will contain less than a hundred or less than ten template molecules.

Digital amplification can be used to detect mutations present at relatively low levels in the samples to be analyzed. The limit of detection is defined by the number of wells that can be analyzed and the intrinsic mutation rate of the polymerase used for amplification. 384 well PCR plates are commercially available and 1536 well plates are on the horizon, theoretically allowing sensitivities for mutation detection at the ~0.1% level. It is also possible that Digital Amplification can be performed in microarray format, potentially increasing the sensitivity by another order of magnitude. This

10

25

30

sensitivity may ultimately be limited by polymerase errors. The effective error rate in PCR as performed under our conditions was 1.1%, i.e., four out of 351 PCR products derived from WT DNA sequence appeared to contain a mutation by RED/GREEN ratio criteria. However, any individual mutation (such as a G to T transversion at the second position of codon 12 of c-Ki-Ras), are expected to occur in < 1 in 50 of these polymerase-generated mutants (there are at least 50 base substitutions within or surrounding codons 12 and 13 that should yield high RED/GREEN ratios). Determining the sequence of the putative mutants in the positive wells, by direct sequencing as performed here or by any of the other techniques, provides unequivocal validation of a prospective mutation: a significant fraction of the mutations found in individual wells should be identical if the mutation occurred in vivo. Significance can be established through rigorous statistical analysis, as positive signals should be distributed according to Poisson probabilities. Moreover, the error rate in particular Digital Amplification experiments can be precisely determined through performance of Digital Amplification on DNA templates from normal cells.

Digital Amplification is as easily applied to RT-PCR products generated from RNA templates as it is to genomic DNA. For example, the fraction of alternatively spliced or mutant transcripts from a gene can be easily determined using fluorescent probes specific for each of the PCR products generated. Similarly, Digital Amplification can be used to quantitate relative levels of gene expression within an RNA population. For this amplification, each well would contain primers which are used to amplify a reference transcript expressed constitutively as well as primers specific for the experimental transcript. One fluorescent probe would then be used to detect PCR products from the reference transcript and a second fluorescent probe used for the test transcript. The number of wells in which the test transcript is amplified divided by the number of wells in which the reference transcript is amplified provides a quantitative measure of gene expression. Another group of examples involves the investigations of allelic status when two mutations are observed upon sequence analysis of a standard DNA sample.

10

30

To distinguish whether one variant is present in each allele (vs. both occurring in one allele), cloning of PCR products is generally performed. The approach described here would simplify the analysis by eliminating the need for cloning. Other potential applications of Digital Amplification are listed in Table 1. When the goal is the quantitation of the proportion of two relatively common alleles or transcripts rather than the detection of rare alleles, techniques such as those employing TaqMan and real time PCR provide an excellent alternative to use of molecular beacons. Advantages of real time PCR methods include their simplicity and the ability to analyze multiple samples simultaneously. However, Digital Amplification may prove useful for these applications when the expected differences are small, (e.g., only ~2-fold, such as occurs with allelic imbalances.)

The ultimate utility of Digital Amplification lies in its ability to convert the intrinsically exponential nature of PCR to a linear one. It should thereby prove useful for experiments requiring the investigation of individual alleles, rare variants/mutations, or quantitative analysis of PCR products.

In one preferred embodiment each diluted sample has on average one half a template molecule. This is the same as one half of the diluted samples having one template molecule. This can be empirically determined by amplification. Either the analyte (selected genetic sequence) or the reference genetic sequence can be used for this determination. If the analysis method being used can detect analyte when present at a level of 20%, then one must dilute such that a significant number of diluted assay samples contain more than 20% of analyte. If the analysis method being used requires 100% analyte to detect, then dilution down to the single template molecule level will be required.

To achieve a dilution to approximately a single template molecule level, one can dilute such that between 0.1 and 0.9 of the assay samples yield an amplification product. More preferably the dilution will be to between 0.1 and 0.6, more preferably to between 0.3 and 0.5 of the assay samples yielding an amplification product.

10

25

30

The digital amplification method requires analysis of a large number of samples to get meaningful results. Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. As in any method, the accuracy of the determination will improve as the number of samples increases, up to a point. Because a large number of samples must be analyzed, it is desirable to reduce the manipulative steps, especially sample transfer steps. Thus it is preferred that the steps of amplifying and analyzing are performed in the same receptacle. This makes the method an *in situ*, or "one-pot" method.

The number of different situations in which the digital amplification method will find application is large. Some of these are listed in Table 1. As shown in the examples, the method can be used to find a tumor mutation in a population of cells which is not purely tumor cells. As described in the examples, a probe for a particular mutation need not be used, but diminution in binding to a wild-type probe can be used as an indicator of the presence of one or more mutations. Chromosomal translocations which are characteristic of leukemias or lymphomas can be detected as a measure of the efficacy of therapy. Gene amplifications are characteristic of certain disease states. These can be measured using digital amplification. Alternatively spliced forms of a transcript can be detected and quantitated relative to other forms of the transcript using digital amplification on cDNA made from mRNA. Similarly, using cDNA made from mRNA one can determine relative levels of transcription of two different genes. One can use digital amplification to distinguish between a situation where one allele carries two mutations and one mutation is carried on each of two alleles in an individual. Allelic imbalances These can be detected using digital often result from a disease state. amplification.

Biological samples which can be used as the starting material for the analyses may be from any tissue or body sample from which DNA or mRNA can be isolated. Preferred sources include stool, blood, and lymph nodes. Preferably the biological sample is a cell-free lysate.

10

25

30

Although the working examples demonstrate the use of molecular beacon probes as the means of analysis of the amplified dilution samples, other techniques can be used as well. These include sequencing, gel electrophoresis, hybridization with other types of probes, including TaqManTM (dual-labeled fluorogenic) probes (Perkin Elmer Corp./Applied Biosystems, Foster City, Calif), pyrene-labeled probes, and other biochemical assays.

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention.

EXAMPLE 1

Step 1: PCR amplifications. The optimal conditions for PCR described in this section were determined by varying the parameters described in the Results. PCR was performed in 7 ul volumes in 96 well polypropylene PCR plates (RPI). The composition of the reactions was: 67 mM Tris, pH 8.8, 16.6 mM NH₄SO₄ 6.7 mM MgCl₂, 10 mM β-mercaptoethanol, 1 mM dATP, 1 mM dCTP, 1 mM dGTP, 1 mM TTP, 6% DMSO, 1 uM primer F1, 1 uM primer R1, 0.05 units/ul Platinum Taq polymerase (Life Technologies, Inc.), and "one-half genome equivalent" of DNA. To determine the amount of DNA corresponding to one-half genome equivalent, DNA samples were serially diluted and tested via PCR. The amount that yielded amplification products in half the wells, usually ~1 pg of total DNA, was defined as "one-half genome equivalent" and used in each well of subsequent Digital Amplification experiments. Fifty ul light mineral oil (Sigma M-3516) was added to each well and reactions performed in a HybAid Thermal cycler at the following temperatures: denaturation at 94° for one min; 60 cycles of 94° for 15 sec, 55° for 15 sec., 70° for 15 seconds; 70° for five minutes. Reactions were read immediately or stored at room temperature for up to 36 hours before fluorescence analysis.

EXAMPLE 2

10

25

30

Step 2: Fluorescence analysis. 3.5 ul of a solution with the following composition was added to each well: 67 mM Tris, pH 8.8, 16.6 mM NH₄SO₄ 6.7 mM MgCl₂, 10 mM β-mercaptoethanol, 1 mM dATP, 1 mM dCTP, 1 mM dGTP, 1 mM TTP, 6% DMSO, 5 uM primer INT, 1 uM MB-GREEN, 1 uM MB-RED, 0.1 units/ul Platinum Taq polymerase. The plates were centrifuged for 20 seconds at 6000 g and fluorescence read at excitation/emission wavelengths of 485 nm/530 nm for MB-GREEN and 530 nm/590 nm for MB-RED. This fluorescence in wells without template was typically 10,000 to 20,000 fluorescence "units", with about 75% emanating from the fluorometer background and the remainder from the MB probes. The plates were then placed in a thermal cycler for asymmetric amplification at the following temperatures: 94° for one minute: 10 - 15 cycles of 94° for 15 sec. 55° for 15 sec., 70° for 15 seconds; 60° for five minutes. The plates were then incubated at room temperature for at least 20 minutes and fluorescence measured as described above. The fluorescence readings obtained were stable for several hours. Specific fluorescence was defined as the difference in fluorescence before and after the asymmetric amplification. RED/GREEN ratios were defined as the specific fluorescence of MB-RED divided by that of MB-GREEN. RED/GREEN ratios were normalized to the ratio exhibited by the positive controls (25 genome equivalents of DNA from normal cells, as defined in Materials and Methods). We found that the ability of MB probes to discriminate between WT and mutant sequences under our conditions could not be reliably determined from experiments in which they were tested by hybridization to relatively short complementary single oligonucleotides, and that actual PCR products had to be used for validation.

EXAMPLE 3

Oligonucleotides and DNA sequencing. Primer F1: 5'-CATGTTCTAATATAGTCACATTTTCA-3'; Primer R1: 5'-TCTGAATTAGCTGTATCGTCAAGG-3'; Primer INT: 5'-TAGCTGTATCGTCAAGGC-3'; MB-RED: 5'-Cy3-CACGGGCCTGCTGAAAATGACTGCGTG-Dabcy1-3';

30

5

10

M В G R E Ε N 5'-Fluorescein-CACGGGAGCTGGTGGCGTAGCGTG-Dabcyl-3'. Molecular Beacons were synthesized by Midland Scientific and other oligonucleotides were synthesized by Gene Link. All were dissolved at 50 uM in TE (10 mM Tris, pH 8.0/1 mM EDTA) and kept frozen and in the dark until use. PCR products were purified using QIAquick PCR purification kits (Qiagen). In the relevant experiments described in the text, 20% of the product from single wells was used for gel electrophoresis and 40% was used for each sequencing reaction. The primer used for sequencing was 5'-CATTATTTTATTATAAGGCCTGC-3'. Sequencing was performed using fluorescently-labeled ABI Big Dye terminators and an ABI 377 automated sequencer.

EXAMPLE 4

Principles underlying experiment. The experiment is outlined in Fig. 1A. First, the DNA is diluted into multiwell plates so that there is, on average, one template molecule per two wells, and PCR is performed. Second, the individual wells are analyzed for the presence of PCR products of mutant and WT sequence using fluorescent probes.

As the PCR products resulting from the amplification of single template molecules should be homogeneous in sequence, a variety of standard techniques could be used to assess their presence. Fluorescent probe-based technologies, which can be performed on the PCR products "in situ" (i.e., in the same wells) are particularly well-suited for this application. We chose to explore the utility of one such technology, involving Molecular Beacons (MB), for this purpose. MB probes are oligonucleotides with stem-loop structures that contain a fluorescent dye at the 5' end and a quenching agent (Dabcyl) at the 3' end (Fig. 1B). The degree of quenching via fluorescence energy resonance transfer is inversely proportional to the 6th power of the

30

5

10

distance between the Dabcyl group and the fluorescent dye. After heating and cooling, MB probes reform a stem-loop structure which quenches the fluorescent signal from the dye. If a PCR product whose sequence is complementary to the loop sequence is present during the heating/cooling cycle, hybridization of the MB to one strand of the PCR product will increase the distance between the Dabcyl and the dye, resulting in increased fluorescence.

A schematic of the oligonucleotides used for Digital Amplifications shown in Fig. 1C. Two unmodified oligonucleotides are used as primers for the PCR reaction. Two MB probes, each labeled with a different fluorophore, are used to detect the PCR products. MB-GREEN has a loop region that is complementary to the portion of the WT PCR product that is queried for mutations. Mutations within the corresponding sequence of the PCR product should significantly impede the hybridization of it to the MB probe. MB-RED has a loop region that is complementary to a different portion of the PCR product, one not expected to be mutant. It thus should produce a signal whenever a well contains a PCR product, whether that product is WT or mutant in the region queried by MB-GREEN. Both MB probes are used together to simultaneously detect the presence of a PCR product and its mutational status.

Practical Considerations. Numerous conditions were optimized to define conditions that could be reproducibly and generally applied. As outlined in Fig. 1A, the first step involves amplification from single template molecules. Most protocols for amplification from small numbers of template molecules use a nesting procedure, wherein a product resulting from one set of primers is used as template in a second reaction employing internal primers. As many applications of digital amplification are expected to require hundreds or thousands of separate amplifications, such nesting would be inconvenient and could lead to contamination problems. Hence, conditions were sought that would achieve robust amplification without nesting. The most important of these conditions involved the use of a polymerase that was activated only after

10

heating and optimized concentrations of dNTP's, primers, buffer components, and temperature. The conditions specified in Examples 1-3 were defined after individually optimizing each of these components and proved suitable for amplification of several different human genomic DNA sequences. Though the time required for PCR was not particularly long (~2.5 hr), the number of cycles used was high and excessive compared to the number of cycles required to amplify the "average" single template molecule. The large cycle number was necessary because the template in some wells might not begin to be amplified until several PCR cycles had been completed. The large number of cycles ensured that every well (not simply the average well) would generate a substantial and roughly equal amount of PCR product if a template molecule were present within it.

The second step in Fig 1A involves the detection of these PCR products. It was necessary to considerably modify the standard MB probe approach in order for it to function efficiently in Digital Amplification applications. Theoretically, one separate MB probe could be used to detect each specific mutation that might occur within the queried sequence. By inclusion of one MB corresponding to WT sequence and another corresponding to mutant sequence, the nature of the PCR product would be revealed. Though this strategy could obviously be used effectively in some situations, it becomes complex when several different mutations are expected to occur within the same queried sequence. For example, in the c-Ki-Ras gene example explored here, twelve different base substitutions resulting in missense mutations could theoretically occur within codons 12 and 13, and at least seven of these are observed in naturally-occurring human cancers. To detect all twelve mutations as well as the WT sequence with individual Molecular Beacons would require 13 different probes. Inclusion of such a large number of MB probes would not only raise the background fluorescence but would be expensive. We therefore attempted to develop a single probe that would react with WT sequences better than any mutant sequence within the queried sequence. We found that the length of the loop sequence, its melting temperature, and the length and sequence of the stem were each

30

5

10

important in determining the efficacy of such probes. Loops ranging from 14 to 26 bases and stems ranging from 4 to 6 bases, as well as numerous sequence variations of both stems and loops, were tested during the optimization procedure. For discrimination between WT and mutant sequences (MB-GREEN probe), we found that a 16 base pair loop, of melting temperature (Tm) 50-51°, and a 4 bp stem, of sequence 5'-CACG-3', were optimal. For MB-RED probes, the same stem, with a 19-20 bp loop of Tm 54-56°, proved optimal. The differences in the loop sizes and melting temperatures between MB-GREEN and MB-RED probes reflected the fact that only the GREEN probe is designed to discriminate between closely related sequences, with a shorter region of homology facilitating such discrimination.

Examples of the ratios obtained in replicate wells containing DNA templates from colorectal tumor cells with mutations of c-Ki-Ras are shown in Fig. 2. In this experiment, fifty copies of genomic DNA equivalents were diluted into each well prior to amplification. Each of six tested mutants yielded ratios of RED/GREEN fluorescence that were significantly in excess of the ratio obtained with DNA from normal cells (1.5 to 3.4 in the mutants compared to 1.0 in normal DNA; p < 0.0001 in each case, Student's t-Test). The reproducibility of the ratios can be observed in this figure. Direct DNA sequencing of the PCR products used for fluorescence analysis showed that the RED/GREEN ratios were dependent on the relative fraction of mutant genes within the template population (Fig. 2). Thus, the DNA from cells containing one mutant C-Ki-Ras allele per every two WT c-Ki-Ras allele yielded a RED/GREEN ratio of 1.5 (Gly12Arg mutation) while the cells containing three mutant c-Ki-Ras alleles per WT allele exhibited a ratio of 3.4 (Gly12Asp). These data suggested that wells containing only mutant alleles (no WT) would yield ratios in excess of 3.0, with the exact value dependent on the specific mutation.

Though this mode is the most convenient for many applications, we found it useful to add the MB probes after the PCR-amplification was complete (Fig. 1). This allowed us to use a standard multiwell plate

30

5

fluorometer to sequentially analyze a large number of multiwell plates containing pre-formed PCR products and bypassed the requirement for multiple real time PCR instruments. Additionally, we found that the fluorescent signals obtained could be considerably enhanced if several cycles of asymmetric, linear amplification were performed in the presence of the MB probes. Asymmetric amplification was achieved by including an excess of a single internal primer (primer INT in Fig. 1C) at the time of addition of the MB probes.

EXAMPLE 5

Analysis of DNA from tumor cells. The principles and practical considerations described above was demonstrated with DNA from two colorectal cancer cell lines, one with a mutation in c-Ki-Ras codon 12 and the other in codon 13. Representative examples of the MB-RED fluorescence values obtained are shown in Fig. 3. There was a clear biphasic distribution, with "positive" wells yielding values in excess of 10,000 specific fluorescence units (SFU, as defined in Materials and Methods) and "negative" wells yielding values less than 3500 SFU. Gel electrophoreses of 127 such wells demonstrated that all positive wells, but no negative wells, contained PCR products of the expected size (Fig. 3). The RED/GREEN fluorescence ratios of the positive wells are shown in Fig. 4. Again, a biphasic distribution was observed. In the experiment with the tumor containing a Gly12Asp mutation, 64% of the positive wells exhibited RED/GREEN ratios in excess of 3.0 while the other 36% of the positive wells exhibited ratios ranging from 0.8 to 1.1. In the case of the tumor with the Gly13Asp mutation, 54% of the positive wells exhibited RED/GREEN ratios >3.0 while the other positive wells yielded ratios ranging from 0.9 to 1.1. The PCR products from 16 positive wells were used as sequencing templates (Fig. 4). All the wells yielding a ratio in excess of 3.0 were found to contain mutant c-Ki-Ras fragments of the expected sequence, while WT sequence was found in the other PCR products.

The presence of homogeneous WT or mutant sequence confirmed that the

10

amplification products were usually derived from single template molecules. The ratios of WT to mutant PCR products determined from the Digital Amplificationassay was also consistent with the fraction of mutant alleles inferred from direct sequence analysis of genomic DNA from the two tumor lines (Fig. 2).

Digital Analysis of DNA from stool. As a more practical example, we analyzed the DNA from stool specimens from colorectal cancer patients. A representative result of such an experiment is illustrated in Fig. 5. From previous analyses of stool specimens from patients whose tumors contained c-Ki-Ras gene mutations, we expected that 1% to 10% of the c-Ki-Ras genes purified from stool would be mutant. We therefore set up a 384 well Digital Amplification experiment. As positive controls, 48 of the wells contained 25 genome equivalents of DNA (defined in Materials and Methods) from normal cells. Another 48 wells served as negative controls (no DNA template added). The other 288 wells contained an appropriate dilution of stool DNA. MB-RED fluorescence indicated that 102 of these 288 experimental wells contained PCR products (mean +/- s.d. of 47,000 +/- 18,000 SFU) while the other 186 wells did not (2600 +/- 1500 SFU). The RED/GREEN ratios of the 102 positive wells suggested that five contained mutant c-Ki-Ras genes, with ratios ranging from 2.1 to 5.1. The other 97 wells exhibited ratios ranging from 0.7 to 1.2, identical to those observed in the positive control wells. To determine the nature of the mutant c-Ki-Ras genes in the five positive wells from stool, the PCR products were directly sequenced. The four wells exhibiting RED/GREEN ratios in excess of 3.0 were completely composed of mutant c-Ki-Ras sequence (Fig. 5B). The sequence of three of these PCR products revealed Gly12Ala mutations (GGT to GCT at codon 12), while the sequence of the fourth indicated a silent C to T transition at the third position of codon 13. This transition presumably resulted from a PCR error during the first productive cycle of amplification from a WT template. The well with a ratio of 2.1 contained a ~1:1 mix of WT and Gly12Ala mutant sequences. Thus 3.9% (4/102) of the c-Ki-Ras alleles present in this stool sample contained a Gly12Ala mutation. The mutant alleles in the stool presumably arose from the colorectal cancer of the patient, as direct sequencing of PCR products generated from DNA of the cancer revealed the identical Gly12Ala mutation (not shown).

CLAIMS

1. A method for determining the ratio of a selected genetic sequence in a population of genetic sequences, comprising the steps of:

diluting nucleic acid template molecules in a biological sample to form a set comprising a plurality of assay samples;

amplifying the template molecules within the assay samples to form a population of amplified molecules in the assay samples of the set;

analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence;

comparing the first number to the second number to ascertain a ratio which reflects the composition of the biological sample.

- 2. The method of claim 1 wherein the step of diluting is performed until at least one-tenth of the assay samples in the set comprise a number (N) of molecules such that 1/N is larger than the ratio of selected genetic sequences to total genetic sequences required for the step of analyzing to determine the presence of the selected genetic sequence.
- 3. The method of claim 1 wherein the step of diluting is performed until between 0.1 and 0.9 of the assay samples yield an amplification product when subjected to a polymerase chain reaction.
- 4. The method of claim 1 wherein the step of diluting is performed until all of the assay samples yield an amplification product when subjected to a polymerase chain reaction and each assay sample contains less than 10 nucleic acid template molecules containing the reference genetic sequence.

- 5. The method of claim 1 wherein the step of diluting is performed until all of the assay samples yield an amplification product when subjected to a polymerase chain reaction and each assay sample contains less than 100 nucleic acid template molecules containing the reference genetic sequence.
- 6. The method of claim 1 wherein the biological sample is cell-free.
- 7. The method of claim 1 wherein the number of assay samples within the set is greater than 10.
- 8. The method of claim 1 wherein the number of assay samples within the set is greater than 50.
- 9. The method of claim 1 wherein the number of assay samples within the set is greater than 100.
- 10. The method of claim 1 wherein the number of assay samples within the set is greater than 500.
- 11. The method of claim 1 wherein the number of assay samples within the set is greater than 1000.
- 12. The method of claim 1 wherein the step of amplifying and the step of analyzing are performed on assay samples in the same receptacle.
- 13. The method of claim 1 wherein a molecular beacon probe is used in the step of analyzing, wherein a molecular beacon probe is an oligonucleotide with a stem-loop structure having a fluorescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end.

25

25

- 14. The method of claim 1 wherein the step of analyzing employs gel electrophoresis.
- 15. The method of claim 1 wherein the step of analyzing employs hybridization to at least one nucleic acid probe.
- 16. The method of claim 1 wherein the step of analyzing employs hybridization to at least two nucleic acid probe.
- 17. The method of claim 13 wherein two molecular beacon probes are used, each having a different fluorescent dye.
- 18. The method of claim 13 wherein the molecular beacon probe detects a wild-type selected genetic sequence better than a mutant selected genetic sequence.
- 19. The method of claim 1 wherein the step of amplifying employs a single pair of primers.
- 20. The method of claim 1 wherein the step of amplifying employs a polymerase which is activated only after heating.
- 21. The method of claim 1 wherein the step of amplifying employs at least 40 cycles of heating and cooling.
- 22. The method of claim 1 wherein the step of amplifying employs at least 50 cycles of heating and cooling.
- 23. The method of claim 1 wherein the step of amplifying employs at least 60 cycles of heating and cooling.

30

5

10

24. The method of claim 1 wherein the biological sample is selected from the group consisting of stool, blood, and lymph nodes.

25. The method of claim 1 wherein the biological sample is blood or bone marrow of a leukemia or lymphoma patient who has received anticancer therapy.

- 26. The method of claim 1 wherein the selected genetic sequence is a translocated allele.
- 27. The method of claim 1 wherein the selected genetic sequence is a wild-type allele.
- 28. The method of claim 1 wherein the selected genetic sequence is within an amplicon which is amplified during neoplastic development.
- 29. The method of claim 1 wherein the selected genetic sequence is a rare exon sequence.
- 30. The method of claim 1 wherein the nucleic acid template molecules comprise cDNA of RNA transcripts and the selected genetic sequence is present on a cDNA of a first transcript and the reference genetic sequence is present on a cDNA of a second transcript.
- 31. The method of claim 1 wherein the selected genetic sequence comprises a first mutation and the reference genetic sequence comprises a second mutation.
- 32. The method of claim 1 wherein the selected genetic sequence and the reference genetic sequence are on distinct chromosomes.
 - 33. A molecular beacon probe comprising:

5

20

25

an oligonucleotide with a stem-loop structure having a fluorescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 16 base pairs, wherein the loop has a T_m of 50-51°C and the stem consists of 4 base pairs having a sequence 5'-CACG-3'.

- 34. The probe of claim 33 wherein the molecular beacon probe detects a wild-type selected genetic sequence better than a mutant selected genetic sequence.
- 35. The probe of claim 33 wherein the molecular beacon probe detects a mutant genetic sequence better than a wild-type genetic sequence.

36. A molecular beacon probe comprising:

an oligonucleotide with a stem-loop structure having a fluorescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 19-20 base pairs, wherein the loop has a $T_{\rm m}$ of 54-56°C and the stem consists of 4 base pairs having a sequence 5'-CACG-3'.

37. A pair of molecular beacon probes comprising:

a first molecular beacon probe which is an oligonucleotide with a stem-loop structure having a first fluorescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 16 base pairs having a T_m of 50-51 °C and the stem consists of 4 base pairs having a sequence 5'-CACG-3'; and

a second molecular beacon probe which is an oligonucleotide with a stem-loop structure having a second fluorescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end, wherein the loop consists of 19-20 base pairs having a T_m of 54-56°C and the stem consists of 4 base pairs having a sequence 5'-CACG-3';

wherein the first and the second fluorescent dyes are distinct.

5

10

38. A method for determining the ratio of a selected genetic sequence in a population of genetic sequences, comprising the steps of:

amplifying template molecules within a set comprising a plurality of assay samples to form a population of amplified molecules in each of the assay samples of the set;

analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence, wherein at least one-fiftieth of the assay samples in the set comprise a number (N) of molecules such that 1/N is larger than the ratio of selected genetic sequences to total genetic sequences required to determine the presence of the selected genetic sequence;

comparing the first number to the second number to ascertain a ratio which reflects the composition of the biological sample.

- 39. The method of claim 38 wherein the number of assay samples within the set is greater than 10.
- 40. The method of claim 38 wherein the number of assay samples within the set is greater than 50.
- 41. The method of claim 38 wherein the number of assay samples within the set is greater than 100.
- 42. The method of claim 38 wherein the number of assay samples within the set is greater than 500.
- 43. The method of claim 38 wherein the number of assay samples within the set is greater than 1000.
- 44. The method of claim 38 wherein the step of amplifying and the step of analyzing are performed on assay samples in the same receptacle.

SOTIET SORDING

20

25

10

- 45. The method of claim 38 wherein a molecular beacon probe is used in the step of analyzing, wherein a molecular beacon probe is an oligonucleotide with a stem-loop structure having a fluorescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end.
- 46. The method of claim 38 wherein the step of analyzing employs gel electrophoresis.
- 47. The method of claim 38 wherein the step of analyzing employs hybridization to at least one nucleic acid probe.
- The method of claim 38 wherein the step of analyzing employs 48. hybridization to at least two nucleic acid probe.
- 49. The method of claim 45 wherein two molecular beacon probes are used, each having a different fluorescent dye.
- 50. The method of claim 45 wherein the molecular beacon probe detects a wild-type selected genetic sequence better than a mutant selected genetic sequence.
- The method of claim 38 wherein the step of amplifying 51. employs a single pair of primers.
- 52. The method of claim 38 wherein the step of amplifying employs a polymerase which is activated only after heating.
- 53. The method of claim 38 wherein the step of amplifying employs at least 40 cycles of heating and cooling.

30

5

10

- 54. The method of claim 38 wherein the step of amplifying employs at least 50 cycles of heating and cooling.
- 55. The method of claim 38 wherein the step of amplifying employs at least 60 cycles of heating and cooling.
- 56. The method of claim 38 wherein the template molecules are obtained from a body sample selected from the group consisting of stool, blood, and lymph nodes.
- 57. The method of claim 38 wherein the template molecules are obtained from a body sample of a leukemia or lymphoma patient who has received anti-cancer therapy, said body sample being selected from the group consisting of blood and bone marrow.
- 58. The method of claim 38 wherein the selected genetic sequence is a translocated allele.
- 59. The method of claim 38 wherein the selected genetic sequence is a wild-type allele.
- 60. The method of claim 38 wherein the selected genetic sequence is within an amplicon which is amplified during neoplastic development.
- 61. The method of claim 38 wherein the selected genetic sequence is a rare exon sequence.
- 62. The method of claim 38 wherein the nucleic acid template molecules comprise cDNA of RNA transcripts and the selected genetic sequence is present on a cDNA of a first transcript and the reference genetic sequence is present on a cDNA of a second transcript.

- 63. The method of claim 38 wherein the selected genetic sequence comprises a first mutation and the reference genetic sequence comprises a second mutation.
- 64. The method of claim 38 wherein the selected genetic sequence and the reference genetic sequence are on distinct chromosomes.

10

DIGITAL AMPLIFICATION

ABSTRACT

The identification of pre-defined mutations expected to be present in a minor fraction of a cell population is important for a variety of basic research and clinical applications. The exponential, analog nature of the polymerase chain reaction is transformed into a linear, digital signal suitable for this purpose. Single molecules can be isolated by dilution and individually amplified; each product is then separately analyzed for the presence of pre-defined mutations. The process provides a reliable and quantitative measure of the proportion of variant sequences within a DNA sample.


Fig. 1A

DNA

- -


Step 1

Dilute to ~1/2 copy/well PCR





Step 2

Add Fluorescent Probes Fluorometry




- = No PCR Product
- = Wild Type PCR Product
- = Mutant PCR Product





:



Page 272 of 1224

Fig. 3





Fig. 4



-

Fig. 5




	Table 1 Potential Applications of Dig-PCK	S of Dig-PCK	
	e)cusamile	Probe 1 Detects:	Probe 2 Detects:
Application	odinya		
Base substitution	Cancer gene mutations in stool, blood, lymph nodes	mutant or WT alleles	WT PCR products
mutations	Т	normal or translocated	
Chromosomal	Residual leukemia cells after therapy (DNA or RNA)	alleles	translocated allele
translocations		cogneroe within	segmence from another part
Gene amplifications	Determine presence or extent of amplification	amplicon	of same chromosome arm
Alternatively spliced	determine fraction of alternatively spliced transcripts	minor exons	common exons
products			
Changes in gene	determine relative levels of expression of two genes	first transcript	reference transcript
expression	(A) (A)		
All-lis discrimination	Two different alleles mutated vs. one mutation in each	first mutation	second mutation
Alfelic discillination	OI IWO Alleico		marker from another
Allelic imbalance	Quantitative analysis with non-polymorphic markers	marker sequence	chromosome

EXHIBIT 5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Bert VOGELSTEIN et al.) Examiner: WOOLWINE, Samuel C.
Serial No. 13/071,105)) Group Art Unit: 1637
Filed: March 24, 2011) Confirmation No. 3361
For: DIGITAL AMPLIFICATION) Atty. Dkt. No. 001107.00866

RESPONSE TO OFFICE ACITON

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the office action mailed October 10, 2012, applicants request entry of the amendment and reconsideration of the patentability of the claims in view of the remarks.

A petition for a two-month extension of time to an including March 11, 2013 accompanies this submission. The Commissioner is authorized to charge any fees which may be required or credit any overpayment to our Deposit Account 19-0733.

IN THE CLAIMS

Please replace the following claim set for that currently of record.

1. -48. (Cancelled)

49. (Proposed amendment) A method for detecting <u>quantity of</u> a genetic sequence in a mixed population of <u>human genomic</u> nucleic acid sequences <u>comprising at least a first and a second human genomic sequence</u>, wherein the first sequence is a wild-type sequence of an allele and a second sequence is a mutant sequence of the allele, comprising:

distributing or diluting a mixed population of <u>cell-free</u>, <u>human genomic</u> nucleic acid <u>sequences</u> <u>template molecules</u> into <u>a set comprising</u> at least ten assay samples such that said at least ten assay samples each comprises less than ten template molecules;

amplifying the template molecules in the assay samples, wherein an assay sample with a single template molecule forms homogeneous amplification products in the assay sample;

analyzing by determining nucleic acid sequence of amplification products from an assay sample in the assay samples of the set with homogeneous amplification products to determine a first number of assay samples which contain the first sequence and a second number of assay samples which contain the second sequence;

comparing the first number to the second number to ascertain a ratio which reflects the composition of the mixed population;

identifying a mutation in the mixed population if a statistically significant fraction of samples comprises the second sequence.

- 50. (Currently amended) The method of claim 49 wherein each of the assay samples of the set have has on average 0.5 molecules of template.
- 51. (Previously Presented) The method of claim 49 wherein between 0.1 and 0.9 of the assay samples yield an amplification product.

- 52. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acid sequences is distributed or diluted to a single template molecule level in the assay samples.
- 53. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acid sequences is from a tissue or body sample.
- 54. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acids sequences is from a sample selected from the group consisting of stool, blood, and lymph nodes.
- 55. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least fifteen assay samples comprise less than ten template molecules.
- 56. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least twenty assay samples comprise less than ten template molecules.
- 57. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least twenty-five assay samples comprise less than ten template molecules.
- 58. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least thirty assay samples comprise less than ten template molecules.
- 59. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least forty assay samples comprise less than ten template molecules.

- 60. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least fifty assay samples comprise less than ten template molecules.
- 61. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least seventy-five assay samples comprise less than ten template molecules.
- 62. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one hundred assay samples comprise less than ten template molecules.
- 63. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least five hundred assay samples comprise less than ten template molecules.
- 64. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one thousand assay samples comprise less than ten template molecules.
- 65. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one thousand assay samples are diluted to a single template molecule level.
- 66. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one thousand assay samples has on average 0.5 molecules of template.
- 67. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that between 0.1 and 0.9 of at least one thousand assay samples yield an amplification product.

68. (Previously Presented) The method of claim 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that one half of at least one thousand assay samples have one template molecule.

Remarks

The amendments to claim 49 are fully supported and do not add new matter. Quantitative analysis is taught at page 9, last paragraph. First and second sequences as mutant and wild-type sequence of an allele are taught at page 6, last paragraph. Sequencing and determining ratios to determine a mutation is taught at the paragraph spanning pages 7 and 8. The step of identifying a mutation is also taught at the paragraph spanning pages 7 and 8. Dilution/distribution of cell-free nucleic acids is taught *inter alia* at page 11, first full paragraph. The amendment to claim 49 to recite human genomic sequences is supported at page 17, lines 1-3.

The rejection under § 112, second paragraph

Claim 50 has been amended to address the unclear claim language. Please withdraw the rejection under § 112, second paragraph in view of the amendment.

Rejection under § 102(b)

Claims 49, 51-53, and 55-62 stand rejected as anticipated by Li. Li is cited as teaching dilution of a sample comprising sperm and subsequently lysing the sperm and amplifying. This is distinct from dilution of a cell-free sample of nucleic acids. Li does not teach dilution of a cell-free sample of nucleic acids. Thus Li does not anticipate the claimed invention. Please withdraw the rejection under § 102 in view of the amendment to recite dilution of a cell-free nucleic acid population.

Rejection under § 102(a)

Claims 49, and 52-54 stand rejected as anticipated by Irving. Irving is cited as teaching amplification of end-point dilution aliquots and sequencing the amplification products. Irving studies the variants in a population of TTV virus in a single individual. Irving does not identify human genomic mutant and wild-type sequences, nor does Irving use the fraction of mutant sequences to identify mutations. For at least these reasons, Irving does not anticipate claims 49 and 52-54.

The first rejection under § 103(a)

Claims 63-68 are rejected as obvious over Li. Claims 63-68 specify the number of assay samples into which the nucleic acids are distributed or diluted. Li is cited as suggesting typing as many as 500 products in a week. However, Li, did not suggest the dilution or distribution of cell-free DNA. Li's technique relied on dilution of whole, intact sperm cells. For at least this reason, Li does not render obvious the subject matter of claims 63-68.

The second rejection under § 103(a)

Claims 50, 51, and 55-68 stand rejected as obvious over Irving in view of Simmonds. As discussed above, Irving taught detection of variants within a virus population from a single infected patient.

With regard to claims 55-65 which recite various numbers of assay samples between 15 and 1000, the Patent and Trademark Office urges that although Irving did not actually report such large experiments, it would have been obvious to do them in order to find more variants. It is not clear why one of ordinary skill in the art would want to find more variants. The rejection does not identify what unanswered question in Irving's study more variants would address. As it stand, the rejection lacks any articulated reason why one of skill would do the proposed experiments.

With regard to claims 50 and 66 which recite a particular level of dilution/distribution, the Patent and Trademark Office urges that Simmonds teaches that the number of templates in an assay is a function of the level of dilution. Neither Simmonds nor Irving teaches that the recited average of 0.5 molecules is a desired level. Simmonds teaches 0.33 and 0.125, but not 0.5. Even if one accepts for the sake of argument that Irving did want 1 template per assay, the combination of Simmonds with Irving does not teach an average of 0.5. The Patent and Trademark Office bootstraps its argument by suggesting that 0.5 molecules is mere optimization. But neither Simmonds nor Irving is alleged to teach for what the parameter is being optimized.

The Patent and Trademark Office's rejection with regard to claims 51 and 67 is derivative of the rejection of claims 55-65. But that rejection is deficient, as noted.

Perhaps more significantly, Irving does not identify mutant and wild-type sequences, nor does Irving use the fraction of mutant sequences to identify mutations which occurred *in vivo* rather than *in silico*. All of claims 50, 51, and 55-68 depend from claim 49 which identifies the the fraction of allegedly mutant sequence which is used to determine whether the mutation is "real" or artifactual, *i.e.*, generated *in vivo* or generated in the amplification reaction.

Neither Irving nor Simmonds suggests such steps. For that reason as well, the method of claims 50, 51, and 55-68 are not obvious over Irving in view of Simmonds.

Please withdraw the rejection under § 103, in view *inter alia* of the amendments to claim 49.

Respectfully submitted,

Date: March 11, 2013

By: /Sarah A. Kagan/

Sarah A. Kagan

Registration No. 32,141

Banner & Witcoff, Ltd. Customer No. 11332 PTO/SB/22 (09-11)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)			Docket Number (Optional)			
PETHON FOR EXTENSION OF THME ONDER 37 OF R 1.130(a)		001107.00866				
Application Number 13/071,105			Filed March 24, 2011			
For Digital Amplification						
Art Unit 1637			Examiner Samuel C. Woolwine			
This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.						
The requested extension and fee are as follows (check time period desired and enter the appropriate fee below):						
terreno		<u>Fee</u>	Small Entity Fee	_		
	One month (37 CFR 1.17(a)(1))	\$150	\$75	\$		
V	Two months (37 CFR 1.17(a)(2))	\$560	\$280	\$ <u>570.00</u>		
	Three months (37 CFR 1.17(a)(3))	\$1270	\$635	\$		
	Four months (37 CFR 1.17(a)(4))	\$1980	\$990	\$		
	Five months (37 CFR 1.17(a)(5))	\$2690	\$1345	\$		
Applicant claims small entity status. See 37 CFR 1.27.						
A chec	k in the amount of the fee is enclosed.					
Payme	ent by credit card. Form PTO-2038 is atta	ched.				
☐ The Director has already been authorized to charge fees in this application to a Deposit Account.						
The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to						
Deposit Account Number 190733 WARNING: Information on this form may become public. Credit card information should not be included on this form.						
Provide credit card information and authorization on PTO-2038.						
I am the applicant/inventor.						
assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed (Form PTO/SB/96).						
attorney or agent of record. Registration Number 32,141						
attorney or agent under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34						
/Sarah A. Kagan/			11 March 2013			
Signature			Date			
Sarah A. Kagan		(202) 824-3000				
Typed or printed name Telephone Number						
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.						
Total of 1 forms are submitted.						

This collection of information is required by 37 CFR 1.136(a). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 6 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Patent Application Fee Transmittal								
Application Number:	13071105							
Filing Date:	24-Mar-2011							
Title of Invention:	Digital Amplification							
First Named Inventor/Applicant Name:	Bert VOGELSTEIN							
Filer:	Sarah Anne Kagan./Jennifer Hazzard							
Attorney Docket Number:	001107.00866							
Filed as Large Entity								
Utility under 35 USC 111(a) Filing Fees								
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)			
Basic Filing:								
Pages:								
Claims:								
Miscellaneous-Filing:								
Petition:								
Patent-Appeals-and-Interference:								
Post-Allowance-and-Post-Issuance:								
Extension-of-Time:								
Extension - 2 months with \$0 paid 1252 1 570 570								

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
	Tot	al in USD	(\$)	570

Electronic Acknowledgement Receipt				
EFS ID:	15168667			
Application Number:	13071105			
International Application Number:				
Confirmation Number:	3361			
Title of Invention:	Digital Amplification			
First Named Inventor/Applicant Name:	Bert VOGELSTEIN			
Customer Number:	11332			
Filer:	Sarah Anne Kagan./Jennifer Hazzard			
Filer Authorized By:	Sarah Anne Kagan.			
Attorney Docket Number:	001107.00866			
Receipt Date:	11-MAR-2013			
Filing Date:	24-MAR-2011			
Time Stamp:	12:43:15			
Application Type:	Utility under 35 USC 111(a)			

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$570
RAM confirmation Number	22590
Deposit Account	190733
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		Response-to-NFOA-as-filed.PDF	95962	yes	8
		'	c2b10b9891e55742fa615f10b56cd60a6bc 4bf0a		
	Multip	oart Description/PDF files in .	zip description		·
	Document De	Start	Е	nd	
	Amendment/Req. Reconsiderat	1		1	
	Claims	2		5	
	Applicant Arguments/Remarks	6		8	
Warnings:					
Information:					
2	Extension of Time	Petition-for-EOT.PDF	289378	no	2
-	<u> </u>	reuton-tor-zona bi	8919/47c7ad4711247bcaa1c/63e1efecb83 6297		
Warnings:					
Information:					
3	Fee Worksheet (SB06)	fee-info.pdf	30272	no	2
, , , , , , , , , , , , , , , , , , ,	i ee workstieet (3000)		92ce82a7a1eb8b0196183f2ecec64f34b3c6 93e2		_
Warnings:					
Information:					
		Total Files Size (in bytes)	4	15612	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Approved for use through 1/31/2007, OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875						A	pplication or 13/07	Docket Number 1,105		ing Date 24/2011	To be Mailed		
	AF	PPLICAT		S FILE			Column 2)		SMALL	ENTITY [OR		HER THAN ALL ENTITY
	FOR		NUI	MBER FIL	.ED	NUM	BER EXTRA		RATE (\$)	FEE (\$)		RATE (\$)	FEE (\$)
	BASIC FEE (37 CFR 1.16(a), (b), (c)	or (c))		N/A			N/A		N/A			N/A	
	SEARCH FEE (37 CFR 1.16(k), (i), o	or (m))		N/A			N/A	State of the latest and the latest a	N/A			N/A	
	EXAMINATION FE (37 CFR 1.16(o), (p), (N/A			N/A	(Constitution of Constitution	N/A			N/A	
	TAL CLAIMS CFR 1.16(i))			min	us 20 =	•			X \$ =	'	OR	X \$ =	
IND	EPENDENT CLAIM CFR 1.16(h))	S		mi	nus 3 ≔	•			X \$ =			X \$ =	
	APPLICATION SIZE (37 CFR 1.16(s))	FEE	sheets is \$250 additio	of pape 0 (\$125 onal 50 s	er, the ap for small sheets or	plication entity) t fraction	is exceed 100 in size fee due for each thereof. See CFR 1.16(s).				The state of the s		
	MULTIPLE DEPEN	DENT CLA	IM PRE	SENT (37	7 CFR 1.16	(j))							
* If t	he difference in colu	ımn 1 is les	s than z	ero, ente	r "0" in colu	umn 2.			TOTAL			TOTAL	
-constant	APPI	Column		AMEND	(Colum	nn 2)	(Column 3)		SMAL	L ENTITY	ÓR		ER THAN ALL ENTITY
AMENDMENT	03/11/2013	CLAIMS REMAINI AFTER AMENDN			HIGHES NUMBER PREVIO PAID FO	R USLY	PRESENT EXTRA		RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)
Š	Total (37 CFR 1.16(i))	· 20		Minus	·· 68		= 0		X\$ =		OR	X \$62=	0
볾	Independent (37 CFR 1.16(h))	* 1		Minus	***6		= 0		X\$ =		OR	X \$250=	0
√NE	Application Si	ze Fee (37	CFR 1.1	i6(s))									
	FIRST PRESEN	ITATION OF	MULTIPL	E DEPENI	DENT CLAIM	M (37 CFF	l 1.16(j))				OR		
		×							TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	0
		(Columi	n 1)		(Colun	nn 2)	(Column 3)	¥25000000					
		GLAIM REMAIN AFTE AMENDM	iing R		HIGHI NUME PREVIO PAID I	BER DUSLY	PRESENT EXTRA		RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)
E	Total (37 CFR 1.16(i))	*		Minus	**		=	Separate Spring	X \$ =		OR	X\$ =	
S	Independent (37 CFR 1.16(h))	*		Minus	***		=	g constant	X\$ =		OR	X \$ =	
Total (37 CFR 1.15(n)) Application Size Fee (37 CFR 1.16(s)) FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(i))						g) constant							
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					l 1.16(j))	No. of Contract of	·		OR				
* If I	TOTAL ADD'L OR ADD'L FEE FEE												
** lf *** l	* If the entry in column 1 is less than the entry in column 2, write "0" in column 3. **If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". **If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.												

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/071,105	03/24/2011	Bert VOGELSTEIN	001107.00866	3361
11332 Banner & Witco	7590 10/10/201 off. Ltd.	2	EXAM	INER
Attorneys for cl	lient 001107		WOOLWINE	SAMUEL C
1100 13th Stree Suite 1200	t N.W.		ART UNIT	PAPER NUMBER
Washington, Do	C 20005-4051		1637	
			Company of the Compan	
			MAIL DATE	DELIVERY MODE
			10/10/2012	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)				
		13/071,105	VOGELSTEIN ET AL.				
	Office Action Summary	Examiner	Art Unit				
		SAMUEL WOOLWINE	1637				
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address				
A SHI WHIC - Exter after - If NO - Failu Any I	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Operiod for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	TE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	J. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
1)🛛	Responsive to communication(s) filed on 11 Ju	<u>ne 2012</u> .					
2a)□	This action is FINAL . 2b)⊠ This	action is non-final.					
3)[An election was made by the applicant in response	nse to a restriction requirement s	set forth during the interview on				
	; the restriction requirement and election	·					
4)	Since this application is in condition for allowan	,					
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	33 O.G. 213.				
Dispositi	on of Claims						
6)□ 7)⊠ 8)□	5) ☐ Claim(s) 1-68 is/are pending in the application. 5a) Of the above claim(s) 1-48 is/are withdrawn from consideration. 6) ☐ Claim(s) is/are allowed. 7) ☐ Claim(s) 49-68 is/are rejected. 8) ☐ Claim(s) is/are objected to. 9) ☐ Claim(s) are subject to restriction and/or election requirement.						
Applicati	ion Papers						
10)	The specification is objected to by the Examiner	·.					
11)	The drawing(s) filed on is/are: a) acce	epted or b) \square objected to by the E	Examiner.				
	Applicant may not request that any objection to the o						
	Replacement drawing sheet(s) including the correcti						
12)	The oath or declaration is objected to by the Ex-	aminer. Note the attached Office	Action or form PTO-152.				
Priority ι	ınder 35 U.S.C. § 119						
 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachmen	et(s) e of References Cited (PTO-892)	4) Interview Summary	(PTO-413)				
2) Notice (3) Inform	the of Helerences Gled (PTO-692) the of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) or No(s)/Mail Date 03/24/2011.	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate				

U.S. Patent and Trademark Office PTOL-326 (Rev. 03-11)

Art Unit: 1637

DETAILED ACTION

Election/Restrictions

Applicant's election of Group IV claims 49-68 in the reply filed on 06/11/2012 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Claims 1-48 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 06/11/2012.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 50 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Each assay sample cannot have an average number of template molecules. Any sample has precisely the number of template molecules it contains. An average would be applied to a population of assay samples.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

Art Unit: 1637

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 49, 51-53, 55-62 are rejected under 35 U.S.C. 102(b) as being anticipated by Li et al (Nature 335:414-417 (1988), cited on the IDS of 03/24/2012).

With regard to claim 49, Li taught:

distributing or diluting a mixed population of nucleic acid sequences into at least ten assay samples such that said at least ten assay samples each comprises less than ten template molecules;

The mixed population of nucleic acid sequences was "a semen sample": page 415, column 1, last [partial] paragraph: "Sperm were purified from a semen sample...". Each sperm would contain 23 chromosomes, and some sperm would comprise maternally derived chromosomes, while others would comprise paternally derived chromosomes. In addition, some sperm would comprise Y chromosomes, whereas others would comprise X chromosomes. Furthermore, the semen sample was obtained from an individual known to be heterozygous at a locus of the LDLr gene (page 415, column 1, last [full] paragraph). Li took single sperm and placed them into separate tubes for amplification (page 415, column 1, last [partial] paragraph). By doing so, Li distributed the mixed population into at least ten (in this case, 80) "assay samples" such that each of the assay samples comprised less than ten (in this case, 1) template molecules; the template, in this case, is the LDLr gene.

Art Unit: 1637

amplifying the template molecules in the assay samples, wherein an assay sample with a single template molecule forms bomogeneous amplification products in the assay sample;

Li amplified each of the assay samples containing individual sperm; page 415, column 1, last [partial] paragraph: "Individual sperm were drawn into a fine plastic needle under microscopic observation and delivered to a tube for lysis and amplification." Since each sample containing one sperm would contain one template molecule (i.e. LDLr gene), the amplification product from such a sample would inherently be homogeneous.

determining nucleic acid sequence of amplification products from an assay sample with homogeneous amplification products.

Li amplified a known sequence: a 254 bp fragment of the LDLr gene (page 415, column 1, last [full] paragraph). The only missing sequence information was which single nucleotide polymorphism was present in each of the homogeneous amplified products, which Li determined using allele-specific oligonucleotides (see figure 2 and legend). In this way, Li determined "nucleic acid sequence of amplification products from an assay sample with homogeneous amplification products".

With regard to claim 51, Li notes that of the 80 individual sperm, 55% produced a hybridization signal (thus indicating an amplification product; page 415, sentence spanning columns 1-2). This is between 0.1 (10%) and 0.9 (90%).

With regard to claim 52, since Li distributed individual sperm to individual assay samples, he distributed to a single template molecule in the assay samples.

Art Unit: 1637

With regard to claim 53, semen is a "body sample" (it's a sample from a body).

With regard to claims 55-61, Li set up 80 assay samples containing less than 10 template molecules as described in the experiment on page 415 entitled "Analysis in single human sperm".

With regard to claim 62, Li performed a similar analysis on 150 individual sperm (page 415, column 2, under section entitled "Independent assortment of chromosomes".

Claims 49, 52-54 are rejected under 35 U.S.C. 102(a) as being anticipated by Irving et al (The Journal of Infectious Diseases 180:27-34, July 1999).

With regard to claims 49, 52, Irving used dilution to allow for sequence determination of individual molecules of TT virus (TTV) DNA in a sample; page 28, column 1, last [full] paragraph:

amplification of undiluted DNA extracts. Analysis of the population diversity within individual patients was done by directly sequencing the PCR products derived from amplification of multiple aliquots of DNA at the end-point dilution. Unincorporated

In one case, Irving determined the sequence of 11 different individual molecules of TTV from a single sample; page 30, column 2, last paragraph:

Art Unit: 1637

Analysis of viral variants within patient 30. To investigate further the possibility of viral evolution and the coexistence of distinct viral variants, multiple amplifications of single TTV DNA molecules present in the DNA extracts obtained from the first and last serum samples from patient 30 were directly sequenced. Nucleotide sequence data from 22 single molecule amplifications of samples 30a and 30e were obtained. The resulting phylogenetic analysis (figure 4) was similar but not iden-

As seen from figure 4, the "22 samples" consist of 9 molecules of TTV from the first sample, and 13 molecules of TTV from the last sample. Thus, in the latter case, there were at least 13 "assay samples" formed by dilution of the last sample, each such "assay sample" comprising a single molecule of template (which is less than 10). The assay samples were amplified, producing homogeneous products (the inherent result of amplifying a single template molecule) and sequenced. As the sequencing results indicate the original sample contained multiple genotypes of TTV, the original sample was a "mixed population of nucleic acid sequences". Not only that, the sample was serum from a human subject, which was clearly obtained in the form of blood (the true "original sample"), and as such would have also comprised all the chromosomal and mitochondrial genomic DNA, plus all the various forms of RNA (tRNA, rRNA, mRNA) present in a human blood sample. In this manner, too, it can be said that Irving began with a mixed population of nucleic acid sequences.

With regard to claims 53, 54, one of ordinary skill in the art knows that one does not obtain serum directly from a body. Rather, one obtains blood, allows

Art Unit: 1637

the blood to clot, and separates the serum from the cellular components by centrifugation. In this manner, Irving's original sample was blood.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 63-68 are rejected under 35 U.S.C. 103(a) as being unpatentable over Li et al (Nature 335:414-417 (1988), cited on the IDS of 03/24/2012).

The teachings of Li have been discussed. With regard to claim 63, Li did not actually distribute into 500 assay samples. With regard to claims 64, 67 and 68, Li did not distribute into 1000 assay samples.

However, Li expressly suggested analyzing 500 assay samples; page 416, last paragraph: "With PCR, we can envisage typing as many as 500 meiotic products in a week."

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to distribute 500, or even 1000 individual sperm and assay according to Li's technique. One would have been motivated to do so because Li stated (page 416, first paragraph of "Discussion"): "A significant advantage of the approach described here is that a large number of meiotic products can be examined from a single individual allowing determination of the recombination frequency of recombination between genetic markers which are

Art Unit: 1637

physically very close." Li's express contemplate of 500 individual meiotic event certainly renders claim 63 obvious, and, by simple extrapolation, the subject matter of claims 64, 65, 67 and 68, which merely require more assay samples (i.e. 1000).

Claims 50, 51 and 55-68 are rejected under 35 U.S.C. 103(a) as being unpatentable over Irving et al (The Journal of Infectious Diseases 180:27-34, July 1999) in view of Simmonds et al (Journal of Virology 64(2):864-872 (1990)).

The teachings of Irving have been discussed.

With regard to claims 55-65, it would have been obvious to one of skill in the art at the time the invention was made to make up to 1000 (or more) assay samples in order to obtain more virus templates for sequencing, in order to discover more viral variants within the sample.

With regard to claims 50 and 66, Irving did not specifically say that the "end-point dilution" (page 28, column 1, last [full] paragraph) used to obtain single molecules for DNA sequencing was a dilution that produced, on average, 0.5 templates per assay sample. However, Irving cites to Simmonds (ref. 12). Simmonds states (page 871, last paragraph):

cule is present will usually be greater than this. From the Poisson distribution, when 50% of reactions are positive, about one-third of the positive reactions will contain two template molecules; when 25% are positive, about one-eighth of the positive reactions will contain two templates.

From this it is clear that the number of assay samples containing a single molecule would be dependent upon how much dilution of the original sample was made (and, consequently, on the average number of template molecules per assay sample). As such, the average number of template molecules per assay samples is a variable affecting the number of assay samples containing a single template, which was the desire of Irving. Therefore, the average number of template molecules per assay sample was a variable subject to routine optimization (MPEP 2144.05(II)(B)). "Where the general conditions in a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955).

With regard to claims 51 and 67, in arriving at an average of 0.5 molecules per assay sample, one would also have arrived at a state wherein between 0.1 and 0.9 assay samples produced an amplification product, as 50% is between 10% and 90%.

Conclusion

No claims are free of the prior art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAMUEL WOOLWINE whose telephone number is (571)272-1144. The examiner can normally be reached on Mon-Fri 9:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571) 272-0782. The

Art Unit: 1637

fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Samuel Woolwine/ Primary Examiner

Applicant(s)/Patent Under Application/Control No. Reexamination 13/071,105 VOGELSTEIN ET AL. Notice of References Cited Examiner **Art Unit** Page 1 of 1 SAMUEL WOOLWINE 1637 U.S. PATENT DOCUMENTS **Document Number** Date Classification Name Country Code-Number-Kind Code MM-YYYY US-Α US-В US-С US-D US-Ε US-F US-G US-Н US-J US-US-К US-L US-M FOREIGN PATENT DOCUMENTS Document Number Date Country Name Classification MM-YYYY Country Code-Number-Kind Code N O Ρ Q R s T **NON-PATENT DOCUMENTS** Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages) Irving et al. TT Virus Infection in Patients with Hepatitis C: Frequency, Persistence, and Sequence Heterogeneity. The Journal of U Infectious Diseases 180:27-34, July 1999. Simmonds et al. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. Journal of Virology 64(2):864-872 (1990). W

A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

Χ

Notice of References Cited

Part of Paper No. 20121003

Googl	© SChOlar Advanced Scholar Search	Advanced Search Tips About Google Scholar
Find articles	with all of the words smd haplotype blood	Results per page: 10 Sections
	with the exact phrase	
	with at least one of the words	
	without the words	
	where my words occur anywhere in the article	
Author	Return articles written by	
	e.g., <i>"PJ Hayes"</i> or <i>McCarthy</i>	
Publication	Return articles published in	
Date	e.g., <i>J Biol Chem</i> or <i>Nature</i> Return articles published between	
Date	e.g., 1996	
Collections	Articles and patents	
	Search articles in all subject areas (include patents).	
	O Search only articles in the following subject areas:	
	☐ Biology, Life Sciences, and Environmental Science ☐ Medicin	ne, Pharmacology, and Veterinary Science
	Business, Administration, Finance, and Economics Physics	
	☐ Chemistry and Materials Science ☐ Social S☐ Engineering, Computer Science, and Mathematics	Sciences, Arts, and Humanities
	Legal opinions and journals	
	Search all legal opinions and journals.	
	O Search opinions of All federal courts	
	Search opinions of Virginia courts.	
	Select specific courts to search	
50000000000000000000000000000000000000	Sparch Schridge	

	line general More		Samuel Veckine or	
Googl	€ SChOlar Advanced	l Scholar Search Advi	anced Search Tips About	Google Scholar
Find articles	with all of the words	blood	Results per page; 10	
	with the exact phrase	single molecule pcr]	
	with at least one of the words	sequencing sequenced]	
	without the words			
	where my words occur	anywhere in the article		
Author	Return articles written by			
		e.g., "PJ Hayes" or McCarthy	7	
Publication	Return articles published in			
Date	Return articles published between	e.g., <i>J Biol Chem</i> or <i>Nature</i> — 1999 e.g., 1996		
Collections	Articles and patents	0.9., 1990		
300000000000000000000000000000000000000	Search articles in all subject ar	reas (☑ include patents).		
300 300 300 300 300 300 300 300 300 300	Search only articles in the follo	wing subject areas:		
	☐ Biology, Life Sciences, and	Environmental Science Medicine, P	harmacology, and Veterina	ry Science
	Constitution .	inance, and Economics Physics, As	•	ence
	☐ Chemistry and Materials Sc ☐ Engineering, Computer Science		nces, Arts, and Humanities	
	Legal opinions and journals	•		
000	Search all legal opinions and jo	ournals.		
0.00	Search opinions of All federal court	S		
	Search opinions of Virginia	courts.		
000000000000000000000000000000000000000	Select specific courts to search			
	Sparik sakelat			

	Images More Samuel Woolwine@gmail.com
Googl	C SCholar Advanced Scholar Search Advanced Search Tips About Google Scholar
Find articles	with all of the words Results per page; 10
	with the exact phrase
	with at least one of the words
	without the words
	where my words occur anywhere in the article
Author	Return articles written by
Publication	e.g., "PJ Hayes" or McCarthy Return articles published in e.g., J Biol Chem or Nature
Date	Return articles published between
References	e.g., 1996 Search within articles citing Ruano: Haplotype of multiple polymorphisms resolved by enzymatic amplification of single
Collections	Articles and patents
	⊕ Search articles in all subject areas (☐ include patents).
	Search only articles in the following subject areas:
	Biology, Life Sciences, and Environmental Science Medicine, Pharmacology, and Veterinary Science Business, Administration, Finance, and Economics Physics, Astronomy, and Planetary Science Chemistry and Materials Science Social Sciences, Arts, and Humanities Engineering, Computer Science, and Mathematics
	Legal opinions and journals
	○Search all legal opinions and journals.
	OSearch opinions of All federal courts
	◯ Search opinions of Virginia courts.
	Select specific courts to search
9,000	Senich Gobila

	Images More Samuel Woolwine@gmail.com
Googl	SCHOIAL Advanced Scholar Search Advanced Search Tips About Google Scholar
Find articles	with all of the words Results per page: 10
	with the exact phrase
	with at least one of the words
	without the words
	where my words occur anywhere in the article
Author	Return articles written by
	e.g., <i>"PJ Hayes"</i> or <i>McCarthy</i>
Publication	Return articles published in
D-4-	e.g., <i>J Biol Chem</i> or <i>Nature</i>
Date	Return articles published between e.g., 1996
References	Search within articles citing Stephens: Theoretical underpinning of the single-molecule-dilution (SMD) method of direct
Collections	Articles and patents
	OSearch only articles in the following subject areas:
	☐Biology, Life Sciences, and Environmental Science ☐ Medicine, Pharmacology, and Veterinary Science
	Business, Administration, Finance, and Economics Physics, Astronomy, and Planetary Science
	☐ Chemistry and Materials Science ☐ Social Sciences, Arts, and Humanities ☐ Engineering, Computer Science, and Mathematics
	Legal opinions and journals
one contraction of the contracti	OSearch all legal opinions and journals.
o constant	Search opinions of All federal courts
	OSearch opinions of virginia courts.
and	Select specific courts to search
second reach	Synch-Schold:

The second			samuel Woolwinergmail.com
Googl	€ SChOlar <mark>Advance</mark> d	l Scholar Search Adva	nced Search Tips About Google Scholar
Find articles	with all of the words	pcr	Results per page: 10
	with the exact phrase	single molecule dilution	
	with at least one of the words		
	without the words		
	where my words occur	anywhere in the article	
Author	Return articles written by		***************************************
		e.g., "PJ Hayes" or McCarthy	1
Publication	Return articles published in	I Dist Olement Melane	
Date	Return articles published between	hattacatatatatatatata hattacatatatatatatatatatatatatatatatatat	
Collections	Articles and patents	e.g., <i>1996</i>	
	Search articles in all subject a	reas (include patents).	
	Search only articles in the follo	owing subject areas:	
		Environmental Science Medicine, Ph	
	Business, Administration, FChemistry and Materials So	inance, and Economics Physics, Ast	ronomy, and Planetary Science ces, Arts, and Humanities
	☐ Engineering, Computer Sci		oes, Arts, and Framaintes
	Legal opinions and journal	S	
	Search all legal opinions and j	ournals.	
	Search opinions of All federal cour	ts	
	Search opinions of Virginia	courts.	
	Select specific courts to search		
	Spirch Scholat		

			Signific
Googl	© SChOlar <mark>Advance</mark> c	l Scholar Search Adva	nced Search Tips About Google Scholar
Find articles	with all of the words	pcr background dilution	Results per page: 10
	with the exact phrase	detecting rare	
	with at least one of the words	genome copy copies molecule molecules	
	without the words		
	where my words accur	anywhere in the article	
Author	Return articles written by		
		e.g., "PJ Hayes" or McCarthy	
Publication	Return articles published in		
		e.g., J Biol Chem or Nature	
Date	Return articles published between	taracaracan baracaracan baracan ba	
Collections	Articles and patents	e.g., 1996	
	Search articles in all subject articles.	reas (☑ include patents).	
	Search only articles in the follo	wing subject areas:	
	☐Biology, Life Sciences, and	Environmental Science Medicine, Ph	armacology, and Veterinary Science
		inance, and Economics 🔲 Physics, Asti	
	Chemistry and Materials So		ces, Arts, and Humanities
	☐ Engineering, Computer Science	ence, and Mathematics	
	Legal opinions and journals	•	
	Search all legal opinions and jo	ournals.	
	Search opinions of All federal court	S	
	Search opinions of Virginia	courts.	
	Select specific courts to search		
	Starch Scholai		

Googi	€ SCholar <mark>Advance</mark> d	l Scholar Search Adva	nced Search Tips About C	Google Scholar
Find articles	with all of the words	pcr background dilution	Results per page: 10	
	with the exact phrase	detection of rare		
	with at least one of the words	genome copy copies molecule molecules		
	without the words			
	where my words occur	anywhere in the article		
Author	Return articles written by			
		e.g., "PJ Hayes" or McCarthy	•	
Publication	Return articles published in			
		e.g., J Biol Chem or Nature — 1999		
Date	Return articles published between	e.g., <i>1996</i>		
Collections	Articles and patents	e.g., 1330		
	Search articles in all subject a	reas (☑ include patents).		
	O Search only articles in the follo	wing subject areas:		
		Environmental Science Medicine, Ph	= '	· .
	☐ Business, Administration, F☐ Chemistry and Materials So	inance, and Economics Physics, Astronomy	ronomy, and Planetary Scie ces, Arts, and Humanities	ence
	Engineering, Computer Sci		ces, Aits, and Humanities	
	Legal opinions and journals	3		
	Search all legal opinions and ju	ournals.		
	Search opinions of All federal cour	IS .		
	Search opinions of Virginia	courts.		
	Select specific courts to search			
	South Echolar			

Web Startin More ₃○○♀[€ SCholar Advanced Scholar Search Advanced Search Tips | About Google Scholar Find articles with all of the words Results per page: 10 digital per with the exact phrase with at least one of the words without the words anywhere in the article where my words occur Author Return articles written by e.g., "PJ Hayes" or McCarthy Publication Return articles published in e.g., J Biol Chem or Nature 1999 Date Return articles published between e.g., 1996 Collections Articles and patents Search articles in all subject areas (include patents). O Search only articles in the following subject areas: Biology, Life Sciences, and Environmental Science Medicine, Pharmacology, and Veterinary Science Business, Administration, Finance, and Economics Physics, Astronomy, and Planetary Science Social Sciences, Arts, and Humanities Chemistry and Materials Science ☐ Engineering, Computer Science, and Mathematics Legal opinions and journals Search all legal opinions and journals. O Search opinions of All federal courts Search opinions of Virginia courts. Select specific courts to search Search Scholar

Vel	Images More		Signific
Googl	€ SCholar Advanced	d Scholar Search Adva	nced Search Tips About Google Scholar
Find articles	with all of the words	emulsion pcr	Results per page: 10
	with the exact phrase		
	with at least one of the words	sequenced sequencing	j
	without the words		Ï
		anywhere in the article	4
	where my words accur		_
Author	Return articles written by	griffiths	
		e.g., "PJ Hayes" or McCarthy	3
Publication	Return articles published in		
		e.g., J Biol Chem or Nature	
Date	Return articles published between		
Collections	A.11-1	e.g., <i>1996</i>	
o o no o mond	Articles and patents		
	Search articles in all subject a	reas (🗹 include patents).	
	Search only articles in the follo	owing subject areas:	
	Godardi only articles in the folic	wing subject areas.	
		Environmental Science 🗔 Medicine, P	\$
		inance, and Economics Physics, As	ronomy, and Planetary Science ices, Arts, and Humanities
	☐ Chemistry and Materials So☐ Engineering, Computer Sci		ces, Arts, and Humanities
	<u> </u>		
	Legal opinions and journal	S	
***	Search all legal opinions and j	ournais.	· ·
	O Search opinions of All federal coun	ts	

	Search opinions of Virginia	courts.	
	Select specific courts to search		
	Sparile Scholag		

	More seems	Establishment of the second of	Sign in
Googl	€ SChOlar <mark>Advance</mark> d	d Scholar Search Adva	nced Search Tips About Google Scholar
Find articles	with all of the words	emulsion pcr	Results per page: 10
	with the exact phrase		
	with at least one of the words	sequenced sequencing	
	without the words]
	where my words accur	anywhere in the article	
Author	Return articles written by	tawfik	
		e.g., "PJ Hayes" or McCarthy	•
Publication	Return articles published in		
Date	Return articles published between	e.g., J Biol Chem or Nature	
Date	riciani antoico published between	e.g., <i>1996</i>	
Collections	Articles and patents		
	Search articles in all subject a	reas (☑ include patents).	
	Search only articles in the follo	owing subject areas:	
	☐ Biology, Life Sciences, and	Environmental Science 🔲 Medicine, Pl	narmacology, and Veterinary Science
		inance, and Economics Physics, Ast	
	☐ Chemistry and Materials So ☐ Engineering, Computer Sci		ces, Arts, and Humanities
	Li Engineering, computer con	onoo, and manomanoo	
	Legal opinions and journal	S	
	Search all legal opinions and j	ournals.	
	Search opinions of All federal cour	ts	000000000000000000000000000000000000000
	Search opinions of Virginia	courts.	
	Select specific courts to search		
	Saarch scholar		

Application/Control No. Search Notes 13071105 Examiner SAMUEL WOOLWINE Applicant(s)/Patent Under Reexamination VOGELSTEIN ET AL. Art Unit 1637

SEARCHED							
Class	Subclass	Date	Examine				

SEARCH NOTES		
Search Notes	Date	Examiner
Inventor name/keyword search in EAST, Google Scholar.	10/04/2012	SCW

INTERFERENCE SEARCH							
Class	Subclass	Date	Examine				
			SCW				

I	
ı	
ı	
ı	
ı	
ı	
ı	

	Images More		Samuel Woolvine @	mail com			
Googl	€ SChOlar Advanced	l Scholar Search	Advanced Search Tips About	Google Scholar			
Find articles	with all of the words	single molecules	Results per page: 10	240 500			
	with the exact phrase						
	with at least one of the words	template dna nucleic					
	without the words	stranded					
	where my words occur	in the title of the article					
Author	Return articles written by						
Publication	Return articles published in	e.g., "PJ Hayes" or McCarthy e.g., J Biol Chem or Nature					
Date	Return articles published between						
Collections	Articles and patents	e.y., 1330					
	Search articles in all subject a	reas (🔲 include patents).					
	Search only articles in the follo	owing subject areas:					
		Environmental Science Medicin					
	☐ Business, Administration, F☐ Chemistry and Materials So	Finance, and Economics Physics, Astronomy, and Planetary Science Science Social Sciences, Arts, and Humanities					
	☐ Engineering, Computer Sci						
	Legal opinions and journal	5					
	Search all legal opinions and j	ournals.					
	O Search opinions of All federal coun	ts					

courts.

O Search opinions of Virginia

Sparik Scholar

Select specific courts to search

Doc code: IDS

Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (01-10)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number			
	Filing Date		2011-03-16	
INFORMATION DISCLOSURE	First Named Inventor Bert V		Vogelstein et al.	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit			
(Not for Submission under or or it 1.33)	Examiner Name			
	Attorney Docket Num	er	001107.00866	

				PATENTS	Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5213961	Α	1993-05-15	Bunn et al.	
	2	5736333	A	1998-04-07	Livak et al.	
	3	5518901	A	1996-05-21	Murtagh	
	4	5804383	A	1998-09-08	Gruenert et al.	
	5	5858663	A	1999-01-12	Nisson et al.	
	6	5670325	A	1997-09-23	Lapidus et al.	
	7	6037130	A	2000-03-14	Tyagi et al.	
	8	5925517	A	1999-07-20	Tyagi et al.	

		A-10-10-10-10-10-10-10-10-10-10-10-10-10-		Applic	ation N	umber						
				Filing	Filing Date 2011-03-16							
		ION DISCLOSU		First N	First Named Inventor Bert Vogelstein et al.							
		NT BY APPLICA ssion under 37 CFR		Art Ur	Art Unit							
(1401 101 1	Subim	ssion under 37 OFK	1.33]	Exam	Examiner Name							
				Attorn	ey Doc	ket Numb	er	001107.00866				
	9	5928870	A	1999-07	'-27	Lapidus e	t al.					
	10	6020137	A	2000-02	000-02-01 Lapidus et al.							
	11	6143496	A	2000-11	I-07	Brown et a	al.					
	12	6291163	B1	2001-09)-18	Sidransky						
If you wis	h to ad	ld additional U.S. Pate	nt citatio	n inform	ation pl	ease click	the /	Add button.		Add		
<u>. </u>			U.S.P	ATENT	APPLIC	CATION F	UBL	ICATIONS		Remove		
Examiner Initial*	Cite N	Publication Number	Kind Code ¹	1	Publication Name of Patentee or Applicant R			Releva		Lines where ges or Relev		
	1											
If you wis	h to ad	ld additional U.S. Publ	ished Ap	plication	n citation	n informat	ion p	lease click the Ad	d buttor	1. Add		
				FOREIG	GN PAT	ENT DO	CUMI	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication	on	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	T5
	1	95/13399	wo		A1	1995-05-1	18					П

1999-03-18

A1

99/13113

WO

2

r												
				Applic	cation N	lumber						
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date				2011-03-16				
				First I	Vamed	Inventor	Bert '	Vogelstein et al.	/ogelstein et al.			
				Art Ur	nit							
(Not for submission under 37 CFR 1.99)			1.00	Examiner Name								
				Attorn	ey Doc	ket Numb	er	001107.00866				
			T		T					T		
	3	0643140	 EP		A1	1995-03-	15	Canon Kabushiki Kaisha		$ \Box $		
		0043140				1990-00-	,	Odnon Rabushiki Raisha				
If you wie	h to a	d additional Foreign P	atent Do	cument	citation	informati	on nle	ase click the Add butto	Add	<u> </u>		
ii you wis	II to at	ad additional Foreign F				ERATURE			Remove			
	I	Include name of the s						ne article (when approp	All a lateral control of the second s	[
Examiner Initials*	Cite No		nal, seria	al, symp	osium,	catalog, e		ate, pages(s), volume-is		T 5		
	1		GHLIN ET AL., "Association of the Interleukin-1 Gene Cluster on Chromosome 2q13 With Knee Osteoarthritis," ritis & Rheumatism, June 2002, 46(6):1519-1527									
	2	P. J. SYKES, "Quantitation of Targets for PCR by Use of Limiting Dilution," BioTechniques, 1992, Vol. 13, No. 3, pp. 444-449										
	A. PIATEK ET AL., "Molecular Beacon Sequence Analysis for Detecting Drug Resistance in Mycobacterium Tuberculosis," Nature Biotechnology, April 1998, Vol. 16, No. 4. pp. 359-363											
	4	S. TYAGI ET AL., "Multicolor Molecular Beacons for allele discrimination," Nature Biotechnology, January 1998, Vol. 16, No. 1, pp. 303-308										
	5	J. A.M. VET ET AL., "Multilex Detection of Four Pathogenic Retroviruses Using Molecular Beacons," Proceedings of the National Academy of Sciences of the United States", May 25, 1999, Vol. 96, No. 11, pp. 6394-6399										
	6	S. TYAGI ET AL., "Mole 14, No. 3, pp. 303-308	cular Bea	icons: pro	obes the	nt Fluoresce	Upon	Hybridization," Nature Bio	otechnology, 1996, Vol.			

Application Number Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) First Named Inventor Art Unit Examiner Name Attorney Docket Number 001107.00866

S. D.E. EVERETT ET AL., "Identification of Nine Species of the Chlamydiaceae Using PCR-RFLP," Int. J. Syst. Bacteriol., April 1999, Vol. 49, No. 2, pp. 803-813	 		
and Variant Repeat Mapping." Genomics, 1991, Vol. 11, pp. 465-467 11 G. RUANO ET AL., "Haplotype of Multiple Polymorphisms Resolved by Enzymatic Amplification of Single DNA Molecules," Proc. National Science USA, 1990, pp. 6296-8300 12 W. NAVIDI ET AL., "Using PCR in Preimplantation Genetic Disease Diagnosis," Human Reproduction, 1991, Vol. 6, No. 6, pp. 836-849 13 H. LI ET AL., "Amplification and Analysis of DNA Sequences in Single Human Sperm and Diploid Cells," Nature, September 29, 1988, Vol. 335, pp. 414-417 14 L. ZHANG ET AL., "Whole Genome Amplification from a Single Cell: Implications for Genetic Analysism," Proc. National Science USA, July 1992, Vol. 89, pp. 5947-5851 15 D. SIDRANSKY ET AL., "Clonal Expansion of p53 Mutant Cells is Associated with Brain Tumour Progression," Nature, February 27, 1992, pp. 846-847 16 A. J. JEFFREYS ET AL., "Mutation Processes at Human Minisatellites," Electophoresis, 1995, pp. 1577-1585 17 C. SCHMITT ET AL., "High Sensitive DNA Typing Approaches for the Analysis of Forensic Evidence: Comparison of Nested Variable Number of Tandem Repeats (VNTR) Amplification and a Short Tandem Repeats (STR) Polymorphism," Forensic Science International, 1994, Vol. 66, pp. 129-141 18 P. M. LIZARDI ET AL., "Mutation Detection and Single-Molecule Counting Using Isothermal Rolling-Circle Amplification," Nature Genetics, July 1998, Vol. 19, pp. 225-232	9		
Molecules,* Proc. National Science USA, 1990, pp. 6296-6300 W. NAVIDI ET AL., "Using PCR in Preimplantation Genetic Disease Diagnosis," Human Reproduction, 1991, Vol. 6, No. 6, pp. 836-849 H. LI ET AL., "Amplification and Analysis of DNA Sequences in Single Human Sperm and Diploid Cells," Nature, September 29, 1986, Vol. 335, pp. 414-417 L. ZHANG ET AL., "Whole Genome Amplification from a Single Cell: Implications for Genetic Analysism," Proc. D. SIDRANSKY ET AL., "Clonal Expansion of p53 Mutant Cells is Associated with Brain Tumour Progression," Nature, February 27, 1992, pp. 846-847 A. J. JEFFREYS ET AL., "Mutation Processes at Human Minisatellites," Electophoresis, 1995, pp. 1577-1585 C. SCHMITT ET AL., "High Sensitive DNA Typing Approaches for the Analysis of Forensic Evidence: Comparison of Nested Variable Number of Tandem Repeats (VNTR) Amplification and a Short Tandem Repeats (STR) C. M. LIZARDI ET AL., "Mutation Detection and Single-Molecule Counting Using Isothermal Rolling-Circle Amplification," Nature Genetics, July 1998, Vol. 19, pp. 225-232	10	D. G. MONCKTON ET AL., "Minisatellite "Isoallele" Discrimination in Pseudohomozygotes by Single Molecule PCR and Variant Repeat Mapping," Genomics, 1991, Vol. 11, pp. 465-467	
H. LI ET AL., "Amplification and Analysis of DNA Sequences in Single Human Sperm and Diploid Cells," Nature, September 29, 1988, Vol. 335, pp. 414-417 L. ZHANG ET AL., "Whole Genome Amplification from a Single Cell: Implications for Genetic Analysism," Proc. National Science USA, July 1992, Vol. 89, pp. 5847-5851 D. SIDRANSKY ET AL., "Clonal Expansion of p53 Mutant Cells is Associated with Brain Turnour Progression," Nature, February 27, 1992, pp. 846-847 A. J. JEFFREYS ET AL., "Mutation Processes at Human Minisatellites," Electophoresis, 1995, pp. 1577-1585 C. SCHMITT ET AL., "High Sensitive DNA Typing Approaches for the Analysis of Forensic Evidence: Comparison of Nested Variable Number of Tandern Repeats (VNTR) Amplification and a Short Tandern Repeats (STR) P. M. LIZARDI ET AL., "Mutation Detection and Single-Molecule Counting Using Isothermal Rolling-Circle Amplification," Nature Genetics, July 1998, Vol. 19, pp. 225-232 R. PARSONS ET AL., "Mismatch Repair Deficiency in Phenotypically Normal Human Cells," Science, May 5, 1995,	11		
September 29, 1988, Vol. 335, pp. 414-417 L. ZHANG ET AL., "Whole Genome Amplification from a Single Cell: Implications for Genetic Analysism," Proc. National Science USA, July 1992, Vol. 89, pp. 5947-5851 D. SIDRANSKY ET AL., "Clonal Expansion of p53 Mutant Cells is Associated with Brain Tumour Progression," Nature, February 27, 1992, pp. 846-847 A. J. JEFFREYS ET AL., "Mutation Processes at Human Minisatellites," Electophoresis, 1995, pp. 1577-1585 C. SCHMITT ET AL., "High Sensitive DNA Typing Approaches for the Analysis of Forensic Evidence: Comparison of Nested Variable Number of Tandem Repeats (VNTR) Amplification and a Short Tandem Repeats (STR) Polymorphism," Forensic Science International, 1994, Vol. 66, pp. 129-141 P. M. LIZARDI ET AL., "Mutation Detection and Single-Molecule Counting Using Isothermal Rolling-Circle Amplification," Nature Genetics, July 1998, Vol. 19, pp. 225-232	12		
15 D. SIDRANSKY ET AL., "Clonal Expansion of p53 Mutant Cells is Associated with Brain Tumour Progression," Nature, February 27, 1992, pp. 846-847 16 A. J. JEFFREYS ET AL., "Mutation Processes at Human Minisatellites," Electophoresis, 1995, pp. 1577-1585 17 C. SCHMITT ET AL., "High Sensitive DNA Typing Approaches for the Analysis of Forensic Evidence: Comparison of Nested Variable Number of Tandem Repeats (VNTR) Amplification and a Short Tandern Repeats (STR) Polymorphism," Forensic Science International, 1994, Vol. 66, pp. 129-141 18 P. M. LIZARDI ET AL., "Mutation Detection and Single-Molecule Counting Using Isothermal Rolling-Circle Amplification," Nature Genetics, July 1998, Vol. 19, pp. 225-232	13	H. LI ET AL., "Amplification and Analysis of DNA Sequences in Single Human Sperm and Diploid Cells," Nature, September 29, 1988, Vol. 335, pp. 414-417	
February 27, 1992, pp. 846-847 16 A. J. JEFFREYS ET AL., "Mutation Processes at Human Minisatellites," Electophoresis, 1995, pp. 1577-1585 C. SCHMITT ET AL., "High Sensitive DNA Typing Approaches for the Analysis of Forensic Evidence: Comparison of Nested Variable Number of Tandem Repeats (VNTR) Amplification and a Short Tandem Repeats (STR) Polymorphism," Forensic Science International, 1994, Vol. 66, pp. 129-141 P. M. LIZARDI ET AL., "Mutation Detection and Single-Molecule Counting Using Isothermal Rolling-Circle Amplification," Nature Genetics, July 1998, Vol. 19, pp. 225-232	14		
C. SCHMITT ET AL., "High Sensitive DNA Typing Approaches for the Analysis of Forensic Evidence: Comparison of Nested Variable Number of Tandem Repeats (VNTR) Amplification and a Short Tandem Repeats (STR) Polymorphism," Forensic Science International, 1994, Vol. 66, pp. 129-141 P. M. LIZARDI ET AL., "Mutation Detection and Single-Molecule Counting Using Isothermal Rolling-Circle Amplification," Nature Genetics, July 1998, Vol. 19, pp. 225-232	15		
Nested Variable Number of Tandem Repeats (VNTR) Amplification and a Short Tandem Repeats (STR) Polymorphism," Forensic Science International, 1994, Vol. 66, pp. 129-141 P. M. LIZARDI ET AL., "Mutation Detection and Single-Molecule Counting Using Isothermal Rolling-Circle Amplification," Nature Genetics, July 1998, Vol. 19, pp. 225-232	16	A. J. JEFFREYS ET AL., "Mutation Processes at Human Minisatellites," Electophoresis, 1995, pp. 1577-1585	
Amplification," Nature Genetics, July 1998, Vol. 19, pp. 225-232 R. PARSONS ET AL., "Mismatch Repair Deficiency in Phenotypically Normal Human Cells," Science, May 5, 1995,	17	Nested Variable Number of Tandem Repeats (VNTR) Amplification and a Short Tandem Repeats (STR)	
	18		
	19		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number Filing Date First Named Inventor Bert Vogelstein et al. Art Unit Examiner Name Attorney Docket Number 001107.00866

	20	MARRAS ET AL., "Multiplex Detection of Single-Nucleotide Variations Using Molecular Beacons," Genetic Analysis: Biomolecular Engineering, Feb. 1999, Vo. 14, pp. 151-156	
-	21	WHITCOMB ET AL., "Detection of PCR Products Using Self-Probing Amplicons and Fluorescence," Nature Biotechnology, August 1999, Vol. 17, pp. 804-807	
	22	M.J. BRISCO ET AL., "Detection and Quantitation of Neoplastic Cells in Acute Lymphoblastic Leukemia, by Use of the Polymerase Chain Reaction," British Journal of Haematology, 1991, Vol. 79, pp. 211-217	
	23	M. J. BRISCO ET AL., "Outcome Prediction in Childhood Acute Lymphoblastic Leukemia by Molecular Quantification of Residual Disease at the End of Induction," The Lancet, January 22, 1994, Vol. 343, pp. 196-200	
	24	Notice of Reasons for Rejection dispatched April 28, 2010 in Japanese Application No. 2001-513641 and English translation thereof.	
	25	Stephens, J. Clairborne, et al. "Theoretical underpinning of the Single-Molecular-Dilution (SMD) Method of Direct Haplotype Resolution," Am. J. Hum. Gen., Vol. 46, pp. 1149-1155 (1990).	
	26	NEWTON, PCR Essential Data, pages 51-52, 1995	
	27	Office Action dated June 11, 2010, in co-pending application 11/709,742	
	28	Office Action dated December 29, 2009 in co-pending application 11/709,742	
	29	Office Action dated September 18, 2009 in co-pending application 11/709,742	
	30	Office Action dated June 5, 2009 in co-pending application 11/709,742	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number Filing Date First Named Inventor Bert Vogelstein et al. Art Unit Examiner Name Attorney Docket Number 001107.00866

If you wish to add additional non-patent literature document citation information please click the Add button Add					
	EXAMINE	R SIGNATURE			
Examiner Signature	/Samuel Woolwine/	Date Considered	10/02/2012		
		ation is in conformance with MPEP 609. y of this form with next communication t			
Standard ST.3). 3 For Japane	ese patent documents, the indication of the year opportunities as indicated on the document	EP 901.04. ² Enter office that issued the documen of the reign of the Emperor must precede the seri under WIPO Standard ST.16 if possible. ⁵ Applic	al number of the patent document.		

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2449	(sample with (split splitting divide divided dividing dilute diluting diluted dilution)) same ((fragment molecule template) near5 (single one "less than" "more than" "greater than" "fewer than" fewer less))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/02 15:01
L2	361	11 and (@ad<"19990802" @pd<"19990802")	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/02 15:01
L3	12232	rare near5 (sequence target mutation variant variation polymorphism)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/02 15:02
L4	14	I2 and I3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/02 15:02
S2	4	("7915015" "7824889" "6753147" "6440706").PN.	USPAT	OR	OFF	2012/10/01 07:49
S3	1	("20080287318").PN.	US-PGPUB; USPAT	OR	OFF	2012/10/01 15:54
S4	1132	"limiting dilution" same pcr	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2012/10/01 16:52
\$5	123	S4 and (@ad<"19990802" @pd<"19990802")	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2012/10/01 17:04
S6	85	S5 and sequencing	US-PGPUB; USPAT; USOCR; FPRS; EPO;	OR	OFF	2012/10/01 17:04

			JPO; DERWENT; IBM_TDB			
S7	26	S5 and (sequencing sequenced) with ((pcr amplification) near2 product)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/01 17:05
S8	4	(vogelstein kinzler).in. and (dilut\$3 distribut\$3).clm. and (sequencing (determin\$5 near2 sequence)).clm. and (samples aliquots portions tubes wells).clm.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/01 17:13
S9	289	((distributing diluting aliquotting dividing splitting) with (dna nucleic sample)) same (amplif\$7 pcr) same (sequencing sequenced)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/01 17:31
S10	16	S9 and (@ad<"19990802" @pd<"19990802")	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2012/10/01 17:31
S11	1337	((distributing diluting aliquotting dividing splitting) with (dna nucleic sample)) same (amplif\$7 pcr) and (sequencing sequenced)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/01 17:32
S12	312	S11 and ((less fewer) near5 molecules)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/01 17:33
S13	8	S12 and (@ad<"19990802" @pd<"19990802")	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2012/10/01 17:33
S18	506	(rare adj1 (sequence target mutation)) and ((pcr "polymerase chain") same (dilution diluting diluted))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/01 22:55
S19	56	S18 and (@ad<"19990802" @pd<"19990802")	US-PGPUB; USPAT;	OR	ON	2012/10/01 22:55

			USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB			
S20	12	("5213961" "5518901" "5670325" "5736333" "5804383" "5858663" "5925517" "5928870" "6020137" "6037130" "6143496" "6291163").PN.	US-PGPUB; USPAT	OR	OFF	2012/10/01 23:07
S21	10	S20 and (dilution diluted diluting)	US-PGPUB; USPAT	OR	OFF	2012/10/01 23:08
S22	234225	pcr and (sequencing sequenced sequence)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/02 12:06
S23	49987	S2 and (sample with (split splitting divide divided dividing dilute diluting diluted dilution))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/02 12:07
S24	33237	\$23 and ((molecule template) near5 (single one "less than" "more than" "greater than" "fewer than" fewer less))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/02 12:09
S25	17275	\$23 and (((fragment molecule template) near5 (single one "less than" "more than" "greater than" "fewer than" fewer less)) same (pcr amplif\$7))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/02 12:09
S26	1366	(sample with (split splitting divide divided dividing dilute diluting diluted dilution)) same (((fragment molecule template) near5 (single one "less than" "more than" "greater than" "fewer than" fewer less)) same (pcr amplif\$7))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/02 12:10
\$27	60	S26 and (@ad<"19990802" @pd<"19990802")	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/02 12:11
S28	1	ruano.in. and ("single molecule" "single-molecule") adj1 dilution	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2012/10/02 12:30

10/ 2/ 2012 3:45:50 PM C:\ Users\ swoolwine\ Documents\ EAST\ Workspaces\ 13071105.wsp

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1			US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/02 17:49
L2	7	l1 and (@ad<"19990802")	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/02 17:50
L3	1 1	l2 and (sequenced sequencing)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2012/10/02 17:50

10/2/2012 5:51:13 PM

C:\ Users\ swoolwine\ Documents\ EAST\ Workspaces\ 13071105.wsp

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Bert VOGELSTEIN et al.) Examiner: WOOLWINE, Samuel C
Serial No. 13/071,105)) Group Art Unit: 1637
Filed: March 24, 2011) Confirmation No. 3361
For: Digital Amplification) Attv. Dkt. No. 001107.00866

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the office action mailed May 10, 2012, applicants elect claim Group IV (claim 49 and 50-68, drawn to methods for detecting a generic sequence comprising distributing or diluting a mixed population of nucleic acid sequences into at least 10 assay samples such that at least 10 assay samples each comprise less than 10 template molecules and determining nucleic acid sequence of amplification products from an assay sample with homogeneous amplification products). Claims 50-68 are amended below to depend from claim 49.

In addition, applicants elect species: A-1 (less than all), B-1 (in same pot), C-2 (blood), and D-3 (a rare exon sequence). Claims which read on all of the elected species are: claims 49-68.

The Commissioner is authorized to charge any fees which may be required or credit any overpayment to our Deposit Account 19-0733.

IN THE CLAIMS

Please replace the following claim set for that currently of record.

1. (Original) A method for detecting a cancer-associated mutant nucleic acid that is present in a patient sample at a low level relative to a corresponding wild-type nucleic acid, the method comprising:

diluting nucleic acids in a biological sample to form a set comprising a plurality of assay samples;

amplifying the nucleic acids in the assay samples to form a population of amplified molecules;

performing an assay on the amplified molecules in each assay sample to determine whether a cancer-associated mutation is present in at least one of the assay samples;

wherein the step of diluting in performed until at least one-fiftieth of the assay samples in the set comprise a number (N) of molecules such that 1/N is larger than a ratio of the mutant nucleic acid to the wild-type nucleic acid required to detect the mutant nucleic acid if it is present in the assay sample.

- 2. (Original) The method of claim 1 wherein the step of diluting is performed until between 0.1 and 0.9 of the assay samples yield an amplification product when subjected to a polymerase chain reaction.
- 3. (Original) The method of claim 1 wherein the step of diluting is performed until all of the assay samples yield an amplification product when subjected to a polymerase chain reaction and each assay sample contains less than 10 nucleic acid template molecules containing a reference genetic sequence.
- 4. (Original) The method of claim 1 wherein the step of diluting is performed until all of the assay samples yield an amplification product when subjected to a polymerase chain reaction and each assay sample contains less than 100 nucleic acid template molecules containing a reference genetic sequence.
- 5. (Original) The method of claim 1 wherein the biological sample is cell-free.
- 6. (Original) The method of claim 1 wherein the number of assay samples within the set is greater than 10.

- 7. (Original) The method of claim 1 wherein the number of assay samples within the set is greater than 50.
- 8. (Original) The method of claim 1 wherein the number of assay samples within the set is greater than 100.
- 9. (Original) The method of claim 1 wherein the number of assay samples within the set is greater than 500.
- 10. (Original) The method of claim 1 wherein the number of assay samples within the set is greater than 1000.
- 11. (Original) The method of claim 1 wherein the step of amplifying and the step of analyzing are performed on assay samples in the same receptacle.
- 12. (Original) The method of claim 1 wherein a molecular beacon probe is used in the step of analyzing, wherein a molecular beacon probe is an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end.
- 13. (Original) The method of claim 1 wherein the step of analyzing employs gel electrophoresis.
- 14. (Original) The method of claim 1 wherein the step of analyzing employs hybridization to at least one nucleic acid probe.
- 15. (Original) The method of claim 1 wherein the step of analyzing employs hybridization to at least two nucleic acid probe.
- 16. (Original) The method of claim 12 wherein two molecular beacon probes are used, each having a different photoluminescent dye.
- 17. (Original) The method of claim 12 wherein the molecular beacon probe detects a wild-type nucleic acid better than a mutant nucleic acid.
- 18. (Original) The method of claim 1 wherein the step of amplifying employs a single pair of primers.

- 19. (Original) The method of claim 1 wherein the step of amplifying employs a polymerase which is activated only after heating.
- 20. (Original) The method of claim 1 wherein the step of amplifying employs at least 40 cycles of heating and cooling.
- 21. (Original) The method of claim 1 wherein the step of amplifying employs at least 50 cycles of heating and cooling.
- 22. (Original) The method of claim 1 wherein the step of amplifying employs at least 60 cycles of heating and cooling.
- 23. (Original) The method of claim 1 wherein the biological sample is selected from the group consisting of stool, blood, and lymph nodes.
- 24. (Original) The method of claim 1 wherein the biological sample is blood or bone marrow of a leukemia or lymphoma patient who has received anti-cancer therapy.
- 25. (Original) The method of claim 1 wherein the mutant nucleic acid is a translocated allele
- 26. (Original) The method of claim 1 wherein the mutant nucleic acid is within an amplicon which is amplified during neoplastic development.
- 27. (Currently amended) The method of claim 1 wherein the mutant nucleic acid is a rare exon sequence.
- 28. (Original) The method of claim 1 wherein the nucleic acids being analyzed comprise cDNA of RNA transcripts.
- 29. (Original) A method for determining the ratio of a selected genetic sequence in a population of genetic sequences from a blood sample, comprising the steps of:

diluting nucleic acid template molecules from a blood sample to form a set comprising a plurality of assay samples;

amplifying the template molecules within the assay samples to form a population of amplified molecules in the assay samples of the set;

analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence;

comparing the first number to the second number to ascertain a ratio which reflects the composition of the blood sample.

- 30. (Original) The method of claim 29 wherein the step of amplifying employs real-time polymerase chain reactions.
- 31. (Original) The method of claim 30 wherein the real-time polymerase chain reactions comprise a dual-labeled fluorogenic probe.
- 32. (Original) The method of claim 29 further comprising the step of: identifying an allelic imbalance based on the ratio ascertained.
- 33. (Original) The method of claim 29 wherein the selected genetic sequences and the reference genetic sequence are non-polymorphic markers.
- 34. (Original) The method of claim 29 wherein the selected genetic sequence and the reference genetic sequence are on distinct chromosomes.
- 35. (Original) A method for determining the ratio of a selected non-polymorphic marker in a population of genetic sequences in a biological sample, comprising the steps of:

diluting nucleic acid template molecules in a biological sample to form a set comprising a plurality of assay samples;

amplifying the template molecules within the assay samples to form a population of amplified molecules in the assay samples of the set;

analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected non-polymorphic marker and a second number of assay samples which contain a reference non-polymorphic marker, wherein the selected and reference non-polymorphic markers are on distinct chromosomes;

comparing the first number to the second number to ascertain a ratio which reflects the composition of the biological sample; and

identifying an allelic imbalance based on the ratio ascertained.

- 36. (Original) The method of claim 35 wherein the biological sample is a blood sample.
- 37. (Original) The method of claim 35 wherein the step of amplifying employs real-time polymerase chain reactions.
- 38. (Original) The method of claim 37 wherein the real-time polymerase chain reactions comprise a dual-labeled fluorogenic probe.
- 39. (Original) A method for determining the ratio of a selected genetic sequence in a population of genetic sequences from a blood sample, comprising the steps of:

amplifying template molecules within a set comprising a plurality of assay samples to form a population of amplified molecules in each of the assay samples of the set, wherein the template molecules are obtained from a blood sample;

analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence, wherein at least one-fiftieth of the assay samples in the set comprise a number (N) of molecules such that 1/N is larger than the ratio of selected genetic sequences to total genetic sequences required to determine the presence of the selected genetic sequence;

comparing the first number to the second number to ascertain a ratio which reflects the composition of the blood sample.

- 40. (Original) The method of claim 39 wherein the step of amplifying employs real-time polymerase chain reactions.
- 41. (Original) The method of claim 40 wherein the real-time polymerase chain reactions comprise a dual-labeled fluorogenic probe.
- 42. (Original) The method of claim 39 further comprising the step of : identifying an allelic imbalance based on the ratio ascertained.
- 43. (Original) The method of claim 39 wherein the selected genetic sequences and the reference genetic sequence are non-polymorphic markers.
- 44. (Original) The method of claim 39 wherein the selected genetic sequence and the reference genetic sequence are on distinct chromosomes.

45. (Original) A method for determining the ratio of a selected non-polymorphic marker in a population of non-polymorphic markers from a biological sample, comprising the steps of:

amplifying template molecules within a set comprising a plurality of assay samples to form a population of amplified molecules in each of the assay samples of the set, wherein the template molecules are obtained from a biological sample;

analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected non-polymorphic marker and a second number of assay samples which contain a reference non-polymorphic marker, wherein at least one-fiftieth of the assay samples in the set comprise a number (N) of molecules such that 1/N is larger than the ratio of selected non-polymorphic marker to total non-polymorphic markers required to determine the presence of the selected non-polymorphic marker, wherein the selected genetic sequence and the reference genetic sequence are on distinct chromosomes;

comparing the first number to the second number to ascertain a ratio which reflects the composition of the biological sample; and

identifying an allelic imbalance based on the ratio ascertained.

- 46. (Original) The method of claim 45 wherein the step of amplifying employs real-time polymerase chain reactions.
- 47. (Original) The method of claim 46 wherein the real-time polymerase chain reactions comprise a dual-labeled fluorogenic probe.
- 48. (Original) The method of claim 45 wherein the biological sample is from blood.
- 49. (Previously Presented) A method for detecting a genetic sequence in a mixed population of nucleic acid sequences, comprising:

distributing or diluting a mixed population of nucleic acid sequences into at least ten assay samples such that said at least ten assay samples each comprises less than ten template molecules;

amplifying the template molecules in the assay samples, wherein an assay sample with a single template molecule forms homogeneous amplification products in the assay sample;

determining nucleic acid sequence of amplification products from an assay sample with homogeneous amplification products.

- 50. (Currently amended) The method of claim ± 49 wherein each of the assay samples has on average 0.5 molecules of template.
- 51. (Currently amended) The method of claim $\frac{1}{2}$ wherein between 0.1 and 0.9 of the assay samples yield an amplification product.
- 52. (Currently amended) The method of claim $\frac{1}{2}$ wherein the mixed population of nucleic acid sequences is distributed or diluted to a single template molecule level in the assay samples.
- 53. (Currently amended) The method of claim $\frac{1}{2}$ wherein the mixed population of nucleic acid sequences is from a tissue or body sample.
- 54. (Currently amended) The method of claim $\frac{1}{2}$ wherein the mixed population of nucleic acids sequences is from a sample selected from the group consisting of stool, blood, and lymph nodes.
- 55. (Currently amended) The method of claim $\frac{49}{49}$ wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least fifteen assay samples comprise less than ten template molecules.
- 56. (Currently amended) The method of claim $\frac{1}{2}$ wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least twenty assay samples comprise less than ten template molecules.
- 57. (Currently amended) The method of claim $\frac{49}{9}$ wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least twenty-five assay samples comprise less than ten template molecules.
- 58. (Currently amended) The method of claim $\frac{1}{2}$ wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least thirty assay samples comprise less than ten template molecules.
- 59. (Currently amended) The method of claim ± 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least forty assay samples comprise less than ten template molecules.

- 60. (Currently amended) The method of claim ± 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least fifty assay samples comprise less than ten template molecules.
- 61. (Currently amended) The method of claim ± 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least seventy-five assay samples comprise less than ten template molecules.
- 62. (Currently amended) The method of claim ± 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one hundred assay samples comprise less than ten template molecules.
- 63. (Currently amended) The method of claim ± 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least five hundred assay samples comprise less than ten template molecules.
- 64. (Currently amended) The method of claim ± 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one thousand assay samples comprise less than ten template molecules.
- 65. (Currently amended) The method of claim $\frac{1}{2}$ wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one thousand assay samples are diluted to a single template molecule level.
- 66. (Currently amended) The method of claim ± 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one thousand assay samples has on average 0.5 molecules of template.
- 67. (Currently amended) The method of claim ± 49 wherein the mixed population of nucleic acids sequences is distributed or diluted such that between 0.1 and 0.9 of at least one thousand assay samples yield an amplification product.
- 68. (Currently amended) The method of claim $\frac{1}{2}$ wherein the mixed population of nucleic acids sequences is distributed or diluted such that one half of at least one thousand assay samples have one template molecule.

Respectfully submitted,

/Sarah A. Kagan/ Sarah A. Kagan Date: June 11, 2012 By:

Registration No. 32,141

Banner & Witcoff, Ltd. Customer No. 11332

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Docket Number (Optional)						
PETITION	I FOR EXTENSION OF TIME UNDER 37	001107.00866						
Application	Number 13/071,105		Filed March 24, 201	1				
For Digi	tal Amplification							
Art Unit 16	37		Examiner WOOLWIN	E, Samuel C.				
This is a re application.	quest under the provisions of 37 CFR 1.136(a) to extend the perio	od for filing a reply in the	above identified				
The reques	ted extension and fee are as follows (check ti	me period desired a		fee below):				
		<u>Fee</u>	Small Entity Fee	. 150.00				
V	One month (37 CFR 1.17(a)(1))	\$150	\$75	\$ <u>150.00</u>				
	Two months (37 CFR 1.17(a)(2))	\$560	\$280	\$				
	Three months (37 CFR 1.17(a)(3))	\$1270	\$635	\$				
	Four months (37 CFR 1.17(a)(4))	\$1980	\$990	\$				
	Five months (37 CFR 1.17(a)(5))	\$2690	\$1345	\$				
Applica	ant claims small entity status. See 37 CFR 1.2	7.						
A che	ck in the amount of the fee is enclosed.							
☐ Paym	ent by credit card. Form PTO-2038 is atta	iched.						
The D	irector has already been authorized to ch	arge fees in this a	pplication to a Deposi	t Account.				
	irector is hereby authorized to charge an	y fees which may	be required, or credit a	any overpayment, to				
	NG: Information on this form may become publi credit card information and authorization on P		ation should not be includ	ded on this form.				
I am the	applicant/inventor.							
	assignee of record of the entire in Statement under 37 CFR 3.73	nterest. See 37 Cl 3(b) is enclosed (F	FR 3.71. Form PTO/SB/96).					
	attorney or agent of record. Regi	stration Number 3	32141					
	attorney or agent under 37 CFR Registration number if acting under 3							
/Sarat	/Sarah A. Kagan/ June 11, 2012							
	Signature Date							
Sarah	A. Kagan		(202) 824-3000					
	Typed or printed name Telephone Number							
NOTE: Signat signature is re	res of all the inventors or assignees of record of the entire quired, see below.	interest or their represen	tative(s) are required. Submit m	ultiple forms if more than one				
	of 1 forms are	submitted.						

This collection of information is required by 37 CFR 1.136(a). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 6 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Patent Application Fee Transmittal								
Application Number:	13071105							
Filing Date:	24-Mar-2011							
Title of Invention:	Digital Amplification							
First Named Inventor/Applicant Name:	Bei	rt VOGELSTEIN						
Filer:	Sar	ah Anne Kagan./Le	atrice sims					
Attorney Docket Number:	001107.00866							
Filed as Large Entity								
Utility under 35 USC 111(a) Filing Fees								
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)			
Basic Filing:								
Pages:								
Claims:								
Miscellaneous-Filing:								
Petition:								
Patent-Appeals-and-Interference:								
Post-Allowance-and-Post-Issuance:								
Extension-of-Time:	Extension-of-Time:							
Extension - 1 month with \$0 paid Page 341 of 1224		1251	1	150	150			

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
	(\$)	150		

Electronic Acknowledgement Receipt						
EFS ID:	12978167					
Application Number:	13071105					
International Application Number:						
Confirmation Number:	3361					
Title of Invention:	Digital Amplification					
First Named Inventor/Applicant Name:	Bert VOGELSTEIN					
Customer Number:	11332					
Filer:	Sarah Anne Kagan./Leatrice sims					
Filer Authorized By:	Sarah Anne Kagan.					
Attorney Docket Number:	001107.00866					
Receipt Date:	11-JUN-2012					
Filing Date:	24-MAR-2011					
Time Stamp:	11:37:15					
Application Type:	Utility under 35 USC 111(a)					

Payment information:

Submitted with Payment	yes	
Payment Type	Deposit Account	
Payment was successfully received in RAM	\$150	
RAM confirmation Number	9628	
Deposit Account	190733	
Authorized User		

File Listing:

Document	Document Description	Eilo Namo	File Size(Bytes)/	Multi	Pages
Number		File Name	Message Digest	Part /.zip	(if appl.)

		Total Files Size (in bytes)	40	0242	
Information:					
Warnings:					
3	ree worksneet (2806) tee-Into.par		07c17696daf0ce93600409d2e67488efe9da f944		4
3	Fee Worksheet (SB06)	fee-Info.pdf	30091	no	2
Information:					
Warnings:			 		
2	Extension of time	Lo1_filed_with_fin.pdf	1f2225aaa12244d9c218066b5f8025f32bfb 15fb	110	2
2	Extension of Time	EOT_filed_with_RR.pdf	286857	no	2
Information:					
Warnings:					
	Claims	Claims			
	Response to Election /	1	1		
	Document De	scription	Start	End	
	Multip	oart Description/PDF files in	zip description		
•			abib45b23bf7dbe6e6d49bd5fb4b0d6ae17 58080	,	
1		response_to_RR.pdf	83294	yes	10

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875						A	Application or Docket Number 13/071,105 Filing Date 03/24/2011			To be Mailed		
APPLICATION AS FILED - PART I (Column 1) (Column 2)						OTHER THAN SMALL ENTITY OR SMALL ENTITY						
	FOR		IUMBER FIL	.ED	NUN	BER EXTRA		RATE (\$)	FEE (\$)		RATE (\$)	FEE (\$)
	BASIC FEE (37 CFR 1.16(a), (b), (c)	or (c))	N/A			N/A		N/A		Total designation of the	N/A	
	SEARCH FEE (37 CFR 1.16(k), (i), o		N/A			N/A	Que construction and a second	N/A		A CONTRACTOR OF THE CONTRACTOR	N/A	
	EXAMINATION FE	E	N/A			N/A		N/A		Permanata	N/A	
	TAL CLAIMS CFR 1.16(i))		mir	us 20 =	•		AND AND AND ADDRESS OF THE PARTY OF THE PART	X\$ =		OR	X \$ =	
IND	EPENDENT CLAIM CFR 1.16(h))	S	m	nus 3 =	•			X\$ =		gy and a second	X \$ =	
	APPLICATION SIZE (37 CFR 1.16(s))	she is \$	ets of pape 250 (\$125 itional 50 :	er, the a for sma sheets o	pplication Il entity) r fraction	gs exceed 100 in size fee due for each in thereof. See CFR 1.16(s).			-			
	MULTIPLE DEPEN	DENT CLAIM P	RESENT (3	7 CFR 1.1	6(j))							
* If I	he difference in colu	ımn 1 is less tha	zero, ente	r "0" in co	lumn 2.			TOTAL			TOTAL	
	APPI	(Column 1)	S AMENC	(Colu	ımn 2)	(Column 3)	9 1 i	SMAL	L ENTITY	OR		ER THAN ALL ENTITY
AMENDMENT	06/11/2012	CLAIMS REMAINING AFTER AMENDMENT		HIGHE NUMBI PREVIO PAID F	ER OUSLY	PRESENT EXTRA		RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)
Š	Total (37 CFR 1.16(i))	→ 68	Minus	··· 68		= 0		X\$ =		OR	X \$60=	0
Z.	Independent (37 CFR 1.16(h))	* 6	Minus	***6		= 0	Street of the last	X\$ =		OR	X \$250=	0
AMI	Application Si	ze Fee (37 CFR	1.16(s))	a nodazzone en e			Amount					
	FIRST PRESEN	ITATION OF MULT	IPLE DEPEN	DENT CLA	MM (37 CFF	R 1.16(j))	AND PROPERTY.			OR		
								TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	0
		(Column 1)		(Colu	ımn 2)	(Column 3)				CONTRACTOR OF THE STATE OF THE		
	,	CLAIMS REMAINING AFTER AMENDMENT		NUN PREVI	HEST MBER IOUSLY FOR	PRESENT EXTRA	Planta my annual contract of the contract of t	RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)
ENI	Total (37 CFR 1.16(i))	*	Minus	**		=		X \$ =		OR	X\$ =	
ENDM	Independent (37 CFR 1.16(h))	*	Minus	***		=		X\$ =		OR	x \$ =	
EN	Application Si	ize Fee (37 CFR	1.16(s))									
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))								OR				
	TOTAL TOTAL ADD'L FEE FEE											
***	* If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.											

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/071,105	03/24/2011	Bert VOGELSTEIN	001107.00866	3361
11332 Banner & Witc	7590 04/10/2012 off, Ltd.	EXAMINER		
Attorneys for c	lient 001107		WOOLWINE	SAMUEL C
1100 13th Stree Suite 1200	et N.W.		ART UNIT	PAPER NUMBER
Washington, D	C 20005-4051		1637	
			MAIL DATE	DELIVERY MODE
			04/10/2012	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		I	Application No.	Applicant(s)		
Office Action Summary			13/071,105	VOGELSTEIN ET	ΓAL.	
		E	Examiner	Art Unit		
			SAMUEL WOOLWINE	1637		
Period fo	The MAILING DATE of this communic r Reply	cation appea	rs on the cover sheet wit	h the correspondence a	ddress	
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)	Responsive to communication(s) filed	d on				
*	•		ction is non-final.			
3)	An election was made by the applica	nt in respons	se to a restriction require	ement set forth during th	ne interview on	
	; the restriction requirement an	d election h	ave been incorporated ir	nto this action.		
4)	Since this application is in condition f	or allowance	e except for formal matte	ers, prosecution as to th	e merits is	
	closed in accordance with the practic	e under <i>Ex</i>	<i>parte Quayle</i> , 1935 C.D.	11, 453 O.G. 213.		
Dispositi	on of Claims					
5) ☐ Claim(s) 1-68 is/are pending in the application. 5a) Of the above claim(s) is/are withdrawn from consideration. 6) ☐ Claim(s) is/are allowed. 7) ☐ Claim(s) is/are rejected. 8) ☐ Claim(s) is/are objected to. 9) ☐ Claim(s) 1-68 are subject to restriction and/or election requirement.						
Application Papers						
 10) The specification is objected to by the Examiner. 11) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 12) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 						
Priority under 35 U.S.C. § 119						
 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application 6) Other:						

U.S. Patent and Trademark Office PTOL-326 (Rev. 03-11) Application/Control Number: 13/071,105 Page 2

Art Unit: 1637

DETAILED ACTION

Note: New claims 50-68 depend from original claim 1, rather than new independent claim 49. Applicant is requested to confirm whether this is the case. The restriction requirement set forth below applies to the claims as written. If claims 50-68 were intended to depend from claim 49, those claims will be included in Group IV rather than Group I.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-28 and 50-68, drawn to methods for detecting a cancerassociated mutation comprising diluting until at least 1/50 of the assay
 samples comprise a number (N) of molecules such that 1/N is larger than
 a ratio of the mutant nucleic acid to the wild-type nucleic acid required to
 detect the mutant nucleic acid if it is present in the assay sample,
 classified in class 435, subclass 6.12.
- II. Claims 29-38, drawn to methods for determining a ratio of a selected genetic sequence to a reference genetic sequence comprising determining a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence and comparing the first number to the second number to ascertain a ratio, classified in class 435, subclass 6.12.
- III. Claims 39-48, drawn to methods for determining a ratio of a selected genetic sequence to a reference genetic sequence wherein at least 1/50

of the assay samples comprise a number (N) of molecules such that 1/N is larger than a ratio of selected genetic sequences to total genetic sequences required to determine the presence of the selected genetic sequence and determining a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence and comparing the first number to the second number to ascertain a ratio, classified in class 436, subclass 6.12.

IV. Claim 49, drawn to methods for detecting a genetic sequence comprising distributing or diluting a mixed population of nucleic acid sequences into at least 10 assay samples such that at least 10 assay samples each comprise less than 10 template molecules and determining nucleic acid sequence of amplification products from an assay sample with homogeneous amplification products, classified in class 435, subclass 6.12.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and (II & III) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the different inventions have different designs. Invention I requires detection of a cancer-associated mutation, which is not required for inventions II & III. Inventions II & III require determining the ratio of a selected genetic sequence to a reference genetic

Page 4

Art Unit: 1637

sequence, which is not required for invention I. In addition, invention I requires at least 1/50 of the assay samples comprise a number (N) of molecules such that 1/N is larger than a ratio of a nucleic acid comprising a cancer-associated mutation *to wild-type nucleic acid* required to determine the presence of the mutation, which is not required by invention III. Note that in invention III, what is required is that 1/50 of the assay samples comprise a number (N) of molecules such that 1/N is larger than a ratio of a selected genetic sequence *to total nucleic acid* (which is presumed, based on plain language, to mean "selected" genetic sequence + "reference" genetic sequence). This is not required for invention I.

Inventions II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the different inventions have different designs. Invention II requires diluting nucleic acid template molecules from a sample to form a plurality of assay samples, which is not required for invention III. Invention III requires at least 1/50 of the assay samples comprise a number (N) of molecules such that 1/N is larger than a ratio of selected genetic sequences to total genetic sequences required to determine the presence of the selected genetic sequence, which is not required for invention II.

Inventions IV and (I-III) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the different inventions have different designs. Invention IV requires distributing or diluting

Application/Control Number: 13/071,105

Art Unit: 1637

a mixed population of nucleic acid sequences into at least ten assay samples such that at least ten assay samples each comprise less than ten template molecules, which is not required by inventions I-III. Inventions II & III require determining a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence and comparing the first number to the second number to ascertain a ratio, which is not required by invention IV. In addition, invention I requires at least 1/50 of the assay samples comprise a number (N) of molecules such that 1/N is larger than a ratio of a nucleic acid comprising a cancer-associated mutation to wild-type nucleic acid required to determine the presence of the mutation, which is not required by invention IV. Invention III requires at least 1/50 of the assay samples comprise a number (N) of molecules such that 1/N is larger than a ratio of selected genetic sequences to total genetic sequences required to determine the presence of the selected genetic sequence, which is not required for invention IV.

Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above and there would be a serious search and/or examination burden if restriction were not required because at least the following reason(s) apply:

Due to the fact that each group of inventions requires limitations not required by the other groups, a search each invention would be conducted using different search strategies. While these different searches might be partially overlapping, they would not be the same. This would place an undue burden of search on the Office.

Applicant is advised that the reply to this requirement to be complete <u>must</u> include (i) an election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

This application contains claims directed to the following patentably distinct species:

A1: less than all assay samples yield an amplification product/contain template (claims 2, 50, 51, 66, 67).

A2: all assay samples yield an amplification product/contain template (claims 3, 4, 52, 65).

B1: analyzing performed in same receptacle/employs hybridization probes (claims 11, 12, 14-17, 31, 38, 41, 47).

B2: analyzing employs gel electrophoresis (claim 13).

C1: sample is stool (claims 23 in-part, 54 in-part).

C2: sample is blood (claims 23 in-part, 24 in-part, 29-34, 36, 39-44, 48, 54 in-part).

C3: sample is lymph node (claims 23 in-part, 54 in-part).

C4: sample is bone marrow (claim 24 in-part).

D1: mutation is translocated allele (claim 25).

D2: mutation is a nucleic acid sequence amplified during neoplastic development (claim 26).

D3: mutation is a rare exon sequence (claim 27).

The species are independent or distinct because each species within a group A, B, C or D is mutually exclusive of the others. In addition, these species are not obvious variants of each other based on the current record.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from each of A, B, C and D for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Depending on the *invention* elected (I-IV), some elections of species may not apply. Currently, claims 1, 5-10, 18-22, 28, 35, 37, 45, 46, 49, 53, 55-64 and 68 are generic.

There is a search and/or examination burden for the patentably distinct species as set forth above because at least the following reason(s) apply:

Since each species within a group A, B, C or D is mutually exclusive of the others and would require a different search. There is no certainty that a prior art reference anticipating or rendering obvious any one species would be applicable to the others.

Applicant is advised that the reply to this requirement to be complete <u>must</u> include (i) an election of a species or a grouping of patentably indistinct species to be examined even though the requirement <u>may</u> be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected species or grouping of patentably indistinct species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

The election may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the election of species requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected species or grouping of patentably indistinct species.

Should applicant traverse on the ground that the species, or groupings of patentably indistinct species from which election is required, are not patentably distinct,

applicant should submit evidence or identify such evidence now of record showing them to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the species unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other species.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAMUEL WOOLWINE whose telephone number is (571)272-1144. The examiner can normally be reached on Mon-Fri 9:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 13/071,105 Page 10

Art Unit: 1637

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Samuel Woolwine/ Primary Examiner

UTILITY PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Group Art Unit: 1637
Bert VOGELSTEIN et al.)	Docket No. 001107.00866
Serial No. 13/071,105)	Confirmation No: 3361
Filed: March 24, 2011)	Examiner: Woolwine, Samuel C.
Eom DICITAL AMBI IEICATION		

For: DIGITAL AMPLIFICATION

PRELIMINARY AMENDMENT

U.S. Patent and Trademark Office Customer Service Window Randolph Building, Mail Stop: Missing Parts 401 Dulany Street Alexandria, VA 22314

Dear Sir:

Please enter the following amendment to the application before examination commences. Should any additional fees be required to enter this amendment, please charge our deposit account no. 19-0733.

IN THE CLAIMS

Please substitute the following set of claims for those currently pending.

1. (Original) A method for detecting a cancer-associated mutant nucleic acid that is present in a patient sample at a low level relative to a corresponding wild-type nucleic acid, the method comprising:

diluting nucleic acids in a biological sample to form a set comprising a plurality of assay samples;

amplifying the nucleic acids in the assay samples to form a population of amplified molecules; performing an assay on the amplified molecules in each assay sample to determine whether a cancer-associated mutation is present in at least one of the assay samples;

wherein the step of diluting in performed until at least one-fiftieth of the assay samples in the set comprise a number (N) of molecules such that 1/N is larger than a ratio of the mutant nucleic acid to the wild-type nucleic acid required to detect the mutant nucleic acid if it is present in the assay sample.

- 2. (Original) The method of claim 1 wherein the step of diluting is performed until between 0.1 and 0.9 of the assay samples yield an amplification product when subjected to a polymerase chain reaction.
- 3. (Original) The method of claim 1 wherein the step of diluting is performed until all of the assay samples yield an amplification product when subjected to a polymerase chain reaction and each assay sample contains less than 10 nucleic acid template molecules containing a reference genetic sequence.
- 4. (Original) The method of claim 1 wherein the step of diluting is performed until all of the assay samples yield an amplification product when subjected to a polymerase chain reaction and each assay sample contains less than 100 nucleic acid template molecules containing a reference genetic sequence.
- 5. (Original) The method of claim 1 wherein the biological sample is cell-free.
- 6. (Original) The method of claim 1 wherein the number of assay samples within the set is greater than 10.

- 7. (Original) The method of claim 1 wherein the number of assay samples within the set is greater than 50.
- 8. (Original) The method of claim 1 wherein the number of assay samples within the set is greater than 100.
- 9. (Original) The method of claim 1 wherein the number of assay samples within the set is greater than 500.
- 10. (Original) The method of claim 1 wherein the number of assay samples within the set is greater than 1000.
- 11. (Original) The method of claim 1 wherein the step of amplifying and the step of analyzing are performed on assay samples in the same receptacle.
- 12. (Original) The method of claim 1 wherein a molecular beacon probe is used in the step of analyzing, wherein a molecular beacon probe is an oligonucleotide with a stem-loop structure having a photoluminescent dye at one of the 5' or 3' ends and a quenching agent at the opposite 5' or 3' end.
- 13. (Original) The method of claim 1 wherein the step of analyzing employs gel electrophoresis.
- 14. (Original) The method of claim 1 wherein the step of analyzing employs hybridization to at least one nucleic acid probe.
- 15. (Original) The method of claim 1 wherein the step of analyzing employs hybridization to at least two nucleic acid probe.
- 16. (Original) The method of claim 12 wherein two molecular beacon probes are used, each having a different photoluminescent dye.
- 17. (Original) The method of claim 12 wherein the molecular beacon probe detects a wild-type nucleic acid better than a mutant nucleic acid.
- 18. (Original) The method of claim 1 wherein the step of amplifying employs a single pair of primers.
- 19. (Original) The method of claim 1 wherein the step of amplifying employs a polymerase which is activated only after heating.
- 20. (Original) The method of claim 1 wherein the step of amplifying employs at least 40 cycles of heating and cooling.

- 21. (Original) The method of claim 1 wherein the step of amplifying employs at least 50 cycles of heating and cooling.
- 22. (Original) The method of claim 1 wherein the step of amplifying employs at least 60 cycles of heating and cooling.
- 23. (Original) The method of claim 1 wherein the biological sample is selected from the group consisting of stool, blood, and lymph nodes.
- 24. (Original) The method of claim 1 wherein the biological sample is blood or bone marrow of a leukemia or lymphoma patient who has received anti-cancer therapy.
- 25. (Original) The method of claim 1 wherein the mutant nucleic acid is a translocated allele
- 26. (Original) The method of claim 1 wherein the mutant nucleic acid is within an amplicon which is amplified during neoplastic development.
- 27. (Original) The method of claim 1 wherein the mutant nucleic acid is a rare exon sequence
- 28. (Original) The method of claim 1 wherein the nucleic acids being analyzed comprise cDNA of RNA transcripts.
- 29. (Original) A method for determining the ratio of a selected genetic sequence in a population of genetic sequences from a **blood** sample, comprising the steps of:

diluting nucleic acid template molecules from a **blood** sample to form a set comprising a plurality of assay samples;

amplifying the template molecules within the assay samples to form a population of amplified molecules in the assay samples of the set;

analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence;

comparing the first number to the second number to ascertain a ratio which reflects the composition of the **blood** sample.

30. (Original) The method of claim 29 wherein the step of amplifying employs real-time polymerase chain reactions.

- 31. (Original) The method of claim 30 wherein the real-time polymerase chain reactions comprise a dual-labeled fluorogenic probe.
- 32. (Original) The method of claim 29 further comprising the step of: identifying an allelic imbalance based on the ratio ascertained.
- 33. (Original) The method of claim 29 wherein the selected genetic sequences and the reference genetic sequence are **non-polymorphic markers**.
- 34. (Original) The method of claim 29 wherein the selected genetic sequence and the reference genetic sequence are **on distinct chromosomes**.
- 35. (Original) A method for determining the ratio of a selected **non-polymorphic** marker in a population of genetic sequences in a **biological** sample, comprising the steps of:

diluting nucleic acid template molecules in a biological sample to form a set comprising a plurality of assay samples;

amplifying the template molecules within the assay samples to form a population of amplified molecules in the assay samples of the set;

analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected **non-polymorphic marker** and a second number of assay samples which contain a reference **non-polymorphic marker**, wherein the selected and reference non-polymorphic markers are on distinct chromosomes;

comparing the first number to the second number to ascertain a ratio which reflects the composition of the biological sample; and

identifying an allelic imbalance based on the ratio ascertained.

36. (Original) The method of claim 35 wherein the biological sample is a blood sample.

- 37. (Original) The method of claim 35 wherein the step of amplifying employs real-time polymerase chain reactions.
- 38. (Original) The method of claim 37 wherein the real-time polymerase chain reactions comprise a dual-labeled fluorogenic probe.
- 39. (Original) A method for determining the ratio of a selected genetic sequence in a population of genetic sequences from a **blood** sample, comprising the steps of: amplifying template molecules within a set comprising a plurality of assay samples to form a population of amplified molecules in each of the assay samples of the set, wherein the template molecules are obtained from a **blood** sample;

analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected genetic sequence and a second number of assay samples which contain a reference genetic sequence, wherein at least one-fiftieth of the assay samples in the set comprise a number (N) of molecules such that 1/N is larger than the ratio of selected genetic sequences to total genetic sequences required to determine the presence of the selected genetic sequence;

comparing the first number to the second number to ascertain a ratio which reflects the composition of the **blood** sample.

- 40. (Original) The method of claim 39 wherein the step of amplifying employs real-time polymerase chain reactions.
- 41. (Original) The method of claim 40 wherein the real-time polymerase chain reactions comprise a dual-labeled fluorogenic probe.
- 42. (Original) The method of claim 39 further comprising the step of: identifying an allelic imbalance based on the ratio ascertained.

- 43. (Original) The method of claim 39 wherein the selected genetic sequences and the reference genetic sequence are **non-polymorphic markers**.
- 44. (Original) The method of claim 39 wherein the selected genetic sequence and the reference genetic sequence are **on distinct chromosomes**.
- 45. (Original) A method for determining the ratio of a selected **non-polymorphic** marker in a population of **non-polymorphic markers** from a **biological** sample, comprising the steps of:

amplifying template molecules within a set comprising a plurality of assay samples to form a population of amplified molecules in each of the assay samples of the set, wherein the template molecules are obtained from a biological sample;

analyzing the amplified molecules in the assay samples of the set to determine a first number of assay samples which contain the selected **non-polymorphic marker** and a second number of assay samples which contain a reference **non-polymorphic marker**, wherein at least one-fiftieth of the assay samples in the set comprise a number (N) of molecules such that 1/N is larger than the ratio of selected **non-polymorphic marker** to total **non-polymorphic markers** required to determine the presence of the selected **non-polymorphic marker**, wherein the selected genetic sequence and the reference genetic sequence are **on distinct chromosomes**;

comparing the first number to the second number to ascertain a ratio which reflects the composition of the biological sample; and

identifying an allelic imbalance based on the ratio ascertained.

- 46. (Original) The method of claim 45 wherein the step of amplifying employs real-time polymerase chain reactions.
- 47. (Original) The method of claim 46 wherein the real-time polymerase chain reactions comprise a dual-labeled fluorogenic probe.

- 48. (Original) The method of claim 45 wherein the biological sample is from blood.
 - 49. (New) A method for detecting a genetic sequence in a mixed population of nucleic acid sequences, comprising:

distributing or diluting a mixed population of nucleic acid sequences into at least ten assay samples such that said at least ten assay samples each comprises less than ten template molecules;

amplifying the template molecules in the assay samples, wherein an assay sample with a single template molecule forms homogeneous amplification products in the assay sample;

determining nucleic acid sequence of amplification products from an assay sample with homogeneous amplification products.

- 50. (New) The method of claim 1 wherein each of the assay samples has on average 0.5 molecules of template.
- 51. (New) The method of claim 1 wherein between 0.1 and 0.9 of the assay samples yield an amplification product.
- 52. (New) The method of claim 1 wherein the mixed population of nucleic acid sequences is distributed or diluted to a single template molecule level in the assay samples.
- 53. (New) The method of claim 1 wherein the mixed population of nucleic acid sequences is from a tissue or body sample.
- 54. (New) The method of claim 1 wherein the mixed population of nucleic acids sequences is from a sample selected from the group consisting of stool, blood, and lymph nodes.
- 55. (New) The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least fifteen assay samples comprise less than ten template molecules.
- 56. (New) The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least twenty assay samples comprise less than ten template molecules.

- 57. (New) The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least twenty-five assay samples comprise less than ten template molecules.
- 58. (New) The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least thirty assay samples comprise less than ten template molecules.
- 59. (New) The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least forty assay samples comprise less than ten template molecules.
- 60. (New) The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least fifty assay samples comprise less than ten template molecules.
- 61. (New) The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least seventy-five assay samples comprise less than ten template molecules.
- 62. (New) The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one hundred assay samples comprise less than ten template molecules.
- 63. (New) The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least five hundred assay samples comprise less than ten template molecules.
- 64. (New) The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one thousand assay samples comprise less than ten template molecules.
- 65. (New) The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one thousand assay samples are diluted to a single template molecule level.
- 66. (New) The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one thousand assay samples has on average 0.5 molecules of template.

Bert VOGELSTEIN et al. U.S. Patent Application No. 13/071,105

- 67. (New) The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that between 0.1 and 0.9 of at least one thousand assay samples yield an amplification product.
- 68. (New) The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that one half of at least one thousand assay samples have one template molecule.

Remarks

The new claims are fully supported in the application as filed, as indicated below.

Claim	Claim recitations	Specification Support
49	A method for detecting a genetic sequence in a mixed population of nucleic acid sequences, comprising:	Thus there is a need in the art for methods for accurately and quantitatively detecting genetic sequences in mixed populations of sequences. Page 2, second full paragraph
	distributing or diluting a mixed population of nucleic acid sequences into at least ten assay samples such that said at least ten assay samples each comprises less than ten template molecules;	The biological sample is diluted to a point at which a practically usable number of the diluted samples contain a proportion of the selected genetic sequence (analyte) relative to total template molecules such that the analyzing technique being used can detect the analyte Alternatively, dilute sources of template nucleic acids can be used. Page 7, paragraph 2 Preferably at least ten diluted assay samples are amplified and analyzed. Page 10, paragraph 3 Desirably each assay sample prior to amplification will contain less than a hundred or less than ten template molecules. Page 7, paragraph 2
	amplifying the template molecules in the assay samples, wherein an assay sample with a single template molecule forms homogeneous amplification products in the assay sample;	At its limit, single template molecules can be amplified so that the products are completely mutant or completely wild-type

Claim	Claim recitations	Specification Support
		(WT). The homogeneity of these amplification products makes them trivial to distinguish through existing techniques. Page 6, last paragraph.
	determining nucleic acid sequence of amplification products from an assay sample with homogeneous amplification products.	Determining the sequence of the putative mutants in the positive wells, by direct sequencing as performed here or by any of the other techniquesPage 8, first paragraph
		Although the working examples demonstrate the use of molecular beacon probes as the means of analysis of the amplified dilution samples, other techniques can be used as well. These include sequencingPage 12, second full paragraph
50	The method of claim 1 wherein each of the assay samples has on average 0.5 molecules of template.	A particularly preferred degree of dilution is to a point where each of the assay samples has on average one-half of a template. Page 7, paragraph 2
51	The method of claim 1 wherein between 0.1 and 0.9 of the assay samples yield an amplification product	To achieve a dilution to approximately a single template molecule level, one can dilute such that between 0.1 and 0.9 of the assay samples yield an amplification product. Page 10, paragraph 2
52	The method of claim 1 wherein the mixed population of nucleic acid sequences is distributed or diluted to a single template molecule level in the assay samples.	To achieve a dilution to approximately a single template molecule level, one can dilute such that between 0.1 and 0.9 of the assay samples yield an amplification product. Page 10, paragraph 2
53	The method of claim 1 wherein the mixed population of nucleic acid sequences is from a	Biological samples which can be used as the starting material for the analyses may be from any

Claim	Claim recitations	Specification Support
	tissue or body sample.	tissue or body sample from which DNA or mRNA can be isolated. Page 11, first full paragraph
54	The method of claim 1 wherein the mixed population of nucleic acids sequences is from a sample selected from the group consisting of stool, blood, and lymph nodes.	Preferred sources include stool, blood, and lymph nodes. Page 11, first full paragraph
55	The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least fifteen assay samples comprise less than ten template molecules.	Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. Page 10, paragraph 3
		Desirably each assay sample prior to amplification will contain less than a hundred or less than ten template molecules. Page 7, paragraph 2
56	The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least twenty assay samples comprise less than ten template molecules.	Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. Page 10, paragraph 3
		Desirably each assay sample prior to amplification will contain less than a hundred or less than ten template molecules. Page 7, paragraph 2
57	The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least twenty-five assay samples comprise less than ten template molecules.	Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. Page 10, paragraph 3
		Desirably each assay sample prior to amplification will

Claim	Claim recitations	Specification Support
		contain less than a hundred or less than ten template molecules. Page 7, paragraph 2
58	The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least thirty assay samples comprise less than ten template molecules.	Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. Page 10, paragraph 3
		Desirably each assay sample prior to amplification will contain less than a hundred or less than ten template molecules. Page 7, paragraph 2
59	The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least forty assay samples comprise less than ten template molecules.	Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. Page 10, paragraph 3
		Desirably each assay sample prior to amplification will contain less than a hundred or less than ten template molecules. Page 7, paragraph 2
60	The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least fifty assay samples comprise less than ten template molecules.	Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. Page 10, paragraph 3
		Desirably each assay sample prior to amplification will contain less than a hundred or less than ten template molecules. Page 7, paragraph 2
61	The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least seventy-	Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75,

Claim	Claim recitations	Specification Support
	five assay samples comprise less than ten template molecules.	100, 500, or 1000 diluted assay samples are amplified and analyzed. Page 10, paragraph 3
		Desirably each assay sample prior to amplification will contain less than a hundred or less than ten template molecules. Page 7, paragraph 2
62	The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one hundred assay samples comprise less than ten template molecules.	Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. Page 10, paragraph 3
=		Desirably each assay sample prior to amplification will contain less than a hundred or less than ten template molecules. Page 7, paragraph 2
63	The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least five hundred assay samples comprise less than ten template molecules.	Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. Page 10, paragraph 3
		Desirably each assay sample prior to amplification will contain less than a hundred or less than ten template molecules. Page 7, paragraph 2
64	The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one thousand assay samples comprise less than ten template molecules.	Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. Page 10, paragraph 3
		Desirably each assay sample prior to amplification will contain less than a hundred or

Claim	Claim recitations	Specification Support
		less than ten template molecules. Page 7, paragraph 2
65	The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one thousand assay samples are diluted to a single template molecule level.	Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. Page 10, paragraph 3
		To achieve a dilution to approximately a single template molecule level, one can dilute such that between 0.1 and 0.9 of the assay samples yield an amplification product. Page 10, paragraph 2
66	The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that at least one thousand assay samples has on average 0.5 molecules of template.	Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. Page 10, paragraph 3
		A particularly preferred degree of dilution is to a point where each of the assay samples has on average one-half of a template. Page 7, paragraph 2
67	The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that between 0.1 and 0.9 of at least one thousand assay samples yield an amplification product.	Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. Page 10, paragraph 3
		To achieve a dilution to

Claim	Claim recitations	Specification Support
		approximately a single template molecule level, one can dilute such that between 0.1 and 0.9 of the assay samples yield an amplification product. Page 10, paragraph 2
68	The method of claim 1 wherein the mixed population of nucleic acids sequences is distributed or diluted such that one half of at least one thousand assay samples have at least one template molecule.	Preferably at least ten diluted assay samples are amplified and analyzed. More preferably at least 15, 20, 25, 30, 40, 50, 75, 100, 500, or 1000 diluted assay samples are amplified and analyzed. Page 10, paragraph 3
		In one preferred embodiment each diluted sample has on average one half a template molecule. This is the same as one half of the diluted samples having one template molecule. Page 10, paragraph 1

Respectfully submitted,

By: /Sarah A. Kagan/ Sarah A. Kagan Registration. No. 32,141

Customer No. 11332

Dated: November 30, 2011